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This document presents the results of efforts to apply the Yeast Consensus 
Reconstruction model of the Saccharomyces cerevisiae metabolic network to develop a 
metabolic engineering strategy for industrial strain improvement. Following a review of the 
development of mathematical models of metabolism, it describes an evaluation of the Consensus 
Reconstruction. We find that the computational reconstruction of this portion of metabolism 
differs from the biochemistry of this pathway as described in the literature. Our efforts to correct 
these discrepancies are described in Chapter 4. The updated model improves both the accuracy 
of the metabolic reconstruction and the prediction of viability and auxotrophy phenotypes, thus 
demonstrating that literature-based curation is a technique which can be successfully applied to 
improve the model. 
Chapter 5 describes an in silico screen for formate-producing yeast mutants. By working 
to reproduce an in silico screen previously conducted using the iND750 model, we found that the 
computational prediction of formate-producing yeast mutants is sensitive to implementation 
details and reaction constraints when using either the iND750 or the Yeast model. Our results 
suggest that comparative analysis of constraint based models is a useful tool for improving 
models of the yeast metabolic network. The main text concludes with a summary and discussion 
 of future research opportunities in Chapter 6. MATLAB scripts which enable evaluation of 
model predictive accuracy and demonstrate model applications such growth simulation and 
mutant library screening are included as appendices. 
This work contributes to the ongoing effort to develop systems biotechnology tools which 
will enable the rational design of new microbial strains, and which may enable broader 
industrial-scale application of biotechnology. The fields of computational biology and systems 
biotechnology are young, and abundant opportunity remains to develop and apply this 
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CHAPTER 1 - INTRODUCTION 
 
Work to characterize, harness, and improve the use of microbial metabolism for human 
benefit is an ongoing effort, involving the disparate techniques of biological scientists, process 
engineers, and increasingly, computational experts. Archeological evidence suggests that this 
work has been ongoing, perhaps since the dawn of human civilization: fermentation to produce 
bread or beer may have motivated the domestication of cereal grains [1]. Fermentation research 
led to the modern science of biochemistry [2], and the genome of Saccharomyces cerevisiae was 
the first eukaryotic genome sequence to be completed [3]. In our effort to maximize yeast’s 
productive capacity for industrial-scale biotechnology applications, we have refined fermentation 
vessels and processes, optimized media, and used selective breeding methods for strain 
improvement. Most recently, in the post-genome era, we have begun working to apply the 
knowledge gained through techniques of molecular biology and genetics to develop predictive 
computer models of yeast physiology to implement rational strain design and synthetic biology 
approaches. 
An illustrative example is provided by research efforts to improve the industrial 
production of ethanol via fermentation for use as a liquid transportation fuel, thus reducing our 
society’s dependence upon petroleum [4]. In working to improve the production of first-
generation biofuels, researchers and process engineers have taken a variety of approaches in 
attempts reduce fermentation process time and to improve product yield. Efforts have included 
the use of various substrate feeding modes [5]; novel fermentation process designs, such as those 
involving multiple vessels with cell recycling [6]; supplementing with nutrients [7] or vitamins 
[8]; and optimizing temperature [9]; oxygen concentration [10]; initial inoculum size [11]; and 
combinations of these factors [12]. This strategy of fermentation process optimization has been 
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very successful at the laboratory scale, with results including a fermentation of a high-sugar 
wheat media to produce 21.5% (v/v) ethanol in approximately 175 hr without nutritional 
supplement [11]. However, the production of such a high ethanol concentration required large 
quantities of dry yeast as the inoculums, a technique which causes extended lag times in the 
absence of yeast preconditioning [13]. Such increased fermentation time would increase 
industrial scale capital costs significantly due to fermentation vessel size requirements. There are 
other obstacles to industrial-scale application of successful laboratory-scale approaches: the 
inoculum required to replicate these results at a large scale would be prohibitively expensive, and 
the organism is subject to a wide variety of stresses in the industrial context, including osmotic, 
temperature, and pH stresses which arise from process considerations [14]. Other 
supplementation and process control strategies face similar economic challenges when scaled up. 
What’s more, strategies of altering nutritional or process approaches are not sufficient for the 
industrial production of compounds which are not endogenously biosynthesized. Thus, it is 
hoped that improved bioprocesses and biocatalysts may be obtained more economically by 
modifying the fermentative organism itself through metabolic engineering or synthetic biology 
approaches. 
Traditional genetic approaches to yeast strain development and improvement include 
breeding programs [15] and generating and screening libraries of mutants for a desired 
phenotype [16]. These approaches are time- and labor-intensive – drawbacks which must be 
overcome for rapid development of industrial biotechnology. With the emergence of large 
datasets in the post-genomic era, scientists and engineers have built upon the computational 
foundations built by earlier efforts to model metabolism to develop new high-throughput and in 
silico approaches to strain improvement, approaches which have been termed “Systems 
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Biotechnology” [17]. 
As described in the next chapter, the ideas of mathematically modeling single reactions 
have been extended to metabolic pathways, and scaled up to model entire metabolic networks. In 
the face of challenges to organism-scale kinetic models, researchers have developed other 
approaches, such as using steady state assumptions and applying mathematical programming 
algorithms to stoichiometrically constrained computational reconstructions of the metabolic 
reaction network – an approach that has been termed “flux balance analysis” [18], or FBA. 
With FBA providing the mathematical foundation for the analysis of reconstructed 
metabolic networks, researchers began encoding the hard-gained knowledge represented by 
metabolic pathway maps into computer formats amenable to simulation. Ongoing efforts by 
different research groups have led to a proliferation of such models – including at least 16 
different genome-scale models of yeast metabolism (Table 2.2). Further, efforts to reduce the 
need for extensive manual review of model details and to increase the rate at which such models 
can be built have led to the development of software pipelines to automate the process of 
building metabolic models from genomic data [19]. As they were developed, these automated 
processes were quickly applied to create stoichiometrically-constrained models for hundreds of 
organisms, and have now been extended in hopes of generating metabolic models as quickly as 
new genomes are sequenced (there are 1541 models in the Model SEED database at time of 
writing [20]). 
The development of reconstruction and simulation methods has been driven by the desire 
to facilitate application. Indeed, the increasing range of published applications of FBA to 
stoichiometrically constrained metabolic models has been the subject of at least two recent 
review articles which summarize their application for contextualizing high-throughput data, 
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metabolic engineering, model-directed discovery, interrogating multi-species relationships, 
interpretations of phenotypic screens, analysis of network properties and studies of evolutionary 
processes [21, 22] 
The research described in this dissertation is an effort to validate and improve the 
computational reconstruction of yeast metabolism so that a yeast model may be applied to inform 
metabolic engineering. In beginning this work, my objective was to apply an existing model of 
yeast metabolism [23] to develop strategies to enhance the production of compounds which have 
previously been linked to improve stress tolerance. However, when I reviewed the biochemical 
reactions included in the Consensus Reconstruction of Yeast Metabolism [23, 24], I found that 
this model did not accurately reconstruct the metabolic pathways involved in the biosynthesis of 
complex sphingolipids (Chapter 3, [25]). Thus, I expanded my objectives to: 
1. Conduct literature-based validation of the reconstruction of sphingolipid 
metabolism included in the Consensus Reconstruction of Yeast Metabolism 
2. Update the existing model by incorporate any changes required to correct errors in 
the reconstruction 
3. Evaluate the impact of these changes on the predictive accuracy of the model 
4. Apply the updated model to develop metabolic engineering strategies for strain 
improvement 
5. Evaluate any differences in strategies suggested by the updated model with 
predictions of previously published models 
I found that correcting errors in the reconstruction of established biochemistry improved 
model predictions of gene essentiality and knockout-induced auxotrophies (Chapter 4, [26]). 
Following these corrections to the model, I reviewed published examples of applying constraint-
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based models of yeast metabolism to implement metabolic engineering strategies. I re-
implemented an in silico screen of simulated knockout mutants for strains predicted to produce 
formate, and found that my simulations made different predictions than earlier yeast metabolic 
models. This comparative approach of evaluating phenotype and metabolic flux predictions 
using different metabolic models also proved to be a valuable tool for further model refinement 
(Chapter 5). 
This work documents that there remains a need for careful manual curation of the 
biochemistry included in stoichiometrically constrained models of yeast metabolism, and that a 
curation approach based upon manual review of relevant literature is a successful strategy for 
improving the predictive accuracy of such models. I observe that model-based metabolic 
engineering tools are sensitive to details of implementation, but can be successfully applied to 
strain improvement. Thus, this dissertation contributes to the ongoing effort to develop systems 
biotechnology tools which will enable the rational design of new microbial strains, and which 
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CHAPTER 2 – LITERATURE REVIEW 
 
Improving industrial yeast strains 
Stress tolerance is critically important for yeast strains in industrial biotechnology 
application because “in industrial practices, yeast never encounters the physiologically optimum 
environment and instead is exposed to a variety of stresses” which reduce their productivity [1]. 
Our understanding of the mechanisms by which yeast adapts to stress has improved over time. In 
1974, Hayashida et al. found that yeasts acquired enhanced ethanol tolerance when grown in the 
presence of a fungal mycelium extract traditionally used in the production of sake, concluding 
that “the formation of a high concentration of alcohol in sake mash is related to the lipid 
metabolism of yeast” [2]. Hayashida expanded upon this work in a series of articles, showing 
that supplementation with the proteolipid extract increased fermentative activity and “alcohol-
durability” [3]; that the proteolipid extract consisted primarily of phospholipids and protein; that 
the phospholipids included phosphatidylcholine (PC), “a sphingolipid”, and 
lysophosphatidylcholine (LPC) [4]; and that supplementation with PC and ergosteryl oleate 
resulted in effects similar to supplementation with the fungal extract [5]. Other supplements have 
also been found to increase yeast’s tolerance to stress caused by increasing ethanol 
concentrations in their environment, including linoleic acid and oleic acid [6] and inositol [7, 8]. 
More recently, research has documented endogenously produced inositol in genetically 
modified strains has the same effect of improving ethanol tolerance as inositol supplemented 
from exogenous sources, though stress tolerance of such strains is further enhanced by additional 
inositol supplementation [9]. Thus, metabolic engineering of yeast strains by redirecting 
metabolic flux to the production of compounds which have been documented to improve stress 





the process of rationally designing such metabolic engineering strategies remains a challenge to 
the development such stress-tolerant strains. 
Computational context for the development of industrial yeast strains 
Successful development of predictive models of yeast metabolism will permit more 
effective industrial application of yeast-based biotechnology. Such models of metabolism would 
enable a rational design approach to genetic engineering for developing industrial yeast strains, 
an approach which has the potential to provide industrial biotechnology solutions to current 
constraints on microbe-dependent production of fuels or other chemicals [10]. Historical 
approaches to organizing emerging knowledge of the biochemistry of metabolism into models 
can be separated into two general classes: 1) qualitative or conceptual maps of the chemical 
pathways through which substrates are transformed by cells to produce new biomass; and 2) 
quantitative mathematical models which describe the dynamics of metabolism. The ability to use 
the conceptual information embodied in pathway maps for quantitative analysis of biological 
systems is a fairly recent innovation. The emergence of this modeling approach is described 
below. 
Emergence of the reductionist approach 
Attempts to develop mathematical tools to describe metabolism have taken both top-
down and bottom-up approaches. Top-down approaches consider metabolism as a “black box” 
and attempt to predict gross physiological behavior without consideration of the underlying 
mechanism (an example of this approach is predicting optimal feed rates for cultures based upon 





models are based upon the reductionist approach which attempts to develop holistic kinetic 
models from mechanistic descriptions of individual reactions. Top-down models describing the 
gross kinetics of cellular physiology without consideration of the chemical reactions which 
constitute metabolism have long been successfully applied by engineers in an industrial context 
for processes such as wastewater treatment with activated sludge [12]. However, because such 
models do not describe internal metabolic processes, they are of only limited use for providing 
insights for rational design strategies for manipulating metabolic networks to improve substrate 
utilization or product formation.  
Models which may be applied to the challenge of testing rational design strategies have 




 century which focused on developing 
mechanistic models from a reductionist kinetic approach. Development of such models continues 
[13]. However, as our understanding of in vivo enzyme kinetics has advanced, it has become 
clear that this reductionist approach is currently insufficient for describing emergent properties of 
systems-level functions and the control of metabolism [14]. Further, it has become apparent that 
enzyme kinetic characteristics in conditions applied for most in vitro characterization 
experiments may vary greatly from in vivo conditions. Fully characterizing in vivo kinetics has 
proven to be an extremely challenging problem. 
As recently as 2006, Minton [15] demonstrated our lack of knowledge of in vivo kinetics 
when his commentary concluded with the question “By how much do biochemical reactions 
within cells differ from those in test tubes?” As described in the “Kinetics of multi-reaction 





assessing uncertainty of in vivo kinetics, including various parameter estimation and sensitivity 
analysis approaches.  
While it had been previously thought that the reductionist approach of characterizing the 
kinetics of individual enzyme-mediated reactions was more amenable to developing 
computational models than the conceptual mapping approach of drawing chemical pathway 
maps, there has recently been a reconsideration of the potential to create predictive quantitative 
models from data embodied in pathway maps. Using an approach rooted in network theory and 
systems analysis, a modeling framework of applying constraints has been developed that has 
predictive capabilities without full kinetic characterization of the reactions such maps represent. 
In this framework, the model does not depend upon complete kinetic information, but any 
available kinetic information can serve as a constraint on the set of feasible metabolic states. 
Such constrained network models serve as the foundation for the proposed research, and are 
described in the “Stoichiometric modeling” section of this chapter. 
Kinetics of enzyme-mediated reactions 
Improved understanding of yeast metabolism has been a scientific goal since before the 
19
th
 century debate of whether fermentation was a chemical process or solely a biological 
function – a debate described as being between “vitalists” and biochemists [16]. When the 
Buchner brothers observed fermentation of sucrose by cell extract [17], they laid the foundation 
for our current understanding of enzyme-mediated reactions and their role in converting 
environmental resources to cell biomass, energy, and waste products. Although enzymology was 





enzymes at that time were exo-enzymes which catalyzed hydrolysis reactions [18]. In fact, when 
the term “enzyme” was coined in 1877 [19], was used to describe the catalyzing agent for 
reactions occurring outside of organisms. Neither theories describing the mechanism of action 
nor mathematical models for enzyme kinetics had been well established at the time the Buchners 
were investigating fermentation. Further, the key role of enzymes in catalyzing metabolic 
reactions had not been conclusively demonstrated prior to their work. Through their cell-free 
fermentation, the Buchners demonstrated a link between enzyme activity and the chemical 
reactions of metabolism, and are thus generally credited with laying the cornerstone for the new 
science of biochemistry. With the understanding that metabolism consisted of a series of 
enzymatically-catalyzed reactions, biochemists had a new tool – enzymology – with which to 
build a theoretical framework for metabolic pathways. Other tools are essential for mapping 
metabolic pathways, but enzymology was the starting point for developing mathematical models 
of metabolism. 
Search for a rate-limiting step 
From the beginning, enzymologists embraced a reductionist approach to understanding 
the kinetics of metabolic pathways by characterizing the kinetics of enzymes which had been 
extracted from cells and purified. This approach was explicitly justified in an influential 1905 
paper by British plant physiologist Frederick Blackman [20]. Beginning with the axiom “When a 
process is conditioned as to its rapidity by a number of separate factors, the rate of the process is 
limited by the pace of the ‘slowest’ factor”, Blackman argued that the enzyme-catalyzed 





“Regarding the cell, as we now may, from the metabolic point of view, as a 
congeries of enzymes, a colloidal honeycomb of katalytic agents, as many in 
number as there are cell-functions, and each capable of being isolated and made to 
do its particular work alone in vitro, we look for light on the action of chemical 
stimuli in the cell to their effect on the action of isolated enzyme in vitro.” 
Such reasoning was extended to developing mathematical models of metabolism. If the 
kinetics of each enzyme in a metabolic pathway could be described mathematically, the rate-
limiting enzyme would determine the kinetics of an entire metabolic pathway. It was thought 
that, the interdependence of various metabolic pathways could be explored mathematically, and 
the rate-limiting pathway would control the kinetics of a cell’s metabolism. Thus, metabolism 
could be mathematically described with the same formulation as the kinetics of the key rate-
limiting enzyme. Presumably, metabolic rates were controlled by the key rate-limiting enzymes– 
if the kinetics of the rate-limiting step could be influenced, it would create a mechanism to affect 
the rate of the entire pathway [21]. 
The Michaelis-Menten formulation 
Development of mathematical models of enzyme kinetics proceeded throughout the 20
th
 
century as enzymologists worked to extract, purify, and quantify the action of key enzymes. By 
1902, Henri [22] and Brown [23] had independently devised kinetic models for enzyme-
catalyzed reactions which were based on the idea of the formation of an enzyme-substrate 
complex, relying upon the assumption that substrates reach enzymes by diffusion at rates that are 
governed by chemical mass-action kinetics. This theoretical approach was given a firmer 
experimental foundation in 1913 by L. Michaelis and M. Menten [24]. In 1925, Briggs and 





intermediates is constant, and rederived Michaelis and Menten’s kinetic model into to the now-
classic Michaelis-Menten kinetic equation for irreversible enzyme-mediated reactions [25]. The 
Michaelis-Menten equation relates the substrate concentration (a) to the initial (vo) and limiting 




The Michaelis-Menten equation remains a key mathematical model for describing the 
kinetics of irreversible reactions catalyzed by purified enzymes. However, attempting to apply 
the Michaelis-Menten equation to the regulated reactions of metabolic pathways can be 
problematic. For example, metabolic pathways must be able to rapidly respond to subtle 
environmental changes to maintain homeostasis inside a cell. Michaelis-Menten kinetics do not 
reflect this property. As Cornish-Bowden discusses, “a simple calculation shows that the rate is 
0.1v when a = KM/9, and that it is 0.9v when a = 9KM. In other words, an enormous increase in 
substrate concentration, 81-fold, is required to bring about a comparatively modest increase in 
rate from 10% to 90% of the limit” [21]. In other words, Michaelis-Menten kinetics alone do not 
adequately describe the dynamics observed in metabolic pathway responses to environmental 
changes.  
Further problems with Michaelis-Menten 
Michaelis-Menten kinetics are often, but not universally, appropriate for describing the 
kinetics of a single enzyme. Even early in the 20
th
 century, single-enzyme reactions had been 





of oxygen binding to hemoglobin, Bohr observed a cooperative effect in which binding of a 
single oxygen molecule with hemoglobin facilitated the binding of more hemoglobin [26] – a 
process now known as cooperative binding. Using empirical methods, Hill derived an equation 
(equation 2.a.2) to describe the kinetics of such reactions with the introduction of a coefficient to 




Note that the Hill equation is equivalent to the Michaelis-Menten equation in the trivial 
case that the Hill coefficient, h, is 1. Hill did not hypothesize about the mechanism of 
cooperative binding. It was not until the mid 1960’s that theoretical models of allosteric effects, 
in which the binding of a substrate or cofactor alters the conformation of an enzyme, which in 
turn affects the affinity of other binding sites, were elaborated to describe cooperative binding 
[28, 29]. 
The mathematical framework for describing the kinetics of enzyme-mediated reactions 
has continued to advance and become more complex. Equations have been developed to describe 
the kinetics of reversible reactions, reactions with product and substrate inhibition, enzyme 
complex formation, temperature and pH effects, and other situations observed in biochemical 
pathways [21]. Continuing the paradigm of the early enzymologists, much of the effort of 
characterizing enzyme kinetics has focused on individual enzyme-mediated reactions, and the 
bulk of enzyme kinetic data has been collected by enzymologists working with extracted and 





models of the kinetics of enzyme catalyzed reactions in their biological context. 
Kinetics of multi-reaction systems 
A key feature of the biological context for enzymatically catalyzed reactions is that they 
are linked together in the multi-reaction systems that make up metabolic pathways. Efforts to 
develop mathematical models describing the multi-reaction pathways of metabolism have grown 
from and progressed in tandem with the development of a theoretical framework for the kinetics 
of purified enzymes. Like the efforts to develop kinetic models for reactions catalyzed by 
individual enzymes, research efforts to model multi-reaction systems are ongoing. 
Biotechnologists have been particularly interested in multi-reaction pathway models which could 
be used to evaluate strategies for increasing the production of a target metabolite. As described 
below, although early models of metabolic pathways focused on the reductionist approach 
espoused by Blackman [20], evidence was mounting by the mid 1950’s that the analysis of 
metabolism required consideration of emergent systems properties which would not be evident in 
experiments following the reductionist approach of characterizing the kinetics of individually 
purified enzymes. 
Pathway effects 
In 1952, three papers were published [30–32] which demonstrated that an end product of 
a metabolic pathway could inhibit reactions early in the pathway, though the mechanism was 
unclear at that time. In 1953, Adelberg and Umbarger [33] observed that the presence of valine 





valine precursor. From this, they concluded that “an end product, in this case valine, can regulate 
the rate of its own biosynthesis”. By 1956, Umbarger had demonstrated that in E. coli, isoleucine 
specifically inhibited the first enzyme-catalyzed reaction in the pathway for its biosynthesis from 
threonine [34]. He described this process using the terminology of systems control theory, 
calling it a “negative feedback mechanism”. Such a feedback mechanism would not be observed 
in experiments with a single purified enzyme – multiple pathway enzymes or a media containing 
many compounds would need to be present to observe the feedback effect in a typical enzyme 
kinetic experiment. While such an experiment could be set up, the observed feedback effects 
demonstrated the existence of parameters which alter enzyme kinetics exist in metabolic 
systems. Such parameters had not previously been considered in the in vitro experimental 
conditions of classical enzymology. 
Consideration of metabolic flux 
Umbarger’s concept of feedback suggested that metabolism could be considered from the 
viewpoint of dynamical systems analysis – that “cellular dynamics” should be a field of study 
akin to the evaluation mechanical and electronic systems, described using systems of 
simultaneous nonlinear ordinary and partial differential equations. Viewing the control of 
metabolic flux
1
 in the context of cellular dynamics represented a major conceptual shift. In this 
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 As described by [16], the word flux has multiple meanings. In some contexts, it is used for the system 
property corresponding to the rate of reaction of a single enzyme (such as “the flux through glucokinase in central 





new paradigm, rates of enzyme-mediated reactions may be considered local properties which 
refer to enzymes isolated from the system, but steady-state fluxes and metabolite concentrations 
(and their control) are the systemic properties of critical interest [21]. Thus, the study of the 
control of metabolic flux requires examination of the entire biochemical system, not just the 
component pieces of individual reactions.  
In 1965, Joseph Higgins wrote an article to “develop these ideas to the point where they 
may provide a more analytical basis and broader viewpoint for the future development and 
understanding of cellular dynamics” [35]. Higgins suggested that the control of metabolic flux be 
considered as a function of “Structural Control Variables” (SCV), which he used as a general 
term for parameters that might influence the flux through a given reaction sequence, such as rate 
constants, enzyme concentrations, or substrate concentrations. He suggested that the portion of 
control allocated to a particular SCV could be calculated by measuring the change in flux that 
resulted from a change in one of the SCVs. He called this parameter the “control strength” of the 
SCV. Higgins hypothesized that if SCVs were ranked by control strength, one might be found to 
be “many times greater than the others.” In such cases, the SCV with greatest control strength 
would be said to have control of the flux relative to other variables. However, refining 
Blackman’s concept of a “rate-limiting factor”, Higgins noted that the existence of a SCV with 
the greater control strength was not the same as a “rate limiting” enzyme, as had been generally 
                                                                                                                                                             
“the net flux of carbon to biomass formation”). For an unbranched pathway in steady state, the flux through each 





conceived: “[i]n a normal (constant) stationary state the dynamical variables adjust themselves so 
that all steps in the sequence will have the same flux …. Consequently, no one step can be 
considered as rate limiting …. It is preferable to refer to a “rate controlling” step” [35]. Further, 
he cautioned that the possibility of a dominant SCV did not mean that control was necessarily 
limited to a single SCV when he wrote, “there need not be any great difference in the control 
strengths implying that no one step has dominant rate control.”  
Elaborating upon his suggestion that the control strength was a key parameter in 
describing the dynamics of cellular metabolism, Higgins suggested that enzyme concentration is 
a “natural choice” for the SCV for metabolic reactions. This “natural choice” leads to an obvious 
approach to measuring control strengths: varying the amount of enzyme in a cellular extract and 
measuring the resulting change in flux. Successful identification of a rate controlling SCV would 
be particularly useful for biotechnology, since it would provide a method for increasing 
metabolic flux to a desired product: overexpression of the gene coding for the rate controlling 
enzyme. However, though the study of cellular dynamics continued to advance, it would be 
many years before this strategy was tested, and was found to achieve mixed results. Further 
advances in the analysis of control would give a theoretical basis for other approaches to 
metabolic engineering. 
Examining the control of metabolism 
Cellular dynamics research continued after Higgins’ work to provide a stronger analytical 
basis for the field, with particular focus on both the control of metabolism and dynamic modeling 





rooted in sensitivity analysis and established 1973 by Kacser and Burns [36], and independently 
by Heinrich and Rapoport [37]. In their paper, Kacser and Burns first summarized previous 
research concerning the control of biochemical systems as an attempt to synthesize the 
information represented by metabolic maps with the information discovered through 
enzymology. They argued that this synthesis lead to “a large set of simultaneous non-linear 
equations for which there is no explicit solution.” Computers could be used to solve particular 
cases, but more often than not, simulations simply confirmed assumptions about the system, and 
did not “yield a general theory of control.” They argued that the concept of a ‘controlling 
enzyme’ was based upon different criteria in different studies, and the field was hampered by 
imprecise definitions regarding different aspects of control. In an attempt to work towards a 
general theory of control, they suggested a more quantitative approach to analyzing the 
sensitivity of enzyme mediated reactions and metabolic fluxes to changes in external parameters, 
an approach which came to be known as MCA, “a theoretical bridge from the kinetic properties 
of enzymes to the systems properties of metabolism” [38].  
Kacser and Burns began their consideration of the control of flux by differentiating 
between parameters – constraints that can be controlled in an experimental situation (such as 
enzyme concentration or concentration of a substrate or inhibitor in the media) – and variables, 
which represent “levels of metabolites and the diverse molecular forms arising from them”. In 
other words, the “pools” of metabolites and the fluxes into and out of these pools are the 
variables that are controlled by various system parameters. With this distinction between 





metabolism must be analyzed holistically. As Kacser and Burns argued, “flux is a systemic 
property and questions of its control cannot be answered by looking at one step in isolation – or 
even each step in isolation.”  
From their definitions of parameters and variables, Kacser and Burns began formalizing 
MCA by proposing three “vague questions” which they considered to be “what many people 
have in mind when talking about control.” They demonstrated that the questions could be 
restated more precisely, thus becoming amenable to quantitative analysis. These “vague 
questions” were: 1) What is the quantitative influence of one parameter on a variable?; 2) How 
much can any single enzyme be controlled?; and 3) How do changes in pool concentrations 
affect the rate of a reaction? The authors illustrated these questions with an example (Figure 
2.a.1), which served as the basis for their development of a quantitative approach to sensitivity 







To enable quantitative analysis of the first vague question (What is the quantitative 
influence of one parameter on a variable?), Kacser and Burns proposed the use of the “Response 
Coefficient”, which is now designated as  (using the notation standardized in 1985 [39]). The 
Response Coefficient is a simple ratio of the normalized variation of a flux, J, to a normalized 




Kacser and Burns considered the Response Coefficient to be “an overall measure of the 
 
Figure 2.a.1: A thought experiment on the control of flux.  
Assume that the flux, J, carried by an enzyme-mediated step, E, is influenced by 
the level of an internal parameter, such as an inhibitor, I. If I is dependent only upon the 






control exerted” on the flux by the parameter I at its level in the system at the time of interest. 
Continuing their formalization of the “vague questions”, they next described how this overall 
measure could be decomposed into two factors, which captured the essence of the second and 
third questions (How much can any single enzyme be controlled? and How do changes in pool 
concentrations affect the rate of a reaction?). The first factor is the response of the enzyme in 
isolation to variation of a parameter, which they quantified with a “Controllability Coefficient”, 
 . Like the Response Coefficient, the Controllability Coefficient is a ratio – in this case of the 




The Controllability Coefficient is nonlinear over a range of parameters, so Kacser and 
Burns argue that it is important to determine it for a given enzyme using substrate and product 
concentrations held precisely at the steady-state levels obtained in an organism (which is not an 
easy thing to do experimentally!). The Controllability Coefficient describes the sensitivity of a 
particular enzyme to particular changes in the environment in otherwise fixed system conditions. 
It is noted that the rate change measured to determine the Controllability Coefficient is generally 
different from – and usually higher – than the system flux change which would be measured in 
determining the Response Coefficient. This difference is due to systemic effects, discussed 
below. Their formulation of the “Controllability Coefficient” has not been widely adopted in 
subsequent MCA research, and is now considered a specific form of “Elasticity”, a term which 





generated in the system, which would themselves also be classified as variables, as opposed to 
parameters. For Kacser and Burns, the distinction between a controllability coefficient and an 
elasticity was that the controllability coefficient referred to the response of an isolated enzyme to 
a parameter which was determined externally to the system under consideration, and elasticity 
referred to the response of an isolated enzyme to a metabolite whose concentration was set by the 
metabolic system itself, a variable. In more recent studies, this distinction has not been 
emphasized [40]. 
The second factor is the response of the whole system to changes of the enzyme, which 
they quantified with the “Flux Control Coefficient”, . The Flux Control Coefficient is another 
ratio – of normalized flux change to normalized change in enzyme concentration (the flux 
change due to a change in enzyme concentration can be considered equivalent to a flux change 




Thus the Flux Control Coefficient is a quantification of the system’s sensitivity to 
changes in its components.  
The decomposition of the Response Coefficient into the Controllability Coefficient (or 
elasticity) and the Flux Control Coefficient was not merely semantic. Kacser and Burns showed 
that the Response Coefficient is in fact the product of the Controllability Coefficient and the Flux 








Thus, while both and can be evaluated independently, neither is sufficient for 
explaining the control exerted on the flux by a given parameter, such as enzyme activity, gene 
copy number, or inhibitor concentration in media, except in extreme cases. As Kacser and Burns 
wrote, “This relationship reveals that in vitro studies can be misleading in predicting the effects 
in the in vivo situation without a knowledge of Flux Control Coefficients. The Flux Control 
Coefficient is a system property independent of whether any effectors act on the enzyme or what 
their strength is.” 
Kacser and Burns extended their consideration of Flux Control Coefficients from single 
reactions to evaluating the control of pathways, leading to a derivation of the Flux Summation 
Theorem, which states “if all the enzymes that can affect a particular metabolic flux in a cell or a 
metabolic system are taken and the values of their control coefficients on that flux added up, the 




The Flux Summation Theorem has many practical implications. Kacser and Burns 
pointed out that it suggests that in a chain of enzyme-mediated reactions, either one (or few) 
enzymes approach full control, or none of them do (and thus control is distributed across the 
pathway). Evaluating which case holds for a particular pathway requires quantitative analysis. 
Another corollary of the theorem is that for a system with a sufficiently large number of 
enzymes, almost all of the enzymes could be said to be present “in excess” because the quantity 





the other hand, if any single enzyme is drastically reduced, that step may change from having 
little control to having a great deal of control – its Flux Control Coefficient would increase as it 
became a bottleneck. Though Kacser and Burns did not explicitly state it in their early work, this 
formulation of the Summation Theorem suggests a strategy for biotechnological attempts at 
modifying metabolic fluxes: since the Flux Control Coefficient is most likely to be large (and 
thus the enzyme of interest will be controlling) when the enzyme concentration is very low, gene 
deletion-based strategies are more likely to be effective for modifying metabolic fluxes than 
overexpression approaches, which would have a smaller impact on pathway flux due to the low 
Flux Control Coefficient of most enzymes. 
In their seminal paper, Kacser and Burns also discussed some limitations of their 
consideration of Metabolic Control: they had only considered the steady state, which applies to 
either constant volume or expanding systems (expanding systems can have a steady state because 
while volume increases exponentially, so do enzymes, pools, and fluxes, so concentrations 
remain time-invariant); and they did not consider compartmentalization that is not associated 
with organelles, which would affect the “effective concentration surrounding the in vivo 
enzyme”. 
Expanding and applying MCA 
The field of Metabolic Control Analysis was built upon the foundation laid by Kacser and 
Burns in the early 1970s by an array of theoretical and experimental approaches throughout the 
1970’s, and 1980’s. Theoretical advances included the generalization of Flux Control 





and its application to branching pathways [43–45]; applications to cycling and moiety 
conservation [46, 47]; and restatement in a matrix-oriented approach [48, 49], which was 
generalized [50]. 
As Kacser and Burns demonstrated with the decomposition of the response coefficient 
(Equation 2.a.6), MCA requires quantitative information about both kinetic parameters of 
individual reactions and of the systemic effects described by control coefficients, . Since 
characterizing enzyme kinetic parameters has been a focus of enzymology from the field’s 
origins in the 19
th
 century, the new experimental work required for application of MCA has 
focused upon measuring  values for enzymes in pathways. A variety of experimental 
approaches have been applied [41]. Approaches have included altering gene dosage in 
Neurospora crassa to investigate fluxes of arginine synthesis [51]; measuring flux differences 
arising because of various allelic forms of certain enzymes in diploid organisms including 
Drosophila melanogaster [52], Escherichia coli [53], Clarkia xantiana [54], Arabidopsis 
thaliana [55]; altering gene dose through the use of plasmids [56–58]; using antisense RNA 
inhibition [59, 60]; measuring natural flux changes due to environmental changes [61]; and 
titrations by either purified enzymes [62] or specific inhibitors [63]. By the early 1990s, the field 
of MCA was sufficiently established for a series of review articles that describe many of these 
advances [40, 64, 65]. However, as the field became established, practical difficulties grew 
apace. 
Experimental challenges to MCA 





requires careful quantification of an enzyme’s response to small perturbations in a static 
environment which is identical to its in vivo microenvironment. While the differences between in 
vivo and in vitro chemical microenvironments have a long history of investigation [66], the 
apparent necessity of detailed kinetic information for MCA made the distinction between an 
aqueous and a “crowded” intracellular environment critically important. Such differences include 
macromolecular crowding [67, 68]; intracellular compartmentalization due to organelles and 
other spatial effects such as “macromolecular confinement” (Minton 2006); and differing 
thermodynamic regimes due to low water content (Clegg 1984). By 1984, it was abundantly 
clear that the water content in a cell “exhibits physical properties that differ from those of dilute 
solutions” and so “the microenvironment in which metabolic activity actually occurs in cells is 
not equivalent to the conditions used to determine the properties of enzymes in vitro and which 
are extensively used to model metabolism” [69].  
The hypothesis that enzymatically catalyzed reactions in cells do not depend upon freely 
diffusing substrates was supported by experiments performed by Kempner and Miller, in which 
they found cells that were centrifuged to separate proteins from a soluble phase remained viable 
although there were no macromolecules remaining in the lighter fraction [70]. In describing this 
work, Clegg wrote, “these studies suggest that few macromolecules may be free in solution in 
intact cells” and thus even small molecules might be “structure associated”, rather than freely 
diffusing [69]. Further, an assumption that chemical reaction rates are a continuous function may 
not be true in the case of reactions involving a small number of enzymes, in which case the 





based model of chemical kinetics which underlie even simple models of enzyme kinetics may 
not hold in the internal metabolic environment of intact cells [71]. 
The magnitude and significance of changes in enzyme activity due to changes in local 
chemical environment is not a well-studied field. As recently as 2006, Minton wrote that “greater 
than order-of-magnitude increases in association rate and equilibrium constants attributable to 
background interactions have been observed” [15]. New kinetic models have been suggested, 
including the addition of corrective factors to Michaelis-Menten [72], the power-law 
approximation [73], and the development of “fractal-like kinetics” [74]. The latter have been 
simulated with automata on a mathematical grid in a particularly interesting work by Schnell and 
Tuner [71], but many alternative modeling frameworks require a greater level of detailed 
knowledge of the local conditions than the classical approaches. Although it is known that “the 
limited solvent capacity is a relevant constraint acting on S. cerevisiae at physiological growth 
conditions” [75], the impact of such alternative kinetic frameworks upon MCA has not been 
fully explored in the literature. 
Data management challenges to MCA 
A second challenge to practical application of MCA arose with the explosion of data 
following genome sequencing efforts. On one hand, increasing computational power means 
some larger systems of differential equations can be solved, which has allowed the development 
of kinetic models on the scale of pathways, such as the sphingolipid pathway model presented by 
Alvarez-Vasquez [13]. On the other hand, however, such models have not yet scaled to whole 





more than 180 species between 1995 and 2004 [76]. No kinetic models exist at the scale of even 
one of these species. Further, many of the putative enzymes assigned through sequencing efforts 
have had no classical biochemical measurements. Until such measurement occurs, kinetic 
modeling of reactions they catalyze is “virtually impossible” [16].  
In face of the challenge of uncertainty related to the accurate determination of kinetic 
parameters, efforts to develop predictive models of multi-reaction systems have followed various 
paths, including parameter estimation approaches and a re-evaluation of the potential to make 
predictive models from pathway maps without well-defined kinetic information. Both of these 
approaches have yielded significant results from the perspective of applying modeling 
techniques to metabolic engineering - recent parameter sensitivity analyses have demonstrated 
that metabolic networks are “sloppy” by nature, and that parametric sensitivity can vary widely 
across parameters, an implication that has led to the suggestion that “modelers should focus on 
predictions rather than parameters” [77]. Reconsideration of mass-balance constraints on multi-
reaction systems has given rise to stoichiometric modeling, which has potential for significant 
application in the field of metabolic engineering. 
Stoichiometric modeling 
The stoichiometric modeling approach serves as a framework for quantitative analysis of 
the information contained in biochemical pathway maps. It arose over the course of two decades, 
beginning with a conceptual separation of the structural constraints on a dynamic system 
imposed by mass balance, and the dynamic constraints imposed by kinetics. Among the earliest 





stoichiometric model that exhibited the nonlinear behavior previously explained by allosteric 
regulation in central carbon metabolism of red blood cells [78]. Despite this demonstration of the 
significance of stoichiometric constraints, it was some time before the techniques of 
stoichiometric modeling were developed and gained wider acceptance. Between 1981 and 1994, 
stoichiometric modeling was given a formal mathematical foundation, and preliminary results 
established it as a valid modeling framework. After 1994, continuing research led to a great 
expansion of stoichiometric models in application and scale, as well as attempts to standardize 
notation, annotation of data sources, and nomenclature. 
Separating kinetic and stoichiometric constraints 
Consideration of the dynamic mass balance of a simple network can help understand the 
separation of stoichiometric and kinetic constraints that gave rise to stoichiometric modeling. For 
the purposes of this example, consider a reaction network consisting of three metabolites and six 






A dynamic mass balance may be written for each component of a network by summing 
the fluxes into and out of each pool. For the simple network under consideration, this mass 




This system of equations can be rewritten in matrix form (Equation 2.a.9) 
 
Figure 2.a.2: A simple chemical network.  
A simple network consisting of metabolite pools A, B, and C, with internal fluxes 













Since there are more fluxes than metabolites, equation 2.b.10 is generally 
underdetermined – there may not be a unique solution. In other words, there may be more than 






As described in the “Kinetics of enzyme-mediated reactions” section of this chapter, the 
primary focus of metabolic modeling prior to 1992 was describing the time-varying kinetics of 
enzyme-mediated reactions, which are embodied in the vector v of equation 2.a.10.  
Although the development of kinetic models was a primary focus of efforts to simulate 
metabolism, it must be noted that this was not the only approach being explored. In a pioneering, 
but subsequently under-cited work, Howard M. Shapiro drew upon methods used to build 
economic models to formulate an input-output model of metabolism [79]. Shapiro’s work 
anticipated future developments through discussion of the use of mathematical programming. As 
discussed below, a similar approach to modeling metabolism would be re-invented two more 
times before becoming popularized as flux balance analysis of constraint-based stoichiometric 
 
Figure 2.a.3: Multiple valid fluxes.  
Since the system is underdetermined, there may be multiple valid fluxes through 
the network. Active fluxes are shown with bold red arrows. In both cases pictured,  is 0, 
and no metabolites accumulate within the cell. Note that there may also be other 






Theoretical foundations and mathematical advances 
By the 1980s emergence of computers enabled the development of approaches for large-
scale examination of constraints imposed by the stoichiometric matrix, S. An early theoretical 
foundation for stoichiometric modeling of metabolism was presented in 1981 [80]. In this work, 
Clark presents “a complete parametric description of all steady states on the closed domain of the 
general stoichiometric dynamical system.” Although this paper describes much of the theoretical 
basis of stoichiometric network analysis as it is currently practiced, it is a fairly abstract work, 
and it would be 13 years before some of its ideas were reformulated and popularized through 
application to large-scale modeling of biological networks. Using differential geometry, Clark 
provides a proof that the complete set of steady states for stoichiometric dynamical systems can 
be generated for a range of rate constants and concentrations. This theoretical approach provides 
“a general mathematical framework for investigating a chemical network’s static properties.” 
Among other observations, Clark notes that for all stoichiometric dynamical systems, there exists 
an equivalent system of equations for which all the steady state solutions exist in a “convex 
polyhedral cone” – a key description of the solution space that was later used extensively in a 
popular textbook on stoichiometric modeling [81]. Clark defines the stoichiometric matrix as a 
matrix whose elements are the stoichiometric coefficients of the reactions being examined, and a 
stoichiometric network as a class of matrices and functions that can be described by the general 









 (where  is the time derivative of concentrations, v is the stoichiometric matrix, u(X) is 
the “reaction velocity vector”, and k is the kinetic rate constant). Clark notes that these equations 
of motion determine a flow on the network, and that the steady-state flows exist in the left null 
space of the stoichiometric matrix. 
Additional advances to the field of stoichiometric modeling were achieved through 
examination of the mathematical implications of a full-rank stoichiometric matrix. In a paper that 
demonstrated the ability of stoichiometrically constrained models to describe various topologies 
of metabolic networks, Hofmeyr examined the steady-state modeling of four “metabolic 
structures” – loops, cycles, linear, and branched chains [82]. In this paper, Hofmeyer shows that 
conservation constraints and flux relationships can be deduced through analysis of the 
stoichiometric matrix. Although this approach requires a full-rank matrix, Hofmeyer limited the 
number of required measurements by lumping reactions to reduce degrees of freedom. 
Another key mathematical advance was achieved in 1988 when Reder generalized the 
summation and connectivity theorems from Metabolic Control Analysis, showing that they could 
be derived from invertible stoichiometric matrices [50]. In this paper, Reder argues that the 
structural properties alone can provide enough information about the system to describe key 
behaviors, demonstrating that from a dynamical systems perspective, the conservation 
relationships of stoichiometry represent a linear “first invariant” of the system. From the basis of 





order to apply the philosophy of metabolic control theory, which examines small variations from 
the steady state, finds the Jacobian matrix of an invertable stoichiometric matrix, and derives 
expressions for the familiar MCA concepts of elasticity, summation, and control. Thus, Reder 
gave formal mathematical justification for the statement that “much information can be derived 
from the study of the metabolic networks structure alone”. 
This mathematical sentiment was advanced again in 1988, when Clark (the same author 
who provided the foundational mathematical theory paper in 1981) described the use of 
stoichiometric analysis for examining qualitative features of dynamic systems, such as whether a 
steady state is globally attracting, or whether a chaotic or oscillatory domain is a global attractor 
[83]. As in the 1981 paper, Clark again describes the geometry of the solution space of the 
underdetermined system of equations which make up the model as a “convex polyhedral cone” 
which is created by linear combinations of the “significant overall reactions” that make up its 
edges. Through mathematical derivation, Clark shows that sensitivity analysis can determine 
which rate constants have the greatest effect on period and amplitude of chemical oscillators, and 
concludes that “stoichiometric analysis is an extremely powerful approach for learning about all 
aspects of the dynamics of nonlinear systems, in which stoichiometric constraints dominate the 
dynamics. The approach allows one to invalidate mechanisms using only qualitative information 
about steady-state concentrations and flows, without any information about rate constants.” 
Working with stoichiometric constraints 
The consideration of dynamic mass balances and subsequent partitioning of constraints 





and its associated equations. As methods for applying stoichiometrically constrained models 
were developed, two primary approaches were investigated for selecting unique solutions from 
the family of all possible solutions to the underdetermined equation 2.a.10. Some researchers 
sought to limit the degrees of freedom by lumping reactions or excising portions of the metabolic 
network from the model. Others sought to apply techniques of mathematical optimization. Both 
approaches contributed advances to the understanding of stoichiometric modeling. 
Solving the underdetermined problem 
An early application of lumping reactions to apply large-scale mass-balance constraints 
was to determine “the maximal allowable butanol (or any other product) yield”, which “is 
determined by both thermodynamic constraints and the biochemical topology” [84]. To model 
key yields, Papoutsakis derives a generalized “fermentation equation” that accounts for balances 
of ATP and reducing energy by exploring the linear dependencies of metabolic pathways. 
Paoutsakis suggests that the fermentation equation could be used for the development of 
“gateway sensors” which measure one parameter from which other key parameters can be 
deduced. 
Papoutsakis and Meyer then extend their earlier work on a “fermentation equation” to 
butanediol and mixed-acid fermentations [85]. As in their earlier paper, they derived a system of 
equations by lumping reactions into common algebraic expressions. After noting that the 
stoichiometrically-derived fermentation equations can be written in matrix form as Lu = v, the 
authors suggest that this equation can be used “to calculate the ‘best’ values of certain desired 





more experimental data values”. As a stoichiometrically-constrained model, they emphasize that 
their equations are independent of any particular kinetics of biomass growth or product 
formation.  
Rather than using the least-squares approach of Papoutsakis and Meyer, another approach 
was to reduce the degrees of freedom to a manageable number, and determining the value of 
remaining variables experimentally. This approach was applied to one of the first stoichiometric 
models of S. cerevisiae [86], which was based upon the stoichiometric growth equations for 
ethanol and glucose metabolism. The model used 3 different stoichiometric equations for the 
growth of S. cerevisiae: two describing oxidative pathways, and one describing reductive 
pathways. Based upon elemental biomass composition, the authors found that they needed to 
experimentally measure 1 component for each pathway in order to solve the system of equations. 
When they did so, the model had good agreement with experimental results. 
In addition to reducing the degrees of freedom in the stoichiometric matrix by lumping or 
removing equations and using least squares techniques, statistical methods were also employed 
to integrate stoichiometric model predictions with experimental measurements. In 1987, 
Papoutsakis and Meyer’s 1984-1985 work was applied to analyzing bioreactor data by Chemical 
Engineers at Drexel University [87]. Rather than using Papoutsakis and Meyer’s least squares 
approach, Tsai and Lee applied the statistical maximum likelihood method to the stoichiometric 
model to identify any gross measurement errors in bioreactor data collection. A key insight from 
their work was in a description of the solution space of possible metabolic states in a 





linear combination of all pathway reactions.” 
The most advanced stoichiometric model prior to the decisive demonstration of the utility 
of optimization-based methods described below was published in 1992 [88]. The authors 
evaluated the metabolic network of C. glutamicum with a stoichiometrically constrained mass 
balance modeling approach in which they solved the dynamic mass balance equation with a 
steady state assumption that intracellular metabolites do not accumulate, and by lumping 
equations into “singular groups” which accounted for all dependent reactions so that the 
stoichiometric matrix was full-rank. Thus, the authors developed a model of batch fermentation 
based upon stoichiometry rather than dynamics. 
The optimization approach 
While some researchers worked to reduce the dimensionality of the stoichiometric matrix 
so that they could find unique solutions to the model, others worked to apply other methods to 
solving an underdetermined system of equations. A biochemistry instructor named MR Watson 
presented software intended for teaching with metabolic maps in 1984. In this under-appreciated 
paper [89], Watson re-invented many aspects of Shapiro’s input-output modeling approach [79] 
and described his application of the Simplex algorithm [90] to find the best solution to the under-
determined system of equations represented by equation 2.a.10. This approach would be re-
invented again before becoming popularized as “Flux Balance Analysis” (FBA). 
Mathematically, the linear programming approach may be stated as follows: 





Subject to  2 
Where  represents a criterion, or “objective function” which is to be minimized or 
maximized, and  represent constraints which are applied to the model. The process 
of evaluating the best objective function for the application of linear optimization techniques is 
an ongoing area of research, though the objective of maximizing biomass has become generally 
accepted for determining the maximal growth rate for a cell in a given environment [91]. In his 
model, Watson suggests using “minimum free-energy dissipation” as the objective function. In 
considering his novel approach to metabolic modeling, Watson writes “there seems no reason in 
principle … to prevent the tailoring of the models to the species level if this is desired.” 
Following a procedure that is now regarded as the standard FBA approach, Watson’s approach 
involves listing reactions to build a stoichiometric matrix, and solving for the optimal flux 
through the network defined by the stoichiometric constraints with the Simplex method of linear 
programming. Notably, this approach uses matrix representation of stoichiometry; requires no 
net accumulation or depletion of intermediates; estimates relative contributions of competing 
pathways; and generates sequences of maps representing metabolic adaptations. Although 
Watson’s application of the simplex algorithm is equivalent to the modern approach of FBA, his 
application was limited in scope, and it took some time to formalize and popularize this 
approach. 
By 1986, Watson had expanded upon his earlier efforts to develop an instructional 
program to teach students about metabolic pathways [92]. Watson describes that it is common to 





balance between reactions that provide and consume energy. Realizing that this idea of balancing 
production and consumption need not be limited to energy, he extended the idea of calculating 
yields which demonstrated the balanced consumption and production of other metabolites. 
However, as manual calculation of such balances quickly becomes a laborious process, he 
suggests the application of computer algorithms. As he writes, “what initially seemed to be a 
balancing of inputs against outputs has broadened out into a modeling procedure” [92]. In 
Watson’s paper, he describes a program he has written for balancing 33 different metabolites. He 
conceives of metabolism as an optimization process in which an organism opens and closes 
pathways via regulation as it adjusts to its environment – a “continual search for new optimal 
states”. Citing [93], Watson describes metabolism as “like an economy, in which chemical 
resources are automatically disposed to the best effect.” Thus, perhaps considering the tools used 
by economists, Watson reasserts his suggestion that a suitable framework for an optimization and 
flow based model of cellular metabolism is linear programming. He describes how to construct 
such a model: 1) break the system up into a number of elementary functions which he calls 
“activities” – enzyme catalyzed reactions could be an example of an activity; 2) develop a 
statement of constraints; 3) select an objective function – as in his earlier paper, Watson again 
uses “minimal free energy loss” as his objective function; and 4) use the simplex algorithm to 
find an optimal solution. 
In addition to describing his method, Watson offers a brief discussion of the 
philosophical difference between his modeling approach and earlier kinetic models: he considers 





applied to problems such as modeling metabolism in two different ways: since they can rapidly 
perform computations, they can be applied to extending the “familiar calculations from chemical 
and enzyme kinetics to multi-enzyme systems”; alternatively, computers can be viewed as 
fundamentally new tools, which allow for new types of models. Watson considers his model to 
be fundamentally different, a model in which “transitions between configurations are governed 
by an objective function.” 
Applying optimization to metabolic pathways 
In 1986, the same year that Watson elaborated upon his optimization-based approach, 
Fell and Small, who had previously published work on Metabolic Control Analysis (see 
“Kinetics of multi-reaction systems”), applied Watson’s linear programming approach to 
examine stoichiometric constraints on fat synthesis in rat adipose tissue [94]. They describe 
Watson’s approach as one which “selects the particular solution that minimizes some cost … or 
maximizes some yield … from amongst the possible solutions that are consistent with the 
requirements of balance”. Using a metabolic simulation and control analysis software package 
called SCMP, they programmatically built the stoichiometry matrices to describe “over 50 
reactions and intermediates, even after condensation of some of the processes into a single 
overall reaction.” Significantly, Fell and Small note that with the application of linear 
programming, “it would also be possible to build in limitations on the flux allowed through 
individual steps to accommodate information on maximal enzyme activities.” Perhaps because of 
Fell’s significant previous work on enzyme control, this paper is more widely cited than 





The next publication of the optimization approach appeared in 1989, when in an effort to 
apply “the cybernetic perspective”, Majewski and Domach used the linear programming 
approach to describe the phenomenon of acetate overflow observed in the metabolism of the 
bacterium E. coli [95]. This model represented something of a hybrid approach, since they use a 
lumped network formulation similar to the approach used by Papoutsakis and Meyer [85], but 
solve it with linear programming using an objective of maximal ATP synthesis and constraints 
on electron transport and the capacity of the Krebs cycle. 
Applying optimization to cell-scale models 
Between 1992 and 1994, the Palsson group (then at the University of Michigan) 
published a series of papers firmly establishing the application of linear optimization to 
stoichiometrically constrained networks as a valuable modeling technique for considering 
metabolic fluxes, including analysis of fluxes in intermediary metabolism. These papers began 
by describing the mathematical framework of this approach, moved to development of models of 
hybridoma cells and the metabolism of E. coli, and cumulated in a 1994 review article describing 
the practical application of “Metabolic Flux Balancing”, which came to be known as flux 
balance analysis (FBA). 
These papers mark the first application of Watson’s approach of applying the simplex 
algorithm to find an optimal to a specific organism at a scale encompassing multiple portions of 
metabolism, with added emphasis on features of linear programming that Watson did not 
address, such as the concepts of shadow prices and reduced costs. In addition to finding 





prices to identify the relative value of cofactors and metabolic intermediates, thus finding which 
compounds cause the growth to be limited. The first paper [96] describes the mathematical basis 
for the approach. This paper develops the modern nomenclature of flux balance analysis, and 
was the first comprehensive assessment of the value and limitations of applying linear 
optimization to modeling metabolic networks. The authors begin by stating the dynamic mass 





Where S is the stoichiometric matrix, v(x) is the vector of reaction rates, and b is the 
vector of consumption and production rates and biosynthetic fluxes. This equation is equivalent 
to equation 2.a.10. The authors make the distinction between kinetic and static portions of this 
equation, stating that “a large body of literature is available discussing the applications of this 
model equation to different systems, and the emphasis is usually placed on the enzyme 
mechanisms, given v(X), and the parameters found therin.” In contrast, Savinell and Palsson 
chose to focus on the stoichiometric constraints embodied in S, seeking to “derive as much 
information as possible” with “no information on reaction rate expressions or kinetic 
parameters”.  
To justify the use of linear programming techniques, Savinell and Palsson comment upon 
the fact that the dynamic equations are underconstrained: “the stoichiometry of the metabolic 
network does not uniquely specify the fluxes through the cell’s pathways.” Thus, the challenge 





a cell’s behavior. Noting a benefit of linear programming, the authors discuss two auxiliary 
quantities that are computed by the simplex algorithm that may be interpreted as biologically 
meaningful concepts: the shadow prices and the reduced cost. Shadow prices quantify the 
sensitivity of the objective function with respect to each constraint, and reduced costs can be 
interpreted as the sensitivity of the objective function with respect to “non-basic fluxes”. 
The first cell-scale model: hybridoma 
Like previous modelers, Savinell and Palsson lumped some linear pathways of their 
reconstruction of the hybridoma metabolic network into single reactions in their 1992 work, 
though they did so to reduce computational overhead rather than to obviate the need for linear 
programming techniques. Cytoplasmic and mitochondrial pools were treated separately (that is, 
the model was compartmentalized), and the network consisted of 83 reactions and 42 
metabolites. The model included the metabolism of monoclonal antibody synthesis, nucleotide 
synthesis, phospholipid synthesis, polysaccharide synthesis, and energy metabolism. In this early 
application of linear programming, Savinell and Palsson evaluated three objective functions: 1) 
optimize energy efficiency by minimizing ATP production; 2) optimize use of substrates by 
minimizing total nutrient uptake; and 3) optimize redox metabolism by minimizing NADH 
production. While they found that “no single objective function gave results that completely 
describe the actual behavior of the hybridoma cell, certain objectives do give results 
characteristic of particular aspects of hybridoma cell behavior” [97]. Specifically, they found that 
optimizing energy efficiency predicted glutamine utilization well, as well as a preference for 





characteristics of hybridoma metabolism, but minimizing NADH production predicted the 
reduced yields, low oxygen uptake, high glutamine uptake, and high alanine production observed 
in hybridoma cells. Significantly, the authors noted that applying linear optimization allowed 
them to “predict how the deletion of a gene for a particular enzyme, or the inhibition of an 
enzyme, would affect the cell’s performance”. 
In the second paper [97], the authors examine the application of the linear optimization 
approach to the metabolism of the hybridoma cell in more detail, including comparison to 
experimental results obtained during exponential growth of a hybridoma culture. In this work, 
the authors used maximized growth rate as the objective function, and noted that the model 
predicted a higher maximal growth rate than the culture attained. They reasoned that the culture 
was limited by factors other than flux through the metabolic network, such as the rate at which 
DNA is replicated. However, they suggested that adding boundaries establishing the maximum 
and minimum allowable fluxes through various reactions would limit the maximum growth rate 
predicted by the model to better agree with measured rates. Another approach the authors 
pursued was to fix the growth rate at the experimentally measured value, and examine fluxes 
with a different objective function – in this case, the authors examined maximizing and 
minimizing ATP production. Using the ATP maximization function, the model predicted 
secretion of alanine at the measured growth rate, a result that had been observed in vitro. 
By examining the shadow prices for intermediates at different model conditions, the 
researchers were able to evaluate which nutrients were “most valuable” in those conditions, and 





glutamine uptake rates, glucose uptake rates, antibody production rates, and dissolved oxygen 
concentration. Together, these two papers firmly established linear optimization as a valuable 
tool for applying models based on stoichiometrically constrained networks. 
Extending FBA: E. coli 
The Palsson group built upon these early efforts at stoichiometric models with 
applications beyond the hybridoma cell. In a series of papers in 1993 and 1994, Varma and 
Palsson described their work building and evaluating a stoichiometrically constrained model of 
E. coli, which they evaluated using linear optimization techniques. In describing their approach, 
Varma and Palsson noted that stoichiometric analysis had the potential for both exploring the 
boundaries of achievable metabolic performance and “systematizing knowledge of metabolic 
systems” [98]. They noted that the linear optimization approach could provide “a rational basis 
for modifying cellular metabolism”, which “is the subject of the recently defined field of 
metabolic engineering” [99] since it would allow the determination of the optimal flux for a 
desired goal, “such as the commercial production of a metabolite” [100], thereby identifying the 
important reactions which could be subjected to genetic engineering to achieve that goal. Varma 
and Palsson noted three limitations to the stoichiometric approach to metabolic modeling at that 
time: 1) there was no consideration of regulation of enzymes; 2) there was no accounting for 
concentrations of metabolites within the cell; and 3) there was no incorporation of 
thermodynamic information in the form of rate expressions - time is not a variable in the model, 





Compiling a metabolic database 
 Since, as they noted at the time of their work, “no single source exists that compiles and 
documents the active metabolic pathways, with their associated stoichiometry, in E. coli” [98], 
they began by developing a “biochemical database” of comprehensive information about the 
biochemical pathways in the organism. They divided the reactions leading to synthesis of a 
bacterial cell into “fueling, biosynthetic, polymerization and assembly reactions”. Their first 
paper [98] examined the ability of the flux balance model to produce individual biosynthetic 
precursors. 
In this paper, they extracted information from the biochemical database to “formulate a 
stoichiometric model of the bacterial network of fueling reactions,” which they reduced to 53 
reactions and 30 metabolites by applying a set of rules to lump reactions. They used linear 
optimization to define the solution space of the under-determined system of equations 
represented by this mass balance system, and applied various objective functions to investigate 
the capabilities of this “reconstructed network” to maximally produce 12 biosynthetic precursors 
and three key cofactors.  
Biomass formation 
Following the approach described by Watson [92], Varma and Palsson next considered 
the balance of metabolite supply and demand. After demonstrating that a stoichiometrically 
constrainted network evaluated with linear optimization techniques could be used to model the 
production of biosynthetic precursors and cofactors, Varma and Palsson studied the ability of the 





requirements in their second paper [100]. Varma and Palsson defined an overall reaction to 





where M represents biosynthetic precursors and cofactors, dM represents the amount in 
which they are needed per unit of biomass, and vgro is the flux to biomass. For the weightings 
represtend by dM, Varma and Palsson used values previously established in studies on cellular 
composition. Although cellular biomass composition varies in response to changing 
environmental conditions (for example, membrane lipid composition alters in response to stress 
[101]), Varma and Palsson used a fixed biomass composition as the primary demand for 
metabolites. Varma and Palsson suggested that the optimal solution for the production of this 
defined “biomass” could be found with the linear optimization approach, thus establishing the 
use of a “biomass function” as a sink of metabolites, and the maximization of this flux as a 
possible objective function. By applying the optimization approach, Varma and Palsson 
computed a theoretical yield of biomass, then evaluated which factors constrained the growth 
through examination of shadow prices. Varma and Palsson observed that fluxes computed in the 
optimal solution for biomass yield differed from experimentally measured fluxes, and so 
performed an analysis to determine the sensitivity of the optimal solution to changes in fluxes, 
metabolic demands (ie, biomass composition), P/O ratio, and maintenance energy requirements. 
Their sensitivity analysis approach relied upon computing logarithmic sensitivity coefficients 





multi-reaction systems”). Varma and Palsson found that constraints on selected fluxes had little 
effect on the optimal biomass yield, nor did variation in requirements for any single precursor or 
cofactor, but varying the P/O ratio (a measurement of the number of high-energy phosphate 
bonds formed by the electron transfer system) and ATP maintenance requirements could have 
effects upon the maximum biomass yield. In comparing model performance to in vivo 
measurements, the authors report “remarkably close agreement”. 
Applying reconstructed metabolic models 
In three more papers, Varma and Palsson applied the E. coli model to the metabolic 
engineering problem of predicting biochemical production capabilities [99], conducted a series 
of experiments for in vivo validation of quantitative flux predictions from the in silico model 
[102], and expanded upon the parametric sensitivity analysis [103]. In the latter paper, they 
simulated aerobic chemostat, batch, and fed-batch experiments, and found that the model was 
sensitive to parameters describing metabolic capacity and relatively insensitive to parameters 
describing metabolic requirements for growth. They noted the good fortune that the parameters 
that have higher sensitivities are more readily measured in in vivo experimental settings. 
Maturation of the FBA approach 
After demonstrating the utility of flux-balance models, Varma and Palsson published a 
review article summarizing the FBA approach, which requires only knowledge of metabolic 
stoichiometry, including energy and metabolite balances [104]. Their article defended an 





reducing the dimensionality of the stoichiometric matrix so that it can be explicitly solved. With 
the publication of this review article, the application of metabolic flux balancing to problems in 
the field of metabolic engineering was firmly established. As will be described in the next 
section, subsequent work included expanding metabolic network reconstructions, developing 
networks for other organisms, applying reconstructed metabolic network models to a variety of 
basic science and engineering problems, and on standardizing data formats for sharing 
information and reproducing previous results. 
Genome-scale metabolic reconstructions 
The process of manually reconstructing metabolic networks by listing reactions and 
representing that information in a stoichiometric matrix continued and advanced, including 
efforts to model a variety of organisms, including S. cerevisiae. Early reconstructions of the 
yeast metabolic network included a 1995 reconstruction with 81 reactions and 88 metabolites 
[105], and a 1997 reconstruction with 37 reactions and 43 compounds [106]. However, metabolic 
reconstructions of E. coli, were the most extensive reconstructions throughout the 1990s. A 
significant 1997 E. coli reconstruction had 289 metabolites and 300 reactions [107]. 
Automating reconstruction 
In 1995, the first bacterial genome – that of Haemophilus influenza Rd - was sequenced 
[108], and biology transformed from “a data-poor to a data-rich environment” [109]. 
Stoichiometric reconstructions offered a tool to manage “the large volume of genome-scale data 





the emergence of genomic information almost immediately affected the process used to 
“reconstruct whole-cell metabolic networks for sequenced organisms” [111].  
The emergence of genomic information enabled a new protocol for developing 
reconstructed metabolic networks [112]. Instead of starting with biochemistry texts to compile a 
metabolic database, a draft reconstruction can now be programmatically constructed from 
genome annotation and public databases, then refined through an iterative process of editing, 
supplementing with auxiliary data sources, and testing the draft reconstruction (Figure 2.a.4). 
This time-intensive process of “curating” a draft reconstruction necessarily forces close 
examination of metabolic function, and serves both to structure existing biochemical knowledge 
and to highlight areas needing additional basic research. A metabolic function required for 
viability may not be included in early genomic annotation, but the functional necessity may be 
revealed through metabolic network reconstruction. Thus, metabolic reconstruction can provide 
hypothesized functions for unannotated open reading frames. Efforts to improve automated the 
reconstruction of metabolic networks are ongoing, including the recent development of method 
of “comparative model reconstruction”, in which a draft metabolic network is built from the 
reconstructed network of a related organism, using synteny between the species annotated 






Yeast genome-scale reconstructions 
The first metabolic reconstruction which applied the protocol of building a draft 
reconstruction from annotated genomic information was published in 1999, and constituted the 
 
Figure 2.a.4: Overview of metabolic reconstruction procedure.  
With the emergence of annotated genomic information and public databases, a 
Draft reconstruction can now be generated programmatically. Note that stages 2-4 are 
iterated until model predictions are similar to observed phenotypes or data sources are 





first “genome scale” metabolic reconstruction [114]. This model, of Haemophilus influenza Rd, 
included 488 reactions and 343 reactions and demonstrated that “the synthesis of in silico 
metabolic genotypes from annotated genome sequences is possible” [114]. The construction of 
the metabolic model directly contributed to the genomic research because FBA methods were 
used to analyze pathways and the reconstruction was “used to reconcile and curate the sequence 
annotation by identifying reactions whose function was not supported” and “to predict gene 
products that should be co-regulated and perhaps co-expressed” [115]. The model was applied to 
engineering problems by predicting necessary constituents of minimal media, and essential genes 
were identified through an in silico knockout procedure (ibid). 
With this demonstration of applying annotated genomic information as the basis for 
reconstructing metabolic networks, the method was applied to other organisms as the sequences 
became available, including E. coli strain MG1655 [116] and, in 2003, the first genome-scale 
reconstruction of a eukaryote, Saccharomyces cerevisiae [117]. Following a naming convention 
proposed in 2004 [118], this first genome-scale reconstruction of the yeast metabolic network 
came to be known as iFF708, since it is an in silico model developed by Forster and Famili, and 
includes reactions catalyzed by 708 gene products. iFF708 included 1175 reactions and 584 
metabolites, and accounted for ~16% of the characterized open reading frames of the yeast 
genome at that time. The authors of iFF708 constructed the model from genomic, biochemical, 
and physiological information sourced from pathway databases, biochemistry textbooks, the 
annotated genome, and relevant literature through a “nonautomated and iterative decision-





2.1) that defined a drain of metabolites from the system. FBA was applied to the model and used 
to predict growth phenotypes. FBA produced in silico results that “were consistent with observed 
phynotypic functions for ~70-80% of the conditions considered” [119]. Subsequently, a large-
scale evaluation of the effect of 599 single gene deletions was performed with this model [120]. 
In 87.8% of the cases, the in silico results were in agreement with published experimental 
observations. The authors suggested that reasons for false predictions of knockout results 
included errors in 1) model media composition; 2) substituted biomass components; 3) 
incomplete biochemical information; and 4) the lack of regulatory information in the model. 
As the first genome-scale reconstruction of a eukaryotic metabolic network, iFF708 has 
proven to be a very useful model, and continues to be applied to research questions (see [121], 
[122], and [123] for examples of recent applications of this model). It has also served as the basis 
for a series of updated and expanded genome-scale reconstructions of yeast metabolism (Table 
2.2). 
Though this document focuses on the application of reconstructed yeast metabolic 
networks, the process of developing reconstructed networks for other species has continued 
concurrently. By 2009, there were more than 50 reconstructions, including representative species 
from the domains Eukaryota, Bacteria, and Archaea [124]. Reconstructions of plant metabolic 
networks have been underrepresented, but recent reconstructions have been published for 





Table 2.1: iFF708 biomass composition. 
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Emerging yeast reconstructions 
As the authors of iFF708 noted, “the in silico model-building procedure at the genome 





scope of properties that can be computed widens” [119]. Subsequent researchers embraced this 
iterative approach, and efforts to expand the reconstruction of yeast metabolism led to the release 
of many new models as groups released reconstructions based on iFF708 (Table 2.2). The first 
model based on iFF708 was iND750 [118]. iND750 expanded some of the lumped reactions 
from iFF708 to account for individual reactions, thus accounting for more genes (750 genes, 
compared to iFF708’s 708). iND750 expanded iFF708’s compartmentalization from three 
compartments (cytosol, mitochondria, and extracellular space) to eight compartments by locating 
reactions in five additional compartments (peroxisome, nucleus, golgi apparatus, vacuole, and 
endoplasmic reticulum). The addition of these compartments required an increased inclusion of 
transport reactions – iND750 added 297 new transport reactions to those derived from iFF708. 
iND750 also added explicit association between genes and reactions in the form of a gene-
protein-reaction association table. However, despite the greater number of compartments, 
improved annotation, and increased number of metabolites and reactions, the lethality 
predictions for gene knockout simulations was lower than those of iFF708 (iND750 reported 
82.6% agreement with large-scale knockout studies, and iFF708 reported 87.8% agreement 
[120]). 
In an effort to improve the agreement, and to apply FBA to questions of gene duplication 
function, Kuepfer et al. revised iFF708 to produce another model, iLL672 [133]. iLL672 
improved the ability to predict viability of single knockouts with FBA to “95%-98%” through a 
combination of reformulating biomass composition, removing 110 “dead-end metabolites” which 





on new biochemical knowledge to connect 33 other metabolites. Along with other modifications, 
the improved biomass definition of iLL762 was incorporated to iND750 to form an updated 
model, iMM904 [134]. In revising iND750 to create iMM904, the authors also revisited gene-
protein-reaction associations, updated reactions with information based upon new biochemical 
discoveries, and expanded lipid, transport, and carbohydrate subsystems. 
From this proliferation of yeast metabolic reconstructions, a group of 34 researchers 
worked to build a common, “consensus” network reconstruction, which came to be Yeastnet 
version 1.0 [135]. The Yeastnet reconstruction combined iMM904 and iLL672, integrating them 
with common metabolite names and reaction description nomenclature. To avoid ambiguous 
metabolite names, a significant effort was expended to annotate molecules in the model with 
references to persistent databases and other external resources. As the goal of the Yeastnet 
reconstruction was to provide a common inventory of metabolites and network structure as a 
shared resource, it did not include a biomass function, leaving the biomass definition to 
researchers who hoped to evaluate the Yeastnet reconstruction with FBA. Yeastnet v1 was 
limited by the network reconstructions that it was based upon. Since neither iMM904 nor iLL672 
included comprehensive descriptions of lipid pathways, Yeastnet did not either. 
In an attempt to correct this deficiency, another metabolic reconstruction was created as a 
“scaffold to query lipid metabolism. This model, based upon iFF708, was called iIN800 [136]. 
Like the iLL672 reconstruction, iIN800 included a refined biomass function in addition to its 
greatly expanded description of lipid pathways, particularly the biosynthesis and elongation of 





differentiate between very long-chain fatty acid moieties (see Chapter 3). iIN800 also expanded 
coverage of reactions involving esterification of sterols, degradation of lipids. iIN800 included 
17.2% of the characterized open reading frames in the yeast genome at the time of its 
publication, and was the most comprehensive reconstruction at that time. 
The updates of iIN800 were integrated to the Yeastnet model to create Yestnet version 
2.0 [137]. Yeastnet has continued to be updated, and the current release of this consensus 
reconstruction is Yeastnet version 4.02 [138]. Modifications that I have suggested as a result of 
validation of the Yeastnet version 3.0 reconstruction of sphingolipid metabolism will be 
integrated into an upcoming release, with the addition of 136 new reactions (the results of the 
validation work are discussed in Section 4, “Preliminary results”). The Yeastnet reconstruction 
of lipid metabolism has not yet been fully validated, but with the recent documentation of 120 





Table 2.2: Reconstructed yeast metabolic networks.  
Following the first genome-scale reconstruction, iFF708, researchers embraced an 
iterative process of updating models based upon previous reconstructions, a process which led to 
the formation of many models. These models were re-integrated to form the Yeastnet model, 











- 81 88   1   [105] 
- 99 98       [140] 
- 37 43   3   [106] 
-           [141] 
- 64 67       [142] 
iFF708 1175 733 708 3   [119] 
iND750 1489 646 750 8 iFF708 [118] 
iLL672 1038 636 672 2 iFF708 [133] 
iMH805/775 1489 646 805 8 iND750 [143] 
iJH732 1152 935 732 2 iND750 [144] 
iIN800 1446 1013 800   iFF708 [136] 
iMM904 1412 1228 904 8 iND750 [134] 
Yeastnet 1857 2153 832 15 iLL672 
iMM904 
[135] 
Yeastnet 2.0 2576 2491   16 Yeastnet 
iIN800 
 
Yeastnet 3.0 2830 3057   16 Yeastnet 
2.0 
 
Yeastnet 4.0 2342 2657   16 Yeastnet 
3.0 
 
iAZ900 1597 1398 900 8 iMM904 [145] 














Applications of yeast metabolic models to metabolic engineering 
To date, the majority of papers relating to stoichometrically constrained models of yeast 
metabolism have provided commentary, model development, or other theoretical approaches. 
Despite the proliferation of yeast models and review papers discussing their development, there 
have been comparatively few reports of successful efforts to apply such models to in vivo 
metabolic engineering efforts. These efforts include: an effort to manipulate redox metabolism to 
increase ethanol yield [147], development of a gene-deletion strategy to manipulate C1 
metabolism [148], and an effort to improve the production of sesquiterpenes [149]. The relative 
paucity of successful attempts to apply these models to metabolic engineering has led some to 
question whether the underlying method of flux balance analysis can describe eukaryotic 
metabolism as well as it works for simpler organisms [145, 150]. However, since yeast model 
development is an ongoing effort, this question seems premature. 
Challenges encountered reconstructing the yeast metabolic network 
Flux balance analysis of stoichiometrically constrained metabolic models requires three 
components: accurate reconstruction of the biochemical reaction network of metabolism; a set of 
constraints on the reactions in the network; and an objective function to be maximized or 
minimized via linear programming. Each of these components has provided challenges to 
researchers working to improve computational models of yeast metabolism, and there remains 
opportunity to refine each component to improve model predictions and applicability. 
Work presented in this thesis documents that review of published literature is an effective 





(Chapters 3 and 4) and the constraints on that network (Chapter 5). The sensitivity of such 
models to reaction constraints has also been reported previously [151]. Additionally, many 
authors of reconstructions of yeast metabolic networks have commented upon the challenges and 
importance of accurately defining the biomass function. Two significant challenges in creating 
the biomass definition are 1) biomass composition changes in response to different 
environmental conditions (such as stress or nutrient deficiency), and 2) in some cases, organisms 
can substitute one chemical species for another to form a biomass composition. Since the 
components included in a biomass definition are considered a fixed requirement for growth in in 
silico simulations, each component must be produced by the metabolic network. There exist 
deletion mutants in vivo that are not able to produce an original biomass precursor, but the strains 
are viable because “other metabolites can replace these initial precursors or building blocks” 
[120], an effect which leads to incorrect viability predictions in silico. Examples of this problem 
include the substitution of phosphatidylethanolamine for phosphatidylcholine in lipid 
metabolism [120], and the use of fatty acids of different lengths as membrane constituents [136]. 
As the authors of iIN800 stated to justify their use of different biomass functions for different 
growth regimes (carbon or nitrogen limited), “more accurate biomass compositions lead to 
improved leathality predictions” (ibid).  
Authors have taken different approaches to dealing with the challenges of accurately 
reconstructing the biochemical network, appropriately applying constraints, and selecting an 
appropriate biomass definition for the objective function. The primary approach to developing 





every genome-scale stoichiometrically constrained yeast metabolic model to date is derived from 
iFF708. However, a variety of gap-filling and computational procedures have been applied to 
improve model lethality predictions by adding reactions from other sources [145, 152, 153]. 
Similarly, computational approaches have been applied to modify constraints [154]. The 
differing constituents of biomass in different growth conditions are addressed by modeling a 
specific period of the cell cycle – usually exponential growth – and using carefully defined 
experimental results as the basis for model validation. Model developers have also taken 
different approaches to dealing with biomass constituents which may be substituted. In some 
cases, “Available experimental data often report the average composition of these compounds” 
[112] and so the model represents average compounds, rather than all possible compounds. In 
other cases, the model is simplified and certain biomass components, such as chitin and 
glycoprotein, are neglected [117]. Similarly, sphingolipid metabolism was not completely 
elucidated, and was not included in iFF708 [117], though “ceramide” was considered as two 
moieties, using C24:0 and C26:0 very long-chain fatty acids, in iND750 [118]. When Yeastnet 
was constructed, lipid pathways were lumped, pending further elucidation of the pathway [135]. 
The representation of these pathways was expanded for iIN800, which expanded reactions in 
-oxidation, sphingolipid synthesis, ergosterol 
esterification, and lipid degradation [136]. These reactions were incorporated into Yeastnet to 
create version 2 [137]. However, no currently published reconstruction of the yeast metabolic 






Software tools for working with existing genome-scale reconstructed metabolic networks 
The increase in model complexity and size that accompanied the availability of genome-
scale data sets created new problems for researchers. Previously, smaller scale models published 
in peer-reviewed journals had been accompanied by instructions for recreating the work, which 
enabled easy review and application of published models. However, this approach suffered from 
a variety of drawbacks: models published in this fashion became unusable when simulation 
software was no longer supported, transferring models between different simulation or analysis 
tools was difficult, and subsequent users needed to obtain the same modeling environment as the 
original authors, making such models difficult to examine, test, and reuse [155]. The approach of 
publishing all the reactions described by a model in a journal paper became unworkable with the 
emergence of genome-scale reconstructed metabolic networks. These problems were addressed 
with the creation of syntax for encoding computational models of biochemical reaction networks, 
the Systems Biology Markup Language (SBML). 
Sharing models: SBML 
In Spring 2000, a group of researchers were invited to Caltech for a workshop entitled 
“Platforms for Systems Biology” [156]. The workshop was held to discuss the development of a 
software framework to facilitate sharing and evaluation of the computational models and 
approaches in the genomic era. A their first meeting in April 2000, the workshop participants 
decided to develop a simple computer language for representing and exchanging models between 
software tools. This language, which was to be based upon the eXtensible Markup Language 





SBML is a structured text-based, machine-readable format that can be used to describe models 
and exchange data between various modeling software applications. SBML has since become 
“the de facto standard format for representing formal, quantitative and qualitative models at the 
level of biochemical reactions and regulatory networks” [158].  
Using SBML: LibSBML 
The establishment of SBML standardized the data format for sharing biochemical 
reaction network models. With this standard, software could be developed to allow a wide 
variety of applications to translate between SBML and their native data structures. Since SBML 
is based on XML, software developers could write custom XML parsers to achieve this task; 
however, an application programming interface (API) would facilitate use of SBML data without 
requiring low-level parsing of the information. This function was published with the release of 
LibSBML, an API “for reading, writing, manipulating and validating content expressed in the 
SBML format” [159]. LibSBML is written in C and C++, and includes bindings for a variety of 
other languages, including MATLAB. This binding allows users to write programs that read a 
SBML document into a MATLAB data structure for further analysis or simulation. 
SBML with MATLAB: SBML and COBRA toolboxes 
The commercially available software package MATLAB (http://www.mathworks.com) 
provides a robust computer environment for mathematical analysis, including graphical output. 
Core MATLAB functionality may be extended with toolboxes, which consist of bundles of short 





Toolbox, and others). In an effort to better support the application of MATLAB to models 
published with SBML, researchers who had been involved in the development of LibSBML 
released the SBML Toolbox [160]. The SBML Toolbox was designed to provide the ability to 
read SBML files to a MATLAB data structure called MATLAB_SBML (Figure 2.a.5) and to 
write SBML files from that data structure. The SBML Toolbox is intended to serve as “a 
facilitator for the development of other functions and toolboxes” [160], and so only limited 






The SBML Toolbox enables programmatic manipulation and analysis of reconstructed 
metabolic networks in MATLAB. However, to conduct FBA, the list of reactions and species in 
the MATLAB_SBML data structure must be converted to the stoichiometric matrix and 
mathematical formulation of constraints required for the linear programming approach. Programs 
 
Figure 2.a.5: The MATLAB_SBML data structure. 
The MATLAB-SBML structure is a native MATLAB structure, created by 





to conduct this translation, along with a variety of analysis tools, were released as the COBRA 
Toolbox [161]. The acronym COBRA is derived from a description of the toolbox’s purpose: 
COnstraint Based Reconstruction and Analysis. The COBRA Toolbox includes a variety of 
functions, including readcbmodel.m. readcbmodel.m uses the SBML Toolbox to read a SBML 
model, and translates it to a structure containing the S matrix, constraints and objectives for 
linear programming, and other information (Figure 2.a.6). 
 
The COBRA Toolbox also includes code for adding and removing reactions from a 
reconstructed metabolic network, printing reaction formulas, analyzing network robustness, 
conducting gene deletion simulations, and other functions. The COBRA Toolbox supports the 
 
Figure 2.a.6: The COBRA toolbox data structure. 
The COBRA structure is a MATLAB data structure translated from the 





use of different linear programming solvers for conducting FBA and dynamic FBA, which is 
used to simulate batch growth. Supported solvers include the GNU Linear Programming Kit 
(GLPK) [162], a free and open-source program for “solving large-scale linear programming 
(LP), mixed integer programming (MIP), and other related problems” [162]. 
Software dependencies 
In summary, conducting FBA on publicly available reconstructed metabolic networks 






A challenge arises because each of these software components (MATLAB, the SBML 
standard, LibSBML, the SBML Toolbox, GLPK, and the COBRA Toolbox) are maintained by 
different groups, and are thus updated at different times. As different versions are released, care 
 
Figure 2.a.7: Software required for FBA with MATLAB. 
The COBRA Toolbox uses functionality of the SBML Toolbox and the 
MATLAB interface to the GLPK linear programming solver (GLPKmex). In turn, 
GLPKmex depends upon GLPK, and the SBML Toolbox uses LibSBML to translate the 





must be taken to ensure interoperability of the software components. 
Summary 
Industrial biofuel production would benefit from yeast strains that could more rapidly 
produce ethanol in high concentrations. Rational design of such strains through a genetic 
engineering approach benefits from the synthesis of biological knowledge into computational 
tools that can be applied for hypothesis generation, analysis of optimal genetic intervention, and 
to predict strain performance and media requirements. Knowledge of the biology of the 
fermentative yeast Saccharomyces cerevisiae and computer modeling techniques have now 
advanced sufficiently to merit the proposed investigation of applying rational design approaches 
devised and tested through the use of FBA to the improvement of ethanol stress tolerance of S. 
cerevisiae. 
In vivo investigations of Saccharomyces cerevisiae’s response to ethanol stress have 
come to focus on the dynamic process by which the organism remodels its plasma membrane. 
Early observations that the ratio of saturated and unsaturated fatty acids in the membrane have 
been refined to focus on the changing chemical species of phospholipid and other membrane 
constituents. PI has been identified as a key species related to ethanol tolerance, and the 
precursor inositol has been found to enhance ethanol tolerance of yeast when added to the 
medium exogenously or via biosynthesis stimulated through the deletion of the OPI1 gene, 
which creates strains with the Opi
-
 phenotype. However, screens of deletion libraries have found 
that the Opi
-
 phenotype is also the result of a variety of other genetic interventions. Any of these 





OPI1 - but the effects or these interventions on factors such as growth rate and ethanol 
productivity have not been well documented. Additionally, the overproduction of other 
membrane constituents, such as complex sphingolipids, and other compounds such as trehalose, 
glycerol, and ergosterol may further increase ethanol tolerance.  
Systems-level computational models are now available which can be used to evaluate the 
consequences of redirecting metabolic flux upon growth rate and ethanol productivity. These 
models have arisen following a century of attempts to understand and model metabolism, 
beginning with early efforts at characterizing the kinetics of individual enzymes. Attempts to 
model multi-enzyme systems gave rise to questions of metabolic control that led to a paradigm 
shift away from the reductionist approaches of enzymology to a systems-level approach to 
modeling metabolism. This approach incorporated modeling techniques from fields such as 
sensitivity analysis and parameter estimation, control theory, and cybernetics. By the 1980s, the 
explosion of data available in the post-genome age, enabled whole-cell (or “genome-scale”) 
reconstruction of metabolic networks, which could be analyzed with a variety of approaches, 
including FBA. FBA is an optimization-based technique for analysis of metabolic fluxes arising 
from stoichiometric constraints on the reaction network, as well as other constraints which may 
be imposed upon the system. A significant benefit of applying FBA to reconstructed metabolic 
networks is that it is a modeling approach which can provide results without detailed kinetic data 
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CHAPTER 3 – EVALUATING SPHINGOLIPID BIOCHEMISTRY IN THE CONSENSUS 





Reconstructed metabolic networks are the basis for genome scale models of cellular 
metabolism. Such models have demonstrated good predictive accuracy when analyzed with the 
optimization-based approach of flux balance analysis, so are of particular interest for informing 
the rational design of metabolic engineering strategies for industrial biotechnology applications. 
As a preliminary step towards applying a metabolic model of the industrially important 
yeast Saccharomyces cerevisiae, we validated the underlying reconstruction of yeast metabolism 
in the Yeast Consensus Reconstruction by examining the model’s representation of yeast 
sphingolipid metabolism. Sphingolipids, which comprise 30% of the plasma membrane lipids in 
yeast, incorporate very long chain fatty acids of lengths up to C-26. Such long-chain 
hydrocarbons are of particular interest for the production of liquid transportation fuels. 
We began with literature review and consultation with experts in yeast sphingolipid 
metabolism to compile a list a list of 243 reactions associated with yeast sphingolipid 
metabolism. We found that the Yeast Reconstruction contains only 41 reactions in this pathway, 
and that the reconstruction includes inaccuracies. 
This documentation of the incomplete reconstruction of sphingolipid metabolism in the 
Yeast Consensus Metabolic Reconstruction demonstrates opportunity for improving 
computational reconstruction of established biochemical knowledge. The extent of information 
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missing from the Yeast Reconstruction suggests that incorporating knowledge from the primary 
literature is an underemphasized tool for refining genome scale metabolic models. Our expert-
knowledge driven and pathway-centric approach to reconstruction curation provides a rational 




Application of constraint-based analysis and simulation methods to computational 
models derived from reconstructed metabolic networks[1] provides a theoretical framework that 
has shown great potential for facilitating rational metabolic engineering.[2, 3] Successful 
application of such methods for strain engineering requires both that the metabolic network 
model is capable of accurate predictions of phenotypes resulting from genetic modifications and 
that the biochemical network reconstruction, the structured knowledge base from which a 
metabolic model is derived,[4] contains detail of sufficient scope and accuracy to describe the 
metabolic process of interest. Although algorithms have been developed for adding reactions to 
metabolic models in order to improve their ability to predict gene essentiality[5–7], evaluation of 
the details, scope, and biochemical accuracy of a metabolic reconstruction requires careful 
manual curation of the reconstructed metabolic network relying upon relevant literature. 
Motivated by increasing interest in the microbial production of long-chain aliphatic 
hydrocarbons for advanced cellulosic biofuels, we undertook an evaluation of the recent update 
to the consensus metabolic reconstruction of the yeast Saccharomyces cerevisiae[8] (“Yeast 
v4.05”), with particular focus on the biosynthesis of complex sphingolipids.  Sphingolipids 
comprise about 7-8% of the plasma membrane mass, and 30% of the plasma membrane lipids in 
Saccharomyces cerevisiae, though the exact lipid composition is dependent upon environmental 
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conditions.[9] Accurate and complete computational reconstruction of sphingolipid metabolism 
is a worthwhile goal because sphingolipids incorporate industrially-useful very long chain fatty 
acids (VLCFAs), [10] and also because the fluxes through reactions of the sphingolipid 
biosynthetic pathway are a focus of active research. Yeast mutants have been observed which 
appear to prioritize inositol flux to the biosynthesis of sphingolipids at the expense of 
phosphatidylinositol (PI), an observation which links sphingolipid biosynthesis with the 
metabolism of storage lipids, phospholipids, and sterols.[11] Sphingolipids play important roles 
in signalling and responding to environmental stress (including heat, osmotic, and low-pH 
stresses),[9, 12, 13] and thus are key players in the dynamic process by which yeast cells 
restructure their plasma membrane in response to effects such as ethanol stress.[14] Metabolic 
precursors of complex sphingolipids have been implicated in both cell growth arrest, and cellular 
proliferation and survival, giving rise to the concept of a “sphingolipid rheostat” which plays an 
important role in determining whether cells survive or die.[15] Compounds involved in 
sphingolipid metabolism have been found to affect yeast metabolism through signal cascades 
resulting in transcriptional regulatory events,[16] but the mechanisms influencing flux through 
sphingolipid pathways are not well understood. Significantly, recent research provides evidence 
that sphingolipid synthesis is at least partially regulated through substrate availability due to 
changes in PI turnover, rather than solely through transcriptional regulation.[17] 
Computational models are an important tool in efforts to understand and manipulate 
sphingolipid metabolism. Dynamic models have been successfully applied to investigate 
sphingolipid regulation,[18] and a small-scale stoichiometrically constrained model has been 
developed to suggest possible targets for antifungal drugs.[19] In this work, we set out to 
examine how well sphingolipid metabolism has been incorporated in a previously published 
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genome-scale model of yeast metabolism. 
Though there are “a large array of theoretical lipid species” in S. cerevisiae,[20] we chose 
to limit our evaluation to the most abundant sphingolipids produced by wild-type S. cerevisiae  
in rich media under normal laboratory conditions - those consisting of a C-18 sphingoid base 
amide-linked to C-24 or C-26 VLCFAs.[21] Since the sphingoid base may be hydroxylated to 
form phytosphingosine and the VLCFA may include 0, 1, or 2 hydroxyl groups,[22] our list of 
reactions included the hydroxylation reactions and substrates required to form the various 
hydroxylation permutations, called ceramide -1, -2’, -2, -3, and -4, with the corresponding 
downstream complex sphingolipids of the –A, -B’, -B, -C, and –D series (Figure 3.1). 
 
 The biosynthetic pathway for complex sphingolipids has been the subject of recent 
Figure 3.1: Yeast complex sphingolipids 
Yeast complex sphingolipids of the –A, -B, -B’, -C, or –D families are derivatives 
of ceramides -1, -2, -2’, -3, and -4, which are distinguished by hydroxylation at the sites 
labeled I, II, and III [22]. Yeast complex sphingolipids include inositol 
phosphorylceramides (IPC), mannose inositol phosphoceramides (MIPC), and inositol 
phosphomannosylinositol phosphoceramides (M(IP)2C). Though the specific location of 
site III is not settled in the literature, we chose to use that indicated in [10]. 
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review articles.[10, 23] Following the example of these articles, the scope of our validation effort 
begins with the condensation of palmitoyl-CoA with serine, and ends with the breakdown of 
complex sphingolipids by Isc1p. Since they are shared with other portions of lipid metabolism, 
the reactions of the fatty acid elongation cycle are outside the scope of this evaluation. 
Following a review of the literature and online resources, we generated a list of 243 
reactions and 23 genes involved in the biosynthesis and catabolism of complex sphingolipids in 
yeast. This list of reactions, with references to supporting literature, is available in Appendix 1 as 
Supplementary Table 3.1. We found that Yeast v4.05 includes only 41 reactions involved in 
sphingolipid metabolism (Appendix 1, Supplementary Table 3.2), a reconstruction that differs 
from the network documented in the literature. This observation supports the conclusion that 
even “well curated metabolic reconstructions” [24] benefit from manual review, particularly in 
important metabolic pathways falling outside central carbon metabolism. Continued curation, 
validation, and refinement of reconstructions remains necessary to yield models that are better 
for informing metabolic engineering strategies. From our detailed notes of the differences 
between the biochemical literature and the Yeast consensus reconstruction, we have generated 
suggested changes to the Yeast Reconstruction, which have been submitted to the model’s 
curators to improve this community resource. 
 
Materials and Methods: 
We examined the reconstruction of sphingolipid metabolism in Yeast v4.05[8] by 
comparing reactions and gene annotation included in the model with information in relevant 
biochemical literature. The list of 243 reactions generated from our literature review, with 
references to supporting literature, is available in Appendix 1 as Supplementary Table 3.1. We 
began by listing 23 genes associated with sphingolipid metabolism (excluding the fatty acid 
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elongation cycle) in a recent review article[10] (Appendix 1 Supplementary Table 3.2), along 
with the loci of these genes, as listed in the Saccharomyces Genome Database (SGD)[25]. After 
reviewing the description of these gene functions in the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) database,[26] SGD, the Universal Protein Resource Knowledge Base 
(UniProtKB),[27] and the MetaCyc and BioCyc databases,[28] we conducted a more detailed 
review of the primary literature to generate a list of biochemical reactions that we could compare 
to the reactions included in Yeast v4.05. Since there is wide variation in the nomenclature used 
to describe chemical intermediates and products in sphingolipid metabolism, we relied upon the 
Nature Lipidomics Gateway (LIPID MAPS)[29] and the Chemical Entities of Biological Interest 
(ChEBI)[30] databases to resolve different compound names. In cases where nomenclature 
varied between primary sources but the compounds of interest were not included in LIPID 
MAPS or ChEBI, we chose the nomenclature that was most frequently used in the literature we 
reviewed. 
We downloaded the SBML[31] distribution of Yeast v4.05[8] from the sourceforge code 
repository[32] and imported the model to MATLAB® version 2010a (MathWorks, Natick, MA), 
on a desktop PC running Windows XP (Microsoft, Redmond WA) using the libSBML[33] 
interface of the “readcbmodel” function of version 2.0 of the COBRA Toolbox.[34] 
Genes are associated with reactions in Yeast v4.05 through reaction annotations 
indicating the open reading frame locus, which corresponds to the gene which codes for the 
protein catalyzing the reaction. We confirmed that none of the genes we selected from the 
literature were included in the list of “poorly characterized genes” distributed as supplemental 
data to the paper describing the Yeast metabolic model.[8] Following confirmation, COBRA 
toolbox functions and our own MATLAB® scripts were used to retrieve information for each 
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reaction in the Yeast model which is annotated with a gene that was identified as relating to 
sphingolipid metabolism. Model information – including reaction substrates, products, 
directionality, compartmentalization, and gene association – was compared to the reaction list 
that had been generated from the literature review. 
 
Results:  
We found that Yeast v4.05 contains 17% of the biochemical and transport reactions 
relating to sphingolipid metabolism and incorporates 87% of the genes identified from our 
review of relevant biochemical literature (Figure 3.2).  
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The Yeast v4.05 reconstruction of sphingolipid metabolism differs from reactions 
described in the literature (Appendix 1 Supplementary Table 3.1), primarily in differentiation 
between ceramide and sphingolipid species. The differences between our literature-based 
reconstruction and the Yeast v4.05 reconstruction are summarized in Table 3.1. 
 
Figure 3.2: Sphingolipid reaction coverage of Yeast v4.05 
Literature review generated a list of 243 reactions involved in yeast sphingolipid 
metabolism, including hypothetical intercompartmental transport reactions necessary for 
modeling. Yeast v4.05 contains 41 reactions in the sphingolipid pathway. Of these 41 




Our review of literature found that the products of 23 genes involved in the yeast 
sphingolipid metabolic pathway (Appendix 1 Supplementary Table 3.3) catalyze 118 reactions. 
This list of reactions was supplemented with an additional 125 hypothetical intercompartmental 
transport reactions which were necessary for modeling purposes. These hypothetical reactions 
enable flux balance analysis of compartmentalized metabolic network models, even though the 
mechanism of such intercompartmental transport may be unknown. The list of reactions is 
included with references in Appendix 1 as Supplementary Table 3.1. 
We found that Yeast v4.05 includes 41 reactions either involved in sphingolipid 






Reactions 243 41 
Unique Chemical Species 747 138 
Complex Sphingolipids 30 4 
Genes 23 20 
Orphan subnetworks 0 1 
 
Table 3.1: Literature-based reconstruction of sphingolipid metabolism differs 
from the Yeast v4.05 reconstruction 
Our literature-based reconstruction of sphingolipid metabolism includes more 
reactions, chemical species, complex sphingolipids, and genes than the Yeast 
reconstruction. Additionally, it does not include an orphan subnetwork involving the 
generic species “inositol phosphosphingolipid” which is included in the Yeast 
reconstruction. 
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sphingolipid metabolism (Appendix 1 Supplementary Table 3.2). This sum includes 5 
hypothetical intercompartmental transport reactions needed for modeling. Yeast v4.05 does not 
contain reactions annotated with three of the 23 genes associated with sphingolipid metabolism: 
TSC3, LIP1, and CSH1 (open reading frames YBR058C-A, YMR298W, and YBR161W, 
respectively) (Appendix 1 Supplementary Table 3.3).  
The Yeast v4.05 network (a network diagram is available in Appendix 1 as Supplemental 
Figure 3.1) includes incomplete and inconsistent differentiation between ceramide and 
sphingolipid species which vary by hydroxylation[22] or length of the VLCFA moiety.[20] 
Though Yeast v4.05 partially differentiates ceramides by hydroxylation through inclusion of 
ceramides-1, -2, -2’, and -3, and includes ceramides with both C-24 and C-26 VLCFAs, it has 
less complete differentiation of the inositol phosphoceramides (IPC) (Yeast v4.05 only contains 
IPC-B, and IPC-C), and does not differentiate between differing VLCFAs for any of the complex 
sphingolipids. Further, Yeast v4.05 does not differentiate among the mannose inositol 
phosphoceramides (MIPC) or the inositol phosphomannosylinositol phosphoceramides 
(M(IP)2C). Ceramide-4 and the derivative complex sphingolipids of the –D family are missing 
from this model, and the model incorrectly includes reactions to produce IPC-B from ceramide-
2’ instead of ceramide-2. 
If the hydroxylation and VLCFA length of ceramide and ceramide species was 
intentionally simplified in Yeast v4.05 for modeling purposes, it was done so inconsistently. 
However, the increased model complexity that would be added due to consistent differentiation 
of ceramide and sphingolipid species is justified because the differentiation has been observed in 
vivo following disruption of genes which are included in Yeast v4.05, such as SCS7[20] and 
CSG1/2.[35] Varying hydroxylation has been shown to affect membrane properties[36], and 
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metabolic enzymes such as CSG1 have been shown to have different affinities for sphingolipids 
of different families[35]. 
Since Yeast v4.05 contains more ceramides than sphingolipids, the reactions responsible 
for the synthesis of complex sphingolipids are lumped together. Though there are two ceramide-
2’ species which differ by VLCFAs, Yeast 4.05 includes reactions (reaction indexes r_0621 or 
r_0622) to convert them both to a single IPC species, incorrectly called IPC-B (metabolite index 
s_0828) instead of IPC-B’. Yeast v4.05 does not include a reaction to produce IPC-B from either 
ceramide-2 species, but does include reactions to produce a single IPC-C species from either of 
the two ceramide-3 species (reaction indexes r_0623 and r_0624). The model does not include 
IPC-A, -B’, or D. The model includes two reactions to produce a single MIPC species 
(metabolite index s_1013) from either IPC-B or IPC-C (reaction indexes r_0723 and r_0724). 
The single M(IP)2C species (metabolite index s_0825) in Yeast v4.05 is produced from this 
generic MIPC. Through this inconsistent lumping of the later stages of the biosynthetic pathway, 
biologically meaningful distinctions are lost, and inaccuracies are introduced to Yeast v4.05 
(such as the production of IPC-B from ceramide-2’). 
Although Yeast v4.05 includes complex sphingolipid degradation reactions correctly 
annotated with ISC1 [21], these reactions (reaction indexes r_0625 and r_0626) do not use any of 
the Yeast v4.05 IPC, MIPC, or M(IP)2C species as a substrate.  Instead, they use an additional 
generic species, “inositol phosphosphingolipid”, which exists in the mitochondrion and 
endoplasmic reticulum compartments of Yeast v4.05 (metabolite ids s_0827 and s_0826, 
respectively). Reactions r_0625 and r_0626 are the only reactions the “inositol 
phosphosphingolipid” metabolite participates in, and it is otherwise unconnected to the 
reconstructed network, forming an orphan subnetwork. Thus, Yeast v4.05 does not include any 
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effective pathway for the degradation of complex sphingolipids. 
The complex sphingolipid synthetic reactions in Yeast v4.05’s “Golgi apparatus” 
compartment are incorrectly modeled as reversible reactions. Thus, a practical consequence of 
the use of general species for IPC-B, IPC-C, MIPC, and M(IP)2C species is that Yeast v4.05 
includes an interconversion pathway for ceramides or sphingolipids with differing VLCFA 
lengths via the reactions catalyzed by Aur1p, the Csg2p /Sur1p complex, and Ipt1p. The 
biochemical details of such interconversion in yeast are poorly understood at this time,[37] but 
there is little evidence suggesting that these enzymes catalyze the reverse reactions included in 
Yeast v4.05 in vivo. 
A second consequence of the incomplete differentiation between ceramide and 
sphingolipid species in Yeast v4.05 is that the constraint based optimization problem solved in 
flux balance analysis does not yield a solution for maximizing biomass production under 
anaerobic conditions. Specifically, the model incorrectly includes only two paths to the required 
biomass component M(IP)2C, and both require oxygen as cofactors. One path in the Yeast v4.05 
model proceeds via the production of ceramide-2’ by hydroxylation of ceramide-1 (reaction 
indexes r_0287 or r_0289), and the other path proceeds via the production of ceramide-3 by 
hydroxylation of ceramide-2 (reaction indexes r_0294 or r_0295).  One way to circumvent this 
problem with Yeast v4.05 is to remove complex sphingolipids from the biomass definition. The 
model’s incorrect oxygen requirement for complex sphingolipid biosynthesis can also be 
corrected by expanding the biochemistry reflected in the yeast metabolic network reconstruction 
to include the reactions to synthesize the unhydroxylated complex sphingolipids derived from 
ceramide-1. However, neither approach is sufficient to enable flux balance analysis prediction of 
anaerobic growth with the model due to errors in the reconstruction which lay outside the scope 
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of this curation effort. 
To resolve differences between the sphingolipid pathway described in yeast biochemical 
literature and Yeast v4.05, we have generated suggested changes to the Yeast Reconstruction (a 
network diagram including our suggested changes is available in Appendix 1 as Supplemental 
Figure 3.2), and have submitted a list of proposed changes to the maintainers of the consensus 
reconstruction for inclusion in future versions of the Yeast model. The proposed changes 
include: 221 new reactions; 70 new chemical species; annotation changes for five reactions; the 
addition of three new genes; the modification of 19 existing reactions to improve cofactor or 
stoichiometric errors; 95 new intercompartmental transport reactions; and 62 new “IS A” 
reactions to create the generic species that are included in the biomass definition used for flux 
balance analysis of the Yeast model. 
Additionally, we have submitted corrections to other pathway or biochemical databases 
where we have noted omissions or errors. Thus, 63 new compounds were submitted to ChEBI; 
the UniProtKB/Swiss-Prot description of SCS7 function was updated; the Nature LipidMaps 
entry for ceramide-3 was corrected; and corrections were submitted to KEGG to assign yeast 
genes to reactions that were previously annotated only with Enzyme Commission numbers. 
Discussion:  
Through collaboration with subject area experts and reviewing biochemical literature, we 
have found that the Yeast Reconstruction does not accurately describe yeast sphingolipid 
metabolism. We have compiled a list of suggested changes to the reconstruction, which will 
enable the construction of genome scale metabolic models which better reconstruct this 
important portion of yeast lipid metabolism.  
Incorporation of the suggested changes will result in a yeast metabolic reconstruction that 
is more complete because of broader inclusion of yeast metabolic genes, more consistent in 
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differentiating between sphingolipid and ceramide species, and more biochemically accurate in 
its description of the biosynthesis and degradation of complex sphingolipids. Further, this 
curation effort will improve the predictive accuracy of the Consensus Model: expanding the 
number of complex sphingolipids from 4 to 30 enables more accurate biomass demand functions, 
and careful examination of the three additional genes to be added to the sphingolipid pathway 
refines the list of essential genes us as the basis for phenotype prediction metrics: TSC3 is an 
essential gene only at elevated temperatures,[38] deletion of CSH1 has been found to increase 
fitness in minimal media,[39] and LIP1 deletion has been found to be cause reduced growth 
rate[40] (though it was scored as essential in multiple large-scale knockout surveys[41, 42] 
which have been used as a basis for evaluating yeast metabolic models[43]). 
Though the process of curating the reconstruction will continue, these improvements to 
sphingolipid metabolism are an important step towards improving the computational 
reconstruction of yeast lipid metabolism, a portion of metabolism which has proved challenging 
to previous reconstructions.[43, 44, 8] Improving the reconstruction of sphingolipid metabolism 
is a prerequisite to applying computer models derived from the reconstruction to research 
questions such as the interplay between fluxes of PI and complex sphingolipids, the 
consequences of genetic engineering on lipid metabolism, and mechanisms of stress response. As 
stoichiometrically constrained models expand to address signalling and regulatory networks,[45] 
accurate reconstruction of sphingolipid metabolism will be necessary to model the signalling role 
of pathway intermediates. 
Our suggested refinements to the consensus reconstruction, though limited in scope to 
sphingolipid metabolism, demonstrate that examining known biochemistry, whether through 
manual literature review or collaboration with experts in yeast metabolism, remains a valuable 
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technique for improving the completeness and accuracy of the computational representation of 
the yeast molecular interaction network as the modeling community works to develop a “highly 
curated organism-specific knowledge base.”[46]  
The benefits of improving the reconstruction extend beyond efforts to apply yeast models 
for engineering applications. Recently developed computational approaches which enable high-
throughput generation of draft metabolic models depend upon a database of well-curated 
reactions for filling gaps in draft reconstructions.[47] The documented limitations of current 
databases,[48] as well as errors encountered in the present study, demonstrate that the databases 
currently used for gap filling may not be sufficient for complete and accurate high-throughput 
model building from draft metabolic reconstructions. 
The expansion of the reconstruction of yeast sphingolipid metabolism which would result 
if the suggested changes are incorporated in the Yeast Reconstruction creates new modeling 
opportunities, but also raises new challenges to existing model evaluation approaches, such as 
flux balance analysis. On one hand, researchers can begin to develop and test more detailed 
hypotheses about complex sphingolipid metabolism in yeast – research that has begun with 
smaller scope reconstructions[19] but has not been expanded to the genome scale. On the other 
hand, the biochemical constraints which determine factors such as the relative abundance of 
chemical species synthesized through parallel metabolic pathways (such as IPC-B and IPC-C) 
are currently unknown. Without imposing constraints (either on specific reactions or in defining 
the objective function), flux balance analysis using a biomass objective function would not be 
expected to correctly predict the mixture of complex ceramides that has been observed in wild-
type yeast of the S288C background.[20, 49] Expanding the biochemistry included in the Yeast 
Reconstruction would facilitate development of such modeling efforts, which is not currently 
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possible because the reconstruction does not differentiate among the great diversity of complex 
sphingolipids.[50] 
It has been suggested that “a draft model reconstruction followed by even a detailed 
manual curation may not be a sufficient strategy to bring a eukaryotic genome-scale model to the 
same quality level as a microbial one.”[51] However, the current work demonstrates that even 
after 8 years of effort by a variety of independent groups, the process of manual curation of the 
yeast biochemical network reconstruction is unfinished, and so a definitive answer to that 
question is not at hand. There remains a large and growing corpus of biochemical knowledge 
which should be added to the Yeast Reconstruction. Consequently, iterative manual curation 
remains an essential and unfinished community project for the computational reconstruction of 
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CHAPTER 4 - YEAST 5 – AN EXPANDED RECONSTRUCTION OF THE 




Background: Efforts to improve the computational reconstruction of the Saccharomyces 
cerevisiae biochemical reaction network and to refine the stoichiometrically constrained 
metabolic models that can be derived from such a reconstruction have continued since the first 
stoichiometrically constrained yeast genome scale metabolic model was published in 2003. 
Continuing this ongoing process, we have constructed an update to the Yeast Consensus 
Reconstruction, Yeast 5. The Yeast Consensus Reconstruction is a product of efforts to forge a 
community-based reconstruction emphasizing standards compliance and biochemical accuracy 
via evidence-based selection of reactions. It draws upon models published by a variety of 
independent research groups as well as information obtained from biochemical databases and 
primary literature.  
Results: Yeast 5 refines the biochemical reactions included in the reconstruction, 
particularly reactions involved in sphingolipid metabolism; updates gene-reaction annotations; 
and emphasizes the distinction between reconstruction and stoichiometrically constrained model. 
Although it was not a primary goal, this update also improves the accuracy of model prediction 
of viability and auxotrophy phenotypes and increases the number of epistatic interactions. This 
update maintains an emphasis on standards compliance, unambiguous metabolite naming, and 
computer-readable annotations available through a structured document format. Additionally, we 
have developed MATLAB scripts to evaluate the model’s predictive accuracy and to 
demonstrate basic model applications, such as simulating aerobic and anaerobic growth. These 
scripts, which provide an independent tool for evaluating the performance of various 
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stoichiometrically constrained yeast metabolic models using flux balance analysis, are included 
as Appendix 2. 
Conclusions: Yeast 5 expands and refines the computational reconstruction of yeast 
metabolism and improves the predictive accuracy of a stoichiometrically constrained yeast 
metabolic model. It differs from previous reconstructions and models by emphasizing the 
distinction between the yeast metabolic reconstruction and the stoichiometrically constrained 
model, and makes both available at http://yeast.sf.net/ as separate systems biology markup 
language (SBML) files. Through this separation, we intend to make the modeling process more 
accessible, explicit, transparent, and reproducible. 
 
Background 
Efforts to improve the computational reconstruction of the Saccharomyces cerevisiae 
biochemical reaction network and to refine the metabolic models that can be derived from such a 
reconstruction have continued since the first yeast genome scale metabolic model was published 
[1]. The distinction between reconstruction (termed GEnome scale Network REconstructions 
(GENREs) [2]) and derived models (termed GEnome scale Models (GEMs) [3]) remains 
important to differentiate between the established biochemical knowledge included in a GENRE 
and the modeling assumptions required for analysis or simulation with a GEM. A GENRE serves 
as a structured knowledge base of established biochemical facts, while a GEM is a model which 
supplements the established biochemical information with additional (potentially hypothetical) 
information to enable computational simulation and analysis. Examples of widely used yeast 
GENREs include the Kyoto Encylopedia of Genes and Genomes, KEGG [4]), and the Yeast 
Biochemical Pathway Database, YeastCyc [5]. The history of yeast GEMs has recently been 
reviewed [6]. 
Though a GEM may be considered finished when it is sufficient for a particular modeling 
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application, the effort to build a complete and accurate GENRE is ongoing as biochemical 
research continues (even information that is fundamental to the construction of a GENRE, such 
as genome annotation, is considered to be a working hypothesis and subject to ongoing revision 
[7]). Reflecting the ongoing process of yeast GEM and GENRE improvement [6], we have 
constructed an update to the Yeast Consensus Reconstruction [8]. The Yeast Consensus 
Reconstruction is a product of efforts to forge a community-based reconstruction emphasizing 
standards compliance and biochemical accuracy via evidence-based selection of reactions. It 
draws upon models published by a variety of independent research groups [1, 9–12], as well as 
information obtained from biochemical databases and primary literature. Thus, the Yeast 
Consensus Reconstruction serves as an example of the community-based approach which has 
given rise to the concept of a “reconstruction annotation jamboree” [13]. Though there remain 
many challenging problems to implementing and maintaining community-based science [14], the 
jamboree approach to network reconstruction and model building has also been successfully 
applied to build a consensus reconstruction and model of Salmonella Typhimurium LT2 [15].  
The Yeast Consensus Reconstruction has benefited from the continued involvement of 
the broader research community. Previous updates to the Yeast Consensus Reconstruction [16] 
have focused on filling gaps in the metabolic reconstruction to improve network connectivity in a 
graph-theoretical sense, expanding the reconstruction of portions of metabolism that had not 
been included in previous reconstructions, and enabling Flux Balance Analysis (FBA) [17] by 
adding the necessary (but hypothetical) transport reactions and sink reactions (such as the 
biomass reaction). These low-confidence reactions in the Yeast Consensus Reconstruction are 
annotated with use of specialized Systems Biology Ontology (SBO) terms [18], an approach 
designed to facilitate differentiation between the higher-confidence reactions which form the 
Yeast GENRE and the lower confidence reactions required to evaluate a GEM with FBA. 
Enabling FBA of the consensus reconstruction has resulted in increased interest in applying the 
model to guide bioengineering efforts [19, 20]. In turn, this increased interest has stimulated 
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community participation, which has highlighted opportunities for further improving the 
Consensus Yeast Reconstruction GENRE and the derived GEM. 
Therefore, we decided to undertake an update to the Yeast Consensus Reconstruction to 
refine the biochemical reactions included in the GENRE, particularly reactions involved in 
sphingolipid metabolism [20, 21]; to review gene-reaction annotation; to emphasize and clarify 
the distinction between GENRE and GEM; to facilitate application of the GEM for 
bioengineering applications; and to solicit and facilitate further collaboration among researchers 
who wish to further improve the yeast GENRE and GEM. Although it was not a primary goal, 
this update also improves the accuracy of GEM phenotype predictions due to the incorporation 
of reaction constraints from previous models and relevant literature. We endeavored to conduct 
this update while maintaining an emphasis on standards compliance, unambiguous metabolite 
naming, and computer-readable annotations available through a structured document format. The 
metabolites included in Yeast 5 are unambiguously annotated with their identifiers in the 
Chemical Entitites of Biological Interest (ChEBI) database [22], and reactions are annotated with 
the PubMed ID of primary literature evidence justifying the reaction’s inclusion in the 
reconstruction. 
We have incorporated the results of these efforts to the consensus reconstruction to 
produce Yeast 5. Yeast 5 expands and refines the yeast GENRE and improves the predictive 
accuracy of the yeast GEM. Further, it differs from previous reconstructions and models by 
emphasizing the distinction between the yeast GENRE and GEM, and makes both available as 
separate systems biology markup language (SBML) files [23]. Through this separation of 
GENRE and GEM, we intend to make the modeling process more explicit, transparent, and 
reproducible. Both files are available from YeastNet (http://yeast.sf.net/). In addition to the GEM 
and GENRE SBML files, we have developed MATLAB scripts to evaluate the model’s 
predictive accuracy and to demonstrate basic model applications, such as simulating aerobic and 
anaerobic metabolism with Yeast 5. These scripts, which provide an independent tool for 
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evaluating the performance of various yeast GEMs are included in Appendix 2. 
Results 
Improvements to facilitate community use and collaboration  
As a consensus reconstruction and model, Yeast 5 will depend upon community use and 
suggested modifications for future improvement. The Yeast 5 GENRE may serve as a resource 
for construction of new models, of both genome and smaller scale. Thus, in addition to the 
emphasis on standards compliance, the Yeast 5 SBML files include coding conventions to 
facilitate use by popular software. Recognizing that MATLAB is a commonly used platform for 
systems and computational biology [24], we include scripts demonstrating use of both the 
GENRE and GEM with the SBML Toolbox [25] and the COBRA Toolbox [26]. These 
MATLAB scripts, testYeastModel.m, modelToReconstruction.m, and fluxDistribution.m, are 
available in Appendix 2. Additionally, as discussed in Materials and Methods, Yeast 5 includes 
conventions for exchange reactions and boundary species which are used in the MATLAB-
compatible COBRA Toolbox, although such conventions are not currently included in SBML 
specifications [23].  
Yeast GENRE Changes 
The Yeast 5 GENRE is an evidence-driven biochemical knowledge-base. It does not 
include the low-confidence or hypothetical reactions and metabolites required to conduct FBA, 
nor does it include constraints on reaction reversibility which may be added in the course of 
model-building. Since it does not include compounds such as “biomass”, reactions such as 
“growth”, or hypothetical intercompartmental transport reactions, the Yeast 5 GENRE is more 
specific than Yeast 4, which did not differentiate between GENRE and GEM. It contains 1418 
metabolites which participate in 2110 reactions, catalyzed by 918 verified Saccharomyces 
cerevisiae genes. In comparison, Yeast 4 includes 1481 metabolites, 2030 reactions, and 924 
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genes. The Yeast 5 GENRE does not include genes annotated in the Saccharomyces Genome 
Database (SGD) as “dubious” or “uncharacterized”, while Yeast 4 includes 4 such genes 
(YFR055W, YML082W, YPL275W, and YPL276W). Yeast 4 included reactions annotated with 
29 open reading frames which are not included in the Yeast 5 GENRE. However, the Yeast 5 
GENRE includes 23 open reading frames which are not included in Yeast 4. The 29 open 
reading frames which are present in Yeast 4 but not Yeast 5 are: YAL014C, YAL030W, 
YAR042W, YCR073W-A, YDL019C, YDR313C, YDR331W, YDR468C, YEL011W, 
YEL013W, YER093C, YFR055W, YGR199W, YHR005C, YHR073W, YMR068W, 
YNL006W, YNR034W, YOL078W, YPL145C, YPL275W, YPL276W, YOR237W, YIL105C, 
YJL058C, YJR160C, YKL203C, YML082W, and YNL047C. These open reading frames were 
removed from reaction annotations because of inadequate literature evidence supporting the 
Yeast 4 annotation. The 23 open reading frames included in the Yeast 5 GENRE but not in Yeast 
4 are: YBR001C, YBR058C-A, YBR161W, YBR199W, YDR196C, YDR367W, YGR138C, 
YGR277C, YMR241W, YMR278W, YMR298W, YPL023C, YPL053C, YPL189W, YPR156C, 
YOR175C, YGL084C, YIL083C, YJL200C, YKL088W, YKL132C, YML056C, and YNL029C. 
Additional annotation information about these ORFs is provided in Appendix 2 as Supplemental 
Table 4.5 (ORFs present in Yeast 4 but not in Yeast 5) and Supplemental Table 4.6 (ORFs 
present in Yeast 5 but not in Yeast 4). 
In addition to being more specific, the Yeast 5 GENRE is also more complete than Yeast 
4. Sphingolipid metabolism has been acknowledged to be a poorly reconstructed portion of the 
yeast metabolic network since the first yeast GEM, iFF708 [1]. Yeast 5 incorporates suggested 
literature-referenced refinements to sphingolipid metabolism [20, 21]. Thus the Yeast 5 GENRE 
contains the most complete reconstruction to date of the broad suite of complex sphingolipids 
that has been observed in yeast [27].  
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Yeast GEM Changes 
The Yeast 5 GEM is a model, and thus includes biomass demand functions and low-
confidence reactions such as intercompartmental transport reactions which enhance network 
connectivity and enable FBA. It also includes reaction directionality constraints to improve the 
accuracy of model phenotype predictions and exchange reactions which allow model users to 
simulate a growth medium. The Yeast 5 GEM includes more reactions and metabolites than 
previously published yeast GEMs (Table 1), though it includes 6 fewer genes than Yeast 4. The 
Yeast 5 GEM includes reactions annotated with 918 different open reading frames, accounting 
for 18.5% of the 4949 verified open reading frames included in the Saccharomyces Genome 
Database [28] as of October 12, 2011. The Yeast 5 GEM has 326 more directionally constrained 
reactions than Yeast 4 (69% of all reactions in the Yeast 5 GEM are constrained, compared to 
55.6% in Yeast 4). The majority of these new constraints are applied to reactions involved in 
cofactor utilization or production, with a particular emphasis on reactions involving ATP/ADP. 
Reactions involving NAD(P)/H are constrained where literature evidence supports irreversible 
reactions in vivo. 
Since the Yeast GEM includes both general classes of compounds (e.g.“fatty acid”) and 
specific members of these classes (e.g. “octanoate”), we use non-reversible encapsulating 
reactions called “isa” reactions to provide pathways from specific to generic compounds (e.g., 
octanoate “isa” fatty acid). The use of “isa” reactions is discussed further in the Discussion 
section. To accommodate the more specific biochemistry included in the Yeast 5 GENRE, the 
Yeast 5 GEM includes 261 “isa” reactions, compared to 162 in Yeast 4. Additionally, the Yeast 
5 GEM includes 2 different lipid pseudoreactions, which create the “lipid” portion of biomass 
(details of the Yeast 5 GEM biomass definition are included in Appendix 2 as Supplemental 
Table 4.3). As described in the “simulating yeast growth” discussion, including two differing 
biomass definitions enables simulation of anaerobic yeast metabolism despite the incomplete 
reconstruction of yeast lipid biochemistry in the Yeast 5 GENRE.  
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Table 1: Comparison of yeast metabolic models 








   
  
  Number of metabolites 1655 1481 1228 1061 
  Number of reactions 2110 2030 1575 1266 
  Number of genes 918 924 904 750 
  Number of dubious genes
d
 0 4 17 17 
  Blocked reactions
e
 38% 26% 31% 41% 
  
 
   
  
Viability analysis 




 97% 95% 93% 96% 
  Specificity
g
 47% 44% 57% 43% 
  Positive predictive value
h
 86% 85% 89% 87% 
  Negative predictive value
i
 84% 73% 69% 77% 
  Geometric mean
j
 46% 42% 53% 41% 
  
 
   
  
Auxotrophy analysis 
   
  
  Auxotroph-inducing genes included
k
 70 73 73 69 
  Correct auxotroph predictions 73% 66% 69% 58% 
  Incorrectly predicted as viable in minimal media 24% 30% 27% 39% 
  Incorrectly predicted as inviable in supplemented media 3% 4% 4% 3% 
  
 





   
  
  Epistatic interations (% of pairwise genes) 16% - 15% 21% 
  Total number of epistatic interactions 65,730 - 63,176 57,808 
  Average Additional Interactions per additional gene
m
 196.46 - 34.63 - 
a




iND750: [9]  
d
dubious genes are ORFs annotated as "dubious" (809 ORFs) or "uncharacterized" (857 
ORFs) in SGD 
e
blocked reactions cannot carry flux 
f
True positive / (true positive + false negative) 
g
True negative / (true negative + false positive) 
h
True positive / (true positive + false positive) 
i
True negative / (true negative + false negative) 
j
see Kuepfer et al. 2005 for discussion of applying geometric mean 
k
see Appendix 2 Supplemental Tables 4.1 and 4.2 for list of essential genes and 
auxotroph-inducing genes 
l
At 50%x50% flux reductions. See Appendix 2 Supplemental Table 4.4 for other 
restriction levels. 
m




Yeast GEM Performance 
Though improving gene essentiality predictions was not a primary objective of updating 
Yeast 4, simulations using Yeast 5 have increased agreement with a list of essential genes and 
genes which cause auxotrophies; more realistic prediction of internal fluxes; and increased 
number of genetic interactions. Additionally, simulations with the Yeast 5 GEM predict 
auxotrophies resulting from gene deletions better than other recent yeast GEMs, and predict gene 
essentiality with accuracy comparable to other recent yeast GEMs (Table 1). 
Gene essentiality predictions 
Since the phenotype resulting from a gene mutation is dependent upon media and 
environmental conditions as well as changes to the metabolic network, the use of gene 
essentiality predictions as a metric for model evaluation requires careful definition of both 
simulation assumptions and of the data set used for comparison between simulation and 
observation. This is particularly important if such a metric is to be used for comparison of 
different GEMs. We document our approach to simulating gene essentiality in Materials and 
Methods, and in the testYeastmodel.m MATLAB script included in Appendix 2l.  
The Yeast 5 GEM includes reactions annotated with 918 genes. 144 of these genes are 
included in a list of essential genes we compiled from the Saccharomyces Genome Deletion 
project [29] and annotation included in Saccharomyces Genome Database [28] (Appendix 2 
Supplemental Tables 4.1 and 4.2). An additional 70 genes are included in a list of genes causing 
auxotrophies when deleted (the construction of these gene lists is described in Materials and 
Methods). The remaining 704 genes in the model are not on the compiled lists of essential or 
auxotroph-inducing genes, and are therefore considered. 
The results of single gene deletion simulations conducted via FBA of the Yeast 5 GEM 
using a simulated glucose-limited defined media are summarized in Table 2. The model 
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predicted that biomass could be produced in 684 of the 704 cases in which genes annotated as 
inessential or non-auxotrophic were deleted (true positive results) and that biomass could not be 
produced in 20 cases where these inessential or non-auxotrophic genes were deleted (false 
negative results). Thus, the model has a 97.2% sensitivity for this list of essential genes. If the 
model simulation predicted that biomass could be produced following a gene deletion, the 
deleted gene was not listed as essential or auxotroph-inducing in 86% of the cases (an 86% 
positive predictive value). 
Table 2: Single-gene Deletion Results (918 genes) 
 
684 (75%) True Positives 
(model simulation predicts growth 
when inessential genes are deleted) 
20 (2%) False Negatives  
(model simulation predicts no 
growth when inessential genes are 
deleted) 
113 (12%) False Positives 
(model simulation predicts growth 
when essential genes are deleted) 
101 (11%) True Negatives 
(model simulation predicts no 
growth when essential genes are 
deleted) 
The model predicted that biomass could not be produced following deletion of 101 of the 
of the 214 genes included on the essential or auxotrophy-inducing gene lists (true negative 
results), but that biomass could still be produced following deletion of 113 genes included on 
those lists (false positive results). Thus, the model has a 47% specificity for this list of essential 
genes. If the model simulation predicted that biomass could not be produced following a gene 
deletion, the deleted gene was listed as essential or auxotroph-inducing in 83.5% of the cases (an 
83.5% negative predictive value). 
Comparing Yeast 5 GEM knockout simulations with our list of essential and auxotroph-
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inducing genes yields a geometric mean overall predictive accuracy (as suggested by [10] of 
45.88%, an improvement over Yeast 4’s 41.61% geometric mean accuracy for this gene list. 
These results, including comparison of the simulations using other recently published GEMs and 
the same essential and auxotroph-inducing gene lists, are summarized in Table 1. 
Auxotroph-inducing mutations 
To extend our analysis of Yeast 5 GEM simulation capabilities, we conducted additional 
FBA growth simulation focusing on the 70 genes included in both the Yeast 5 GEM and the list 
of genes whose mutation or deletion causes auxotrophies. In 51 single-gene deletion simulations, 
the model predicted that biomass could not be produced in minimal media but could be produced 
in a supplemented media, the expected behavior for an auxotroph mutant (see Materials and 
Methods for more information about our approach to simulated media). In 17 cases, model 
simulation predicted that biomass could be produced in minimal media, and thus did not 
accurately predict the auxotrophic phenotype. In 2 cases, model simulation predicted that 
biomass could not be produced in either minimal or maximal media, and so the model incorrectly 
predicted that the gene deletion could not be saved by media supplementation. 
Auxotroph phenotypes have not previously been a metric used to evaluate yeast GEMs. 
We found that simulation with the Yeast 5 GEM had better agreement with observed auxotrophic 
phenotypes than simulations conducted with other previously published GEMs (Table 1). 
Flux predictions 
Optimal solutions found when conducting FBA of the Yeast 5 GEM to maximize 
biomass flux include fluxes through key internal reactions, a flux distribution which better 
matches fluxes observed in vivo [30] than solutions found when applying FBA to Yeast 4 (Table 
3). Specifically, applying FBA to the Yeast 5 GEM in a simulated glucose-limited aerobic 
environment predicts that the reactions of glycolysis and the TCA cycle have fluxes, and that 
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ethanol is not produced. When the model constraints are adjusted to simulate an anaerobic 
environment, FBA predicts fluxes through the reactions of glycolysis, but not the TCA cycle, 
and ethanol is produced. Thus, simulations with the Yeast 5 GEM reflect the shift from 
respiratory to fermentative metabolism which is observed in oxygen-limited yeast cultures. 
Simulations using the Yeast 4 GEM do not reflect this same behavior. 
Table 3: Yeast 5 and Yeast 4 simulated flux predictions 




Sample FBA flux predictions 
 
  
  glucose-limited, aerobic growth rate 0.09 0.17 
  glucose-limited, anaerobic growth rate 0.02 0 
  aerobic flux through glycolysis
a
 1.33 0.89 
  anaerobic flux through glycolysis 1.85 - 
  aerobic flux through TCA cycle
b
 1.06 0.01 
  anaerobic flux through TCA cycle 0 - 
  aerobic ethanol production 0 0 
  anaerobic ethanol production 1.74 - 
 
Fluxes are normalized to the glucose uptake flux, which is set to 1 mmol/g dry 
weight/h 
a
glycolysis flux measured through pyruvate kinase 
b
TCA cycle flux measured through malate dehydrogenase 
Increased number of genetic interactions 
Recognizing recent efforts to investigate system-level organization of cellular 
metabolism via the phenotypic effects of multiple gene deletions using yeast GEMs [31–35], we 
compared the number of epistatic interactions predicted by growth simulations using the Yeast 5 
GEM with the number of interactions predicted by simulations using the iMM904 [12] and 
iND750 [9] models (Table 1). When reaction fluxes were restricted to 50% of wild-type in a 
pairwise manner, we found that a lower percentage of genes included in the Yeast 5 and 
iMM904 GEMs were predicted to exhibit epistatic interactions in FBA simulations, but the 
expanded size of these models led to an increased number of total epistatic interactions compared 
to the iND750 GEM. If the number of interactions are averaged over the number of genes in each 
model, the Yeast 5 GEM adds an average of 196.5 new epistatic interactions per additional gene, 
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and iMM904 adds an average of 34.6 new interactions per gene. The number of interactions 
predicted using each of these models using varying levels of flux restriction for each gene and 
reaction pair are provided in Appendix 2 as Supplemental Table 4.4. 
Limitations 
Research to expand our understanding of yeast metabolism and biochemistry is ongoing, 
and the process of integrating established biochemical knowledge into computational 
reconstructions lags research advancements. Thus, the Yeast 5 GENRE is not a complete 
reconstruction of the yeast biochemical network, and though it offers improvements over earlier 
models, simulations using the Yeast 5 GEM do not fully reflect observed biological phenomena. 
GENRE and GEM limitations suggest opportunities for future efforts to improve computational 
reconstruction of established biochemistry and can highlight portions of metabolism that are ripe 
for further research [36]. 
A limitation of the Yeast 5 GENRE which suggests future opportunities for improving 
the Yeast Reconstruction is that due to the lack of information about enzyme specificity or the 
metabolic significance of variation among similar chemical species, the Yeast 5 GENRE uses 
general classes of chemical compounds rather than the enumeration of many similar compounds. 
For example, Yeast 5 generalizes the many possible triglyceride compounds which may by 
incorporating fatty acyl moieties of varying length [27] into a single model species, called 
“triglyceride”. Yeast 5 also includes similar generalized species for other compounds, 
particularly those involved in lipid and sterol metabolism. Though this approach is also followed 
by previous yeast GENREs and other metabolic pathway tools, expansion of such general 
species by differentiating among biochemically relevant species has been shown to be a 
successful approach to expanding computational reconstructions of metabolic networks [20]. The 
appropriate level of detail or generalization for metabolic (or biochemical) network 
reconstruction depends upon the intended use of a GEM, and would be expected to change in the 
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future as our knowledge of enzyme specificity and the metabolic relevance of differences among 
similar chemical compounds advances. 
As with other reconstructed metabolic networks, the continued existence of blocked 
pathways (Table 1) highlights that our knowledge of yeast metabolism is incomplete. Such 
blocked reactions are an important tool for documenting portions of metabolism that would 
benefit from further research [36]. The Yeast 5 GENRE remains limited by knowledge gaps. 
Where our knowledge of intercompartmental transport of metabolites is limited, such gaps pose a 
particular challenge to FBA. Thus, the Yeast 5 GEM includes hypothetical transport reactions to 
better connect portions of the metabolic network that are unconnected in a graph-theoretical 
sense. Such hypothetical transport reactions are annotated with SBO term [18] SBO:397 
(“omitted process”). 
Optimal solutions found when conducting FBA on the Yeast 5 GEM may include fluxes 
that differ from those observed in yeast: we have found optimal solutions in which mitochondrial 
coenzyme A is synthesized in situ rather than transported from the cytoplasm, and model growth 
simulations incorrectly predict that yeast is not a pantothenate auxotroph or a nicotinic acid 
auxotroph in anaerobic conditions. Additionally, although the model predicts that biomass can 
only be produced anaerobically if the biomass definition is modified (see Materials and 
Methods), the reason that simulated anaerobic biomass production using an unmodified biomass 
definition is blocked is not because of the biological requirement of yeast fatty acid desaturate 
for oxygen. Instead, simulated anaerobic biomass production is blocked due to other, as yet 
unidentified limitations in the reconstruction of phospholipid and sterol biosynthesis. Refining 
the solution space to more closely match observed biological phenomena through improved 
reconstruction or expanded constraints remains an ongoing research effort for reconstructed 
metabolic networks. 
Due to varying interpretations of experimental evidence, uncertainty of metabolic 
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mechanism, and varying approaches taken as modelers work to reconstruct different portions of 
metabolism, it is likely that the Yeast 5 consensus reconstruction has additional limitations which 
will be discovered as it is used. These limitations provide opportunities for continued research to 
improve the computational reconstruction and simulation of the yeast biochemical network. 
Thus, though Yeast 5 consists of a more complete reconstruction and more accurate model of 
yeast metabolism than previous efforts, the goal of building a complete and accurate 
computational reconstruction of yeast metabolism must remain an ongoing community effort. 
Discussion 
Yeast 5 is the most recent update to the consensus reconstruction of the yeast metabolic 
network. It consists of a genome-scale reconstruction (GENRE), a genome scale model (GEM), 
and MATLAB scripts designed to facilitate evaluation of yeast GEMs and to demonstrate 
simulation and analysis using the COBRA and SBML toolboxes. This update improves the 
consensus reconstruction’s coverage of established biochemical knowledge, and improves the 
predictive ability of simulations using the yeast GEM. The included scripts lower the barriers for 
the research community to use the model and to contribute to the collaborative effort to improve 
the computational reconstruction of yeast metabolism. 
Models and reconstructions 
We emphasize the distinction between a reconstruction, or GENRE, and a model, or 
GEM, to more clearly delineate the established biochemical knowledge of a reconstruction from 
the assumptions and hypotheses that are required for modeling and simulation. This distinction 
makes the modeling process more transparent and reproducible, essential attributes for 
community-based scientific efforts such as the consensus reconstruction of yeast metabolism.  
Evaluating yeast reconstructions and models 
As evidence of improvements to the consensus yeast reconstruction, we have presented a 
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comparison of viability, auxotrophy predictions, and genetic interaction effects, produced using 
FBA of the Yeast 5 GEM and other metabolic models (Table 1). However, we emphasize that 
such metrics of phenotype predictive ability must be evaluated with great care. This need for 
careful use of such metrics has been discussed previously [37], but we have found that this point 
deserves additional emphasis. Specifically, the two goals of expanding the reconstruction of 
metabolic networks and improving model predictions of mutant viability may be contradictory in 
some situations. The Yeast 5 GEM sensitivity, specificity, positive predictive value, negative 
predictive value, and geometric mean could all be improved by the reduction of false positive 
predictions - simulations which predict that biomass can be produced although reactions 
annotated as being catalyzed by “essential genes” have been blocked. The number of false 
positive predictions could be reduced by expanding the biomass function to require products of 
reactions annotated with essential genes, by removing parallel pathways to force fluxes through 
reactions annotated with essential genes, or by removing metabolites and reactions which create 
dead-end pathways which include reactions annotated with essential genes (a method used to 
improve lethality prediction metrics when the iLL672 model was derived from iFF708 [10]). 
However, while such techniques improve a model’s ability to predict single-gene mutant 
viability, they also reduce the scope of a GENRE as a structured knowledge base of established 
biochemical facts. 
Expanding the reconstruction of a metabolic network would be expected to increase both 
dead-end pathways and network redundancy. Dead ends would be introduced through the 
inclusion of established knowledge regarding pathways that are not fully elucidated. In such 
pathways, the production of intermediates may be established, but their fate is not yet known. In 
such cases, expanding the reconstruction of established knowledge would not be expected to 
improve a model’s ability to predict single-gene mutant viability, and so such metrics would not 
reflect the expanded scope of the reconstruction. Another example of network expansion which 
may not be reflected in single-gene deletion metrics is expanding the reconstruction’s coverage 
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of isoenzymes. Network redundancy increases through expanded inclusion of isoenzymes, which 
introduce parallel metabolic paths for the production of chemical intermediates or products. In 
the absence of regulatory constraints (which are beyond the scope of a metabolic reconstruction), 
these parallel pathways would increase the rate of false positive prediction since a metabolic 
pathway from substrate to product would exist in the reconstruction, even if a given isoenzyme 
were individually insufficient to support growth in vivo. Thus, a metabolic model based upon a 
reconstruction with improved coverage of established biochemistry or isoenzymes would make 
less accurate predictions of individual gene essentiality than a model based upon a less complete 
reconstruction. 
A second problem with metrics based upon lists of essential genes is that gene 
essentiality is dependent upon strain, media, and environmental conditions (for example, [38] 
identify mutants which are inositol auxotrophs only at elevated temperatures). Though a general 
definition of “essential” could imply “in complex media at 30º C”, the difficulties of 
computationally reconstructing complex media and the lack of integration of temperature effects 
on metabolic networks means that there remains an element of subjectivity in defining a list of 
essential genes. Researchers have previously used different data sets to define gene essentiality 
for model analysis [9, 12]. Thus, if model predictivity metrics are to be used, care must be taken 
to ensure a common list of essential genes when evaluating different models by such metrics. 
Yeast 5 includes the MATLAB script testYeastModel.m to document the list of genes we 
considered essential for our comparison of yeast GEMs. 
That essentiality metrics must be used with care and considered in context is not to say 
that such metrics are without value, however. Model simulation results that differ from in vivo 
experiments can guide efforts to improve computational reconstruction or to highlight the need 
for additional biochemical investigation of metabolic dead ends. Simulations resulting in false 
negative results, in which the model predicts that biomass cannot be formed, but in vivo 
experiments have observed growth, suggest that the reconstruction is incomplete or the model 
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has limitations such as incorrect biomass definition or missing simulated media components. 
Indeed, the use of gap filling algorithms to improve phenotype predictive metrics for metabolic 
models by adding hypothesized gene functions or reactions is considered standard practice for 
GEM development [39]. 
Like auxotroph phenotype predictions, predicted epistatic interactions have not 
previously been used as a metric for comparing yeast GEMs. And like other metrics based upon 
phenotypic prediction, the use of epistatic interactions must also be qualified. Specifically, 
expansion in the number of reactions in the model is a likely contributor to the amount of 
simulated epistasis. The number of genetic interactions can also be increased by pleiotropy, or 
the number of reactions associated to a particular gene. Yeast 5 has an 8.43% increase in the 
mean number of reactions per gene compared to iMM904. The most prominent example is ISC1, 
a gene important in sphingolipid metabolism. ISC1 is included in annotation for 60 reactions in 
Yeast 5, but only 18 in iMM904. ISC1 accounts for a 1% increase in pleiotropy by itself. FOX2, 
a multi-function enzyme involved in beta-oxidation, ranked highest for pleiotropy in iMM904 
with 23 reactions. It is also associated with 23 reactions in Yeast 5.  Additional trends in positive 
or negative epistasis across different types of mutations can also be observed for these models 
(Appendix 2 Supplemental Table 4.4; Xu & Barker in preparation). 
Generic demand reactions in Yeast 5 - towards a functional biomass definition 
The yeast consensus reconstruction draws upon data sources with varying levels of 
compound specificity. For example, the KEGG database includes a general representation of 
yeast sphingolipid metabolism, while recent suggestions for changes to Yeast 4 include more 
specific chemical species [20]. Thus, some Yeast 5 reactions which are derived from KEGG use 
generic species as substrates or products, while reactions derived from other sources use more 
specific species. To accommodate the formation of generic chemical species for reactions which 
consume them while preserving biochemical accuracy in reactions that have more specific 
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biochemistry, the Yeast GEM includes “isa” reactions. Examples of generic species produced by 
“isa” reactions include “complex sphingolipid”, “fatty acid”, and “acyl-CoA”.  
Where “isa” reactions are reversible, they can introduce unrealistic interconversion of 
metabolites. For example, since octanoate is a fatty acid and hexadecanoate is a fatty acid, 
reversible “isa” reactions in a model would create a nonrealistic pathway by which octanoate 
could be converted to hexadecanoate via the “isa” reaction, instead of through biochemical 
pathways which have been documented in vivo. In order to prevent such non-realistic 
interconversion fluxes, Yeast 5 “isa” reactions are not reversible. Thus, more general compounds 
can only serve as sinks of more specific compounds in the Yeast 5 GEM, and not as sources. 
An unanticipated result of this approach to varying levels of biochemical specificity in 
the model is that “isa” reactions effectively embed the logical OR into the model. Thus, where 
the biomass definition includes “lipid” as a required component, this objective function can be 
satisfied by any of the compounds that can be converted to “lipid” via an “isa” reaction (Figure 
1). Thus, although “biomass” must be defined if maximizing biomass production is the objective 
function for FBA, “biomass” does not need to be a specifically determined compound with a 






Figure 1: Using “isa” reactions 
Yeast 5 uses “isa” reactions to encapsulate specific chemical species within more 
general classes. For example, A) the specific species inositol-P-ceramide-A “isa” inositol 
phosphoceramide (IPC). In turn, IPC “isa” complex sphingolipid. B) Complex sphingolipids 
participate in the stoichiometrically constrained reaction which produces the species “lipid”. 
C) The lipid species is a component of biomass. This hierarchical model structure embeds 
logic in the biomass definition: biomass consists of L-alanine AND phosphatidylcholine 
AND (inositol-P-ceramide-A OR Inositol-P-ceramide-B OR any of the 88 other complex 
sphingolipids included in the reconstruction). A model user is free to constrain the fluxes 
which produce specific complex sphingolipids to model an observed lipid composition, or 





Continuing efforts to reconstruct yeast metabolism - an invitation for continued 
community involvement 
Computational reconstruction and modeling of yeast metabolism is an ongoing project. 
Suggestions for improving the yeast consensus reconstruction or derived models should be 
submitted to network.reconstruction@manchester.ac.uk. Metabolites and enzymes should be 
unambiguously identified, using existing model or database (ChEBI or UniProt) identifiers. New 
reactions should be supplied with primary evidence for their mechanism and catalysis, via 
PubMed identifiers. Reactions without evidence should have clear reasons for their proposed 
addition. 
We also invite researchers to submit models derived from the yeast consensus 
reconstruction for hosting at http://yeast.sf.net/. Assumptions and constraints should be 
documented, for example with code documenting how to build the GEM from the Yeast 
GENRE. Such models may be submitted for publication separately from updates to the Yeast 
GENRE, and may follow the iNNXXX naming convention which has been previously used for 
identifying GEMs [40]. 
Conclusions 
The Yeast 5 expansion of the Yeast Consensus Reconstruction refines the computational 
reconstruction of yeast metabolism and improves the predictive accuracy of a stoichiometrically 
constrained yeast metabolic model. It refines the biochemical reactions included in the 
reconstruction, particularly reactions involved in sphingolipid metabolism; updates gene-reaction 
annotations; and emphasizes the distinction between reconstruction (GENRE) and 
stoichiometrically constrained model (GEM). This update also improves the accuracy of model 
prediction of viability and auxotrophy phenotypes and increases the number of epistatic 
interactions. Yeast 5 differs from previous reconstructions and models by emphasizing the 
distinction between the yeast metabolic reconstruction and the stoichiometrically constrained 
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model, and makes both available at http://yeast.sf.net/ as separate systems biology markup 
language (SBML) files. Through this separation, we intend to make the modeling process more 
accessible, explicit, transparent, and reproducible. The Yeast Consensus Reconstruction remains 
a community-based resource which emphases standards compliance and biochemical accuracy 
via evidence-based selection of reactions.  
Though Yeast 5 consists of a more complete reconstruction and more accurate model of 
yeast metabolism than previous efforts, the goal of building a complete and accurate 
computational reconstruction of yeast metabolism must remain an ongoing community effort. As 
Yeast 5 limitations are identified, they provide opportunities for continued research to improve 
the computational reconstruction and simulation of the yeast biochemical network. 
Methods 
Yeast 5 scope 
The scope of Yeast Consensus Reconstruction was originally determined by the data sets 
used for its construction: the iMM904 [12] and iLL672 [10] models, which included information 
from the KEGG and SGD databases, along with other sources. Subsequently, the Consensus 
Reconstruction was expanded [16] to include information (particularly focusing on lipid 
metabolism) from the iIN800 model [11]. Yeast 5 further expands the scope of reconstruction to 
refine details of sphingolipid metabolism [20, 21]. Though the stoichiometrically constrained 
approach can theoretically be expanded to include all biochemical reactions in the organism 
being modeled [41], the Yeast reconstruction is currently limited to the yeast metabolic network. 
Although Yeast 5 is not strain-specific, the auxotroph information we used for our analysis 
focused on auxotrophies documented in S. cerevisiae reference strain SC288C. Since multiple 
yeast genome sequences are now available, future updates to the Yeast Consensus 
Reconstruction may become strain specific. 
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Deriving reconstruction (GENRE) from model (GEM) 
We must maintain a distinction between the reconstruction of yeast metabolism, an 
evidence-driven biochemical knowledge-base, and its corresponding model, which relies on a 
number of assumptions to make quantitative flux predictions [39]. We discriminate between the 
two through the use of the Systems Biology Ontology (SBO) [18]. Specifically, reactions marked 
up with specific SBO terms may be automatically removed from a model to create a 
reconstruction. Encapsulating “isa” reactions of the form “A isa B” are annotated with SBO:395 
(“encapsulating process”). Other reactions without literature evidence, that are omitted in the 
reconstruction, such as biomass production and most transport reactions without an associated 
transporter are annotated with SBO:397 (“omitted process”). Reaction constraints (lower and 
upper bounds) are also removed in the reconstruction. The transformation is performed using the 
SBMLToolbox [25]. 
Yeast Model Conventions 
The Yeast 5 GEM includes conventions to facilitate model analysis using the COBRA 
Toolbox, such as standardized representation of exchange reactions, though such conventions are 
not required in the SBML specification. However, we have chosen to rely upon the SBML 
standard for encoding reaction and metabolite annotation, rather than the nonstandard custom 
notes field currently used by the COBRA toolbox. This information, which includes metabolite 
ChEBI identifiers and literature references supporting reaction inclusion, is encoded in the model 
.sbml file and is available to MATLAB users via the SBML toolbox. An additional model 
convention is that the Yeast 5 GEM includes biomass as a species in the model to help make our 
approach to simulating biomass production more explicit. 
Exchange reactions in the Yeast 5 GEM follow a convention of using compounds in the 
model as reactants, leading to exchange reactions of the form “reactant -> ”, with an entry of +1 
in the stoichiometric matrix. Thus, positive flux values for exchange reactions represent 
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compounds produced in FBA simulation, and negative flux values represent compounds 
consumed. Since reactions must include both substrate and product in SBML, we have followed 
the COBRA toolbox convention of denoting exchange reaction species which lay outside the 
model with the subscript “_b”. These species are not loaded into the COBRA toolbox data 
structure, and serve only as placeholders for exchange reaction substrates. 
We have chosen to include biomass as a species in the Yeast 5 GEM. Thus, when 
conducting FBA on the Yeast 5 GEM, the biomass exchange reaction can be selected if biomass 
optimization is the desired objective function. For modeling purposes, the species “biomass” is 
produced in the Yeast 5 GEM via a reaction which consumes 37 biomass precursor compounds 
to produce biomass, ADP, protons, and phosphate. The biomass precursors include water, 
polysaccharides, nucleotides, amino acids, riboflavin, sulfate, and the general species “lipid”. 
The “lipid” species in the Yeast 5 GEM serves a function similar to Zanghellini et al.’s “virtual 
membrane particle” [42] or Nookaew et al.’s lipid species [11]. It is a lumped species which 
incorporates many different specific lipid compounds. We have used two different definitions of 
“lipid” to enable simulation of aerobic and anaerobic biomass production (see “Simulating yeast 
growth”). The aerobic lipid pseudoreaction consumes 15 lipids and sterols, to produce the 
generic “lipid” species, while the anaerobic lipid pseudoreaction omits the sterols 14-
demethyllanosterol and ergosta-5,7,22,24(28)-tetraen-3beta-ol. Thus, there are two Yeast 5 GEM 
biomass definitions: an aerobic biomass consisting of 52 compounds, and an anaerobic biomass 
definition consisting of 50 compounds. The growth, biomass pseudoreaction, and lipid 
pseudoreactions are detailed in Appendix 2 Supplemental Table 4.3. 
Constraining reactions in the Yeast 5 GEM 
The Yeast 5 GEM has over 300 more directionally constrained reactions than Yeast 4. 
Such constraints incorporate thermodynamic information into the GEM, and often serve in part 
to limit Type III cycling, which arises from the linear programing approach, but are 
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thermodynamically infeasible [43]. It is noted that such cycling can also be eliminated by 
minimizing the total flux, or by applying geometric FBA [44]. New constraints were added by 
re-evaluating “isa” reactions and applying a heuristic approach to reactions involving energy-
carrying cofactors (ATP and NAD(P)), supported by evidence from other models, literature, and 
pathway databases. As discussed in “Generic demand reactions in Yeast 5 - towards a functional 
biomass definition”, directional constraints were added to “isa” reactions in the Yeast 5 GEM to 
prevent unrealistic interconversion of chemically distinct metabolites via fluxes through general 
species. Additional constraints were added with a heuristic approach similar to [45] which 
focuses on reactions which may produce ATP and those that use NAD or NADP as cofactors. 
We directionally constrained such reactions only when such constraints were supported by 
constraints in the iND750 and iMM904 reconstructions and by the directionality specified in the 
BioCyc database [5]. 
Simulating yeast growth 
The Yeast 5 GEM includes 170 exchange reactions, each of which defines a compound 
that can be included as a medium component for simulation purposes. As distributed, the 
simulated media is a glucose-limited minimal aerobic medium with constrained limited uptake of 
glucose, and unconstrained exchange of oxygen, ammonium, protons, iron(2+), phosphate, 
potassium, sodium, sulfate and water. To simulate anaerobic growth, the oxygen exchange 
reaction may be constrained to disallow oxygen uptake. Simulating anaerobic growth also 
requires that the simulated media be supplemented by allowing exchange of ergosterol, 
lanosterol, zymosterol and phosphatidate, and the biomass definition be changed by removing 
14-demethyllanosterol and ergosta-5,7,22,24(28)-tetraen-3beta-ol from the “lipid” definition. 
These requirements reflect the observation that yeasts require sterols [46, 47] and fatty acids [48] 
when cultured under rigidly anaerobic conditions. However, from a modeling perspective, these 
requirements arise from the biomass definition, for which the biochemistry is not firmly 




Growth simulations were performed using the Cobra toolbox [26]. We have included 
MATLAB scripts which demonstrate simulation of aerobic and anaerobic growth, investigation 
of internal fluxes, and gene essentiality tests in Appendix 2.  
Gene deletion simulation 
Gene deletion simulations were performed using the Cobra toolbox [26]. To compare 
model gene essentiality predictions with observed phenotypes, gene lists were compiled for 
genes considered essential, and those which have been observed to cause auxotrophies when 
deleted. The essential gene list was compiled beginning with 1191 unique open reading frames 
reported to cause inviable mutants upon deletion in the Saccharomyces Genome Deletion Project 
[29] and the YKOv2 supplemental data set available from http://www-
sequence.stanford.edu/group/yeast_deletion_project/data_sets.html. Since this data set screened 
in complex media (which is only incompletely accounted for with FBA simulation due to the 
limited number of exchange reactions), we refined the list of “essential” genes first by removing 
any ORFs which have not been reported as verified in the SGD database [28], and then by 
supplementing it with a list of gene mutations which have been reported to cause auxotroph 
phenotypes. The auxotroph-inducing gene list was generated by by searching the SGD database 
for “inviable” and “auxotrophy” phenotypes. Since the biochemistry of temperature signaling is 
beyond the scope of the Yeast 5 GEM, we removed temperature-dependent inositol auxotroph 
mutants [38] from this list. The lists of genes we used for evaluating model essentiality 
predictions, as well as a MATLAB script which can be used to evaluate other yeast GEMs 
essentiality predictions, are included as Supplemental Information. 
Simulation of genetic interactions 
Genetic interactions were quantified with the nonscaled multiplicative definition of 
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epistasis, =Wxy-WxWy [34]. In this definition, Wx and Wy are fitness scores for organisms with a 
mutation in genes x and y, respectively, and Wxy is the fitness of the organism with both 
mutations present. Any ≠ 0 indicates a genetic interaction under the assumption that both of the 
genes independently and multiplicatively contribute to fitness. Following the example of [31], 
we quantified fitness as maximum biomass production rate (as determined by FBA) relative to 
the rate of biomass production in simulations conducted with the wild-type model. As suggested 
by [34], we simulated genetic perturbation by limiting flux through all reactions associated to a 
specific enzyme by a fixed amount of the wild-type geometric FBA flux (0%, 10%, ..., 90%). 
Constraining the flux to fractions of wild-type flux allows investigation of essential reactions, as 
well as inessential reactions. The number of epistatic interactions for each level of flux 
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CHAPTER 5 - REVISITING SYSTEMS-LEVEL ENGINEERING OF 
NONFERMENTATIVE METABOLISM IN YEAST WITH THE YEAST 5 METABOLIC 
MODEL  
Abstract 
Background: A recent report of the successful use of the iND750 yeast metabolic 
model to engineer endogenous one-carbon metabolism in yeast presents an opportunity to 
assess the robustness of simulation predictions to varying implementations, and to evaluate 
the recently published version of the Yeast Consensus Reconstruction (Yeast) model by 
comparing simulation results using the newer model to those predicted by simulations using 
iND750. 
Results: We were able to obtain results similar but not identical to those reported 
previously using the iND750 model, but not with version 5.01 of the Yeast model. Thus, we 
generated a literature-supported set of updates to Yeast model which enable similar 
predictions of formate production. We found that results of an in silico screen for formate-
producing mutants using the Yeast model are sensitive to constraints on reactions involving 
NAD(P) cofactors and generated a literature-supported set of constraints on these reactions 
which improves screening results. 
We found errors in the reconstruction of C-1 metabolism in iND750, but also found 
that simulations with iND750 better predict formate-producing phenotypes involving 
“uncharacterized” yeast open reading frames than simulations with the updated Yeast model. 
In contrast, we found that simulations using the Yeast model better predict auxotrophic 
phenotypes and predicted formate-producing mutants which were not found in a screen using 
iND750. The code we used for this study, including references for suggested model changes, 
is included in Appendix 3. 
Conclusions: The computational prediction of formate-producing yeast mutants is 
sensitive to implementation details and reaction constraints when using either the iND750 or 
the Yeast model. The models we evaluated had different strengths and weaknesses: the screen 
using the Yeast model predicts more formate-producing strains with mutations in pathways 
which would be expected to affect C-1 metabolism than the screen using iND750, but iND 
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better predicts phenotypes involving mutations in uncharacterized or dubious ORFs. Our 
results suggest that comparative analysis of constraint based models is a useful tool for 
finding phenotypes of poorly characterized yeast genes, characterizing redox metabolism, and 
for improving the computational reconstruction of the yeast metabolic network. 
Background  
In the past sixteen years, many stoichiometrically constrained genome-scale 
computational models of the yeast metabolic network have been published, each intended to 
improve upon previous modeling efforts [1]. These models have been applied to develop 
metabolic engineering strategies for the production of products such as ethanol, succinate, 
glycerol, vanillin, and sesquirtpenes [2]. The development and application of such models has 
been facilitated by the development of COnstraint Based Reconstruction and Analysis 
(COBRA) methods and software, particularly the MATLAB COBRA Toolbox [3]. Many 
metabolic engineering strategies have been proposed based upon computational simulation, 
but few have been implemented or rigorously evaluated in vivo [4]. The development and 
characterization of a formate-producing yeast strain by Kennedy et al. [5] is a noteworthy 
example of successful implementation of a metabolic engineering strategy developed through 
a constraint-based modeling approach. 
Kennedy et al.’s metabolic engineering efforts focused on improving the production 
of non-fermentative by-products, a class of “biologically interesting and commercially 
attractive small molecules”. They developed and implemented a model-driven metabolic 
engineering strategy to increase endogenous formic acid secretion in yeast, using flux balance 
analysis of the iND750 model of yeast metabolism [6] to simulate growth of triple-knockout 
mutants, then screened the simulation results for mutants predicted to produce formate (the 
possible triple deletions were in addition to deletion of FDH1 and FDH2, which encode 
yeast’s formate dehydrogenase enzymes). Kennedy et al. reported 8 strains which their 
simulations predicted would produce formate, at efficiencies ranging from 72.3% to 1.2% 
(Table 5.1). Selecting the top-ranked formate producer from their in silico screen, the authors 
then successfully constructed a formate-producing yeast strain, PSY3642, by knocking out 
the computationally suggested ALT2, FUM1, and ZWF1 genes, each of which catalyze 
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reactions that affect fluxes through central carbon metabolism (Figure 5.1). Additionally, the 
authors constructed and characterized a ZWF1 knockout strain and a FUM1 ZWF1 double 
knockout strain, observing that formate production increased in aerobic batch cultures with 
each additional gene deletion. 
 
 
Table 5.1 – Previously reported strains predicted to produce formate by in silico 
simulation 
Genotype Predicted Efficiency (%)a 
alt2 zwf1 fum1 fdh1 fdh2 72.3 
aat2 zwf1 fum1 fdh1 fdh2 72.2 
cat2 zwf1 fum1 fdh1 fdh2 72.0 
cat2 rpe1 fum1 fdh1 fdh2 71.7 
cat2 fbp1 fum1 fdh1 fdh2  30.5 
cat2 yat2 slc1 fdh1 fdh2  2.4 
cat2 yat2 cho1 fdh1 fdh2  2.3 
cat2 yat2 alt2 fdh1 fdh2  1.2 
 a
One hundred percent efficiency is defined as four formic acid molecules per 
glucose. 
Kennedy et al. reported 8 strains which their in silico screen of simulated yeast 
deletion mutants predicted would produce formate [5]. 
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At least nine genome scale models have been published since iND750, including 
iLL672 [7], iMH805/775 [8], iJH732 [9], iIN800 [10], three versions of the Yeast Consensus 
Reconstruction [11–13], iMM904 [14], and iAZ900 [15]. In this study, we replicate some of 
the previously reported results, and conduct a computational screen of yeast mutants 
following a procedure similar to that used by Kennedy et al., but implemented with the 
Figure 5.1 – Target genes relationship to central carbon metabolism 
 
In the iND750 model, the genes deleted in Kennedy et al.’s PSY3642 strain annotate 
reactions in branchpoints from central carbon metabolism. Though the Saccharomyces 
Genome Database annotates the open reading frame coding for ALT2 as 
“uncharacterized”, the iND750 model annotates a reaction involved in alanine 
biosynthesis with this gene. 
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COBRA Toolbox instead of custom code, and using the most recently published yeast 
metabolic model, Yeast 5 [13] along with the older iND750 model. 
Results  
Our simulations using iND750 replicated the computational prediction of a formate-
producing phenotype for 5 of 8 previously reported cases (Table 5.2), and our in silico screen 
predicted formate-producing mutants, including the previously predicted top-performing 
strain, though it was not the highest predicted formate-producing mutant in our screen. We 
found that simulations using iND750 correctly predicted that deletion of the ALT2 gene in 
addition to FUM1 and ZWF1 in a fdh1 fdh2 background strain led to increased formate 
production, as has been observed in vivo. 
 
Although we found broader pathway coverage in the Yeast model than iND750 and 
found errors in iND750’s reconstruction of C-1 metabolism, we found that version 5.01 of the 
Yeast model did not replicate the prediction of formate-producing strains. Following two 
Table 5.2 - Comparing model predictions of formate production 








alt2 zwf1 fum1 fdh1 fdh2 72.3 72.1 0.0 69.6 71.9 
aat2 zwf1 fum1 fdh1 fdh2 72.2 72.0 0.0 69.6 71.9 
cat2 zwf1 fum1 fdh1 fdh2 72.0 71.8 0.0 69.6 71.9 
cat2 rpe1 fum1 fdh1 fdh2 71.7 71.4 0.0 69.2 71.5 
cat2 fbp1 fum1 fdh1 fdh2  30.5 30.4 0.0 69.6 2.1 
cat2 yat2 slc1 fdh1 fdh2  2.4 - 0.0 0.0 0.0 
cat2 yat2 cho1 fdh1 fdh2  2.3 - no growth no growth no growth 
cat2 yat2 alt2 fdh1 fdh2  1.2 - 0.0 0.0 0.0 
 a
One hundred percent efficiency is defined as four formic acid molecules per 
glucose. 
Growth simulations implemented with the COBRA Toolbox using iND750 
agreed with 5 of the 8 reported by Kennedy et al. [5]. The version of iND750 available 
via the BIGG database [16] does not include reactions annotated with YAT2, so we could 
not reproduced the three lowest-ranked strains reported by Kennedy et al. Yeast 5.01 did 
not replicate the iND750 predictions, but Yeast 5.30 did.  
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rounds of model curation and updates, model predictions are more similar to simulations with 
iND750 (Table 5.2). However, simulations using the Yeast model did not predict the 
observed additional increase in formate flux due to additional deletion of ALT2 (Table 5.3). 
This result is not surprising, since the open reading frame which encodes ALT2, YDR111C, is 
annotated as “uncharacterized” in the Saccharomyces Genome Database, and so is not 
included in version 5.01 of the Yeast model. 
 
We found that the prediction of formate-producing mutants by the Yeast model was 
sensitive to constraints on reactions involving NAD(P) cofactors and developed a literature-
supported set of constraints to these reactions which improved the performance of the Yeast 
model (Table 5.4). Additionally, as described in the below, we found that a screen using the 
Yeast model predicted formate-producing mutants that were not predicted by the iND750 
screen.  
Table 5.3 – Model predictions of increasing formate production with additional 
gene deletions 





fdh1 fdh2 0.0 0.0 
fdh1 fdh2 zwf1 0.0 0.0 
fdh1 fdh2 zwf1 fum1 71.8 71.9 
fdh1 fdh2 zwf1 fum1 alt2 72.1 71.9 
a
One hundred percent efficiency is defined as four formic acid molecules per 
glucose. 
The iND750 model accurately predicts increasing formate production with the 
deletion of ALT2 in addition to ZWF1 and FUM1 while the Yeast model does not. 
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iND750 growth simulations with the COBRA Toolbox predict similar formate 
fluxes to those reported by Kennedy et al. 
Since Kennedy et al. implemented their computational screen using different software 
than our efforts (they reported conducting flux balance analysis with “the GNU MathProg 
language and solved with custom-generated C code” to interface with the GNU linear 
programming kit), we began by simulating growth of the 8 predicted formate-producing 
strains reported in Kennedy et al.’s Table 5.1. The code used for these simulations, along 









Model description       
  Number of metabolites 1602 1655 1481 
  Number of reactions 2051 2110 2030 
  Number of genes 904 918 924 
  Number of dubious genes 1 0 4 
  Blocked reactions 43% 38% 26% 
          
Viability analysis       
  Sensitivity 96% 97% 95% 
  Specificity 52% 47% 44% 
  Positive predictive value 87% 86% 85% 
  Negative predictive value 78% 84% 73% 
  Geometric mean 50% 46% 42% 
          
Auxotrophy analysis       
  Auxotroph-inducing genes included 70 70 73 
  Correct auxotroph predictions 74% 73% 66% 
  
Incorrectly predicted as viable in minimal 
media 21% 24% 30% 
  Incorrectly predicted as inviable in 
supplemented media 4% 3% 4% 
Additional curation, which was conducted to improve the predictions of the 
formate-producing phenotype, also improved model prediction of gene essentiality and 
auxotrophy. 
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with other iND750 simulations reported below, is available in Appendix 3. We successfully 
reproduced the formate production efficiencies for five of the eight candidate high formate 
producing strains reported by Kennedy et al. when we simulated growth using MATLAB, the 
COBRA Toolbox, and the Gurobi solver with the iND750 model and the same in silico media 
composition and appropriate constraints to simulate eliminating the formate dehydrogenase 
reaction as reported by Kennedy et al. (Table 5.2). We could not reproduce the prediction of 
formate production for the remaining candidate strains because the version of iND750 that 
was available from the BIGG database [16] when we conducted our simulation in Spring 
2012 did not include any reactions annotated with YAT2. Thus, we concluded that our 
simulation using the COBRA Toolbox and Gurobi solver provides results comparable to 
those produced from the Kennedy et al. implementation. Differences in simulation results 
may be due to differences in numerical precision and implementation or because the previous 
effort used a different version of the iND750 model than that currently available for 
download from the BIGG database. We consider our results to be similar enough to the 
previously reported results to enable further model and implementation comparison. 
An in silico screen of triple mutants using the iND750 model with the COBRA 
toolbox includes the previously reported top-ranked mutant, but also predicts a higher 
formate-producing mutant 
An in silico screen of 3898895 possible triple mutants using the iND750 model 
predicted 217556 triple mutants (5.58%) would produce formate. The screen found that the 
alt2 fum1 zwf1 mutant, which was the top-ranked mutant reported from the Kennedy screen, 
would produce formate at an efficiency of 72.1%. This result is similar to the predicted 
72.3% efficiency reported by Kennedy et al. However, our screen also predicted that a put1 
fum1 zwf1 mutant would produce formate at a higher 72.2% efficiency (Table 5.5). 
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Simulations using the iND750 model predict the increasing formate produced by 
triple mutants over double and single mutants 
When constructing the alt2 zwf1 fum1 fdh1 fdh2 strain, Kennedy et al. also reported 
that total extracellular formic acid production increased from wild type to zwf1 to zwf1 fum1 
to zwf1 fum1 alt2strains. Growth simulations with the iND750 model using these knockouts 
did not predict formate production in the zwf1 mutant (as was observed in vivo by Kennedy et 
al.), but did predict formate production in zwf1 fum1 and predicted increased formate 
production in the zwf1 fum1 alt2 mutant (Table 5.3). 
Table 5.5 - Strains predicted to be high formate-producing mutants in screen 
using iND750 
Rank Genotypea Predicted 
Efficiency (%)b 
Kennedy et al. 
Rank 
1 put1 zwf1 fum1 72.24   
2 alt2 zwf1 fum1 72.13 1 
3 car1 zwf1 fum1 72.12   
4 car2 zwf1 fum1 72.05   
5 ach1 zwf1 fum1 72.01   
6 aat2 zwf1 fum1 71.98 2 
7 sfc1 zwf1 fum1 71.96   
8 dic1 zwf1 fum1 71.92   
9 aah1 zwf1 fum1 71.90   
10 urk1 zwf1 fum1 71.89   
a
Using a fdh1 fdh2 background. 
b
One hundred percent efficiency is defined as four formic acid molecules per 
glucose. 
The genotype and predicted formate-production efficiency of the top ten 
predicted formate-producing strains found by our in silico screen of 3,898,895 triple 
mutants, using the iND750 model of yeast metabolism. Our screen results included the 
top 5-ranked strains reported by Kennedy et al. [5]  
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An in silico screen of double mutants using the iND750 model predicts three high 
formate-producing mutants 
Since the additional formate flux predicted by the addition of a third gene deletion 
was relatively small, we also conducted an in silico screen of double mutants in a fdh1 fdh2 
background for formate-producing strains. When using the iND750 model, the screen found 
many mutants predicted to produce formate at low concentrations, and 3 high formate-
producing yeast double mutants: fum1 rpe1, fum1 fbp1, and fum1 zwf1 (Figure 5.2A). These 
mutants were predicted to produce formate with efficiencies of 71.45%, 30.38%, and 71.85%, 
respectively. We note that RPE1 and ZWF1 encode proteins in the pentose phosphate 
pathway, and that FBP1encodes Fructose-1,6-bisphosphatase, a key enzyme in the 
gluconeogenic pathway, which would not be expected to have a flux in the glucose-fed 
aerobic environment of this simulation. 
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Figure 5.2 - Predicted formate production in double knockout screen 
 
Results of in silico screening of 41,041 double mutants in a fdh1 fdh2 
background for formate-producing strains using the iND750 model (A), and 61,776 
double mutants using the updated Yeast 5.30 model (B). Simulations with the iND750 
model predicted 1,635 formate-producing double mutants (3.9%), with 3 high formate-
producing yeast double mutants: fum1 rpe1, fum1 fbp1, and fum1 zwf1. Simulations 
with the updated Yeast 5.30 model predicted 19,197 formate-producing mutants 
(31.1%), with 15 high formate-producing double mutants, which are detailed in Table 
5.6. 
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Table 5.6  - Double deletion mutants predicted to produce formate using the updated Yeast 5.30 model 











Notes on gene deleted in addition to FUM1 
Glyoxylate 
Cycle 
1 fum1 dic1 74.39   Mitochondrial dicarboxylate carrier 
1  fum1 mdh2 74.39   Cytoplasmic malate dehydrogenase 




3 fum1 zwf1 71.94 1, 2, 3 Glucose-6-phosphate dehydrogenase, catalyzes the first step of the 
pentose phosphate pathway 
4 fum1 rpe1 71.50 4 D-ribulose-5-phosphate 3-epimerase, catalyzes a reaction in the non-
oxidative part of the pentose-phosphate pathway 




6 fum1 lys20 47.40   Homocitrate synthase isozyme, catalyzes the first step in the lysine 
biosynthesis pathway 
6  fum1 lys4 47.40   Homoaconitase, catalyzes a step in the lysine biosynthesis pathway 
6 fum1 lys12 47.40   Homo-isocitrate dehydrogenase, an NAD-linked mitochondrial 
enzyme required for the fourth step in the biosynthesis of lysine 
6 fum1 lys1 47.40   Saccharopine dehydrogenase, catalyzes the final step in the lysine 
biosynthesis pathway 





7  fum1 bat1 38.39   Mitochondrial branched-chain amino acid aminotransferase 
8 fum1 bat2 36.27   Cytosolic branched-chain amino acid aminotransferase 
9 fum1 leu2 36.05   Beta-isopropylmalate dehydrogenase, catalyzes the third step in the 
leucine biosynthesis pathway 
9 fum1 leu1 36.05   Isopropylmalate isomerase, catalyzes the second step in the leucine 
biosynthesis pathway 
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a
Genotype in addition to fdh1 fdh2 background required to allow formate production 
b
One hundred percent efficiency is defined as four formic acid molecules per glucose 
 
An in silico screen of double deletion yeast mutants in a fdh1 fdh2 background using the Yeast metabolic model predicted 15 high 
formate-producing yeast mutants. A similar screen using iND750 predicted 3 high formate-producing yeast mutants (fum1 rpe1, fum1 fbp1, and 
fum1 zwf1, with efficiencies of 71.45%, 30.38%, and 71.85%, respectively).
152 
The Yeast 5 model must be modified to match in vivo observations and 
iND750 predictions. 
We found that growth simulations using version 5.01 of the Yeast model did 
not predict formate production for any of the 8 strains reported by Kennedy et al. 
(Table 5.2). The code used for these simulations is available in Appendix 3. Since 
formate production was observed in the alt2 zwf1 fum1 strain, this prediction is 
incorrect. The simulations predicted that biomass could be formed in 6 of the 8 strains, 
correctly predicting the auxotrophy caused by CHO1deletion.  
To improve the Yeast model’s prediction of the observed formate producing 
phenotype, we manually reviewed the reconstruction of C-1 metabolism by comparing 
it to literature describing this portion of metabolism [17–19]. During this review, we 
generated a list of literature-supported modifications to the Yeast model, which are 
documented with references in Appendix 3. These changes have been incorporated 
(along with changes suggested by Jouhten et al. [20]) to make version 5.30 of the 
Yeast model. 
Growth simulations using Yeast version 5.30 predict formate production for 
the same 5 strains as our simulation using iND750. Additionally, Yeast version 5.30 
predicts that the CHO1 mutant will not grow in media that does not contain choline. 
However, as discussed below, we found that additional constraints are needed to 
improve the performance of a double knockout screen using Yeast 5.30. These 




In silico double mutant screening results differ between the Yeast 5 model 
and the iND750 model, and are sensitive to constraints on reactions involving 
NAD(P) cofactors 
As we did using the iND750 model, we conducted an in silico screen of double 
mutants in a fdh1 fdh2 background for formate-producing strains using the Yeast 5.30 
model. While the iND750 screen predicted 3 high formate-producing mutants, the 
Yeast 5.30 screen predicted thousands. When reviewing this preliminary result, we 
observed that the simulations predicted that all FUM1 mutants produced formate. 
However, we also found that if we relaxed constraints on all cytoplasmic reactions 
involving NAD(P), none of these mutants were predicted to produce formate. Thus, 
we reviewed the literature for reactions involving these cofactors for which 
biochemical evidence of in vivo reversibility has been reported. Since efforts to 
incorporate thermodynamic information with genome-scale metabolic models are 
ongoing [4], we chose to restrict the directionality of other reactions involving these 
cofactors, a choice which may make the model predictions less robust in differing 
redox conditions. The set of reversible reactions involving NAD that we used for 
further simulation consists of the model reactions named (R,R)-butanediol 
dehydrogenase, aldehyde dehydrogenase (2-methylbutanol, NAD), aldehyde 
dehydrogenase (2-phenylethanol, NAD), aldehyde dehydrogenase (isoamyl alcohol, 
NAD), aldehyde dehydrogenase (isobutyl alcohol, NAD), aldehyde dehydrogenase 
(tryptophol, NAD), formaldehyde dehydrogenase, glutamate dehydrogenase (NAD), 
glyceraldehyde-3-phosphate dehydrogenase, malate dehydrogenase, cytoplasmic, 
saccharopine dehydrogenase (NAD, L-lysine forming), and NAD transport (reaction 
ids r_0003, r_0166, r_0169, r_0179, r_0182, r_0186, r_0443, r_0470, r_0486, r_0714, 
r_0988, and r_1956). The set of reversible reactions involving NADP consists of 
model reactions named D-arabinose 1-dehydrogenase (NADP), glutamate 
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dehydrogenase (NADP), methylenetetrahydrofolate dehydrogenase (NADP), 
saccharopine dehydrogenase (NADP, L-glutamate forming), and NADP(+) transport 
(reaction ids r_0321, r_0471, r_0732, r_0989, and r_1963). 
During the review of cytosolic reactions involving NAD(P), we also found 
literature evidence for further updates to the Yeast model, which are documented with 
references in Appendix 3. We incorporated these updates and constraints for an 
Updated Yeast 5.30. This updated model predicted 15 high formate-producing strains 
in an in silico screen of double knockout mutants for (Figure 5.2B). The highest-
ranked predicted formate-producing mutants included knockouts in the TCA and 
glyoxylate cycles, as well as the pentose phosphate pathway. Additional formate-
producers were predicted from deletions in amino acid biosynthetic metabolism (Table 
5.6). It remains unclear whether the simulated formate producing strains with 
knockouts in amino acid metabolism reflect accurate predictions of a possible link 
between nitrogen metabolism and C-1 metabolism or are an artifact of the complexity 
of reconstructing this portion of yeast biochemistry. Thus, amino acid and nitrogen 
metabolism is a good target for futher model curation. However, the screen of in silico 
double deletion mutants using the updated Yeast model suggests deletions in pathways 
which are the same branchpoints in carbon metabolism as those suggested using the 




Thus, performing a screen of simulated double-knockout mutants found that 
our literature-supported curation efforts affected the prediction of formate producing 
strains. As in our previous work, we found that this approach to curation also 
improved viability and auxotrophy predictions (Table 5.4), metrics which have 
Figure 5.3 – Top-ranked predicted formate producing knockout target 
genes’ relationship to central carbon metabolism 
 
The top-ranked predicted formate-producing mutants in an in silico screen using 
the updated Yeast 5 model are involved in the glyoxylate cycle, the TCA cycle, and 
the pentose phosphate pathway, pathways common to genes identified in a screen 
using the iND750 model.  
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previously been used to evaluate the performance of such models [21]. We note that 
growth simulations using either iND750 or the updated Yeast model do not predict the 
formation of glycerol, which has been suggested as a mechanism for balancing excess 
NADH production in S. cerevisiae during growth on glucose [22]. This observation 
supports the assertion that additional efforts are required to accurately model yeast 
redox metabolism [4]. 
Discussion  
Through our work to reimplement the computational methods of Kennedy et al 
[5] with the iND750 model [6] and to apply them to the Yeast [13] model, we have 
documented errors in both models, which we describe below, and have corrected and 
documented using the scripts included in Appendix 3. We have further demonstrated 
the benefits of literature-based curation of metabolic reconstructions as a tool for 
model improvement, and found that a comparative approach in which different model 
predictions are analyzed can give further insights to the use and improvement of these 
and other stoichiometrically constrained metabolic models. Our work also  
demonstrates that constraint-based stoichiometric models are sensitive to appropriate 
constraints on reactions involving redox cofactors when conducting flux balance 
analysis. Discussion of this finding is expanded below in the section entitled 
“Screening results for double and triple mutants for formate-producing strains differs 
between models, reflects model sensitivity to redox reaction constraints”. 
Results of flux balance analysis of previously predicted formate-producing 
mutant strains differs between models, reveals model errors 
Since the version of the iND750 model that was available from the BIGG 
database [16] when we conducted our simulation in Spring 2012 did not include any 
reactions annotated with YAT2, we were unable to simulate growth of the yat2 yeast 
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strains reported by Kennedy et al. Further, our simulations using the updated Yeast 
model (which does include reactions annotated with YAT2) did not predict formate 
production for these strains, and predicted that the 7
th
-ranked strain (a cho1mutant) 
would not be viable in choline-free media (Table 5.1). CHO1mutants have been 
reported to be choline auxotrophs [23]. 
For the five wild type YAT2 strains which were previously reported as 
predicting  formate production, our simulations using both the iND750 and the 
updated Yeast model predicted different formate production efficiencies than reported 
by Kennedy et al. That the differences in predicted formate yield we found using the 
iND750 model were not large suggests that our imposition of constraints to simulate 
the media formulation and strain background was similar to the approach used in the 
previous work. It is likely that the differing simulation results are a result of using 
different linear programming software and FBA implementation than the previous 
effort, not a result of any significant changes to model constraints or other possible 
revisions to the underlying model. 
Flux balance analysis of the predicted fluxes reported for the top-performing 
alt2 fum1 zwf1 strain using iND750 includes solutions which predict a large flux 
through reactions transporting methylene-tetrahydrofolate and tetrahydrofolate 
between the mitochondria and the cytosol (Figure 5.4). These reactions, called 
MLTHFtm and THFtm in the iND750 model are not supported by the literature on 
compartmentalization of C1-metabolism [17–19], suggesting that these reactions were 
erroneously included in iND750 (they are not present in the Yeast model). 
Fortunately, we found that removing these reactions from iND750 did not affect the 
prediction of formate production for this strain, though the model modification did 




Additionally, we noted that simulations with iND750 predicted unusual fluxes 
which we cannot rule out in the absence of further experimental evidence, but seem 
unlikely based on previous efforts to document yeast metabolic fluxes. The 5
th
-ranked 
strain reported by Kennedy et al. includes a mutation in FBP1, which codes for 
fructose-1,6-bisphosphatase [24],a key enzyme involved in gluconeogenesis, a 
pathway which would not be expected to carry a flux in a glucose-rich media [25]. 
When we simulated growth of a fum1 strain using iND750, the simulation predicted a 
Figure 5.4 – Errors in the iND750 reconstruction of formate metabolism 
 
iND750 includes two transport reactions, MLTHFtm and THFtm, which are not 
supported by the literature on compartmentalization of C1-metabolism [17–19]. 




flux through the reaction catalyzed by FBP1 which increased the flux to the pentose 
phosphate pathway – an observation similar to the recently reported finding that 
gluconeogenesis is required to redirect flux to the oxidative pentose phosphate 
pathway in yeast engineered for xylose-metabolism [26]. However, since fructose-1,6-
bisphosphatase is transcriptionally repressed in the presence of hexoses [27], this flux 
distribution seems unlikely in glucose-fed yeast mutants, and does not agree with 
previously reported fluxes through central carbon metabolism for fum1 mutants [25]. 
Simulations of the fum1 mutant using the updated Yeast model did not predict this 
gluconeogenic flux. 
We found that simulations using the updated Yeast 5 model predicted that the 
fum1 zwf1 mutant produced formate, but did not predict additional formate production 
due to deletion of ALT2, AAT2, or CAT2 (the top three-ranked strains reported from 
the Kennedy et al. screen). The Yeast model prediction of no increased flux with the 
additional deletion of ALT2 differs from Kennedy et al.’s in vivo measurement of 
higher formate production in a fum1 zwf1 alt2 mutant than a fum1 zwf1 mutant. 
Our simulations of a fum1 zwf1mutant using iND750 predicted fluxes through 
reactions annotated with ALT2 and AAT2, but not CAT2. We investigated each of these 
flux predictions, finding fluxes through reactions which are not present in the Yeast 
model and fluxes through reactions which are mis-annotated in iND750. We also 
found that the predicted formate flux in the simulated fum1 zwf1 cat2 strain was the 
same as a simulated fum1 zwf1 strain.  
Although the reaction catalyzed by ALT2 in iND750 is supported by literature 
evidence [28], ALT2 is annotated as an “uncharacterized ORF” by the Saccharomyces 
Genome Database (SGD) [29], and is therefore not included in the Yeast 5 model. 
Further, simulation with iND750 predicts an upstream flux through a reaction 
catalyzed by a second uncharacterized ORF, YML082W. We found that adding these 
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two reactions to the updated Yeast model was not sufficient to produce a flux through 
the reaction catalyzed by ALT2, so simulations using a modified Yeast 5 model still 
did not predict an increase in formate production with this third gene deletion. It is not 
clear which model features of iND750 lead to the flux through the reaction annotated 
by ALT2. 
Our simulations of a fum1 zwf1mutant using iND750 predicted fluxes through 
two reactions annotated with AAT2: an aspartate transaminase reaction and a tyrosine 
transaminase reaction. We found that the aspartate transaminase reaction is present in 
the Yeast model, but did not have a flux in simulations using that model. Further, we 
found that the tyrosine transaminase reaction corresponded to the reaction catalyzed 
by ARO8, not AAT2. This annotation appears to be an annotation error in iND750. 
This reaction is correctly annotated in the Yeast model, which may contribute to 
simulations using that model not predicting a different flux for aat2 fum1 zwf1 than for 
fum1 zwf1. 
Screening results for double and triple mutants for formate-producing 
strains differs between models, reflects model sensitivity to redox reaction 
constraints 
Having successfully simulated growth and the formate-producing phenotype 
for the predicted top-performing formate-producing strains reported by Kennedy et al., 
we re-implemented their in silico screen of triple-knockout yeast mutants for a 
formate-producing phenotype using iND750. Our screen implementation identified the 
first five strains reported from Kennedy et al.’s screen, though only Kennedy’s first 
and second ranked mutants were among the 10 top-ranked strains in our screen (Table 
5.5). The top-ranked predicted formate-producing yeast strain in our screen was a put1 
zwf1 fum1 mutant, and Kennedy et al.’s top-ranked alt2 zwf1 fum1 strain was the 
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second highest ranked in our screen. Like ALT2, PUT1is implicated in glutamate 
metabolism in the iND750 model. Additionally, both genes are affected by redox 
metabolism in this model: ALT2 catalyzes a reaction using NAD as a cofactor, and 
PUT2 catalyzes a reaction using glutamate as a substrate to produce 2-oxoglutarate. In 
turn, 2-oxoglutarate produces glutamate in a reaction using NADPH as a cofactor. 
Thus, our top-ranked screen predictions are similar to those reported by Kennedy et 
al., though not identical. As with our efforts to reproduce their simulation of top-
ranked screens, differences are likely due to software implementation details or 
modifications to the iND750 model that are not incorporated to the version we 
downloaded from the BIGG database. Like the Kennedy et al. screening results, the 
computationally suggested third knockouts were at distantly located positions within 
the metabolic network, not directly implicated in formic acid biosynthesis or C1 
metabolism. 
Of the top 259 predicted formate-producing strains using the iND750 model, 
258 were zwf1 fum1mutants (the other strain also had mutants in the pentose 
phosphate pathway and the TCA cycle – a rpe1 put1 fum1 genotype). In all cases, the 
deletion of a third gene in addition to FUM1 and ZWF1 (or RPE1) contributed a 
smaller increase in predicted formate flux than the deletion of a second gene in 
addition to fum1. Therefore, we also conducted in silico screens of double-mutants for 
formate producing strains using both the iND750 and the Yeast 5 models. As 
discussed in the Results section, our initial screen with the Yeast 5.30 model predicted 
that formate producing mutants were very common – in fact, all fum1mutants were 
predicted to be high formate-producers, and no flux was predicted through the 
oxidative pentose phosphate pathway (and so there was no additional formate 
production predicted when ZWF1was deleted). However, when we relaxed the 
constraints to allow all cytosolic reactions involving NAD or NADP to be reversible 
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(an approach suggested to avoid over-constraining the model in the absence of 
thermodynamic information [4]), none of these mutants were predicted to produce 
formate. When relaxing constraints on only the NAD reactions, all fum1mutants were 
predicted to produce formate, demonstrating that this model is sensitive to constraints 
on redox reactions, and suggesting that constraints on reactions involving NAD can be 
tuned to affect model prediction of a flux through the pentose phosphate pathway, and 
C-1 metabolism (which leads to formate production). In the absence of tools to 
thermodynamically constrain these reactions, we chose to relax the reversibility 
constraints only on those reactions for which we could find in vivo observations of 
reversibility reported in the literature. 
We are not the first to report observations of computationally-predicted 
interdependencies between redox reactions, the pentose phosphate pathway, and C-1 
metabolism. Such dependencies have also been noted in efforts to improve flux 
balance predictions using a modified version of the iND750 model [30]. Additionally, 
we note that these fluxes would be expected to be dependent upon media formulation: 
a variable flux through oxidative pentose phosphate pathway has been documented as 
a result of supplementing growth media with amino acids [31]. 
After applying our literature-supported constraints to cytosolic reactions 
involving NAD and NADP to the Yeast 5 model, the results of our double knockout 
mutant screens differed between the iND750 and updated Yeast 5 models (Figure 5.2). 
A screen for formate-producing double mutants using the iND750 model predicted 
3.9% of the double mutants would produce formate, with three strains predicted to be 
unusually high formate producers: fum1 zwf1, fum1 rpe1, and fum1 fbp1. The screen 
conducted with Yeast 5 predicted 31.1% of the double mutants would produce 
formate, with 15 predicted high-performing double mutants (Table 5.6). The screen 
using Yeast 5 did not predict that the fum1 fbp1double mutant would be a high 
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formate-producing strain, and predicted high-performing strains with mutations in the 
TCA cycle, the pentose phosphate cycle, and some amino acid biosynthetic pathways 
(Figure 5.3). Testing these predictions provides an opportunity for further model 
validation and improvement. 
A variety of techniques have been proposed to address perceived shortcomings 
of flux balance analysis predictions in eukaryotes. However, advanced computational 
techniques may be prematurely applied when the underlying reconstruction of 
biochemistry is incomplete or inaccurate. In the current work, we have not applied any 
techniques beyond standard flux balance analysis and literature review to improve the 
reconstruction of established yeast biochemical knowledge. We have found that 
problematic predictions can be corrected through literature-based curation of 
biochemical reconstruction, and do not necessarily imply limitations of the 
computational methods used. The process of reconstructing yeast metabolism is not 
complete, and we expect the iterative process of community model curation will 
continue to improve the Yeast model. 
Conclusions  
Our work emphasizes need for ongoing model validation efforts, which benefit 
from application of genome-scale metabolic models, and emphasizes a need for 
improved documentation of computational models, their modification, and the details 
of their use. Through comparative analysis, we found that flux balance analysis of the 
iND750 model predicted fluxes through reactions annotated with uncharacterized open 
reading frames that are not present in the consensus reconstruction. Kennedy et al.’s 
observation of increased formate production in a fum1 zwf1 alt2 mutant relative to a 
fum1 zwf1 mutant is particularly remarkable given the annotation and reconstruction 
errors we found in the iND750 model and the absence of this prediction in the newer 
Yeast model (which does not include reactions annotated with the ALT2 gene). 
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Observing the differing predictions of a phenotype for this “uncharacterized ORF” 
required comparative analysis of metabolic models which differ in scope (such as 
iND750 and the Yeast model). Screening models for fluxes through hypothesized 
reactions or annotations is a promising technique for guiding future efforts to describe 
the metabolic role of other poorly characterized yeast genes. Thus, the inclusion of 
such hypothetical annotation can reveal novel phenotypes. However, the inclusion of 
ALT2 is not documented as hypothetical in the model, which raises the question: 
which portions of this model are established biochemical fact, and which portions are 
not? Thus, we conclude that the research community would benefit from improved 
annotation of metabolic models. 
We were unable to reproduce the prediction that deletion of YAT2 affected 
formate metabolism using the iND750 model because that gene was not present in the 
version of iND750 that we used for our efforts.  However, we do not know the full 
details of how the version of iND750 we used might differ from that used by Kennedy 
et al. Thus, we conclude that research which applies or modifies constraint-based 
models would also benefit from careful and extensive documentation including 
sharing the model used, along with software code used to modify models and to 
implement simulations. 
We have found that the simulation results are sensitive to details of 
implementation and to applied constraints. Specifically, we found that we could not 
precisely match previously reported in silico screen results with a new 
implementation, and we found that we could tune the frequency of formate-producing 
double mutants by constraining the reversibility of reactions involving NAD(P) 
cofactors in the Yeast model. Since different results can be found with different 
constraints, the set of constraints used for a screen must also be well documented. If 
we hope to discriminate factors which are numerically significant and those which are 
165 
 
biologically significant, we must continue to improve the approach to modeling and 
reporting computational methods and results. 
Phenotype predictive power remains the standard for comparing different 
models of yeast metabolism, but our work demonstrates that in some cases, a correct 
phenotypic prediction does not necessarily imply a more accurate reconstruction of a 
metabolic network, and that an improved biochemical reconstruction does not 
guarantee improved predictive power. Thus, model flux predictions merit careful 
review in all cases. Such review provides a useful tool for evaluating and improving 
yeast models – the iterative process of building an accurate model of yeast metabolism 
continues. 
We found that simulations using the most recent model of yeast metabolism 
predict more formate producing double knockout mutants than simulations using the 
iND750 model, and that the simulations with the Yeast model do not predict a 
gluconeogenic flux which is predicted by iND750. Additional in vivo data is required 
to evaluate these predictions. 
Methods 
All simulations were conducted using version 2.0.4 of the COBRA Toolbox 
[3] for MATLAB version 2011b on PCs running Windows 7. We used version 4.61 of 
the Gurobi Optimizer to solve the linear programming problem underlying flux 
balance analysis. The MATLAB code we wrote for all simulations (which includes 
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CHAPTER 6 – CONCLUSIONS AND FUTURE RESEARCH 
 
 
The original objective of this research was to apply a stoichiometrically constrained 
model of yeast metabolism to develop a metabolic engineering strategy which would be applied 
to improve the stress tolerance of industrially useful organisms. However, during model 
validation, I found that existing models do not fully and accurately reconstruct established 
knowledge of the biochemistry of the yeast metabolic network, and so I expanded the research 
objective to:  
1. Conduct literature-based validation of the reconstruction of sphingolipid 
metabolism included in the Consensus Reconstruction of Yeast Metabolism 
2. Update the existing model by incorporate any changes required to correct errors in 
the reconstruction 
3. Evaluate the impact of these changes on the predictive accuracy of the model 
4. Apply the updated model to develop metabolic engineering strategies for strain 
improvement 
5. Evaluate any differences in strategies suggested by the updated model with 
predictions of previously published models 
I found that such models can be improved by careful review of pertinent literature, 
incorporation of corrections, and comparative simulation efforts. I found that yeast metabolic 
models may be applied to inform metabolic engineering strategies, but that such models are not 
yet sufficiently accurate or predictive to execute such strategies without further expert review 
and analysis. Through the process of improving yeast models, I have demonstrated that such 
models can be used to generate new hypotheses, and are therefore a valuable tool for advancing 
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our understanding of metabolism. 
Manual review of the biochemical reactions included in the Consensus Reconstruction of 
Yeast Metabolism [1, 2] found that this model did not accurately reconstruct the metabolic 
pathways involved in the biosynthesis of complex sphingolipids (Chapter 3, [3]). The model was 
both incomplete, containing only 28 of 243 biochemical reactions I found in the pathway, and 
inaccurate – it contained an additional 13 reactions which were not supported by the literature. I 
found that that correcting these and other errors in the biochemistry improved the model: 
compared to version 4 of the Yeast Consensus Reconstruction, Yeast 5better predicts gene 
essentiality,knockout-induced auxotrophies, and other phenotypes (Chapter 4, [4]). I made 
particular efforts to document my approach to improving the model and conducting simulations 
by including the MATLAB scripts I used as supplemental information to published manuscripts, 
and as Appendices to this dissertation. 
Next, I worked to return to my original objective of applying a stoichiometrically 
constrained model of yeast metabolism to develop metabolic engineering strategies. I wrote 
software to re-implement a previously reported in silico screen of simulated mutants for a 
formate-producing phenotype, and compared the predictions of the updated model to the older 
iND750 model (Chapter 5). I found that Yeast 5 did not accurately predict phenotypes which had 
been predicted by iND750 and observed in vivo. By comparing predicted fluxes between the 
models, and conducting additional literature-based curation, I found errors in both iND750 and 
Yeast 5, and made additional corrections to Yeast 5. Additionally, I found a set of literature-
supported constraints to reaction reversibility which improved flux predictions in the Yeast 
model. Following these corrections, screens of simulated knockout strains using the updated 
Yeast model made different predictions of knockouts that would lead to a formate-producing 
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phenotype than earlier yeast metabolic models. Thus, I found that a comparative approach of 
evaluating phenotype and metabolic flux predictions using different metabolic models is a 
valuable tool for model refinement and improvement (Chapter 5). 
Thus, the primary conclusion drawn from this work is that literature-based curation of 
stoichiometrically constrained models of yeast metabolism can improve model accuracy and 
predictive ability. In turn, improved models can be applied to develop metabolic engineering 
objectives.  
Metabolic reconstructions contain reactions which are descriptive of established 
biochemistry, but also include hypothetical reactions intended to improve model predictive 
accuracy or to enable mathematical analysis. The distinction between established knowledge and 
hypothesis in such models is not always clear. Improved documentation would make such 
models better scientific tools. Similarly, though algorithms and proofs of concept are reported in 
the literature for a variety of techniques for computational analysis of such models, these 
methods may be implemented in different ways, yielding differing results. If metabolic models 
are to be used for hypothesis generation, the methods must be better documented. 
Despite the drawbacks of limited documentation, mass balance-based stoichiometrically 
constrained metabolic models have a great deal of still-unrealized potential.  
Future research 
There are many opportunities to apply the application of stoichiometrically constrained 
models to future research, and many opportunities to refine the scope and techniques of this 
modeling approach. For example, if a metabolic reconstruction accurately reflects established 
biochemical knowledge, then any blocked reactions in the model – those reactions which cannot 
carry a flux because they are not connected (in a graph-theoretical sense) to the rest of the 
metabolic network – reflect gaps in our knowledge of metabolism. As this work demonstrates, 
the process of improving the reconstruction of established biochemistry is an iterative effort to 
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improve the model. 
The differing predictions of phenotypes predicted in simulations involving the 
uncharacterized open reading frame ALT2 highlights the ongoing need for additional 
characterization of yeast genes. The Saccharomyces Genome Database currently includes 848 
uncharacterized open reading frames and 785 dubious open reading frames. As these open 
reading frames are better characterized, new information must be incorporated to computational 
reconstructions of metabolism. 
Simulations using the set of reaction constraints generated for Chapter 5 make predictions 
which both suggest future experimental work and provide a target for further model curation. 
Specifically, the double knockout mutants predicted to produce formate by the model (Table 5.4) 
should be constructed in vivo and the resulting strains should be tested to determine whether 
these model predictions are accurate. The prediction that knockouts in the Lysine biosynthetic 
pathway might affect C1 metabolism are novel, and the reconstruction of amino acid pathways is 
not a portion of yeast metabolism that was carefully evaluated during the course of this work. 
Thus, amino acid metabolism is a good target for future model curation and, if necessary, 
refinement. Similarly, there remains opportunity for additional literature-based model curation, 
of redox reactions, lipid, amino acid, and nitrogen metabolism, and Acetyl-CoA metabolism. 
Application of constraint-based models to scientific and engineering research would also 
benefit from additional consideration of practical issues. Despite the proliferation of models of 
yeast metabolism, there are not well-defined metrics or tools for evaluating models. For example, 
there is not a set of well-defined phenotypes or simulated media that can serve as an objective 
standard for evaluating computational predictions. Additionally, the ongoing effort to improve 
metabolic reconstructions would benefit from tools which facilitated collaborative curation, 
documentation, and model application. 
The future also holds opportunity for expanding modeling approaches such as flux 
balance analysis beyond metabolism. Our knowledge of the relationship between signaling, 
transcriptional regulation, and the metabolic network is incomplete, and the distinction between 
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these aspects of physiology is not clear-cut. As human understanding of these interrelated 
cellular processes improves, modeling techniques will need to be refined to encompass a broader 
range of biochemical reactions than that which is currently described in metabolic models. The 
updated version of the Yeast model presented in this work accounts for 904 open reading frames, 
which is 13.7% of those currently listed in the Saccharomyces Genome Database. As our 
understanding of yeast biochemistry improves, model coverage may expand to account for the 
entire yeast genome. 
This dissertation contributes to the ongoing effort to develop systems biotechnology tools 
which will enable the rational design of new microbial strains, and which may enable broader 
industrial-scale application of biotechnology. The fields of computational biology and systems 
biotechnology are young, and abundant opportunity remains to develop and apply this 
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APPENDIX 1 – SUPPLEMENTARY INFORMATION FOR CHAPTER 3 
 
Supplementary Figure 3.1: The incomplete reconstruction of sphingolipid metabolism in 
Yeast v4.05 
The Yeast v4.05 reconstruction of yeast sphingolipid metabolism includes incomplete and 
inconsistent differentiation between ceramide and sphingolipid species which vary by 





Supplementary Figure 3.2: Suggested modifications to the reconstruction of yeast 
sphingolipid metabolism 
Modifications to the Yeast v4.05 reconstruction of yeast sphingolipid metabolism (red) are 
necessary to resolve differences between the current reconstruction and the pathway described in 
yeast biochemical literature. These proposed changes (which are compiled with references as 
Supplementary Table 3.1) have been submitted to the maintainers of Yeast Reconstruction for 
future expansion. The figure labeled A shows all modifications. The figure labeled B is a portion 
































Supplementary Table 3.1 is the literature-based reaction list, with references. 
Reactions gene locus Gene References (DOI, first author) 
'L-serine [endoplasmic 
reticulum] + palmitoyl-CoA 
[endoplasmic reticulum]  <=> 
3-ketosphinganine 
[endoplasmic reticulum] + 
carbon dioxide [endoplasmic 
reticulum] + coenzyme A 












PNAS August 16, 1994 vol. 91 no. 17 
7899-7902  (Nagiec) 






[endoplasmic reticulum] + 2 
H+ [endoplasmic reticulum] + 
NADPH [endoplasmic 
reticulum]  <=> NADP(+) 
[endoplasmic reticulum] + 
sphinganine [endoplasmic 
reticulum] ' 





CoA [endoplasmic reticulum]  
<=> ceramide-1 (C24) 
[endoplasmic reticulum] + 
coenzyme A [endoplasmic 















[endoplasmic reticulum] + 
sphinganine [endoplasmic 
reticulum]  <=> ceramide-1 
(C26) [endoplasmic reticulum] 
+ coenzyme A [endoplasmic 














'H+ [endoplasmic reticulum] + 
NADPH [endoplasmic 
reticulum] + oxygen 
[endoplasmic reticulum] + 
sphinganine [endoplasmic 
reticulum]  <=> H2O 
[endoplasmic reticulum] + 
NADP(+) [endoplasmic 
reticulum] + phytosphingosine 
[endoplasmic reticulum] ' 






[endoplasmic reticulum] + H+ 
[endoplasmic reticulum] + 
NADPH [endoplasmic 
reticulum] + oxygen 
[endoplasmic reticulum]  <=> 
ceramide-2 (C24) 
[endoplasmic reticulum] + 
H2O [endoplasmic reticulum] 
+ NADP(+) [endoplasmic 
reticulum] ' 




[endoplasmic reticulum] + H+ 
[endoplasmic reticulum] + 
NADPH [endoplasmic 
reticulum] + oxygen 
[endoplasmic reticulum]  <=> 
ceramide-2 (C26) 
[endoplasmic reticulum] + 
H2O [endoplasmic reticulum] 
+ NADP(+) [endoplasmic 
reticulum] ' 




[endoplasmic reticulum] + 
tetracosanoyl-CoA 
[endoplasmic reticulum]  <=> 
ceramide-2 (C24) 
[endoplasmic reticulum] + 
coenzyme A [endoplasmic 















[endoplasmic reticulum] + 
phytosphingosine 
[endoplasmic reticulum]  <=> 
ceramide-2 (C26) 
[endoplasmic reticulum] + 
coenzyme A [endoplasmic 














'ATP [endoplasmic reticulum] 
+ phytosphingosine 
[endoplasmic reticulum]  <=> 
ADP [endoplasmic reticulum] + 
H+ [endoplasmic reticulum] + 
phytosphingosine 1-phosphate 










'ATP [endoplasmic reticulum] 
+ sphinganine [endoplasmic 
reticulum]  <=> ADP 
[endoplasmic reticulum] + H+ 
[endoplasmic reticulum] + 
sphinganine 1-phosphate 





10.1074/jbc.273.31.19437  (Nagiec) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ phytosphingosine 1-
phosphate [endoplasmic 
reticulum]  <=> phosphate 
[endoplasmic reticulum] + 
phytosphingosine 





PNAS January 6, 1998 vol. 95 no. 1 
150-155 (Mandala) 
10.1074/jbc.272.45.28690  (Mao) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ sphinganine 1-phosphate 
[endoplasmic reticulum]  <=> 
phosphate [endoplasmic 
reticulum] + sphinganine 





PNAS January 6, 1998 vol. 95 no. 1 
150-155 (Mandala) 




[endoplasmic reticulum]  <=> 
2-hydroxyhexadecanal 
[endoplasmic reticulum] + O-
phosphoethanolamine 
[endoplasmic reticulum]  








[endoplasmic reticulum] ' 




inositol [Golgi] + ceramide-2'' 
(C24) [Golgi]  <=> diglyceride 
[Golgi] + inositol-P-ceramide 
B'' (C24) [Golgi] ' 




inositol [Golgi] + ceramide-2'' 
(C26) [Golgi]  <=> diglyceride 
[Golgi] + inositol-P-ceramide 
B'' (C26) [Golgi] ' 




inositol [Golgi] + ceramide-3 
(C24) [Golgi]  <=> diglyceride 
[Golgi] + inositol-P-ceramide C 
(C24) [Golgi] ' 






inositol [Golgi] + ceramide-3 
(C26) [Golgi]  <=> diglyceride 
[Golgi] + inositol-P-ceramide C 
(C26) [Golgi] ' 




inositol [Golgi] + ceramide-1 
(C24) [Golgi]  <=> diglyceride 
[Golgi] + inositol-P-ceramide A 
(C24) [Golgi] ' 




inositol [Golgi] + ceramide-1 
(C26) [Golgi]  <=> diglyceride 
[Golgi] + inositol-P-ceramide A 
(C26) [Golgi] ' 




inositol [Golgi] + ceramide-2 
(C24) [Golgi]  <=> diglyceride 
[Golgi] + inositol-P-ceramide B 
(C24) [Golgi] ' 




inositol [Golgi] + ceramide-2 
(C26) [Golgi]  <=> diglyceride 
[Golgi] + inositol-P-ceramide B 
(C26) [Golgi] ' 




inositol [Golgi] + ceramide-4 
(C24) [Golgi]  <=> diglyceride 
[Golgi] + inositol-P-ceramide D 
(C24) [Golgi] ' 




inositol [Golgi] + ceramide-4 
(C26) [Golgi]  <=> diglyceride 
[Golgi] + inositol-P-ceramide D 
(C26) [Golgi] ' 




+ inositol-P-ceramide A (C24) 
[Golgi]  <=> GDP [Golgi] + 
mannosylinositol 














+ inositol-P-ceramide A (C26) 
[Golgi]  <=> GDP [Golgi] + 
mannosylinositol 
















+ inositol-P-ceramide B'' (C24) 
[Golgi]  <=> GDP [Golgi] + 
mannosylinositol 














+ inositol-P-ceramide B'' (C26) 
[Golgi]  <=> GDP [Golgi] + 
mannosylinositol 














+ inositol-P-ceramide B (C24) 
[Golgi]  <=> GDP [Golgi] + 
mannosylinositol 














+ inositol-P-ceramide B (C26) 
[Golgi]  <=> GDP [Golgi] + 
mannosylinositol 














+ inositol-P-ceramide C (C24) 
[Golgi]  <=> GDP [Golgi] + 
mannosylinositol 














+ inositol-P-ceramide C (C26) 
[Golgi]  <=> GDP [Golgi] + 
mannosylinositol 














+ inositol-P-ceramide D (C24) 
[Golgi]  <=> GDP [Golgi] + 
mannosylinositol 














+ inositol-P-ceramide D (C26) 
[Golgi]  <=> GDP [Golgi] + 
mannosylinositol 
















inositol [Golgi] + 
mannosylinositol 
phosphorylceramide A (C24) 
[Golgi]  <=> diglyceride [Golgi] 
+ inositol 
phosphomannosylinositol 
phosphoceramide A (C24) 
[Golgi] ' 




inositol [Golgi] + 
mannosylinositol 
phosphorylceramide A (C26) 
[Golgi]  <=> diglyceride [Golgi] 
+ inositol 
phosphomannosylinositol 
phosphoceramide A (C26) 
[Golgi] ' 




inositol [Golgi] + 
mannosylinositol 
phosphorylceramide B'' (C24) 
[Golgi]  <=> diglyceride [Golgi] 
+ inositol 
phosphomannosylinositol 
phosphoceramide B'' (C24) 
[Golgi] ' 




inositol [Golgi] + 
mannosylinositol 
phosphorylceramide B'' (C26) 
[Golgi]  <=> diglyceride [Golgi] 
+ inositol 
phosphomannosylinositol 
phosphoceramide B'' (C26) 
[Golgi] ' 




inositol [Golgi] + 
mannosylinositol 
phosphorylceramide B (C24) 
[Golgi]  <=> diglyceride [Golgi] 
+ inositol 
phosphomannosylinositol 
phosphoceramide B (C24) 







inositol [Golgi] + 
mannosylinositol 
phosphorylceramide B (C26) 
[Golgi]  <=> diglyceride [Golgi] 
+ inositol 
phosphomannosylinositol 
phosphoceramide B (C26) 
[Golgi] ' 




inositol [Golgi] + 
mannosylinositol 
phosphorylceramide C (C24) 
[Golgi]  <=> diglyceride [Golgi] 
+ inositol 
phosphomannosylinositol 
phosphoceramide C (C24) 
[Golgi] ' 




inositol [Golgi] + 
mannosylinositol 
phosphorylceramide C (C26) 
[Golgi]  <=> diglyceride [Golgi] 
+ inositol 
phosphomannosylinositol 
phosphoceramide C (C26) 
[Golgi] ' 




inositol [Golgi] + 
mannosylinositol 
phosphorylceramide D (C24) 
[Golgi]  <=> diglyceride [Golgi] 
+ inositol 
phosphomannosylinositol 
phosphoceramide D (C24) 
[Golgi] ' 




inositol [Golgi] + 
mannosylinositol 
phosphorylceramide D (C26) 
[Golgi]  <=> diglyceride [Golgi] 
+ inositol 






phosphoceramide D (C26) 
[Golgi] ' 
'H2O [endoplasmic reticulum] 
+ mannosylinositol 
phosphorylceramide A (C24) 
[endoplasmic reticulum]  <=> 
ceramide-1 (C24) 




'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ mannosylinositol 
phosphorylceramide A (C26) 
[endoplasmic reticulum]  <=> 
ceramide-1 (C26) 




'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ mannosylinositol 
phosphorylceramide B'' (C24) 
[endoplasmic reticulum]  <=> 
ceramide-2'' (C24) 




'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ mannosylinositol 
phosphorylceramide B'' (C26) 
[endoplasmic reticulum]  <=> 
ceramide-2'' (C26) 




'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ mannosylinositol 
phosphorylceramide B (C24) 
[endoplasmic reticulum]  <=> 
ceramide-2 (C24) 
[endoplasmic reticulum] + 








'H2O [endoplasmic reticulum] 
+ mannosylinositol 
phosphorylceramide B (C26) 
[endoplasmic reticulum]  <=> 
ceramide-2 (C26) 




'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ mannosylinositol 
phosphorylceramide C (C24) 
[endoplasmic reticulum]  <=> 
ceramide-3 (C24) 




'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ mannosylinositol 
phosphorylceramide C (C26) 
[endoplasmic reticulum]  <=> 
ceramide-3 (C26) 




'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ mannosylinositol 
phosphorylceramide D (C24) 
[endoplasmic reticulum]  <=> 
ceramide-4 (C24) 




'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ mannosylinositol 
phosphorylceramide D (C26) 
[endoplasmic reticulum]  <=> 
ceramide-4 (C26) 
[endoplasmic reticulum] + 








'H2O [endoplasmic reticulum] 
+ inositol 
phosphomannosylinositol 
phosphoceramide A (C24) 
[endoplasmic reticulum]  <=> 
ceramide-1 (C24) 




'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ inositol 
phosphomannosylinositol 
phosphoceramide A (C26) 
[endoplasmic reticulum]  <=> 
ceramide-1 (C26) 




'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ inositol 
phosphomannosylinositol 
phosphoceramide B'' (C24) 
[endoplasmic reticulum]  <=> 
ceramide-2'' (C24) 




'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ inositol 
phosphomannosylinositol 
phosphoceramide B'' (C26) 
[endoplasmic reticulum]  <=> 
ceramide-2'' (C26) 









'H2O [endoplasmic reticulum] 
+ inositol 
phosphomannosylinositol 
phosphoceramide B (C24) 
[endoplasmic reticulum]  <=> 
ceramide-2 (C24) 




'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ inositol 
phosphomannosylinositol 
phosphoceramide B (C26) 
[endoplasmic reticulum]  <=> 
ceramide-2 (C26) 




'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ inositol 
phosphomannosylinositol 
phosphoceramide C (C24) 
[endoplasmic reticulum]  <=> 
ceramide-3 (C24) 




'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ inositol 
phosphomannosylinositol 
phosphoceramide C (C26) 
[endoplasmic reticulum]  <=> 
ceramide-3 (C26) 




'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ inositol 
phosphomannosylinositol 
phosphoceramide D (C24) 
[endoplasmic reticulum]  <=> 
ceramide-4 (C24) 
[endoplasmic reticulum] + 








'H2O [endoplasmic reticulum] 
+ inositol 
phosphomannosylinositol 
phosphoceramide D (C26) 
[endoplasmic reticulum]  <=> 
ceramide-4 (C26) 




'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [mitochondrion] + 
inositol-P-ceramide A (C24) 
[mitochondrion]  <=> 1D-myo-
inositol 3-phosphate 
[mitochondrion] + ceramide-1 
(C24) [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
inositol-P-ceramide A (C26) 
[mitochondrion]  <=> 1D-myo-
inositol 3-phosphate 
[mitochondrion] + ceramide-1 
(C26) [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
inositol-P-ceramide B'' (C24) 
[mitochondrion]  <=> 1D-myo-
inositol 3-phosphate 
[mitochondrion] + ceramide-
2'' (C24) [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
inositol-P-ceramide B'' (C26) 
[mitochondrion]  <=> 1D-myo-
inositol 3-phosphate 
[mitochondrion] + ceramide-
2'' (C26) [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
inositol-P-ceramide B (C24) 
[mitochondrion]  <=> 1D-myo-
inositol 3-phosphate 
[mitochondrion] + ceramide-2 
(C24) [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
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'H2O [mitochondrion] + 
inositol-P-ceramide B (C26) 
[mitochondrion]  <=> 1D-myo-
inositol 3-phosphate 
[mitochondrion] + ceramide-2 
(C26) [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
inositol-P-ceramide C (C24) 
[mitochondrion]  <=> 1D-myo-
inositol 3-phosphate 
[mitochondrion] + ceramide-3 
(C24) [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
inositol-P-ceramide C (C26) 
[mitochondrion]  <=> 1D-myo-
inositol 3-phosphate 
[mitochondrion] + ceramide-3 
(C26) [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson) 
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
inositol-P-ceramide D (C24) 
[mitochondrion]  <=> 1D-myo-
inositol 3-phosphate 
[mitochondrion] + ceramide-4 
(C24) [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
inositol-P-ceramide D (C26) 
[mitochondrion]  <=> 1D-myo-
inositol 3-phosphate 
[mitochondrion] + ceramide-4 
(C26) [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
mannosylinositol 
phosphorylceramide A (C24) 





'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
mannosylinositol 
phosphorylceramide A (C26) 





'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
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'H2O [mitochondrion] + 
mannosylinositol 
phosphorylceramide B'' (C24) 





'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
mannosylinositol 
phosphorylceramide B'' (C26) 





'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
mannosylinositol 
phosphorylceramide B (C24) 





'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
mannosylinositol 
phosphorylceramide B (C26) 





'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
mannosylinositol 
phosphorylceramide C (C24) 





'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
mannosylinositol 
phosphorylceramide C (C26) 




'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 




'H2O [mitochondrion] + 
mannosylinositol 
phosphorylceramide D (C24) 





'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
mannosylinositol 
phosphorylceramide D (C26) 





'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
inositol 
phosphomannosylinositol 
phosphoceramide A (C24) 




phosphate)2 [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
inositol 
phosphomannosylinositol 
phosphoceramide A (C26) 




phosphate)2 [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
inositol 
phosphomannosylinositol 
phosphoceramide B'' (C24) 




phosphate)2 [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
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'H2O [mitochondrion] + 
inositol 
phosphomannosylinositol 
phosphoceramide B'' (C26) 




phosphate)2 [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
inositol 
phosphomannosylinositol 
phosphoceramide B (C24) 




phosphate)2 [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
inositol 
phosphomannosylinositol 
phosphoceramide B (C26) 




phosphate)2 [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson) 
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
inositol 
phosphomannosylinositol 
phosphoceramide C (C24) 




phosphate)2 [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
inositol 
phosphomannosylinositol 
phosphoceramide C (C26) 




phosphate)2 [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
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'H2O [mitochondrion] + 
inositol 
phosphomannosylinositol 
phosphoceramide D (C24) 




phosphate)2 [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [mitochondrion] + 
inositol 
phosphomannosylinositol 
phosphoceramide D (C26) 




phosphate)2 [mitochondrion] ' 
'YER019W' ISC1 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1016/j.bbamem.2007.07.019 
(Ktagaki) - mitochondrial localization 
'H2O [endoplasmic reticulum] 
+ inositol-P-ceramide A (C24) 
[endoplasmic reticulum]  <=> 
1D-myo-inositol 1-phosphate 
[endoplasmic reticulum] + 
ceramide-1 (C24) 
[endoplasmic reticulum] ' 
'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ inositol-P-ceramide A (C26) 
[endoplasmic reticulum]  <=> 
1D-myo-inositol 1-phosphate 
[endoplasmic reticulum] + 
ceramide-1 (C26) 
[endoplasmic reticulum] ' 
'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ inositol-P-ceramide B'' (C24) 
[endoplasmic reticulum]  <=> 
1D-myo-inositol 1-phosphate 
[endoplasmic reticulum] + 
ceramide-2'' (C24) 
[endoplasmic reticulum] ' 
'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ inositol-P-ceramide B'' (C26) 
[endoplasmic reticulum]  <=> 
1D-myo-inositol 1-phosphate 
[endoplasmic reticulum] + 
ceramide-2'' (C26) 
[endoplasmic reticulum] ' 





'H2O [endoplasmic reticulum] 
+ inositol-P-ceramide B (C24) 
[endoplasmic reticulum]  <=> 
1D-myo-inositol 1-phosphate 
[endoplasmic reticulum] + 
ceramide-2 (C24) 
[endoplasmic reticulum] ' 
'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ inositol-P-ceramide B (C26) 
[endoplasmic reticulum]  <=> 
1D-myo-inositol 1-phosphate 
[endoplasmic reticulum] + 
ceramide-2 (C26) 
[endoplasmic reticulum] ' 
'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ inositol-P-ceramide C (C24) 
[endoplasmic reticulum]  <=> 
1D-myo-inositol 1-phosphate 
[endoplasmic reticulum] + 
ceramide-3 (C24) 
[endoplasmic reticulum] ' 
'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ inositol-P-ceramide C (C26) 
[endoplasmic reticulum]  <=> 
1D-myo-inositol 1-phosphate 
[endoplasmic reticulum] + 
ceramide-3 (C26) 
[endoplasmic reticulum] ' 
'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ inositol-P-ceramide D (C24) 
[endoplasmic reticulum]  <=> 
1D-myo-inositol 1-phosphate 
[endoplasmic reticulum] + 
ceramide-4 (C24) 
[endoplasmic reticulum] ' 
'YER019W' ISC1 10.1074/jbc.M007721200  (Sawai) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'H2O [endoplasmic reticulum] 
+ inositol-P-ceramide D (C26) 
[endoplasmic reticulum]  <=> 
1D-myo-inositol 1-phosphate 
[endoplasmic reticulum] + 
ceramide-4 (C26) 
[endoplasmic reticulum] ' 






[endoplasmic reticulum] + H+ 
[endoplasmic reticulum] + 
NADPH [endoplasmic 
reticulum] + oxygen 
[endoplasmic reticulum]  <=> 
ceramide-2'' (C24) 
[endoplasmic reticulum] + 
H2O [endoplasmic reticulum] 
+ NADP(+) [endoplasmic 
reticulum] ' 




[endoplasmic reticulum] + H+ 
[endoplasmic reticulum] + 
NADPH [endoplasmic 
reticulum] + oxygen 
[endoplasmic reticulum]  <=> 
ceramide-2'' (C26) 
[endoplasmic reticulum] + 
H2O [endoplasmic reticulum] 
+ NADP(+) [endoplasmic 
reticulum] ' 




[endoplasmic reticulum] + H+ 
[endoplasmic reticulum] + 
NADPH [endoplasmic 
reticulum] + oxygen 
[endoplasmic reticulum]  <=> 
ceramide-3 (C24) 
[endoplasmic reticulum] + 
H2O [endoplasmic reticulum] 
+ NADP(+) [endoplasmic 
reticulum] ' 




[endoplasmic reticulum] + H+ 
[endoplasmic reticulum] + 
NADPH [endoplasmic 
reticulum] + oxygen 
[endoplasmic reticulum]  <=> 
ceramide-3 (C26) 
[endoplasmic reticulum] + 
H2O [endoplasmic reticulum] 
+ NADP(+) [endoplasmic 
reticulum] ' 






[endoplasmic reticulum] + H+ 
[endoplasmic reticulum] + 
NADPH [endoplasmic 
reticulum] + oxygen 
[endoplasmic reticulum]  <=> 
ceramide-4 (C24) 
[endoplasmic reticulum] + 
H2O [endoplasmic reticulum] 
+ NADP(+) [endoplasmic 
reticulum] ' 




[endoplasmic reticulum] + H+ 
[endoplasmic reticulum] + 
NADPH [endoplasmic 
reticulum] + oxygen 
[endoplasmic reticulum]  <=> 
ceramide-4 (C26) 
[endoplasmic reticulum] + 
H2O [endoplasmic reticulum] 
+ NADP(+) [endoplasmic 
reticulum] ' 
'YMR272C' SCS7 10.1194/jlr.R800003-JLR200 
(dickson)  
10.1074/jbc.272.47.29704 (haak) 
'lignoceric acid [endoplasmic 
reticulum] + sphinganine 
[endoplasmic reticulum]  <=> 
ceramide-1 (C24) 
[endoplasmic reticulum] ' 
'YPL087W' YDC1 10.1074/jbc.M003683200  (Mao) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'cerotic acid [endoplasmic 
reticulum] + sphinganine 
[endoplasmic reticulum]  <=> 
ceramide-1 (C26) 
[endoplasmic reticulum] ' 




[endoplasmic reticulum]  -> 
lignoceric acid [endoplasmic 
reticulum] + phytosphingosine 
[endoplasmic reticulum] ' 




[endoplasmic reticulum]  -> 
cerotic acid [endoplasmic 
reticulum] + phytosphingosine 
[endoplasmic reticulum] ' 
'YPL087W' YDC1 10.1074/jbc.M003683200  (Mao) 
10.1194/jlr.R800003-JLR200 
(dickson) 
'lignoceric acid [endoplasmic 
reticulum] + phytosphingosine 
[endoplasmic reticulum]  -> 
ceramide-2 (C24) 
[endoplasmic reticulum] ' 





'cerotic acid [endoplasmic 
reticulum] + phytosphingosine 
[endoplasmic reticulum]  -> 
ceramide-2 (C26) 
[endoplasmic reticulum] ' 




[endoplasmic reticulum]  <=> 
ceramide-2'' (C24) [Golgi] ' 
''  modelling reaction 
'ceramide-2'' (C26) 
[endoplasmic reticulum]  <=> 
ceramide-2'' (C26) [Golgi] ' 
''  modelling reaction 
'ceramide-3 (C24) 
[endoplasmic reticulum]  <=> 
ceramide-3 (C24) [Golgi] ' 
''  modelling reaction 
'ceramide-3 (C26) 
[endoplasmic reticulum]  <=> 
ceramide-3 (C26) [Golgi] ' 
''  modelling reaction 
'inositol-P-ceramide [Golgi]  -> 
complex sphingolipid [Golgi] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide [Golgi]  -> 
complex sphingolipid [Golgi] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide [Golgi]  -> 
complex sphingolipid [Golgi] ' 
''  modelling reaction 
'inositol-P-ceramide 
[mitochondrion]  -> complex 
sphingolipid [mitochondrion] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide 
[mitochondrion]  -> complex 
sphingolipid [mitochondrion] ' 




[mitochondrion]  -> complex 
sphingolipid [mitochondrion] ' 
''  modelling reaction 
'inositol-P-ceramide B'' (C24) 
[Golgi]  -> inositol-P-ceramide 
[Golgi] ' 
''  modelling reaction 
'inositol-P-ceramide B'' (C26) 
[Golgi]  -> inositol-P-ceramide 
[Golgi] ' 
''  modelling reaction 
'inositol-P-ceramide C (C24) 
[Golgi]  -> inositol-P-ceramide 
[Golgi] ' 
''  modelling reaction 
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'inositol-P-ceramide C (C26) 
[Golgi]  -> inositol-P-ceramide 
[Golgi] ' 
''  modelling reaction 
'inositol-P-ceramide A (C24) 
[Golgi]  -> inositol-P-ceramide 
[Golgi] ' 
''  modelling reaction 
'inositol-P-ceramide A (C26) 
[Golgi]  -> inositol-P-ceramide 
[Golgi] ' 
''  modelling reaction 
'inositol-P-ceramide B (C24) 
[Golgi]  -> inositol-P-ceramide 
[Golgi] ' 
''  modelling reaction 
'inositol-P-ceramide B (C26) 
[Golgi]  -> inositol-P-ceramide 
[Golgi] ' 
''  modelling reaction 
'inositol-P-ceramide D (C24) 
[Golgi]  -> inositol-P-ceramide 
[Golgi] ' 
''  modelling reaction 
'inositol-P-ceramide D (C26) 
[Golgi]  -> inositol-P-ceramide 
[Golgi] ' 
''  modelling reaction 
'inositol-P-ceramide B'' (C24) 
[endoplasmic reticulum]  -> 
inositol-P-ceramide 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol-P-ceramide B'' (C26) 
[endoplasmic reticulum]  -> 
inositol-P-ceramide 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol-P-ceramide C (C24) 
[endoplasmic reticulum]  -> 
inositol-P-ceramide 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol-P-ceramide C (C26) 
[endoplasmic reticulum]  -> 
inositol-P-ceramide 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol-P-ceramide A (C24) 
[endoplasmic reticulum]  -> 
inositol-P-ceramide 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol-P-ceramide A (C26) 
[endoplasmic reticulum]  -> 
inositol-P-ceramide 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol-P-ceramide B (C24) 
[endoplasmic reticulum]  -> 




[endoplasmic reticulum] ' 
'inositol-P-ceramide B (C26) 
[endoplasmic reticulum]  -> 
inositol-P-ceramide 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol-P-ceramide D (C24) 
[endoplasmic reticulum]  -> 
inositol-P-ceramide 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol-P-ceramide D (C26) 
[endoplasmic reticulum]  -> 
inositol-P-ceramide 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide A (C24) 
[Golgi]  -> inositol 
phosphomannosylinositol 
phosphoceramide [Golgi] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide A (C26) 
[Golgi]  -> inositol 
phosphomannosylinositol 
phosphoceramide [Golgi] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide B'' (C24) 
[Golgi]  -> inositol 
phosphomannosylinositol 
phosphoceramide [Golgi] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide B'' (C26) 
[Golgi]  -> inositol 
phosphomannosylinositol 
phosphoceramide [Golgi] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide B (C24) 
[Golgi]  -> inositol 
phosphomannosylinositol 
phosphoceramide [Golgi] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide B (C26) 
''  modelling reaction 
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[Golgi]  -> inositol 
phosphomannosylinositol 
phosphoceramide [Golgi] ' 
'inositol 
phosphomannosylinositol 
phosphoceramide C (C24) 
[Golgi]  -> inositol 
phosphomannosylinositol 
phosphoceramide [Golgi] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide C (C26) 
[Golgi]  -> inositol 
phosphomannosylinositol 
phosphoceramide [Golgi] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide D (C24) 
[Golgi]  -> inositol 
phosphomannosylinositol 
phosphoceramide [Golgi] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide D (C26) 
[Golgi]  -> inositol 
phosphomannosylinositol 
phosphoceramide [Golgi] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide A (C24) 




[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide A (C26) 




[endoplasmic reticulum] ' 





phosphoceramide B'' (C24) 




[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide B'' (C26) 




[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide B (C24) 




[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide B (C26) 




[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide C (C24) 




[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide C (C26) 




''  modelling reaction 
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[endoplasmic reticulum] ' 
'inositol 
phosphomannosylinositol 
phosphoceramide D (C24) 




[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide D (C26) 




[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide A (C24) 




''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide A (C26) 




''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide B'' (C24) 




''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide B'' (C26) 
[mitochondrion]  -> inositol 
phosphomannosylinositol 
phosphoceramide 






phosphoceramide B (C24) 




''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide B (C26) 




''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide C (C24) 




''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide C (C26) 




''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide D (C24) 




''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide D (C26) 








phosphorylceramide B'' (C24) 
[Golgi]  -> mannosylinositol 
phosphorylceramide [Golgi] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide B'' (C26) 
[Golgi]  -> mannosylinositol 
phosphorylceramide [Golgi] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide C (C24) 
[Golgi]  -> mannosylinositol 
phosphorylceramide [Golgi] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide C (C26) 
[Golgi]  -> mannosylinositol 
phosphorylceramide [Golgi] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide A (C24) 
[Golgi]  -> mannosylinositol 
phosphorylceramide [Golgi] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide A (C26) 
[Golgi]  -> mannosylinositol 
phosphorylceramide [Golgi] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide B (C24) 
[Golgi]  -> mannosylinositol 
phosphorylceramide [Golgi] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide B (C26) 
[Golgi]  -> mannosylinositol 
phosphorylceramide [Golgi] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide D (C24) 
[Golgi]  -> mannosylinositol 
phosphorylceramide [Golgi] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide D (C26) 
[Golgi]  -> mannosylinositol 
phosphorylceramide [Golgi] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide B'' (C24) 
[endoplasmic reticulum]  -> 
mannosylinositol 
phosphorylceramide 
[endoplasmic reticulum] ' 




phosphorylceramide B'' (C26) 
[endoplasmic reticulum]  -> 
mannosylinositol 
phosphorylceramide 
[endoplasmic reticulum] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide C (C24) 
[endoplasmic reticulum]  -> 
mannosylinositol 
phosphorylceramide 
[endoplasmic reticulum] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide C (C26) 
[endoplasmic reticulum]  -> 
mannosylinositol 
phosphorylceramide 
[endoplasmic reticulum] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide A (C24) 
[endoplasmic reticulum]  -> 
mannosylinositol 
phosphorylceramide 
[endoplasmic reticulum] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide A (C26) 
[endoplasmic reticulum]  -> 
mannosylinositol 
phosphorylceramide 
[endoplasmic reticulum] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide B (C24) 
[endoplasmic reticulum]  -> 
mannosylinositol 
phosphorylceramide 
[endoplasmic reticulum] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide B (C26) 
[endoplasmic reticulum]  -> 
mannosylinositol 
phosphorylceramide 
[endoplasmic reticulum] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide D (C24) 
[endoplasmic reticulum]  -> 
mannosylinositol 
phosphorylceramide 
''  modelling reaction 
209 
 
[endoplasmic reticulum] ' 
'mannosylinositol 
phosphorylceramide D (C26) 
[endoplasmic reticulum]  -> 
mannosylinositol 
phosphorylceramide 
[endoplasmic reticulum] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide B'' (C24) 




''  modelling reaction 
'mannosylinositol 
phosphorylceramide B'' (C26) 




''  modelling reaction 
'mannosylinositol 
phosphorylceramide C (C24) 




''  modelling reaction 
'mannosylinositol 
phosphorylceramide C (C26) 




''  modelling reaction 
'mannosylinositol 
phosphorylceramide A (C24) 




''  modelling reaction 
'mannosylinositol 
phosphorylceramide A (C26) 








phosphorylceramide B (C24) 




''  modelling reaction 
'mannosylinositol 
phosphorylceramide B (C26) 




''  modelling reaction 
'mannosylinositol 
phosphorylceramide D (C24) 




''  modelling reaction 
'mannosylinositol 
phosphorylceramide D (C26) 




''  modelling reaction 
'ceramide-1 (C24) [Golgi]  <=> 
ceramide-1 (C24) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'ceramide-2 (C24) [Golgi]  <=> 
ceramide-2 (C24) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'ceramide-4 (C24) [Golgi]  <=> 
ceramide-4 (C24) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'ceramide-1 (C26) [Golgi]  <=> 
ceramide-1 (C26) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'ceramide-2 (C26) [Golgi]  <=> 
ceramide-2 (C26) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'ceramide-4 (C26) [Golgi]  <=> 
ceramide-4 (C26) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol-P-ceramide A (C24) 
[Golgi]  <=> inositol-P-
ceramide A (C24) 
[endoplasmic reticulum] ' 
''  modelling reaction 
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'inositol-P-ceramide B (C24) 
[Golgi]  <=> inositol-P-
ceramide B (C24) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol-P-ceramide B'' (C24) 
[Golgi]  <=> inositol-P-
ceramide B'' (C24) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol-P-ceramide C (C24) 
[Golgi]  <=> inositol-P-
ceramide C (C24) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol-P-ceramide D (C24) 
[Golgi]  <=> inositol-P-
ceramide D (C24) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol-P-ceramide A (C26) 
[Golgi]  <=> inositol-P-
ceramide A (C26) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol-P-ceramide B (C26) 
[Golgi]  <=> inositol-P-
ceramide B (C26) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol-P-ceramide B'' (C26) 
[Golgi]  <=> inositol-P-
ceramide B'' (C26) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol-P-ceramide C (C26) 
[Golgi]  <=> inositol-P-
ceramide C (C26) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol-P-ceramide D (C26) 
[Golgi]  <=> inositol-P-
ceramide D (C26) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide A (C24) 
[Golgi]  <=> inositol 
phosphomannosylinositol 
phosphoceramide A (C24) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide B (C24) 
[Golgi]  <=> inositol 




phosphoceramide B (C24) 
[endoplasmic reticulum] ' 
'inositol 
phosphomannosylinositol 
phosphoceramide B'' (C24) 
[Golgi]  <=> inositol 
phosphomannosylinositol 
phosphoceramide B'' (C24) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide C (C24) 
[Golgi]  <=> inositol 
phosphomannosylinositol 
phosphoceramide C (C24) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide D (C24) 
[Golgi]  <=> inositol 
phosphomannosylinositol 
phosphoceramide D (C24) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide A (C26) 
[Golgi]  <=> inositol 
phosphomannosylinositol 
phosphoceramide A (C26) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide B (C26) 
[Golgi]  <=> inositol 
phosphomannosylinositol 
phosphoceramide B (C26) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide B'' (C26) 
[Golgi]  <=> inositol 
phosphomannosylinositol 
phosphoceramide B'' (C26) 
[endoplasmic reticulum] ' 





phosphoceramide C (C26) 
[Golgi]  <=> inositol 
phosphomannosylinositol 
phosphoceramide C (C26) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'inositol 
phosphomannosylinositol 
phosphoceramide D (C26) 
[Golgi]  <=> inositol 
phosphomannosylinositol 
phosphoceramide D (C26) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide A (C24) 
[Golgi]  <=> mannosylinositol 
phosphorylceramide A (C24) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide B (C24) 
[Golgi]  <=> mannosylinositol 
phosphorylceramide B (C24) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide B'' (C24) 
[Golgi]  <=> mannosylinositol 
phosphorylceramide B'' (C24) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide C (C24) 
[Golgi]  <=> mannosylinositol 
phosphorylceramide C (C24) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide D (C24) 
[Golgi]  <=> mannosylinositol 
phosphorylceramide D (C24) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide A (C26) 
[Golgi]  <=> mannosylinositol 
phosphorylceramide A (C26) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide B (C26) 
[Golgi]  <=> mannosylinositol 
''  modelling reaction 
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phosphorylceramide B (C26) 
[endoplasmic reticulum] ' 
'mannosylinositol 
phosphorylceramide B'' (C26) 
[Golgi]  <=> mannosylinositol 
phosphorylceramide B'' (C26) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide C (C26) 
[Golgi]  <=> mannosylinositol 
phosphorylceramide C (C26) 
[endoplasmic reticulum] ' 
''  modelling reaction 
'mannosylinositol 
phosphorylceramide D (C26) 
[Golgi]  <=> mannosylinositol 
phosphorylceramide D (C26) 
[endoplasmic reticulum] ' 




Supplementary Table 3.2 
The literature-based list of genes involved in sphingolipid metabolism, with the number of 
reactions annotated with each gene in the model and literature reaction list. 









LCB1 YMR296C 1 1 component of serine palmitoyltransferase with Lcb2p  
LCB2 YDR062W  1 1 component of serine palmitoyltransferase with Lcb1p 
TSC3 YBR058C-A  0 1 activator of LCB1:LCB2 complex, not essential 
TSC10 YBR265W 1 1 3-ketosphinganine reductase 
LAG1 YHL003C 4 4 lag1 & lac1 are functionally equivalent, and 
associated with lip1 
LAC1 YKL008C 4 4 lag1 & lac1 are functionally equivalent, and 
associated with lip1 
LIP1 YMR298W 0 4 lag1 & lac1 are functionally equivalent, and 
associated with lip1 
SUR2 YDR297W 5 3 Sphinganine C4-hydroxylase 
LCB4 YOR171C 2 2 Sphingolipid long chain base kinase (sphingosine and 
phytosphingosine) 





YJL134W 2 2 may catalyze 2 reactions - DHSP and PHSP 
YSR3 YKR053C 2 2 Like LCB3; catalyze 2 reactions 
AUR1 YKL004W 4 10 Catalyzes the addition of a phosphorylinositol group 




YPL057C 2 10 complex with CSG2; CSG1/SUR1 is the catalytic 
subunit 
CSG2 YBR036C 8 10 CSG2 is the likely regulatory subunit 
CSH1 YBR161W 0 10 Overlapping function with YPL057C:YBR036C complex 
IPT1 YDR072C 1 10 Inositolphosphotransferase 
SKN1 YGR143W 1 1 This seems fairly hypothetical by Dickson, but would 
be a duplicate of IPT1, (r_864) above. 
ISC1 YER019W 2 60 hydrolyzes complex sphingolipids 
DPL1 YDR294C 2 2 Phytosphingosine phosphate lyase 
SCS7 YMR272C 4 6 IPC-B -> IPC-C 
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YDC1 YPL087W 4 4 preferentially hydrolyzes dihydroceramide to a free 
fatty acid and dihydrosphingosine 
YPC1 YBR183W 2 2 ceramides can be hydrolyzed by two ceramidases, 
YDC1 and YPC1, to yield a fatty acid and a long-chain 
base 
     
total # 
rxns 
 54 152 the sum of reactions annotated by a gene is not equal 
to the sum of reactions in the pathway because some 
reactions are annotated with multiple genes 
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Supplementary Table 3.3  




rxn id rxn rxn with names gene locus Gene Note 
7 'r_0007' 's_1415  
<=> s_0004 
+ s_1411 ' 
'UDP-D-glucose [cytoplasm]  <=> 
(1->6)-beta-D-glucan [cell 






44 'r_0044' 's_0218 + 
s_1097  
<=> s_1092 
+ s_1325 ' 
'3-dehydrosphinganine 
[endoplasmic reticulum] + NADPH 
[endoplasmic reticulum]  <=> 
NADP(+) [endoplasmic reticulum] 





186 'r_0186' 's_0174 + 
s_1096  
<=> s_0171 
+ s_1091 ' 
'2-methylbutanal [cytoplasm] + 
NADPH [cytoplasm]  <=> 2-
methylbutan-1-ol [cytoplasm] + 










189 'r_0189' 's_1096 + 
s_1203  
<=> s_0190 
+ s_1091 ' 
'NADPH [cytoplasm] + 
phenylacetaldehyde [cytoplasm]  
<=> 2-phenylethanol [cytoplasm] + 








199 'r_0199' 's_0240 + 
s_1096  
<=> s_0836 
+ s_1091 ' 
'3-methylbutanal [cytoplasm] + 
NADPH [cytoplasm]  <=> isoamylol 









202 'r_0202' 's_0844 + 
s_1096  
<=> s_0839 
+ s_1091 ' 
'isobutyraldehyde [cytoplasm] + 
NADPH [cytoplasm]  <=> 













+ s_1092 ' 
'N-tetracosanylsphinganine 
[endoplasmic reticulum] + NADPH 
[endoplasmic reticulum] + oxygen 
[endoplasmic reticulum]  <=> N-
tetracosanylphytosphingosine 
[endoplasmic reticulum] + 
NADP(+) [endoplasmic reticulum] ' 
YDR297W' SUR2  
218 
 




+ s_1092 ' 
'N-tetracosanylsphinganine 
[endoplasmic reticulum] + NADPH 
[endoplasmic reticulum] + oxygen 
[endoplasmic reticulum]  <=> N-
(24-
hydroxytetracosanyl)sphinganine 
[endoplasmic reticulum] + 
NADP(+) [endoplasmic reticulum] ' 
'YMR272C' SCS7  




+ s_1092 ' 
'N-hexacosanylsphinganine 
[endoplasmic reticulum] + NADPH 
[endoplasmic reticulum] + oxygen 
[endoplasmic reticulum]  <=> N-
hexacosanylphytosphingosine 
[endoplasmic reticulum] + 
NADP(+) [endoplasmic reticulum] ' 
'YDR297W' SUR2  




+ s_1092 ' 
'N-hexacosanylsphinganine 
[endoplasmic reticulum] + NADPH 
[endoplasmic reticulum] + oxygen 
[endoplasmic reticulum]  <=> N-
(26-
hydroxyhexacosanyl)sphinganine 
[endoplasmic reticulum] + 
NADP(+) [endoplasmic reticulum] ' 
'YMR272C' SCS7  
290 'r_0290' 's_1325 + 
s_1356  
<=> s_0515 
+ s_1080 ' 
'sphinganine [endoplasmic 
reticulum] + tetracosanoyl-CoA 
[endoplasmic reticulum]  <=> 
coenzyme A [endoplasmic 
reticulum] + N-
tetracosanylsphinganine 











291 'r_0291' 's_0779 + 
s_1325  
<=> s_0515 
+ s_1077 ' 
'hexacosanoyl-CoA [endoplasmic 
reticulum] + sphinganine 
[endoplasmic reticulum]  <=> 
coenzyme A [endoplasmic 
reticulum] + N-
hexacosanylsphinganine 











292 'r_0292' 's_1247 + 
s_1356  
<=> s_0515 
+ s_1079 ' 
'phytosphingosine [endoplasmic 
reticulum] + tetracosanoyl-CoA 
[endoplasmic reticulum]  <=> 
coenzyme A [endoplasmic 
reticulum] + N-
tetracosanylphytosphingosine 
















293 'r_0293' 's_0779 + 
s_1247  
<=> s_0515 
+ s_1076 ' 
'hexacosanoyl-CoA [endoplasmic 
reticulum] + phytosphingosine 
[endoplasmic reticulum]  <=> 
coenzyme A [endoplasmic 
reticulum] + N-
hexacosanylphytosphingosine 


















+ s_1092 ' 
'N-tetracosanylphytosphingosine 
[endoplasmic reticulum] + NADPH 
[endoplasmic reticulum] + oxygen 
[endoplasmic reticulum]  <=> N-
(24-
hydroxytetracosanyl)phytosphingo
sine [endoplasmic reticulum] + 
NADP(+) [endoplasmic reticulum] ' 
'YMR272C' SCS7  




+ s_1092 ' 
'N-hexacosanylphytosphingosine 
[endoplasmic reticulum] + NADPH 
[endoplasmic reticulum] + oxygen 
[endoplasmic reticulum]  <=> N-
(26-
hydroxyhexacosanyl)phytosphingo
sine [endoplasmic reticulum] + 
NADP(+) [endoplasmic reticulum] ' 
'YMR272C' SCS7  





[Golgi] + mannosylinositol 
phosphorylceramide [Golgi]  <=> 
inositol phosphomannosylinositol 
phosphoceramide [Golgi] ' 
'YDR072C' IPT1  







[Golgi]  <=> inositol-P-ceramide B 
[Golgi] ' 
'YKL004W' AUR1  







[Golgi]  <=> inositol-P-ceramide B 
[Golgi] ' 
'YKL004W' AUR1  







sine [Golgi]  <=> inositol-P-
ceramide C [Golgi] ' 
'YKL004W' AUR1  







sine [Golgi]  <=> inositol-P-
'YKL004W' AUR1  
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ceramide C [Golgi] ' 
625 'r_0625' 's_0826  
<=> s_0130 
+ s_0489 ' 
'inositol phosphosphingolipid 
[endoplasmic reticulum]  <=> 1D-
myo-inositol 3-phosphate 
[endoplasmic reticulum] + 
ceramide [endoplasmic reticulum] 
' 
'YER019W' ISC1  
626 'r_0626' 's_0827  
<=> s_0131 
+ s_0490 ' 
'inositol phosphosphingolipid 
[mitochondrion]  <=> 1D-myo-
inositol 3-phosphate 
[mitochondrion] + ceramide 
[mitochondrion] ' 
'YER019W' ISC1  




'GDP-alpha-D-mannose [Golgi] + 
inositol-P-ceramide B [Golgi]  <=> 
mannosylinositol 












'GDP-alpha-D-mannose [Golgi] + 
inositol-P-ceramide C [Golgi]  <=> 
mannosylinositol 








894 'r_0894' 's_1248  
<=> s_0166 
+ s_1125 ' 
'phytosphingosine 1-phosphate 




[endoplasmic reticulum] ' 
'YDR294C' DPL1  




+ s_1247 ' 
'NADPH [endoplasmic reticulum] + 
oxygen [endoplasmic reticulum] + 
sphinganine [endoplasmic 
reticulum]  <=> NADP(+) 
[endoplasmic reticulum] + 
phytosphingosine [endoplasmic 
reticulum] ' 
'YDR297W' SUR2  
972 'r_0972' 's_0944 + 
s_1188  
<=> s_0218 
+ s_0471 + 
s_0515 ' 
'L-serine [endoplasmic reticulum] 
+ palmitoyl-CoA [endoplasmic 
reticulum]  <=> 3-
dehydrosphinganine [endoplasmic 
reticulum] + carbon dioxide 
[endoplasmic reticulum] + 









984 'r_0984' 's_1326  
<=> s_0789 
+ s_1125 ' 
'sphinganine 1-phosphate 




[endoplasmic reticulum] ' 
'YDR294C' DPL1  
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985 'r_0985' 's_1248  
<=> s_1208 
+ s_1247 ' 
'phytosphingosine 1-phosphate 
[endoplasmic reticulum]  <=> 
phosphate [endoplasmic 
reticulum] + phytosphingosine 








986 'r_0986' 's_1326  
<=> s_1208 
+ s_1325 ' 
'sphinganine 1-phosphate 
[endoplasmic reticulum]  <=> 
phosphate [endoplasmic 
reticulum] + sphinganine 








987 'r_0987' 's_0447 + 
s_1247  
<=> s_0401 
+ s_1248 ' 
'ATP [endoplasmic reticulum] + 
phytosphingosine [endoplasmic 
reticulum]  <=> ADP [endoplasmic 










988 'r_0988' 's_0447 + 
s_1325  
<=> s_0401 
+ s_1326 ' 
'ATP [endoplasmic reticulum] + 
sphinganine [endoplasmic 
reticulum]  <=> ADP [endoplasmic 



















''   









''   





sine [endoplasmic reticulum]  <=> 
N-(24-
hydroxytetracosanyl)phytosphingo
sine [Golgi] ' 
''   





sine [endoplasmic reticulum]  <=> 
N-(26-
hydroxyhexacosanyl)phytosphingo
sine [Golgi] ' 
''   
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phosphoceramide [cytoplasm]  
<=> inositol 
phosphomannosylinositol 
phosphoceramide [Golgi] ' 
''   








1796 'r_1796' 's_0789  -> 
s_0665 ' 
'hexadecanal [endoplasmic 
reticulum]  -> fatty acid 
[endoplasmic reticulum] ' 




APPENDIX 2 – SUPPLEMENTARY INFORMATION FOR CHAPTER 4 
 




% a formalised test-suite for validating yeast models. reliant on the cobra 
% toolbox. 
  




if nargin < 2 
    verbose = false; % should the script display model errors? 
end 
  
ko_tol = 1e-6; 
  
model = readCbModel(filename); 
  
%% create model with complete medium (all exchange reactions switched on) 
  
selExc = findExcRxns(model); 
  
model_maximal = model; 
model_maximal.lb(selExc) = -1000; 
model_maximal.ub(selExc) = 1000; 
  
%% simple model statistics 
  
fprintf('%s\n\n%g\t%s\n%g\t%s\n%g\t%s\n\n',model.description,... 
    length(model.mets),'metabolites',length(model.rxns),'reactions',... 
    length(model.genes),'genes'); 
  
%% number of blocked reactions (cannot carry any flux) 
  
% blockedReactions = findBlockedReaction(model); 
blockedReactions = findBlockedReaction(model_maximal); 
  
fprintf('%g\t(%g%%)\t%s\n\n',length(blockedReactions),... 




    disp('list of blocked reactions:'); 
    for k = 1:length(blockedReactions) 
        disp(blockedReactions{k}); 
    end 





%% dubious genes 
  
dubiousORFs = setdiff(model.genes,verifiedORFs); 
  
fprintf('%g\t(%g%%)\t%s\n\n',length(dubiousORFs),... 
    roundSF(100*length(dubiousORFs)/length(model.genes)),'dubious ORFs'); 
  
if verbose 
    disp('list of dubious ORFs:'); 
    for k = 1:length(dubiousORFs) 
        disp(dubiousORFs{k}); 
    end 
    disp(''); 
end 
  
%% knockout analysis 
  
% combine inviable with auxotrophy list 
%inviableORFsAll = union(inviableORFs,auxotrophicORFs); %auxotrophs should 
%be viable in complex media 
inviableORFsAll = inviableORFs; %only essential genes 
  
exp_retarded = intersect(model.genes,inviableORFsAll); 
exp_retarded = intersect(exp_retarded,verifiedORFs); 
  
exp_viable = setdiff(model.genes,inviableORFsAll); 
exp_viable = intersect(exp_viable,verifiedORFs); 
  
%grRatio = singleGeneDeletion(model); 
grRatio = singleGeneDeletion(model_maximal); %bh changed to use same 
essential def. 
  
mod_viable  = model.genes(grRatio >= ko_tol); 
mod_viable = intersect(mod_viable,verifiedORFs); 
mod_retarded = model.genes(grRatio < ko_tol); 
mod_retarded = intersect(mod_retarded,verifiedORFs); 
  
tp = intersect(exp_viable,mod_viable); n_tp = length(tp) 
tn = intersect(exp_retarded,mod_retarded); n_tn = length(tn) 
fp = intersect(exp_retarded,mod_viable); n_fp = length(fp) 
fn = intersect(exp_viable,mod_retarded); n_fn = length(fn) 
  
n_genes = length(intersect(model.genes,verifiedORFs)); %#ok<NASGU> 
  
disp('knockout analysis (positive = viable):'); 
  
% fprintf('%g\t[%.3g %%]\t%s\n%g\t[%.3g %%]\t%s\n%g\t[%.3g %%]\t%s\n%g\t[%.3g 
%%]\t%s\n\n',... 
%     n_tp,roundSF(100*n_tp/n_genes),'true positive',... 
%     n_tn,roundSF(100*n_tn/n_genes),'true negative',... 
%     n_fp,roundSF(100*n_fp/n_genes),'false positive',... 
%     n_fn,roundSF(100*n_fn/n_genes),'false negative'); 
  
fprintf('%g%%\t%s\n%g%%\t%s\n%g%%\t%s\n%g%%\t%s\n%',... 
    roundSF(100*n_tp/(n_tp+n_fn)),'sensitivity = recall = tp/(tp+fn)',... 
    roundSF(100*n_tn/(n_tn+n_fp)),'specificity = tn/(tn+fp)',... 




    roundSF(100*n_tn/(n_fn+n_tn)),'negative predictive value = tn/(fn+tn)'... 
    ); 
  
% fprintf('g%%\t%s\n%g%%\t%s\n',... 
%     roundSF(100*(n_tn+n_tp)/n_genes),'accuracy = (tp+tn)/(tp+tn+fp+fn)',... 
%     roundSF(100*2*(n_tp/(n_tp+n_fn) * n_tp/(n_tp+n_fp))/(n_tp/(n_tp+n_fn) + 
n_tp/(n_tp+n_fp))),'F-measure = 2.(precision.recall)/(precision+recall)'... 





    disp('list of ko false positives:'); 
    for k = 1:n_fp 
        disp(fp{k}); 
    end 
    disp(' '); 
     
    disp('list of ko false negatives:'); 
    for k = 1:n_fn 
        disp(fn{k}); 
    end 
    disp(' '); 
end 
  
%% testing auxotrophy 
  
% or at least an approximation thereof 
  
auxotrophs = intersect(model.genes,auxotrophicORFs); 
auxotrophs = intersect(auxotrophs,verifiedORFs); 
n_aux = length(auxotrophs); 
  
grRatio = singleGeneDeletion(model_maximal); 
  
aux_fail = intersect(auxotrophs,mod_viable); 
  
aux_viable  = model.genes(grRatio >= ko_tol); 
aux_viable = intersect(aux_viable,auxotrophs); 
aux_viable = setdiff(aux_viable,aux_fail); 
aux_retarded = model.genes(grRatio < ko_tol); 
aux_retarded = intersect(aux_retarded,auxotrophs); 
aux_retarded = setdiff(aux_retarded,aux_fail); 
  
fprintf('auxotrophy analysis:\n%g\t%s\n%g\t[%.3g %%]\t%s\n%g\t[%.3g 
%%]\t%s\n%g\t[%.3g %%]\t%s\n\n',... 
    n_aux,'genes',... 
    length(aux_viable),roundSF(100*length(aux_viable)/n_aux),... 
    'correctly predicted',... 
    length(aux_fail),roundSF(100*length(aux_fail)/n_aux),... 
    'viable in minimal medium',... 
    length(aux_retarded),roundSF(100*length(aux_retarded)/n_aux),... 
    'inviable in maximal medium'); 
  
if verbose 
    disp('list of auxotrophs viable in minimal medium:'); 
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    for k = 1:length(aux_fail) 
        disp(aux_fail{k}); 
    end 
    disp(' '); 
     
    disp('list of auxotrophs inviable in maximal medium:'); 
    for k = 1:length(aux_retarded) 
        disp(aux_retarded{k}); 
    end 






%% required functions 
  
function blockedReactions = findBlockedReaction(model) 
%findBlockedReaction determines those reactions which cannot carry any 
%flux in the given simulation conditions. 
% 
% BlockedReaction = findBlockedReaction(model) 
% 
%INPUT 
% model              COBRA model structure 
% 
%OUTPUT 
% blockedReactions   List of blocked reactions 
% 
% 
% Ines Thiele 02/09 
  
% kieran: 15 aug 11 
  
tol = 1e-10; 
% << changed by ks 
% blockedReactions =[]; 
blockedReactions = {}; 
% >> 
[minMax(:,1),minMax(:,2)] = fluxVariability(model,0); 
cnt = 1; 
for i=1:length(minMax) 
    if (minMax(i,2) < tol && minMax(i,2) > -tol && minMax(i,1) < tol && 
minMax(i,1) > -tol) 
        blockedReactions(cnt) = model.rxns(i); %#ok<AGROW> 
        cnt = cnt + 1; 
    end 
end 
  
function y = roundSF(x,nSF) 
  
%ROUNDSF 
% y = roundSF(x,nSF) returns x rounded to nSF significant figures 
% input x must be a real array 
% 
% kieran: 7 nov 08 




if nargin < 2, nSF = 3; end 
  
y = zeros(size(x)); 
  
for k = 1:numel(x) 
     
    x0 = x(k); 
     
    if ~isfinite(x0) || x0 == 0 
        y0 = x0; 
    else 
        N = nSF-floor(log10(abs(x0)))-1; 
        y0 = round(x0.*10.^N)./10.^N; 
    end 
     
    y(k) = y0; 
end 
  
function genes = inviableORFs 
  
















































































































































































function genes = auxotrophicORFs 
  
% list of 432 auxotrophic ORFs (669 annotated auxotroph minus 52 on YKO 
% essential list minus 87 which are re either temp-sensitive ino  
































































function genes = verifiedORFs 
  












































































































































































































































































































































































































































































































































































































































































































































function genes = kuepfer_glucose_aerobic 
  
% list of 62 genes found to be essential in defined media + glucose + aerobic 












function genes = kuepfer_galactose_aerobic 
  
























































% a function for converting an SBML model to a reconstruction, using SBO 
% terms. reliant on the SBML toolbox. 
  
% kieran smallbone and ben heavner: 18 aug 11 
  
if ~strncmp(fliplr(filename),fliplr('.xml'),length('.xml')) 
    filename = [filename,'.xml']; 
end 
  
m = TranslateSBML(filename); 
  
% only real reactions 
J = ismember([m.reaction.sboTerm],[395,397]); 
m.reaction(J) = []; 
  
% no modelling parameters 
for k = 1:length(m.reaction) 
    m.reaction(k).kineticLaw(1:end) = []; 
end 
  
% % no modelling notes 
% for k = 1:length(m.speciesType) 
%     m.speciesType(k).notes = ''; 
% end 
% for k = 1:length(m.reaction) 
%     m.reaction(k).notes = ''; 
% end 
  
% find unused species 
used_species = {}; 
for k = 1:length(m.reaction) 
    used_species = union(used_species,{m.reaction(k).reactant.species}); 
    used_species = union(used_species,{m.reaction(k).product.species}); 
    used_species = union(used_species,{m.reaction(k).modifier.species}); 
end 
J = ~ismember({m.species.id},used_species); 
m.species(J) = []; 
  
% ... and species types 
J = ~ismember({m.speciesType.id},{m.species.speciesType}); 
m.speciesType(J) = []; 
  
% ... and compartments 
J = ~ismember({m.compartment.id},{m.species.compartment}); 
m.compartment(J) = []; 
  
% save 
filename = strrep(filename,'_model',''); 






[~,errors] = TranslateSBML(filename,1,0); 
if isempty(errors) 
    disp('Results: This document is valid SBML!'); 
else 
    for k = 1:length(errors) 
        fprintf('%s:\tline %g:\t(SBML Validation Rules #%g)\t%s',... 
            
strtrim(errors(k).severity),errors(k).line,errors(k).errorId,errors(k).messag
e); 








model = readCbModel(filename,inf); 
  
% define reactions of interest 
rxnNames = { 
    % glycolysis 
    'glucose transport' 
    'hexokinase (D-glucose:ATP)' 
    'glucose-6-phosphate isomerase' 
    'phosphofructokinase' 
    'fructose-bisphosphate aldolase' 
    'glyceraldehyde-3-phosphate dehydrogenase' 
    'phosphoglycerate kinase' 
    'phosphoglycerate mutase' 
    'enolase' 
    'pyruvate kinase' 
    'pyruvate decarboxylase' 
    %'alcohol dehydrogenase, reverse rxn (acetaldehyde -> ethanol)' % should 
be 'alcohol dehydrogenase (ethanol)' 
    'alcohol dehydrogenase (ethanol)' 
    'ethanol transport' 
    ' ' % TCA 
    'pyruvate dehydrogenase' 
    'citrate synthase' 
    'citrate to cis-aconitate(3-)' 
    'cis-aconitate(3-) to isocitrate' 
    'isocitrate dehydrogenase (NAD+)' 
    'oxoglutarate dehydrogenase (lipoamide)' 
    'oxoglutarate dehydrogenase (dihydrolipoamide S-succinyltransferase)' 
    'succinate-CoA ligase (ADP-forming)' 
    'succinate dehydrogenase (ubiquinone-6)' 
    'fumarase' 
    'malate dehydrogenase' 
    ' ' % PPP 
    'glucose 6-phosphate dehydrogenase' 
    '6-phosphogluconolactonase' 
    'phosphogluconate dehydrogenase' 
    'ribose-5-phosphate isomerase' 
    'ribulose 5-phosphate 3-epimerase' 
    'transketolase 1' 
    'transaldolase' 
    'transketolase 2' 
    ' ' % other 
    }; 
  
FBAsolution = optimizeCbModel(model,[],'one'); 
fprintf('aerobic growth\nrate:\t%.2f\n\n',FBAsolution.f); 
  
for k = 1:length(rxnNames) 
   ind = strcmp(rxnNames{k},model.rxnNames); 
   if sum(ind)>1, disp(rxnNames{k}); end 
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   fprintf('%.2f\t%s\n',FBAsolution.x(ind),rxnNames{k}); 
end 
        
ind = strcmp('oxygen exchange',model.rxnNames); model.lb(ind) = 0; 
  
ind = ismember(model.rxnNames,{... 
    'lipid pseudoreaction [no 14-demethyllanosterol, no ergosta-
5,7,22,24(28)-tetraen-3beta-ol]' 
    'ergosterol exchange' 
    'lanosterol exchange' 
    'zymosterol exchange' 
    'phosphatidate exchange' 
    }); 
model.lb(ind) = -Inf; 
model.ub(ind) = Inf; 
  
ind = strcmp('lipid pseudoreaction',model.rxnNames); model.ub(ind) = 0; 
  
FBAsolution = optimizeCbModel(model,[],'one'); 
fprintf('anaerobic growth\nrate:\t%.2f\n\n',FBAsolution.f); 
  
for k = 1:length(rxnNames) 
   ind = find(strcmp(rxnNames{k},model.rxnNames)); 




Supplementary Table 4.1: Essential Gene List 
 
Essential ORFs in SGD: 
YAL001C; YAL003W; YAL025C; YAL032C; YAL033W; YAL038W; YAL041W; YAL043C; 
YAR007C; YAR008W; YAR019C; YBL004W; YBL014C; YBL018C; YBL020W; YBL023C; 
YBL026W; YBL030C; YBL034C; YBL035C; YBL040C; YBL041W; YBL050W; YBL074C; 
YBL076C; YBL084C; YBL092W; YBL097W; YBL105C; YBR002C; YBR004C; YBR011C; 
YBR029C; YBR038W; YBR049C; YBR055C; YBR060C; YBR070C; YBR079C; YBR080C; 
YBR087W; YBR088C; YBR091C; YBR102C; YBR109C; YBR110W; YBR123C; YBR135W; 
YBR136W; YBR140C; YBR142W; YBR143C; YBR152W; YBR153W; YBR154C; YBR155W; 
YBR160W; YBR167C; YBR192W; YBR193C; YBR196C; YBR198C; YBR202W; YBR211C; 
YBR233W-A; YBR234C; YBR236C; YBR237W; YBR243C; YBR247C; YBR252W; YBR253W; 
YBR254C; YBR256C; YBR257W; YBR265W; YCL004W; YCL017C; YCL031C; YCL043C; 
YCL052C; YCL054W; YCL059C; YCR012W; YCR035C; YCR052W; YCR054C; YCR057C; 
YCR072C; YCR093W; YDL003W; YDL004W; YDL007W; YDL008W; YDL014W; YDL015C; 
YDL017W; YDL028C; YDL029W; YDL030W; YDL031W; YDL043C; YDL045C; YDL055C; 
YDL058W; YDL060W; YDL064W; YDL084W; YDL087C; YDL092W; YDL097C; YDL098C; 
YDL102W; YDL103C; YDL105W; YDL108W; YDL111C; YDL120W; YDL126C; YDL132W; 
YDL139C; YDL140C; YDL141W; YDL143W; YDL145C; YDL147W; YDL148C; YDL150W; 
YDL153C; YDL164C; YDL165W; YDL166C; YDL193W; YDL195W; YDL205C; YDL207W; 
YDL208W; YDL209C; YDL212W; YDL217C; YDL220C; YDL235C; YDR002W; YDR013W; 
YDR016C; YDR021W; YDR023W; YDR037W; YDR041W; YDR044W; YDR045C; YDR047W; 
YDR050C; YDR052C; YDR054C; YDR060W; YDR062W; YDR064W; YDR081C; YDR082W; 
YDR086C; YDR087C; YDR088C; YDR091C; YDR113C; YDR118W; YDR141C; YDR145W; 
YDR160W; YDR164C; YDR166C; YDR167W; YDR168W; YDR170C; YDR172W; YDR177W; 
YDR180W; YDR182W; YDR188W; YDR189W; YDR190C; YDR196C; YDR201W; YDR208W; 
YDR211W; YDR212W; YDR224C; YDR228C; YDR232W; YDR235W; YDR236C; YDR238C; 
YDR240C; YDR243C; YDR246W; YDR267C; YDR280W; YDR288W; YDR292C; YDR299W; 
YDR301W; YDR302W; YDR303C; YDR308C; YDR311W; YDR320C-A; YDR324C; YDR325W; 
YDR328C; YDR331W; YDR339C; YDR341C; YDR353W; YDR356W; YDR361C; YDR362C; 
YDR365C; YDR367W; YDR373W; YDR376W; YDR381W; YDR390C; YDR394W; YDR397C; 
YDR398W; YDR404C; YDR407C; YDR412W; YDR416W; YDR427W; YDR429C; YDR434W; 
YDR437W; YDR449C; YDR454C; YDR460W; YDR464W; YDR468C; YDR472W; YDR473C; 
YDR478W; YDR487C; YDR489W; YDR498C; YDR499W; YDR510W; YDR527W; YDR531W; 
YEL002C; YEL019C; YEL026W; YEL032W; YEL034W; YEL055C; YEL058W; YER003C; 
YER006W; YER008C; YER009W; YER012W; YER013W; YER018C; YER021W; YER022W; 
YER023W; YER025W; YER029C; YER036C; YER038C; YER043C; YER048W-A; YER074W-A; 
YER082C; YER093C; YER094C; YER104W; YER112W; YER125W; YER126C; YER127W; 
YER133W; YER136W; YER146W; YER147C; YER148W; YER157W; YER159C; YER165W; 
YER168C; YER171W; YER172C; YFL002C; YFL005W; YFL008W; YFL009W; YFL017C; 
YFL022C; YFL024C; YFL029C; YFL037W; YFL038C; YFL039C; YFL045C; YFR002W; 
YFR003C; YFR004W; YFR005C; YFR027W; YFR028C; YFR029W; YFR031C; YFR037C; 
YFR042W; YFR050C; YFR051C; YFR052W; YGL001C; YGL008C; YGL011C; YGL018C; 
YGL022W; YGL030W; YGL040C; YGL044C; YGL047W; YGL048C; YGL055W; YGL061C; 
YGL065C; YGL068W; YGL073W; YGL075C; YGL091C; YGL092W; YGL093W; YGL097W; 
YGL098W; YGL099W; YGL103W; YGL111W; YGL112C; YGL113W; YGL116W; YGL120C; 
YGL122C; YGL123W; YGL128C; YGL130W; YGL137W; YGL142C; YGL145W; YGL150C; 
YGL155W; YGL169W; YGL171W; YGL172W; YGL201C; YGL207W; YGL225W; YGL233W; 
YGL238W; YGL245W; YGL247W; YGR002C; YGR005C; YGR009C; YGR013W; YGR024C; 
YGR029W; YGR030C; YGR046W; YGR047C; YGR048W; YGR060W; YGR065C; YGR074W; 
YGR075C; YGR082W; YGR083C; YGR090W; YGR091W; YGR094W; YGR095C; YGR098C; 
YGR099W; YGR103W; YGR113W; YGR116W; YGR119C; YGR120C; YGR128C; YGR140W; 
YGR145W; YGR147C; YGR156W; YGR158C; YGR172C; YGR175C; YGR179C; YGR185C; 
YGR186W; YGR191W; YGR195W; YGR198W; YGR211W; YGR216C; YGR218W; YGR245C; 
YGR246C; YGR251W; YGR253C; YGR264C; YGR267C; YGR274C; YGR277C; YGR278W; 
YGR280C; YHL015W; YHR005C-A; YHR007C; YHR019C; YHR020W; YHR023W; YHR024C; 
YHR036W; YHR040W; YHR042W; YHR058C; YHR062C; YHR065C; YHR068W; YHR069C; 
250 
 
YHR070W; YHR072W; YHR072W-A; YHR074W; YHR083W; YHR085W; YHR088W; YHR089C; 
YHR101C; YHR102W; YHR107C; YHR118C; YHR122W; YHR128W; YHR143W-A; YHR148W; 
YHR164C; YHR165C; YHR166C; YHR169W; YHR170W; YHR172W; YHR186C; YHR188C; 
YHR190W; YHR196W; YHR197W; YHR199C-A; YIL003W; YIL004C; YIL019W; YIL021W; 
YIL022W; YIL026C; YIL031W; YIL046W; YIL048W; YIL051C; YIL061C; YIL062C; 
YIL063C; YIL068C; YIL075C; YIL078W; YIL083C; YIL091C; YIL104C; YIL106W; 
YIL109C; YIL115C; YIL118W; YIL126W; YIL129C; YIL142W; YIL143C; YIL144W; 
YIL147C; YIL150C; YIR006C; YIR008C; YIR010W; YIR011C; YIR012W; YIR015W; 
YIR022W; YJL001W; YJL002C; YJL005W; YJL008C; YJL010C; YJL011C; YJL014W; 
YJL019W; YJL025W; YJL026W; YJL031C; YJL033W; YJL034W; YJL035C; YJL039C; 
YJL041W; YJL050W; YJL054W; YJL061W; YJL069C; YJL072C; YJL074C; YJL076W; 
YJL081C; YJL085W; YJL087C; YJL090C; YJL091C; YJL097W; YJL104W; YJL109C; 
YJL111W; YJL125C; YJL143W; YJL156C; YJL167W; YJL173C; YJL174W; YJL194W; 
YJL203W; YJR002W; YJR006W; YJR007W; YJR013W; YJR016C; YJR017C; YJR022W; 
YJR041C; YJR042W; YJR045C; YJR046W; YJR057W; YJR064W; YJR065C; YJR067C; 
YJR068W; YJR072C; YJR076C; YJR089W; YJR093C; YJR112W; YJR123W; YKL004W; 
YKL006C-A; YKL012W; YKL013C; YKL014C; YKL018W; YKL019W; YKL021C; YKL022C; 
YKL024C; YKL028W; YKL033W; YKL035W; YKL042W; YKL045W; YKL049C; YKL052C; 
YKL058W; YKL059C; YKL060C; YKL078W; YKL082C; YKL088W; YKL089W; YKL095W; 
YKL099C; YKL104C; YKL108W; YKL112W; YKL122C; YKL125W; YKL138C-A; YKL141W; 
YKL144C; YKL145W; YKL152C; YKL154W; YKL165C; YKL172W; YKL173W; YKL180W; 
YKL182W; YKL186C; YKL189W; YKL192C; YKL193C; YKL195W; YKL196C; YKL203C; 
YKL210W; YKR002W; YKR004C; YKR008W; YKR022C; YKR025W; YKR037C; YKR038C; 
YKR062W; YKR063C; YKR068C; YKR071C; YKR079C; YKR081C; YKR083C; YKR086W; 
YLL003W; YLL004W; YLL008W; YLL011W; YLL018C; YLL031C; YLL034C; YLL035W; 
YLL036C; YLL050C; YLR002C; YLR005W; YLR007W; YLR008C; YLR009W; YLR010C; 
YLR022C; YLR026C; YLR029C; YLR033W; YLR045C; YLR051C; YLR060W; YLR066W; 
YLR071C; YLR075W; YLR078C; YLR086W; YLR088W; YLR100W; YLR103C; YLR105C; 
YLR106C; YLR115W; YLR116W; YLR117C; YLR127C; YLR129W; YLR141W; YLR145W; 
YLR147C; YLR153C; YLR163C; YLR166C; YLR167W; YLR175W; YLR186W; YLR195C; 
YLR196W; YLR197W; YLR208W; YLR212C; YLR215C; YLR222C; YLR223C; YLR229C; 
YLR249W; YLR259C; YLR272C; YLR274W; YLR275W; YLR276C; YLR277C; YLR291C; 
YLR293C; YLR298C; YLR305C; YLR310C; YLR314C; YLR316C; YLR321C; YLR323C; 
YLR336C; YLR340W; YLR347C; YLR355C; YLR359W; YLR378C; YLR383W; YLR397C; 
YLR409C; YLR424W; YLR430W; YLR438C-A; YLR440C; YLR457C; YLR459W; YML010W; 
YML015C; YML023C; YML025C; YML031W; YML043C; YML046W; YML049C; YML064C; 
YML065W; YML069W; YML077W; YML085C; YML091C; YML092C; YML093W; YML098W; 
YML105C; YML114C; YML125C; YML126C; YML127W; YML130C; YMR001C; YMR005W; 
YMR013C; YMR028W; YMR033W; YMR043W; YMR047C; YMR049C; YMR059W; YMR061W; 
YMR076C; YMR079W; YMR093W; YMR094W; YMR108W; YMR112C; YMR113W; YMR117C; 
YMR128W; YMR131C; YMR146C; YMR149W; YMR168C; YMR197C; YMR200W; YMR203W; 
YMR208W; YMR211W; YMR213W; YMR218C; YMR220W; YMR227C; YMR229C; YMR235C; 
YMR236W; YMR239C; YMR240C; YMR260C; YMR268C; YMR270C; YMR277W; YMR281W; 
YMR288W; YMR290C; YMR296C; YMR298W; YMR301C; YMR308C; YMR309C; YMR314W; 
YNL002C; YNL006W; YNL007C; YNL024C-A; YNL026W; YNL036W; YNL038W; YNL039W; 
YNL061W; YNL062C; YNL075W; YNL088W; YNL102W; YNL103W; YNL110C; YNL112W; 
YNL113W; YNL118C; YNL124W; YNL126W; YNL131W; YNL132W; YNL137C; YNL138W-A; 
YNL149C; YNL151C; YNL152W; YNL158W; YNL161W; YNL163C; YNL172W; YNL178W; 
YNL182C; YNL188W; YNL189W; YNL207W; YNL216W; YNL221C; YNL222W; YNL232W; 
YNL240C; YNL244C; YNL245C; YNL247W; YNL251C; YNL256W; YNL258C; YNL261W; 
YNL262W; YNL263C; YNL267W; YNL272C; YNL282W; YNL287W; YNL290W; YNL306W; 
YNL308C; YNL310C; YNL312W; YNL313C; YNL317W; YNR003C; YNR011C; YNR016C; 
YNR017W; YNR026C; YNR035C; YNR038W; YNR043W; YNR046W; YNR053C; YNR054C; 
YOL005C; YOL010W; YOL021C; YOL022C; YOL026C; YOL034W; YOL038W; YOL040C; 
YOL066C; YOL069W; YOL077C; YOL078W; YOL094C; YOL097C; YOL102C; YOL120C; 
YOL123W; YOL127W; YOL130W; YOL133W; YOL135C; YOL139C; YOL142W; YOL144W; 
YOL146W; YOL149W; YOR004W; YOR020C; YOR046C; YOR048C; YOR056C; YOR057W; 
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YOR060C; YOR063W; YOR074C; YOR075W; YOR077W; YOR095C; YOR098C; YOR103C; 
YOR110W; YOR116C; YOR117W; YOR119C; YOR122C; YOR143C; YOR145C; YOR148C; 
YOR149C; YOR151C; YOR157C; YOR159C; YOR160W; YOR168W; YOR174W; YOR176W; 
YOR181W; YOR194C; YOR204W; YOR206W; YOR207C; YOR210W; YOR217W; YOR224C; 
YOR232W; YOR236W; YOR244W; YOR249C; YOR250C; YOR254C; YOR256C; YOR257W; 
YOR259C; YOR260W; YOR261C; YOR262W; YOR272W; YOR278W; YOR281C; YOR287C; 
YOR294W; YOR310C; YOR319W; YOR326W; YOR329C; YOR335C; YOR336W; YOR340C; 
YOR341W; YOR353C; YOR361C; YOR362C; YOR370C; YOR372C; YOR373W; YPL007C; 
YPL010W; YPL011C; YPL012W; YPL016W; YPL020C; YPL028W; YPL043W; YPL063W; 
YPL076W; YPL082C; YPL083C; YPL085W; YPL093W; YPL094C; YPL117C; YPL122C; 
YPL124W; YPL126W; YPL128C; YPL131W; YPL143W; YPL146C; YPL151C; YPL153C; 
YPL160W; YPL169C; YPL175W; YPL190C; YPL204W; YPL209C; YPL210C; YPL211W; 
YPL217C; YPL218W; YPL228W; YPL231W; YPL233W; YPL235W; YPL237W; YPL242C; 
YPL243W; YPL252C; YPL255W; YPL266W; YPR010C; YPR016C; YPR019W; YPR025C; 
YPR033C; YPR034W; YPR035W; YPR041W; YPR048W; YPR055W; YPR056W; YPR082C; 
YPR085C; YPR086W; YPR088C; YPR094W; YPR103W; YPR104C; YPR105C; YPR107C; 
YPR108W; YPR110C; YPR112C; YPR113W; YPR133C; YPR137W; YPR143W; YPR144C; 
YPR161C; YPR162C; YPR165W; YPR168W; YPR169W; YPR175W; YPR176C; YPR178W; 
YPR180W; YPR181C; YPR182W; YPR183W; YPR186C; YPR187W; YPR190C 
 
Essential ORFs in Yeast 5.0: 
 
YAL038W; YBL030C; YBL076C; YBR002C; YBR004C; YBR011C; YBR029C; YBR038W; 
YBR110W; YBR153W; YBR192W; YBR196C; YBR252W; YBR256C; YBR265W; YCL004W; 
YCL052C; YCR012W; YDL004W; YDL015C; YDL045C; YDL055C; YDL103C; YDL141W; 
YDL205C; YDR023W; YDR037W; YDR044W; YDR047W; YDR050C; YDR062W; YDR196C; 
YDR208W; YDR232W; YDR236C; YDR302W; YDR341C; YDR353W; YDR367W; YDR376W; 
YDR434W; YDR454C; YDR487C; YDR531W; YEL058W; YER003C; YER023W; YER043C; 
YFL017C; YFL022C; YFL045C; YGL001C; YGL008C; YGL040C; YGL055W; YGL142C; 
YGL155W; YGL225W; YGL245W; YGR060W; YGR065C; YGR094W; YGR175C; YGR185C; 
YGR191W; YGR264C; YGR267C; YGR277C; YHR007C; YHR019C; YHR020W; YHR042W; 
YHR068W; YHR072W; YHR074W; YHR128W; YHR188C; YHR190W; YIL078W; YIL083C; 
YJL005W; YJL026W; YJL091C; YJL097W; YJL167W; YJR013W; YJR016C; YJR057W; 
YKL004W; YKL019W; YKL024C; YKL035W; YKL060C; YKL088W; YKL104C; YKL141W; 
YKL152C; YKL165C; YKL182W; YKL192C; YLL018C; YLL031C; YLR060W; YLR088W; 
YLR100W; YLR153C; YLR195C; YLR305C; YLR355C; YLR359W; YLR459W; YML126C; 
YMR013C; YMR108W; YMR113W; YMR208W; YMR220W; YMR281W; YMR296C; YMR298W; 
YNL247W; YNL256W; YNL267W; YNR016C; YNR043W; YOL066C; YOL097C; YOR074C; 
YOR095C; YOR143C; YOR168W; YOR176W; YOR236W; YOR278W; YOR335C; YPL028W; 
YPL117C; YPL160W; YPL231W; YPL252C; YPR033C; YPR035W; YPR113W; YPR183W 
252 
 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
YLL027W lysine 
 
   
YLL039C myo-inositol 
 
   
YLL043W myo-inositol 
 
   
YLR015W myo-inositol 
 
   
YLR016C myo-inositol 
 
   
YLR021W myo-inositol 
 
   
YLR048W myo-inositol 
 
   
YLR055C myo-inositol 
 
   
YLR056W myo-inositol 
 
   
YLR061W myo-inositol 
 
   
YLR074C myo-inositol 
 
   
YLR079W myo-inositol 
 
   
YLR087C myo-inositol 
 
   
YLR089C myo-inositol 
 
   
YLR100W cholesterol 
 
   
YLR100W ergosterol 
 
   
YLR113W myo-inositol 
 
   
YLR134W myo-inositol 
 
   
YLR146C beta-alanine (0.1 mM) 
 
   
YLR146C pantothenic acid (0.1 mM) 
 
   
YLR146C spermine (0.25 mM) 
 
   
YLR150W myo-inositol 
 
   
YLR192C myo-inositol 
 
   
YLR199C myo-inositol 
 





   
YLR226W myo-inositol 
 
   
YLR226W myo-inositol 
 
   
YLR231C nicotinic acid 
 
   
YLR237W myo-inositol 
 
   
YLR242C myo-inositol 
 
   
YLR262C myo-inositol 
 
   
YLR268W myo-inositol 
 
   
YLR292C myo-inositol 
 
   
YLR303W methionine 
 
   
YLR303W methionine 
 
   
YLR304C glutamic acid 
 
   
YLR315W myo-inositol 
 
   
YLR320W myo-inositol 
 
   
YLR324W myo-inositol 
 
   
YLR332W myo-inositol 
 
   
YLR342W myo-inositol 
 
   
YLR354C myo-inositol 
 
   
YLR355C valine;isoleucine 
 
   
YLR357W myo-inositol 
 
   
YLR359W 
     
YLR359W 
     
YLR371W myo-inositol 
 
   
YLR373C myo-inositol 
 
   
YLR396C methionine 
 
   
YLR417W ethanolamine 
 
   
YLR418C myo-inositol 
 
   
YLR420W uracil 
 
   
YLR426W myo-inositol 
 
   
YLR436C myo-inositol 
 
   
YML008C myo-inositol 
 
   
YML013W myo-inositol 
 
   
YML014W myo-inositol 
 
   
YML022W myo-inositol 
 
   
YML028W myo-inositol 
 
   
YML034W myo-inositol 
 
   
YML055W myo-inositol 
 
   
YML059C inositol 
 
   
YML071C myo-inositol 
 
   
YML103C myo-inositol 
 
   
YML106W 
     
YML115C myo-inositol 
 
   
YML117W myo-inositol 
 
   
YML126C ergosterol 
 
   
YMR010W myo-inositol 
 
   
YMR014W myo-inositol 
 
   
YMR015C myo-inositol 
 





   
YMR020W beta-alanine (0.1 mM) 
 
   
YMR020W pantothenic acid (0.1 mM) 
 
   
YMR029C myo-inositol 
 
   
YMR038C methionine;lysine 
 
   
YMR052W myo-inositol 
 
   
YMR062C arginine 
 
   
YMR067C myo-inositol 
 
   
YMR068W myo-inositol 
 
   
YMR079W myo-inositol 
 
   
YMR092C myo-inositol 
 
   
YMR099C myo-inositol 
 
   
YMR104C myo-inositol 
 
   
YMR108W isoleucine;valine 
 
   
YMR113W 5-formyltetrahydrofolic acid 
 
   
YMR113W 5-formyltetrahydrofolic acid 
 
   
YMR123W myo-inositol 
 
   
YMR165C myo-inositol 
 
   
YMR170C beta-alanine 
 
   
YMR170C pantothenic acid 
 
   
YMR190C myo-inositol 
 
   
YMR202W myo-inositol 
 
   
YMR208W ergosterol 
 
   
YMR214W myo-inositol 
 
   
YMR217W guanine 
 
   
YMR220W ergosterol 
 
   
YMR242C myo-inositol 
 
   
YMR247C inositol 
 
   
YMR272C myo-inositol 
 
   
YMR276W myo-inositol 
 
   
YMR289W 4-aminobenzoic acid 
 
   
YMR289W folic acid 
 
   
YMR300C adenine 
 
   
YMR304W myo-inositol 
 
   
YMR307W myo-inositol 
 
   
YMR312W myo-inositol 
 
   
YNL003C biotin 
 
   
YNL041C myo-inositol 
 
   
YNL051W myo-inositol 
 
   
YNL079C myo-inositol 
 
   
YNL080C myo-inositol 
 





   
YNL104C leucine 
 
   
YNL119W myo-inositol 
 
   
YNL127W myo-inositol 
 
   
YNL133C myo-inositol 
 
   
YNL148C myo-inositol 
 
   
YNL215W myo-inositol 
 
   
YNL219C myo-inositol 
 
   
YNL220W 
     
YNL220W 
     
YNL229C myo-inositol 
 
   
YNL236W myo-inositol 
 
   
YNL241C methionine 
 
   
YNL241C methionine 
 
   
YNL241C methionine 
 
   
YNL256W folic acid 
 
   
YNL267W myo-inositol 
 
   
YNL277W methionine 
 
   
YNL277W methionine 
 
   
YNL307C myo-inositol 
 
   
YNL316C 
     
YNL322C myo-inositol 
 
   
YNL323W myo-inositol 
 
   
YNR055C histidinol 
 
   
YOL018C myo-inositol 
 
   
YOL052C beta-alanine (0.1 mM) 
 
   
YOL052C myo-inositol 
 
   
YOL052C pantothenic acid (0.1 mM) 
 
   
YOL052C spermine (0.25 mM) 
 
   
YOL059W myo-inositol 
 
   
YOL064C methionine 
 
   
YOL066C riboflavin 
 
   
YOL067C glutamate(1-) 
 
   
YOL067C myo-inositol 
 
   
YOL068C myo-inositol 
 
   
YOL087C myo-inositol 
 
   
YOL090W myo-inositol 
 
   
YOL093W myo-inositol 
 
   
YOL098C myo-inositol 
 
   
YOL107W myo-inositol 
 
   
YOL109W myo-inositol 
 
   
YOL110W myo-inositol 
 
   
YOL111C myo-inositol 
 
   
YOL116W myo-inositol 
 
   
YOL121C myo-inositol 
 





   
YOL124C myo-inositol 
 
   
YOL143C riboflavin 
 
   
YOL145C myo-inositol 
 
   
YOR002W myo-inositol 
 
   
YOR008C myo-inositol 
 
   
YOR012W myo-inositol 
 
   
YOR067C myo-inositol 
 
   
YOR070C myo-inositol 
 
   
YOR078W myo-inositol 
 
   
YOR096W myo-inositol 
 
   
YOR106W myo-inositol 
 
   
YOR123C myo-inositol 
 
   
YOR128C adenine 
 
   
YOR151C inositol 
 
   
YOR184W serine 
 
   
YOR184W serine 
 
   
YOR189W myo-inositol 
 
   
YOR202W histidine 
 
   
YOR210W inositol 
 
   
YOR216C myo-inositol 
 
   
YOR224C inositol 
 
   
YOR236W adenine 
 
   
YOR236W dTMP 
 
   
YOR236W histidine 
 
   
YOR236W methionine 
 
   
YOR241W methionine 
 
   
YOR241W methionine 
 
   
YOR246C myo-inositol 
 
   
YOR270C myo-inositol 
 
   
YOR278W heme 
 
   
YOR290C inositol 
 
   
YOR290C myo-inositol 
 
   
YOR303W arginine 
 
   
YOR320C myo-inositol 
 
   
YOR322C myo-inositol 
 
   
YOR359W myo-inositol 
 
   
YOR371C myo-inositol 
 
   
YPL028W ergosterol 
 
   
YPL055C myo-inositol 
 
   
YPL065W myo-inositol 
 
   
YPL089C myo-inositol 
 
   
YPL138C myo-inositol 
 
   
YPL140C myo-inositol 
 
   
YPL144W myo-inositol 
 
   
YPL157W myo-inositol 
 
   
YPL159C myo-inositol 
 





   
YPL177C myo-inositol 
 
   
YPL214C thiamine 
 
   
YPL226W myo-inositol 
 
   
YPL231W fatty acid 
 
   
YPL241C myo-inositol 
 
   
YPL254W myo-inositol 
 
   
YPL264C myo-inositol 
 
   
YPL268W ornithine 
 
   
YPR035W glutamine 
 
   
YPR036W myo-inositol 
 
   
YPR043W myo-inositol 
 
   
YPR056W inositol 
 
   
YPR060C phenylalanine 
 
   
YPR067W glutamate(1-) 
 
   
YPR067W lysine 
 
   
YPR069C beta-alanine (0.1 mM) 
 
   
YPR069C pantothenic acid (0.1 mM) 
 
   
YPR069C spermidine (10 uM) 
 
   
YPR069C spermine (0.25 mM) 
 
   
YPR074C phenylalanine 
 
   
YPR074C tryptophan 
 
   
YPR074C tyrosine 
 
   
YPR139C myo-inositol 
 
   
YPR161C myo-inositol 
 
   
YPR161C myo-inositol 
 
   
YPR167C myo-inositol 
 
   
YPR173C ethanolamine 
 
   
YPR179C myo-inositol 
 
   
YPR187W inositol 
 
   
YPR187W 
     
YPR201W myo-inositol 
 
   
 
Notes: 
The selected auxotroph list removes the following ORFS: those annotated "unverified" in SGD, 
those which are also on the YKO essential list, those annotated in SGD as temperature-sensitive 





Auxotrophy annotation was downloaded from the Saccharomyces Genome Database. Chemical 
auxotrophies including concentration information indicate the concentration of that compound in 
media, as described by White, Gunyuzlu, and Toyn (2001) doi: 10.1074/jbc.M009804200 
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Supplementary Table 4.3: Biomass Definition 
 









growth -1 biomass 
  
     
biomass 
pseudoreaction 
-1.14 (1->3)-beta-D-glucan [cytoplasm] 59.3 
ADP 
[cytoplasm] 












-0.00359 dAMP [cytoplasm] 
  
 
-0.00243 dCMP [cytoplasm] 
  
 
-0.00243 dGMP [cytoplasm] 
  
 
-0.00359 dTMP [cytoplasm] 
  
 
-0.519 glycogen [cytoplasm] 
  
 
-0.051 GMP [cytoplasm] 
  
 
-59.3 H2O [cytoplasm] 
  
 
-0.357 L-alanine [cytoplasm] 
  
 
-0.136 L-arginine [cytoplasm] 
  
 
-0.172 L-asparagine [cytoplasm] 
  
 
-0.172 L-aspartate [cytoplasm] 
  
 
-0.0429 L-cysteine [cytoplasm] 
  
 
-0.0268 L-glutamate [cytoplasm] 
  
 
-0.0268 L-glutamine [cytoplasm] 
  
 
-0.325 L-glycine [cytoplasm] 
  
 
-0.075 L-histidine [cytoplasm] 
  
 
-0.0172 L-isoleucine [cytoplasm] 
  
 
-0.25 L-leucine [cytoplasm] 
  
 
-0.239 L-lysine [cytoplasm] 
  
 
-0.05 L-methionine [cytoplasm] 
  
 
-0.114 L-phenylalanine [cytoplasm] 
  
 
-0.129 L-proline [cytoplasm] 
  
 
-0.254 L-serine [cytoplasm] 
  
 
-0.197 L-threonine [cytoplasm] 
  
 
-0.028 L-tryptophan [cytoplasm] 
  
 
-0.0965 L-tyrosine [cytoplasm] 
  
 
-0.0257 L-valine [cytoplasm] 
  
 
-1 lipid [cytoplasm] 
  
 
-0.821 mannan [cytoplasm] 
  
 
-0.0009 riboflavin [cytoplasm] 
  
 
-0.02 sulphate [cytoplasm] 
  
 





-0.067 UMP [cytoplasm] 
  









-0.000056 14-demethyllanosterol [cytoplasm] 
  
(aerobic) -0.000417 complex sphingolipid [cytoplasm] 
  
 





3beta-ol [cytoplasm]   
 
-0.0056 ergosterol [cytoplasm] 
  
 
-0.000812 ergosterol ester [cytoplasm] 
  
 
-0.000206 fatty acid [cytoplasm] 
  
 
-0.000114 fecosterol [cytoplasm] 
  
 
-0.000032 lanosterol [cytoplasm] 
  
 
-0.000373 phosphatidyl-L-serine [cytoplasm] 
  
 





[cytoplasm]   
 
-0.000781 triglyceride [cytoplasm] 
  
 
-0.000015 zymosterol [cytoplasm] 
  









-0.000417 complex sphingolipid [cytoplasm] 
  
(anaerobic) -0.000096 episterol [cytoplasm] 
  
 
-0.0056 ergosterol [cytoplasm] 
  
 
-0.000812 ergosterol ester [cytoplasm] 
  
 
-0.000206 fatty acid [cytoplasm] 
  
 
-0.000114 fecosterol [cytoplasm] 
  
 
-0.000032 lanosterol [cytoplasm] 
  
 
-0.000373 phosphatidyl-L-serine [cytoplasm] 
  
 





[cytoplasm]   
 
-0.000781 triglyceride [cytoplasm] 
  
 




Supplementary Table 4.4: Epistasis Analysis 
 
Multiplicative Epistasis cutoff threshold = 0.01 
 
Yeast 5 Gene-Based Analysis 





0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
0 (KO) 5566 5435 5313 5111 4843 4700 4466 4197 3800 3512 
0.1 
 
6152 6190 5947 5518 5558 5421 4855 4688 4369 
0.2 
  
5614 5515 5433 5356 5371 4726 4587 3629 
0.3 
   
5396 5363 5243 5067 4682 4514 3505 
0.4 
    
5226 4998 4772 4457 4366 2874 
0.5 
     
4672 4469 4219 3755 2081 
0.6 
      
4122 4098 3560 1414 
0.7 
       
3892 2213 966 
0.8 
        
1198 452 
0.9 
         
242 
  
         
  





0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
0 (KO) 42.63 75.83 76.39 77.58 79.67 80.2 81.12 82.6 84.28 84.34 
0.1 
 
91.05 91.07 91.03 91.77 91.23 91.29 92.13 92.13 90.36 
0.2 
  
91.94 91.97 92.2 92.2 92.26 92.83 92.46 93.55 
0.3 
   
92.04 92.13 92.37 92.5 93.12 92.96 93.57 
0.4 
    
92.21 92.5 92.92 93.31 93.4 94.67 
0.5 
     
92.89 93.15 93.6 94.13 96.04 
0.6 
      
93.55 93.56 94.19 97.2 
0.7 
       
93.8 96.3 98.2 
0.8 
        
97.93 99.18 





iMM904 Gene-Based Analysis 





0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
0 (KO) 3490 4422 4349 4180 4033 3944 4020 3867 3525 3241 
0.1 
 
6910 7079 6938 6762 6500 6704 6446 6003 5592 
0.2 
  
6614 6623 6376 6240 6573 6010 5830 5521 
0.3 
   
6390 6111 6024 6003 5754 5647 4899 
0.4 
    
5762 5855 5897 5666 5627 4200 
0.5 
     
5554 5654 5519 5482 3311 
0.6 
      
5374 5485 5279 2867 
0.7 
       
5096 4619 2371 
0.8 
        
2642 1960 
0.9 
         
1656 
  
         
  





0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
0 (KO) 47.53 77.44 78.2 79.12 79.81 80.82 80.13 80.66 81.97 82.81 
0.1 
 
89.57 89.38 89.53 89.74 89.44 88.57 88.81 89.36 86.5 
0.2 
  
90.04 89.98 90.38 90.41 89.88 90.67 89.86 90.03 
0.3 
   
90.31 90.74 90.67 90.57 90.96 91.03 91.08 
0.4 
    
91.17 90.95 90.7 91.04 91.03 92.04 
0.5 
     
91.21 90.92 91.1 91.15 94.02 
0.6 
      
91.19 90.97 91.28 94.91 
0.7 
       
91.47 92.17 95.74 
0.8 
        
95.34 96.43 





iND750 Gene-Based Analysis 





0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
0 (KO) 2836 3709 3613 3581 3575 3529 3487 3403 3373 3270 
0.1 
 
4668 4750 4704 4727 4436 4411 4353 4325 4373 
0.2 
  
4350 4403 4405 4353 4338 4298 4217 3991 
0.3 
   
4276 4352 4319 4282 4254 4187 3211 
0.4 
    
4246 4296 4282 4231 4189 2397 
0.5 
     
4162 4229 4197 4146 1879 
0.6 
      
4118 4185 3787 1626 
0.7 
       
4010 2147 702 
0.8 
        
1006 350 
0.9 
         
136 
  
         
  





0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
0 (KO) 46.51 77.4 78.71 79.4 79.3 79.69 79.8 80.17 80.46 80.73 
0.1 
 
91.9 91.85 91.96 91.52 91.4 91.41 91.57 91.6 84.71 
0.2 
  
92.53 92.44 92.43 92.51 92.51 92.18 91.74 91.88 
0.3 
   
92.68 92.57 92.56 92.62 92.64 92.3 93.51 
0.4 
    
92.67 92.65 92.66 92.67 92.68 95.02 
0.5 
     
92.8 92.7 92.72 92.75 96.03 
0.6 
      
92.86 92.73 93.26 96.76 
0.7 
       
92.99 96.04 98.58 
0.8 
        
98.11 99.32 





Yeast 5 Reaction-Based Analysis 





0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
0 (KO) 862 909 894 862 802 761 743 696 667 641 
0.1 
 
874 900 857 814 792 784 734 695 669 
0.2 
  
830 835 792 763 769 713 690 664 
0.3 
   
764 763 723 705 677 646 614 
0.4 
    
672 650 640 618 599 566 
0.5 
     
574 595 566 543 510 
0.6 
      
510 524 508 451 
0.7 
       
458 473 406 
0.8 
        
378 373 
0.9 
         
316 
  
         
  





0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
0 (KO) 27.56 73.58 73.95 77.69 81.41 83.57 83.68 86.36 87.35 87.33 
0.1 
 
96.6 96.55 96.69 96.9 96.94 96.96 97.17 97.26 96.52 
0.2 
  
96.82 96.76 96.98 97.03 97.08 97.25 97.32 97.33 
0.3 
   
96.99 97.03 97.19 97.23 97.39 97.47 97.45 
0.4 
    
97.33 97.41 97.47 97.56 97.66 97.65 
0.5 
     
97.68 97.58 97.73 97.81 97.83 
0.6 
      
97.88 97.83 97.87 98 
0.7 
       
98.09 98.01 98.2 
0.8 
        
98.39 98.35 





iMM904 Reaction-Based Analysis 





0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
0 (KO) 262 321 316 307 303 288 280 260 244 218 
0.1 
 
346 360 355 350 329 329 302 286 256 
0.2 
  
346 345 341 328 325 282 270 251 
0.3 
   
324 320 317 298 269 254 232 
0.4 
    
302 302 295 252 243 212 
0.5 
     
270 273 252 237 196 
0.6 
      
246 239 229 184 
0.7 
       
200 199 159 
0.8 
        
146 142 
0.9 
         
110 
  
         
  





0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
0 (KO) 22.02 75.15 76.7 78.33 79.6 80.39 80.54 81.72 82.6 83.68 
0.1 
 
95.63 95.45 95.51 95.61 95.71 95.49 95.84 95.97 94.91 
0.2 
  
95.54 95.59 95.68 95.91 95.9 96.32 96.26 96.42 
0.3 
   
95.88 95.97 95.97 96.19 96.58 96.67 96.75 
0.4 
    
96.16 96.19 96.2 96.76 96.78 96.99 
0.5 
     
96.55 96.5 96.73 96.94 97.3 
0.6 
      
96.77 96.88 96.98 97.43 
0.7 
       
97.35 97.34 97.75 
0.8 
        
98.02 98.03 





iND750 Reaction-Based Analysis 





0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
0 (KO) 276 347 340 333 334 337 335 333 317 301 
0.1 
 
374 388 375 380 376 374 376 357 342 
0.2 
  
366 366 369 365 361 352 338 327 
0.3 
   
334 349 353 346 341 324 299 
0.4 
    
334 344 342 336 320 282 
0.5 
     
316 333 333 311 257 
0.6 
      
310 323 308 232 
0.7 
       
294 254 213 
0.8 
        
194 179 
0.9 
         
136 
  
         
  





0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
0 (KO) 25.41 77.63 78.91 81.15 80.95 81.45 81.49 81.57 82.96 83.47 
0.1 
 
96.33 96.19 96.34 96.22 96.13 96.12 96.12 96.21 91.62 
0.2 
  
96.39 96.39 96.35 96.35 96.36 96.42 96.44 96.35 
0.3 
   
96.7 96.55 96.47 96.54 96.58 96.66 96.77 
0.4 
    
96.64 96.55 96.57 96.6 96.73 96.98 
0.5 
     
96.74 96.6 96.6 96.81 97.23 
0.6 
      
96.8 96.67 96.81 97.54 
0.7 
       
96.96 97.34 97.71 
0.8 
        
97.97 98.09 














ORF type (from 
SGD) 
ORF function (from SGD) Comment 
     
YAL014C SYN8 ORF, Verified Endosomal SNARE related 
to mammalian syntaxin 8 
Y4 annotates a palmitoyl 
transferase reaction with this 
ORF 
YAL030W SNC1 ORF, Verified Vesicle membrane 
receptor protein (v-
SNARE) involved in the 
fusion between Golgi-
derived secretory vesicles 
with the plasma 
membrane 
Y4 annotates a palmitoyl 
transferase reaction with this 
ORF 
YAR042W SWH1 ORF, Verified Protein similar to 
mammalian oxysterol-
binding protein 
Y4 annotates a sterol 
intercompartmental 




SOL2 ORF, Verified Protein with a possible 
role in tRNA export; shows 
similarity to 6-
phosphogluconolactonase 
non-catalytic domains but 
does not exhibit this 
enzymatic activity 
Y4 annotates a  6-
phosphogluconolactonase  
reaction with this ORF 
YDL019C OSH2 ORF, Verified Member of an oxysterol-
binding protein family 
with seven members in S. 
cerevisiae; 
Y4 annotates a sterol 
intercompartmental 
transport reaction with this 
ORF; metabolic function 
unclear 
YDR313C PIB1 ORF, Verified RING-type ubiquitin ligase 





Y4 includes this binding; out 
of Y5 scope 
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YDR331W GPI8 ORF, Verified ER membrane 
glycoprotein subunit of 
the 
glycosylphosphatidylinosit
ol transamidase complex 
 GPI-anchor assembly lumped 
reaction in Y4 
YDR468C TLG1 ORF, Verified Essential t-SNARE that 
forms a complex with 
Tlg2p and Vti1p and 
mediates fusion of 
endosome-derived 
vesicles with the late Golgi 
Y4 annotates a palmitoyl 
transferase reaction with this 
ORF 
YEL011W GLC3 ORF, Verified Glycogen branching 
enzyme, involved in 
glycogen accumulation 
Y4 annotates a reaction using 
the polysaccharide amylose 
as a substrate; a general 
reaction 
YEL013W VAC8 ORF, Verified Phosphorylated and 
palmitoylated vacuolar 
membrane protein that 
interacts with Atg13p 
Y4 annotates a 
palmitoylation reaction with 
this ORF; metabolic function 
unknown 
YER093C TSC11 ORF, Verified Subunit of TORC2 (Tor2p-
Lst8p-Avo1-Avo2-Tsc11p-
Bit61p), a membrane-
associated complex that 
regulates actin 
cytoskeletal dynamics 
during polarized growth 
and cell wall integrity 
Y4 annotates a reaction 
which only uses boundary 
species with this ORF 
YFR055W IRC7 ORF, 
Uncharacterized 
Beta-lyase involved in the 
production of thiols 
Y4 annotates lyase with this 
ORF or YGL184C; YGL184C 
annotation retained in Y5 
YGR199W PMT6  ORF, Verified Protein O-
mannosyltransferase 
PMT6 wasn't among the 
genes analyzed in the 
reference paper linked from 
SGD; Y4 annotates this 
reaction with the other genes 
in this family 
YHR005C GPA1 ORF, Verified GTP-binding alpha subunit 
of the heterotrimeric G 
protein that couples to 
pheromone receptors 
Y4 annotates a YHR005C 
myristoylation reaction using 




YHR073W OSH3 ORF, Verified Member of an oxysterol-
binding protein family 
with seven members in S. 
cerevisiae 
Y4 annotates an oxysterol 
transport and binding 
reaction with this ORF 
YMR068W AVO2 ORF, Verified Component of a complex 
containing the Tor2p 
kinase and other proteins, 
which may have a role in 
regulation of cell growth 
Y4 annotates a reaction 
which only uses boundary 
species with this ORF 
YNL006W LST8 ORF, Verified Protein required for the 
transport of amino acid 
permease Gap1p from the 
Golgi to the cell surface; 
Y4 annotates a reaction 
which only uses boundary 
species with this ORF 
YNR034W SOL1 ORF, Verified Protein with a possible 
role in tRNA export; shows 
similarity to 6-
phosphogluconolactonase 
non-catalytic domains but 
does not exhibit this 
enzymatic activity 
Y4 annotates a  6-
phosphogluconolactonase  
reaction with this ORF 
YOL078W AVO1 ORF, Verified Component of a 
membrane-bound 
complex containing the 
Tor2p kinase and other 
proteins, which may have 
a role in regulation of cell 
growth 
Y4 annotates a reaction 
which only uses boundary 
species with this ORF 
YPL145C KES1 ORF, Verified Member of the oxysterol 
binding protein family 
Y4 annotates two oxysterol 
transport and binding 
reactions with this ORF 
YPL275W FDH2 pseudogene NAD(+)-dependent 
formate dehydrogenase, 
may protect cells from 
exogenous formate; 
YPL275W and YPL276W 
comprise a continuous 
open reading frame in 
some S. cerevisiae strains 
but not in the genomic 
reference strain S288C 
Y4 annotates a formate 




YPL276W FDH2 pseudogene NAD(+)-dependent 
formate dehydrogenase, 
may protect cells from 
exogenous formate; 
YPL275W and YPL276W 
comprise a continuous 
open reading frame in 
some S. cerevisiae strains 
but not in the genomic 
reference strain S288C 
Y4 annotates a formate 
dehydrogenase reaction with 
this ORF 
YOR237W HES1  ORF, Verified Protein implicated in the 
regulation of ergosterol 
biosynthesis 
Y4 annotates an oxysterol 
transport and binding 
reaction with this ORF 
YIL105C SLM1 ORF, Verified Phosphoinositide PI4,5P(2) 
binding protein, forms a 
complex with Slm2p 
Y4 includes this binding; out 
of Y5 scope 




complex that regulates 
Y4 annotates a reaction 
which only uses boundary 
species with this ORF 





Replaced by YDL247W in Y5 
(YJR160C reintroduced in 
subsequent updates) 
YKL203C TOR2 ORF, Verified PIK-related protein kinase 
and rapamycin target 
Y4 annotates a reaction 
which only uses boundary 
species with this ORF 
YML082W - ORF, 
Uncharacterized 
Putative protein predicted 
to have carbon-sulfur 
lyase activity 
Y4 annotates a cystathionine 
gamma-synthase reaction 
and a  O-succinylhomoserine 
lyase with this ORF 
YNL047C SLM2 ORF, Verified Phosphoinositide PI4,5P(2) 
binding protein 
Y4 includes this binding; out 




Supplementary Table 4.6: ORFs in Y5 not in Y4 
 
ORFs in Yeast 5 





ORF function (from SGD) 
    
YBR001C NTH2 ORF, 
Verified 
Putative neutral trehalase, required for thermotolerance 
and may mediate resistance to other cellular stresses 
YBR058C-A TSC3 ORF, 
Verified 
Protein that stimulates the activity of serine 
palmitoyltransferase (Lcb1p, Lcb2p) several-fold; 
involved in sphingolipid biosynthesis 
YBR161W CSH1 ORF, 
Verified 
Probable catalytic subunit of a mannosylinositol 
phosphorylceramide (MIPC) synthase, forms a complex 
with probable regulatory subunit Csg2p; function in 
sphingolipid biosynthesis is overlapping with that of 
Sur1p 
YBR199W KTR4 ORF, 
Verified 
Putative mannosyltransferase involved in protein 






Probable dephospho-CoA kinase (DPCK) that catalyzes 
the last step in coenzyme A biosynthesis; null mutant 
lethality is complemented by E. coli coaE (encoding 
DPCK); detected in purified mitochondria in high-
throughput studies 
YDR367W KEI1 ORF, 
Verified 
Component of inositol phosphorylceramide (IPC) 
synthase; forms a complex with Aur1p and regulates its 
activity; required for IPC synthase complex localization 
to the Golgi; post-translationally processed by Kex2p; 
KEI1 is an essential gene 
YGL084C GUP1 ORF, 
Verified 
Plasma membrane protein involved in remodeling GPI 
anchors; member of the MBOAT family of putative 
membrane-bound O-acyltransferases; proposed to be 
involved in glycerol transport 
YGR138C TPO2 ORF, 
Verified 
Polyamine transport protein specific for spermine; 
localizes to the plasma membrane; transcription of TPO2 
is regulated by Haa1p; member of the major facilitator 
superfamily 
YGR277C CAB4 ORF, 
Verified 
Probable pantetheine-phosphate adenylyltransferase 
(PPAT), which catalyzes the fourth step in the 
biosynthesis of coenzyme A from pantothenate; null 
mutant lethality is complemented by E. coli coaD 
(encoding PPAT); widely conserved 
281 
 
YIL083C CAB2 ORF, 
Verified 
Probable phosphopantothenoylcysteine synthetase 
(PPCS), which catalyzes the second step of coenzyme A 
biosynthesis from pantothenate; null mutant lethality is 
complemented by E. coli coaBC (encoding a bifunctional 
enzyme with PPCS activity) 
YJL200C ACO2 ORF, 
Verified 
Putative mitochondrial aconitase isozyme; similarity to 
Aco1p, an aconitase required for the TCA cycle; 
expression induced during growth on glucose, by amino 
acid starvation via Gcn4p, and repressed on ethanol 
YKL088W CAB3 ORF, 
Verified 
Subunit of a phosphopantothenoylcysteine 
decarboxylase (PPCDC; Cab3p, Sis2p, Vhs3p) complex, 
which catalyzes the third step of coenzyme A 
biosynthesis; null mutant lethality is complemented by 
E. coli coaBC 
YKL132C RMA1 ORF, 
Verified 
Putative dihydrofolate synthetase; has similarity to Fol3p 
and to E. coli folylpolyglutamate 
synthetase/dihydrofolate synthetase; the authentic, 
non-tagged protein is detected in highly purified 
mitochondria in high-throughput studies 
YML056C IMD4 ORF, 
Verified 
Inosine monophosphate dehydrogenase, catalyzes the 
first step of GMP biosynthesis, member of a four-gene 
family in S. cerevisiae, constitutively expressed 
YMR241W YHM2 ORF, 
Verified 
Carrier protein that exports citrate from and imports 
oxoglutarate into the mitochondrion, causing net export 
of NADPH reducing equivalents; also associates with mt 
nucleoids and has a role in replication and segregation of 
the mt genome 
YMR278W PGM3 ORF, 
Verified 
Phosphoglucomutase, catalyzes interconversion of 
glucose-1-phosphate and glucose-6-phospate; 
transcription induced in response to stress; green 
fluorescent protein (GFP)-fusion protein localizes to the 
cytoplasm and nucleus; non-essential 
YMR298W LIP1 ORF, 
Verified 
Ceramide synthase subunit; single-span ER membrane 
protein associated with Lag1p and Lac1p and required 
for ceramide synthase activity, null mutant grows 
extremely slowly and is defective in ceramide synthesis 
YNL029C KTR5 ORF, 
Verified 
Putative mannosyltransferase involved in protein 
glycosylation; member of the KRE2/MNT1 
mannosyltransferase family 
YOR175C ALE1 ORF, 
Verified 
Broad-specificity lysophospholipid acyltransferase, part 
of MBOAT family of membrane-bound O-
acyltransferases; key component of Lands cycle; may 




YPL023C MET12 ORF, 
Verified 
Protein with methylenetetrahydrofolate reductase 
(MTHFR) activity in vitro; null mutant has no phenotype 
and is prototrophic for methionine; MET13 encodes 
major isozyme of MTHFR 
YPL053C KTR6 ORF, 
Verified 
Probable mannosylphosphate transferase involved in the 
synthesis of core oligosaccharides in protein 
glycosylation pathway; member of the KRE2/MNT1 
mannosyltransferase family 
YPL189W GUP2 ORF, 
Verified 
Probable membrane protein with a possible role in 
proton symport of glycerol; member of the MBOAT 
family of putative membrane-bound O-acyltransferases; 
Gup1p homolog 
YPR156C TPO3 ORF, 
Verified 
Polyamine transport protein specific for spermine; 




APPENDIX 3 – SUPPLEMENTARY INFORMATION FOR CHAPTER 5 
Supplementary File 5.1.1: three_knockout1.m script 
 
% FILE NAME: three-knockout1 
% 
% DATE CREATED: 18 January 2012 
% 
% PROGRAMMER: B. Heavner 
% Department of Biological 
% and Environmental Engineering 
% Cornell University 
% Ithaca, NY 14853 
% 
% LAST REVISED: 10 July 2012 
% revisions:  
% 10 July 2012 - BDH - clean up for publication 
% 11 May 2012 - BDH - fix strain background 
% 
% REVISED BY: B. Heavner 
% 
% PURPOSE:  
% To attempt to reproduce the model results reported by Kennedy et al. - 
% that is, to apply constraints to iND750 to demonstrate the prediction of 
% formic acid secretion with the mutants reported in Kennedy et al. Table 
% 1. 
% 
% REFERENCE:  
% Kennedy CJ, Boyle PM, Waks Z, Silver PA. "Systems-Level Engineering of 




% none - it's a script. But you need iND.mat in the working directory (or 
% load iND750 using readcbmodel, and comment out the "load" line of the 
% script). 
% 
% EXPECTED OUTPUT: 
% growth rates and fluxes for the first 5 mutants listed in Table 1 of 
% Kennedy et al. I can't do mutants 6-8 because this version of iND750 
% doesn't include reactions annotated with YAT2 
% 
% REQUIRED SOFTWARE: 






% first, load the iND750 model. This matlab variable was made by running 









fprintf('iND750 model loaded.\n'); 
fprintf(' \r'); 
  
%make sure we're using the gurobi solver (glpk may give different answers!) 
changeCobraSolver('gurobi'); 
  




%next modify the model to add some strain-specific changes. 
  
%paper wt background is fdh1 fdh2 deletion 
[model,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YOR388C','YPL275W','YPL276W'}); 
  
%cytosolic fdh rxn (592) isn’t annotated with fdh1 or fdh2. It needs to be 
%constrained, too 
FDH=strmatch('FDNG',model.rxns); 
model.lb(FDH)=0; %make fdh1/2 mutant, remove mito FDH activity (593) 
model.ub(FDH)=0; %make fdh1/2 mutant, remove mito FDH activity (593) 
     
%% 
%next, make the iND media the same as that in Kennedy et al. (based on 
%their supplemental table 1).  
  
%NOTE: the COBRA exchange reaction convention means that I need to use the 
%opposite sign than Kennedy et al. 
% 
%NOTE 2: Table S1 lists "pydxn", "4abz", "nac", and "dhf" as having an 
%upper bound of 0.5. I think these are: Pyridoxine (met 875), 
%4-Aminobenzoate (met 98), Nicotinate (met 714), and 7,8-Dihydrofolate (met 
%383). They don't have exchange reactions in iND750. Kennedy et al. may 
%have added them, but they don't have fluxes in Table S2, so they're not 
%essential. 
% 
%NOTE 3: I'm guessing rxn names from their met names. 
  
%start with a clean slate: set all exchange reactions to upper bound = 1000 
%and lower bound = 0 (ie, unconstrained excretion, no uptake) 
  




%the following exchange rxns have an upper bound and lower bound of 20 in 






    index=find(strcmp(ub_lb_20(i),model.rxnNames)); 
    model.lb(index)=-20; 





%the following have upper and lower bounds of inf in Table S1.  
% 
%NOTE: oxygen not in table S1, but added to do aerobic, based on 
%text of paper 
  
ub_inf={'H2O exchange', 'Ammonia exchange', 'Phosphate exchange', ... 
    'Sulfate exchange', 'Sodium exchange', 'K+ exchange', ...  
    'CO2 exchange', 'O2 exchange'}; 
  
for i=1:length(ub_inf) 
    index=find(strcmp(ub_inf(i),model.rxnNames)); 
    model.lb(index)=-1000; 
end 
  
%the following have an upper bound of 0.5 in Table S1 (but I'm switching 
%signs, so do a lower bound of -0.5). 
  
ub_05 = {'L-Asparagine exchange', 'L-Aspartate exchange', ...  
    'L-Valine exchange', 'L-Tyrosine exchange', ... 
    'L-Tryptophan exchange', 'L-Threonine exchange', ...  
    'L-Serine exchange', 'L-Proline exchange', ...  
    'L-Phenylalanine exchange', 'L-Methionine exchange', ... 
    'L-Lysine exchange', 'L-Leucine exchange', ... 
    'L-Isoleucine exchange', 'L-Histidine exchange', ... 
    'Glycine exchange', 'L-Glutamate exchange', ... 
    'L-Glutamine exchange', 'L-Cysteine exchange', ... 
    'L-Arginine exchange', 'L-Alanine exchange' ... 
    'Riboflavin exchange', 'Thiamin exchange', 'zymosterol exchange', ... 
    'Uracil exchange', '(R)-Pantothenate exchange', ... 
    'octadecynoate (n-C18:2) exchange', ... 
    'octadecenoate (n-C18:1) exchange', 'myo-Inositol exchange', ... 
    'hexadecenoate (n-C16:1) exchange', 'Ergosterol exchange', ... 




    index=find(strcmp(ub_05(i),model.rxnNames)); 
    model.lb(index)=-0.5; %constrained uptake 
end 
  
%the following have a lower bound of -inf in Table S1 (but I'm switching 
%signs, so do an upper bound of 1000) 
% 
% Note: 'Deoxycytidine exchange' not included in Table S1, but has a flux 
% in Table S2, so I added it here. 
  
lb_inf = {' 1,3-beta-D-Glucan exchange', ... 
    ' 4-Aminobutanoate exchange', ' 5-Amino-4-oxopentanoate exchange', ... 
    ' 8-Amino-7-oxononanoate exchange', 'L-Arabinitol exchange', ... 
    'Acetaldehyde exchange''Acetate exchange', 'Adenosine exchange', ... 
    ' 2-Oxoglutarate exchange', 'Allantoin exchange', ... 
    'S-Adenosyl-L-methionine exchange', 'D-Arabinose exchange', ... 
    'L-Arabinose exchange', 'Choline exchange', 'Citrate exchange', ... 
    'L-Carnitine exchange', 'Cytosine exchange', 'Cytidine exchange', ... 
    'Deoxyadenosine exchange', ' 7,8-Diaminononanoate exchange', ... 
286 
 
    'Deoxyguanosine exchange', 'Deoxyinosine exchange', ... 
    'dTTP exchange', 'Deoxyuridine exchange', 'Ethanol exchange', ... 
    'FMN exchange', 'Hexadecanoate (n-C16:0) exchange', 'H+ exchange', ... 
    'Hypoxanthine exchange', 'Inosine exchange', 'L-Lactate exchange', ... 
    'L-Malate exchange', 'Maltose exchange', 'D-Mannose exchange', ... 
    'Melibiose exchange', 'S-Methyl-L-methionine exchange', ... 
    'NMN exchange', 'octadecanoate (n-C18:0) exchange', ... 
    'Ornithine exchange', 'Adenosine 3'',5''-bisphosphate exchange', ... 
    'peptide exchange', 'Putrescine exchange', 'Pyruvate exchange', ... 
    'D-Ribose exchange', 'D-Sorbitol exchange', 'L-Sorbitol exchange', ... 
    'Spermidine exchange', 'Spermine exchange', 'L-Sorbose exchange', ... 
    'Succinate exchange', 'Sucrose exchange', ... 
    'Thiamin monophosphate exchange', 'Thiamine diphosphate exchange', ... 
    'Thymidine exchange', 'Thymine exchange', 'Trehalose exchange', ... 
    'tetradecanoate (n-C14:0) exchange', 'Urea exchange', ... 
    'Uridine exchange', 'Xanthine exchange', 'Xanthosine exchange', ... 
    'D-Xylose exchange', 'Xylitol exchange', 'Deoxycytidine exchange'}; 
  
for i=1:length(lb_inf) 
    index=find(strcmp(lb_inf(i),model.rxnNames)); 
    model.lb(index)=0; 
    model.ub(index)=1000; 
end 
  




%apply extra constraints (see below) and check that FBA works on the model 
model.lb([876])=0; %rxn 876 is an iND750 error. removing it affects results. 
model.ub([876])=0; %rxn 876 is an iND750 error. removing it affects results. 
  
%Kennedy S2 lists no flux for rxn 693, but it leads to very low fluxes if 
%constrained. There should be a flux, but the rxn 876 model error (above) 
%redirects the flux away from it. So, with the fix above, constraining rxn 
%693 leads to mistakes - so it shouldn't be constrained. 
%model.lb([693])=0; model.ub([693])=0; 
  






fprintf('The WT flux is: %6.4f.\n', wt_sln.f); %2.7257 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 




%next step: demonstrate the results of Table 1 (strains 1-5, b/c yat2 isn't 
%in iND750 - I'm not sure how strains 6-8 were generated) 
% 
  
%Kennedy reported in silico knockouts: 
%1 fdh1=YOR388C fdh2=YPL275W/YPL276W alt2=YDR111C fum1=YPL262W zwf1=YNL241C 
%2 fdh1 fdh2 aat2=YLR027C fum1=YPL262W zwf1=YNL241C 
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%3 fdh1 fdh2 cat2=YML042W fum1=YPL262W zwf1=YNL241C 
%4 fdh1 fdh2 cat2=YML042W fum1=YPL262W rpe1=YJL121C 
%5 fdh1 fdh2 cat2=YML042W fbp1=YLR377C fum1=YPL262W 
%6 fdh1 fdh2 cat2=YML042W yat2=YER024W slc1=YDL052C 
%7 fdh1 fdh2 cat2=YML042W yat2=YER024W cho1=YER026C 
%8 fdh1 fdh2 cat2=YML042W yat2=YER024W alt2=YDR111C 
  
%these genes (except YAT2) are in iND750: 
%fdh1 = gene 692, rxns: 592 
%fdh2 = genes 725, 726 rxns: 592 
%alt2 = gene 145 rxns: 122 
%fum1 = gene 718 rxns: 610 612 
%zwf1 = gene 609 rxns: 627 
%aat2 = gene 482 rxns: 182 184 373 375 1223 1226 
%cat2 = gene 544 rxns: 266 267 
%rpe1 = gene 396 rxns: 1126 
%fbp1 = gene 532 rxns: 589 
  
%make the knockouts and test them 
[KO1,hasEffect,constrRxnNames,deletedGenes] = ... 




fprintf('The KO1 growth flux is: %6.4f.\n', KO1_sln.f); %1.9257 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 





[KO2,hasEffect,constrRxnNames,deletedGenes] = ... 




fprintf('The KO2 growth flux is: %6.4f.\n', KO2_sln.f); %1.9402 
fprintf('Formate exchange is reaction %d.\n', formate_ex); % 





[KO3,hasEffect,constrRxnNames,deletedGenes] = ... 




fprintf('The KO3 growth flux is: %6.4f.\n', KO3_sln.f); %1.9464 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 




[KO4,hasEffect,constrRxnNames,deletedGenes] = ... 






fprintf('The KO4 growth flux is: %6.4f.\n', KO4_sln.f); %1.9492 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 





[KO5,hasEffect,constrRxnNames,deletedGenes] = ... 




fprintf('The KO5 growth flux is: %6.4f.\n', KO5_sln.f); %2.2378 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 





% [KO6,hasEffect,constrRxnNames,deletedGenes] = ... 
%         deleteModelGenes(model,{'YML042W', 'YER024W', 'YDL052C'}); 
% KO6_sln=optimizeCbModel(KO6,[],'one'); 
%  
% fprintf('The KO6 flux is: %6.4f.\n', KO6_sln.f); 
% fprintf('Formate exchange is reaction %d.\n', formate_ex); 
% fprintf('The formate exchange flux is: %6.4f.\n', KO6_sln.x(formate_ex)); 
% fprintf(' \r'); 
%  
% KO7=model; 
% [KO7,hasEffect,constrRxnNames,deletedGenes] = ... 
%         deleteModelGenes(model,{'YML042W', 'YER024W', 'YER026C'}); 
% KO7_sln=optimizeCbModel(KO7,[],'one'); 
%  
% fprintf('The KO7 flux is: %6.4f.\n', KO7_sln.f); 
% fprintf('Formate exchange is reaction %d.\n', formate_ex); 
% fprintf('The formate exchange flux is: %6.4f.\n', KO7_sln.x(formate_ex)); 
% fprintf(' \r'); 
% 
% KO8=model; 
% [KO8,hasEffect,constrRxnNames,deletedGenes] = ... 
%         deleteModelGenes(model,{'YML042W', 'YER024W', 'YDR111C'}); 
% KO8_sln=optimizeCbModel(KO8,[],'one'); 
%  
% fprintf('The KO8 flux is: %6.4f.\n', KO8_sln.f); 
% fprintf('Formate exchange is reaction %d.\n', formate_ex); 
% fprintf('The formate exchange flux is: %6.4f.\n', KO8_sln.x(formate_ex)); 





Supplementary File 5.1.2: two-knockout2.m script 
% FILE NAME: two-knockout2 
% 
% DATE CREATED: 2 February 2012 
% 
% PROGRAMMER: B. Heavner 
% Department of Biological 
% and Environmental Engineering 
% Cornell University 
% Ithaca, NY 14853 
% 
% LAST REVISED: 10 July 2012 
% 
% REVISIONS: 
% 10 July 2012 - BDH - cleaned up for publication 
% 11 May 2012 - BDH - modified candidate doubles list to add alt2 as 
% possible 
% 
% PURPOSE:  
% A variation on the model results reported by Kennedy et al. which 
% compares all viable 2-knockout mutants in iND750 to find one that will 
% cause formic acid secretion. 
% 
% In this second script, I apply a "global" search for double deletions 
% that excrete formic acid to the the constrained iND750 I made in the 
% three-knockout1 script (the variable "model", which has the same 
% media as Kennedy et al.) 
% 
% 
% REFERENCE:  
% Kennedy CJ, Boyle PM, Waks Z, Silver PA. "Systems-Level Engineering of 




% this script requires the model.mat variable built by three_knockout1.m in 
% the working directory, and uses functions from the COBRA toolbox and the 
% gurobi solver. 
% 
% EXPECTED OUTPUT:  
% varibles listing double-gene deleted mutants that are predicted to 





%first, load the modified iND750 model with the Kennedy constraints. This 











%So, now that I have confidence that my iND750 constraints allow 
%predictions similar to what Kennedy et al. found, I'll work on searching 
%to find these mutants. 
  
%Since iND750 has 750 ORFs, there are 70,031,500 possible triple deletions. 
%To get to the ">4 million" mentioned in the Kennedy paper, we need to 
%restrict the list to about 300 possible deletions. I emailed Patrick Boyle 
%(one of the authors), and he sent me a mapping of 293 possible genes and 
%reactions, but it's not obvious how he built it. So, I'll build my own 
%list of candidate genes which can be deleted. 
  
%% 
%First, find reactions that are annotated with just 1 gene. Any of these 
%reactions can be blocked with a single gene deletion, so combinations of 
%three are feasible. Then, I'll remove duplicates and essential genes, to 
%have a first list of candidate genes. 
  




%number_of_genes is a row vector whose entries correspond to the number of 
%genes annotating each reaction (Ex: there are 1266 reactions. 
%number_of_genes(1265) is 1 b/c rxn 1265 is catalyzed by YOR011W.) 
  
single_gene_reaction_genes=model.grRules(number_of_genes == 1); 
%single_gene_reaction_genes is a list of genes which catalyze reactions, 
%when the reaction is annotated as requiring only a single gene. There are 
%579 such genes. 
  
unique_single_gene_reaction_genes=unique(single_gene_reaction_genes); 
%There are 379 unique genes which catalyze reactions annotated as only 
%requiring a single gene (this is a nice reduction from 750 already!). How 
%many of them are essential? 
  
%next, let's remove known essential genes and dubious ORFs from our list. 
  
% 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































% To do set comparison stuff, we need to strip the parantheses from around 
% the gene names in unique_single_gene_reaction_genes. 
  
for i=1:length(unique_single_gene_reaction_genes) 
    pretty_unique_single_gene_reaction_genes{i}= ... 
        unique_single_gene_reaction_genes{i}(2:8); 
end 
  
included_dubiousORFs = setdiff(... 
    pretty_unique_single_gene_reaction_genes, verified_genes);  





    pretty_unique_single_gene_reaction_genes,sgd_essential_genes);  




candidate_singles = setxor(included_essential,candidate_singles); 
  
%So, now there are 287 genes on the list of possible candidates (a 
%manageable number). Patrick had a list of 304 single gene possibilities on 
%his list. What are the differences? 
  
%that list includes:  
%'YBR184W' - SGD says uncharacterized 
%'YDR111C' - SGD says uncharacterized 
%'YFR055W' - SGD says uncharacterized 
%'YJL167W' - SGD says essential 
%'YML082W' - SGD says uncharacterized 
%'YNL247W' - on my essential list 
  
%I'm okay leaving them out. 
  
%As I work, I've found other genes which shouldn't be included 
others_to_remove = {'YNL280C'}; %SGD annotates as inviable in aerobic  
  
candidate_singles = setxor(others_to_remove,candidate_singles); 
  
%and I want to add YDR111C back in to the list of candidates because alt2 
%is in Kennedy's KO1 (it was removed b/c uncharacterized). 
  




%So now I have a list of genes that annotate reactions that are only 
%annotated with a single genes. I (think) I can knock out any three of 
%these genes and look for increased formic acid secretion. 
  
%Begin by generating a list of all possible double deletions of 
%non-essential genes. 















%now loop over all possible double deletions, and look for formate 
%production (there is probably a more clever way to do this - email and let 
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%me know how to do it better! bheavner@gmail.com) 
  
h = waitbar(0,'Checking double knockouts ...'); 
  
for i=1:length(doubles) 
    if mod(i,100) == 0 
        waitbar(i/length(doubles),h); 
    end 
    clear mex; 
    [newmodel,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,candidate_singles(doubles(i,:))); 
    if hasEffect 
        flux=optimizeCbModel(newmodel,[],'one'); 
        if numel(flux.x)==0 
            i 
        elseif (flux.x(formate_ex)>0 && (flux.f>0.5518)) %formate flux + >20% 
WT growth rate 
            double_formate_fluxes = [double_formate_fluxes; i 
flux.x(formate_ex) flux.f]; 
            sprintf('%12i %12.4f %12.4f\n',i, flux.x(formate_ex), flux.f) 
        end 






% the double_formate_fluxes variable is now a 3-column vector. The first 
% column is the "doubles" entry screened, the second is the formate flux, 
% and the third is the growth rate of that strain. To find which deletion 








Supplementary File 5.1.3: three_knockout2.m script 
 
% FILE NAME: three-knockout2 
% 
% DATE CREATED: 19 January 2012 
% 
% PROGRAMMER: B. Heavner 
% Department of Biological 
% and Environmental Engineering 
% Cornell University 
% Ithaca, NY 14853 
% 
% LAST REVISED: 10 July 2012 
% 
% REVISIONS:  
% 
% 7/10/12 - BDH cleaned up code for publication 
% 
% 5/14/12 - BH changed to load list of common candidate singles. Previous 
% screen on multiple machines led to incorrect flux predictions; perhaps 
% because each machine generated own candidate singles. Also, added some 
% java memory statements to try to fix memory leaks observed with Y5 screen. 
% 
% 5/11/12 - BH added YDR111C as possible deletion candidate, fixed 
% genetic background 
% 
% 2/9/12 - BH removed YNL280C as possible single, standardize on gurobi 
% solver for speed and consistency 
% 
% 2/7/12 - BH added fdh mutant, constraint on min growth rate, growth rate 
% to formate_fluxes variable 
% 
% PURPOSE:  
% To attempt to reproduce the model results reported by Kennedy et al. - 
% that is, to compare all viable 3-knockout mutants in iND750 to find those 
% that will cause formic acid secretion. Kennedy et al. report constructing 
% a alt2, fum1, zwf1 mutant that does this. 
% 
% In this script, I apply a "global" search for triple deletions that 
% excrete formic acid to the the constrained iND750 I made in the 
% three-knockout1 script (the variable "model", which has the same media as 
% Kennedy et al.) 
% 
% REFERENCE:  
% Kennedy CJ, Boyle PM, Waks Z, Silver PA. "Systems-Level Engineering of 




% this script requires the model.mat variable built by three-kncokout1.m in 
% the working directory. 
% 
% EXPECTED OUTPUT: 








% If previously run, just load the list of triple deletion strains, don't 
% have to regenerate every time - can uncomment the following 4 lines. If 








%first, load the modified iND750 model with the Kennedy constraints. This 





fprintf('Constrained iND750 model loaded.\n'); 
fprintf(' \r'); 
  




fprintf('Candidate singles loaded.\n'); 
fprintf(' \r'); 
  
%generating a list of all possible tripple deletions of non-essential 
%genes. COMMENT OUT THE FOLLOWING LINE IF YOU LOAD TRIPLETS FROM FILE 
triplets = combntns((1:length(candidate_singles)),3); %there are 3898895 
  




fprintf('LP solver changed to gurobi.\n'); 
fprintf(' \r'); 
  
h = waitbar(0,'Checking triple knockouts ...'); 
%this is not a fast process! 
  
%to run on multiple machines, copy the necessary variables, and adjust 
%lower and upper bounds (as demonstrated below for running on 7 computer) 











%save results as we go in case things crash 
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fileID = fopen('triple_formate_fluxes_1.txt','w'); 
  
for i=lower:upper 
    if mod(i,100) == 0 
        waitbar((i-lower+1)/(upper-lower),h); 
    end 
    clear mex; %an attempt to prevent crashes from gurobi_mex memory leaks 
    [newmodel,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,candidate_singles(triplets(i,:))); 
    if hasEffect 
        formate_ex=find(strcmp('Formate exchange',model.rxnNames)); 
        flux=optimizeCbModel(newmodel,[],'one'); 
        if numel(flux.x)==0 
            i 
        elseif (flux.f>.5518) %20% of WT 
            if (flux.x(formate_ex)>0) 
               fprintf(fileID,'%12i %12.4f %12.4f\n',i, flux.x(formate_ex), 
flux.f); 
                sprintf('%12i %12.4f %12.4f\n',i, flux.x(formate_ex), flux.f) 
%print to screen, too, so we can see where things left off if there's a crash 
            end 
        end 











% the triple_formate_fluxes1.txt file is now a 3-column text file. The first 
% column is the "triplets" entry screened, the second is the formate flux, 
% and the third is the growth rate of that strain. To find which deletion 
% gives a particular formate flux, do something like this: 
  





% %total number screened 
% screened=length(triplets); 
%  
% %number of formate-producing mutants 
% number_of_formate_producers=length(results); 
%  




% %maximum formate flux 
% maximum_formate=max(results(:,2)); 
%  








Supplementary File 5.2.1:Y5_ three_knockout1.m script 
 
% FILE NAME: Y5_three_knockout1_unmodified 
% 
% DATE CREATED: 14 May 2012 
% 
% PROGRAMMER: B. Heavner 
% Department of Biological 
% and Environmental Engineering 
% Cornell University 
% Ithaca, NY 14853 
% 
% LAST REVISED: 11 July 2012 
% 
% REVISED BY: B. Heavner 
% 
% REVISIONS: 
% 7/11/12 - BDH - cleaned up for publication 
% 
% 
% PURPOSE:  
% To attempt to reproduce the model results reported by Kennedy et al. with 
% the unmodified Yeast 5.01 model. 
% 
% In this script, I begin by applying constraints to Y5 to duplicate the 
% Kennedy et al. media and mutants to see if I still get a predicted formic 
% acid secretion with the mutants reported in Kennedy et al. Table 1. 
% 
% REFERENCE:  
% Kennedy CJ, Boyle PM, Waks Z, Silver PA. "Systems-Level Engineering of 




% none - it's a script. But you need Y5.mat in the working directory (or 
% load the Y5 GEM using readcbmodel, and comment out the "load" line of the 
% script. 
% 
% EXPECTED OUTPUT: 
% growth rates and fluxes for the first 5 mutants listed in Table 1 of 
% Kennedy et al. Version 5.01 of the Yeast model does not predict formate 
% production for these strains. 
% 
% REQUIRED SOFTWARE:  














fprintf('Yeast model v 5.01 loaded.\n'); 
fprintf(' \r'); 
  
%make sure we're using the gurobi solver (glpk gives different answers!) 
changeCobraSolver('gurobi'); 
  




%next modify the changed model to add some strain-specific changes. 
  
%add the alt2 gene, which is not in Y5.01 b/c it's a putative ORF in SGD. 
model=addReaction(model,'NRXN4',{'s_0180', 's_0955', 's_0991', ... 
    's_1399'}, [-1 -1 1 1], true, -1000, 1000, 0, '', 'YDR111C'); 
  
%add the fdh2 gene, which isn't annotated b/c it's not in the SGD 
%background strain - rxn 445 can be catalyzed by FDH2 in CEN.PK 113-7D 
%strain (see pmid: 11921099) 
model=changeGeneAssociation(model,model.rxns(445),... 
    '(YOR388C or (YPL275W AND YPL276W))'); 
  
%paper wt background is fdh1 fdh2 deletion 
[model,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YOR388C','YPL275W','YPL276W'}); 
  
%% 
%next, make the media the same as that in Kennedy et al. (based on their 
%supplemental table 1).  
% 
%NOTE: the COBRA exchange reaction convention means that I need to use the 
%opposite sign than Kennedy et al. 
% 
%NOTE 2: Table S1 lists "pydxn", "4abz", "nac", and "dhf" as having an 
%upper bound of 0.5. I think these are: Pyridoxine (met 875), 
%4-Aminobenzoate (met 98), Nicotinate (met 714), and 7,8-Dihydrofolate (met 
%383). They don't have exchange reactions in iND750. Kennedy et al. may 
%have added them, but they don't have fluxes in Table S2, so they're not 
%essential. 
% 
%NOTE 3: I'm guessing rxn names from their met names. 
  
%start with a clean slate: set all exchange reactions to upper bound = 1000 
%and lower bound = 0 (ie, unconstrained excretion, no uptake) 
  




%the following exchange rxns have an upper bound and lower bound of 20 in 






    index=find(strcmp(ub_lb_20(i),model.rxnNames)); 
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    model.lb(index)=-20; 
    model.ub(index)=-20; 
end 
  
%the following have upper and lower bounds of inf in Table S1.  
% 
%NOTE: oxygen not in table S1, but added to do aerobic, based on 
%text of paper 
  
ub_inf={'water exchange', 'ammonium exchange', 'phosphate exchange', ... 
    'sulphate exchange', 'sodium exchange', 'potassium exchange', ...  
    'carbon dioxide exchange', 'oxygen exchange'}; 
  
for i=1:length(ub_inf) 
    index=find(strcmp(ub_inf(i),model.rxnNames)); 
    model.lb(index)=-1000; 
end 
  
%the following have an upper bound of 0.5 in Table S1 (but I'm switching 
%signs, so do a lower bound of -0.5). 
  
ub_05 = {'L-asparagine exchange', 'L-aspartate exchange', ...  
    'L-valine exchange', 'L-tyrosine exchange', ... 
    'L-tryptophan exchange', 'L-threonine exchange', ...  
    'L-serine exchange', 'L-proline exchange', ...  
    'L-phenylalanine exchange', 'L-methionine exchange', ... 
    'L-lysine exchange', 'L-leucine exchange', ... 
    'L-isoleucine exchange', 'L-histidine exchange', ... 
    'glycine exchange', 'L-glutamate exchange', ... 
    'L-glutamine exchange', 'L-cysteine exchange', ... 
    'L-arginine exchange', 'L-alanine exchange' ... 
    'riboflavin exchange', 'thiamine(1+) exchange', ... 
    'zymosterol exchange', 'uracil exchange', ... 
    '(R)-pantothenate exchange', 'linoleic acid exchange', ... 
    'myo-inositol exchange', 'palmitoleate exchange', ... 
    'ergosterol exchange', 'biotin exchange', 'adenine exchange'}; 
  
%note: Y5 doesn't have octadecynoate (n-C18:2) or octadecenoate (n-C18:1) 
%exchange reactions. I used linoleic (18:1). It also doesn't have 
%hexadecenoate (n-C16:1). I used palmitoleate (16:1) for that. I don't 
%think they should really matter for aerobic simulations, though. 
  
for i=1:length(ub_05) 
    index=find(strcmp(ub_05(i),model.rxnNames)); 
    model.lb(index)=-0.5; %constrained uptake 
end 
  
%the following have a lower bound of -inf in Table S1 (but I'm switching 
%signs, so do an upper bound of 1000) 
% 
% Note: 'Deoxycytidine exchange' not included in Table S1, but has a flux 
% in Table S2, so I added it here. 
  
lb_inf = {'(1->3)-beta-D-glucan exchange', ... 
    'gamma-aminobutyrate exchange', '(S)-3-methyl-2-oxopentanoate exchange', 
... 
    ' 8-amino-7-oxononanoate exchange', 'L-arabinitol exchange', ... 
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    'acetaldehyde exchange', 'acetate exchange', 'adenosine exchange', ... 
    ' 2-oxoglutarate exchange', 'allantoin exchange', ... 
    'S-adenosyl-L-methionine exchange', 'D-arabinose exchange', ... 
    'L-arabinose exchange', 'choline exchange', 'citrate(3-) exchange', ... 
    '(R)-carnitine exchange', 'cytosine exchange', 'cytidine exchange', ... 
    '2''-deoxyadenosine exchange', ' 7,8-diaminononanoate exchange', ... 
    '2''-deoxyguanosine exchange', '2''-deoxyinosine exchange', ... 
    'dTTP exchange', '2''-deoxyuridine exchange', 'ethanol exchange', ... 
    'FMN exchange', 'palmitate exchange', 'H+ exchange', ... 
    'hypoxanthine exchange', 'inosine exchange', '(S)-lactate exchange', ... 
    '(S)-malate exchange', 'maltose exchange', 'D-mannose exchange', ... 
    'melibiose exchange', 'S-methyl-L-methionine exchange', ... 
    'NMN exchange', 'stearate exchange', ... 
    'ornithine exchange', 'adenosine 3'',5''-bismonophosphate exchange', ... 
    'peptide exchange', 'putrescine exchange', 'pyruvate exchange', ... 
    'D-ribose exchange', 'D-glucitol exchange', 'L-glucitol exchange', ... 
    'spermidine exchange', 'spermine exchange', 'L-sorbose exchange', ... 
    'succinate exchange', 'sucrose exchange', ... 
    'thiamine(1+) monophosphate exchange', 'thiamine(1+) diphosphate(1-) 
exchange', ... 
    'thymidine exchange', 'thymine exchange', 'alpha,alpha-trehalose 
exchange', ... 
    'myristate exchange', 'urea exchange', ... 
    'uridine exchange', '9H-xanthine exchange', 'xanthosine exchange', ... 
    'D-xylose exchange', 'xylitol exchange', 'deoxycytidine exchange'}; 
  
%note: Y5 doesn't have 4-Aminobutanoate exchangeI used gamma-aminobutyrate. 




    index=find(strcmp(lb_inf(i),model.rxnNames)); 
    model.lb(index)=0; 
    model.ub(index)=1000; 
end 
  




%next step: simulate the strains of Kennedy Table 1 
  
%Kennedy reported in silico knockouts: 
%1 fdh1=YOR388C fdh2=YPL275W/YPL276W alt2=YDR111C fum1=YPL262W zwf1=YNL241C 
%2 fdh1 fdh2 aat2=YLR027C fum1=YPL262W zwf1=YNL241C 
%3 fdh1 fdh2 cat2=YML042W fum1=YPL262W zwf1=YNL241C 
%4 fdh1 fdh2 cat2=YML042W fum1=YPL262W rpe1=YJL121C 
%5 fdh1 fdh2 cat2=YML042W fbp1=YLR377C fum1=YPL262W 
%6 fdh1 fdh2 cat2=YML042W yat2=YER024W slc1=YDL052C 
%7 fdh1 fdh2 cat2=YML042W yat2=YER024W cho1=YER026C 
%8 fdh1 fdh2 cat2=YML042W yat2=YER024W alt2=YDR111C 
  
%looking at Yeast 5.01: 
%fdh1 = gene 848, rxns: 445 
%fdh2 = gene added by my chages, rxns: 445 
%alt2 - added to model, above 
%fum1 = gene 883 rxns: 451 452 
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%zwf1 = gene 743 rxns: 466 
%aat2 = gene 588 rxns: 216 218 681 683 1065 
%cat2 = gene 659 rxns: 253 254 
%rpe1 = gene 476 rxns: 984 
%fbp1 = gene 645 rxns: 449 
%yat2 = gene 263 rxns: 252 
%slc1 = gene 130 rxns: 9 
%cho1 = gene 264 rxns: 880 881 - essential for model. 
  
%% 





fprintf('The WT flux is: %6.4f.\n', wt_sln.f); %2.5889 
fprintf('Formate exchange is reaction %d.\n', formate_ex); %0 
fprintf('The formate exchange flux is: %6.4f.\n', wt_sln.x(formate_ex)); 
fprintf(' \r'); 
  
%make the knockouts and test them 
[KO1,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YDR111C','YPL262W','YNL241C'}); 
KO1_sln=optimizeCbModel(KO1,[],'one'); 
  
fprintf('The KO1 flux is: %6.4f.\n', KO1_sln.f); %1.6065 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 




[KO2,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YLR027C', 'YPL262W', 'YNL241C'}); 
KO2_sln=optimizeCbModel(KO2,[],'one'); 
  
fprintf('The KO2 flux is: %6.4f.\n', KO2_sln.f); %1.6065 
fprintf('Formate exchange is reaction %d.\n', formate_ex); % 




[KO3,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YPL262W', 'YNL241C'}); 
KO3_sln=optimizeCbModel(KO3,[],'one'); 
  
fprintf('The KO3 flux is: %6.4f.\n', KO3_sln.f); %1.6065 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 




[KO4,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YPL262W', 'YJL121C'}); 
KO4_sln=optimizeCbModel(KO4,[],'one'); 
  
fprintf('The KO4 flux is: %6.4f.\n', KO4_sln.f); %1.6065 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 
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[KO5,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YLR377C', 'YPL262W'}); 
KO5_sln=optimizeCbModel(KO5,[],'one'); 
  
fprintf('The KO5 flux is: %6.4f.\n', KO5_sln.f); 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 




[KO6,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YER024W', 'YDL052C'}); 
KO6_sln=optimizeCbModel(KO6,[],'one'); 
  
fprintf('The KO6 flux is: %6.4f.\n', KO6_sln.f); 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 




[KO7,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YER024W', 'YER026C'}); 
KO7_sln=optimizeCbModel(KO7,[],'one'); 
  
fprintf('The KO7 flux is: %6.4f.\n', KO7_sln.f); 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 




[KO8,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YER024W', 'YDR111C'}); 
KO8_sln=optimizeCbModel(KO8,[],'one'); 
  
fprintf('The KO8 flux is: %6.4f.\n', KO8_sln.f); 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 




Supplementary File 5.3.1: apply_y5_changes.m script 
% FILE NAME: apply_y5_changes 
% 
% DATE CREATED: 27 Feb 2012 
% 
% PROGRAMMER: B. Heavner 
% Department of Biological 
% and Environmental Engineering 
% Cornell University 
% Ithaca, NY 14853 
% 
% LAST REVISED: 11 July 2012 
% 
% REVISIONS:  
% 11 July 2012 - BH cleaned up for publication 
% 3 May 2012 - BH added changes from comparing to YeastCyc pathways 
% 
% REVISED BY: B. Heavner 
% 
% PURPOSE:  
% To apply all changes I find to correct the Y5.01 model. 
% 
% REFERENCES:  
% Various, included as comments to changes 
% 
% VARIABLES: 
% none - it's a script. But you need Y5.mat in the working directory (or 
% load the Y5 GEM using readcbmodel, and comment out the "load" line of the 
% script. 
% 
% EXPECTED OUTPUT: 
% updated model based on Y5.01 
% 
% REQUIRED SOFTWARE: 





%first, load the Y5.01 model. This matlab variable was made by running 







fprintf('Yeast model v 5.01 loaded.\n'); 
fprintf(' \r'); 
  
%make sure we're using the gurobi solver (glpk gives different answers!) 
changeCobraSolver('gurobi'); 
  





%check the media: 






fprintf('rxnName \t lb\n') 
for i=1:length(media_indexes) 






%Check the solution prior to any changes 
unchangedsolution = optimizeCbModel(model,[],'one'); 
  
%% 
%model updates and fixes - note: add new to the end - numbers may change! 
  





model=changeRxnBounds(model,model.rxns([733 447 446]),-1000,'l'); 
model=changeRxnBounds(model,model.rxns([733 447 446]),1000,'u'); 
  
%some changes in the NAD biosynthesis pathway - ref: PMID: 18205391 
%"quinaldic acid (dehydroxylated KA, which is produced directly from KA)" 
model=addReaction(model,'NRXN1','s_0147 -> s_1403 + s_0803'); 
  
% from PMID: 12771147 
model=removeRxns(model,'r_0768'); 
%model=addReaction(s_0423 + s_0633 + s_0794 + s_1198 + s_0991'); 
model=addReaction(model,'r_0768',{'s_0999', 's_0434', 's_0591', ... 
    's_0803', 's_0423', 's_0633', 's_0794', 's_1198', 's_0991'}, ... 
    [-1 -1 -1 -1 1 1 1 1 1], false, 0, 1000,'',... 
    'YHR074W'); 
  
%ref: http://www.yeastgenome.org/cgi-bin/locus.fpl?locus=YMR189W 
%I'm not sure about these - BH 2/29/12 







%corrections to mitochondrial NAD metabolism, 3/1/12 
  
%see also http://dx.doi.org/10.1111/j.1574-6976.2001.tb00570.x (ref added 
%3/27/12, after examining individual reactions) 
  









%http://www.jbc.org/content/281/3/1524.long "The main role of Ndt1p and 
%Ndt2p is to import NAD+ into mitochondria by unidirectional transport or 




%next make the function to be irreversible exchange, not symport 
%dAMP 












model.S(782,1232)=1; model.S(784,1232)=-1;  
model=changeRxnBounds(model,model.rxns(1232),0,'l'); 
  
%http://www.jbc.org/content/281/3/1524.long "It transported NAD+ and, to a 
%lesser extent, (d)AMP and (d)GMP but virtually not ?-NAD+, NADH, NADP+, or 




%rxn 12 looks like what PUT2 catalyzes (which is reversible). 




%rxn 31 is http://www.genome.jp/dbget-bin/www_bget?rn:R01199 - per KEGG, 




%The Y5 reference for rxn 71 is a hypothetical pathway. Kegg says "poorly 




%Per SGD, rxn 165 can be catalyzed by ADH3 or ADH4. 
%YMR083W is model.genes(684). YGL256W is model.genes(339) 
model=changeGeneAssociation(model,model.rxns(165),'YMR083W or YGL256W'); 
  
%looking at rxn 201, SGD says YER073W uses NADP, not NAD: 









%the sgd activity is rxn 175. 
  
% On a second look, I don't see this, and rxn 174 has a flux in Kennedy KO1 
KO2 KO3 KO4 
%model.lb([201 174 176])=0; model.ub([201 174 176])=0; 
  
%rxn 672 and 673 aren't in SGD for PUT2, but is in KEGG (which has them as 
%reversible - see http://www.genome.jp/dbget-bin/www_bget?C04281). So I'll 
%consider them low confidence, but leave them in and reversible for now. 
model=changeRxnBounds(model,model.rxns([672 673]),-1000,'l'); 
  
%rxn 766 is right, but should also have NADH kinase activity, per SGD 
%http://www.yeastgenome.org/cgi-bin/locus.fpl?locus=YPL188W 
%this rxn is reaction 771 (r_0772), annotated YEL041W or YJR049C. 
%perhaps both reactions should be annotated "YEL041W or YJR049C or YPL188W" 
%YPL188W is model.genes(873) 
model=changeGeneAssociation(model,model.rxns(766),... 
    '(YEL041W or YJR049C or YPL188W)'); 
model=changeGeneAssociation(model,model.rxns(771),... 
    '(YEL041W or YJR049C or YPL188W)'); 
  
%I'm not sure what to do with rxn 684 - no ref, mis-annotated as PUT2. For 
%now, set to zero (it has no flux in WT anyway) If remove, may also remove 
%rxn 2076 and 685. In fact, met 1501 and 1502 only participate in these, so 
%they should be removed and 1501 should just be proline (see rxn 687 in 
%cytosol, below). 
model=changeRxnBounds(model,model.rxns([684 685 2076]),0,'l'); 
model=changeRxnBounds(model,model.rxns([684 685 2076]),0,'u'); 
  
%rxn 939 should use FAD as the cofactor, not NAD. ref: PMID: 387737 
model.S(1200,939)=0; model.S(1205,939)=0; model.S(799,939)=0; 
model.S(688,939)=-1; model.S(690,939)=1; 
  









%I'm not sure what to do about rxns 167 170 180 183 187. The biochemistry 
%isn't in SGD, though the description seems okay. For now, fix annotation, 
%leave them and check to see if they have fluxes in WT or kennedy KO 
%simulations. 
%YGL256W is model.genes(339). 
model=changeGeneAssociation(model,model.rxns(167), '(YMR083W or YGL256W)'); 
model=changeGeneAssociation(model,model.rxns(170), '(YMR083W or YGL256W)'); 
model=changeGeneAssociation(model,model.rxns(180), '(YMR083W or YGL256W)'); 
model=changeGeneAssociation(model,model.rxns(183), '(YMR083W or YGL256W)'); 





%mitochondrial NADP rxns - started 3/5/12 
  
%not sure of rxn 175 or 178 reversibility (or 178's biochem) 
  






%rxn 345 reversible in KEGG, not SGD; left irreversible for now. 
  
%leave rxns 396 423:431 to fatty acid metabolism check 
  




%rxn 759 is reversible in KEGG, not SGD. leaving irreversible. 
  
%rxn 1038 seems outside scope of YN - protein modification? Additionally, 
%its biochem doesn't agree with SGD. But, it has a flux in each Kennedy KO, 





%cytoplasmic reactions involving NAD - see 
%http://www.ncbi.nlm.nih.gov/pubmed/14977171 for some test cases. 
  
%rxn 61 biochem doesn't agree with SGD, but combined with rxn 29, has same 
%effect. So, don't change it for now. 
  
%per SGD, "In S. cerevisiae, there are five genes that encode alcohol 
%dehydrogenases involved in  ethanol metabolism, ADH1 to ADH5. Four of 
%these enzymes, Adh1p, Adh3p, Adh4p, and Adh5p,  reduce acetaldehyde to 
%ethanol during glucose fermentation, while Adh2p catalyzes the reverse 
%reaction of oxidizing ethanol to acetaldehyde." Combined with localization 
%data, rxn 163 should be split into two rxns, and annotation should change. 
%'YBR145W' 'YDL168W' 'YGL256W' 'YMR303C' and 'YOL086C' are model.genes([66 






model=addReaction(model,'NRXN2',{'s_0359', 's_0794', 's_1203', ... 
    's_0680', 's_1198'}, [-1 -1 -1 1 1], false, 0, 1000, 0, '',... 
    '(YOL086C or YBR145W)'); 
  
%Like rxns 167 170 180 183 187, I'm not sure what to do about 166 169 179 
%182 186. The biochemistry isn't in SGD, though the description seems okay. 
%For now, fix annotation, leave them and check to see if they have fluxes 
%in WT or kennedy KO simulations. 
model=changeGeneAssociation(model,model.rxns(166),... 




    '(YBR145W or YDL168W or YOL086C)'); 
model=changeGeneAssociation(model,model.rxns(179),... 
    '(YBR145W or YDL168W or YOL086C)'); 
model=changeGeneAssociation(model,model.rxns(182),... 
    '(YBR145W or YDL168W or YOL086C)'); 
model=changeGeneAssociation(model,model.rxns(186),... 
    '(YBR145W or YDL168W or YOL086C)'); 
  
%so are model.genes([66 145 339 718 785]) all still used? checking 
%model.rxnGeneMat(:,[66 145 339 718 785]) says yes. 
  
%rxns 172 is and 185 may be a functions of ALD2/ALD3, but that biochem 
%isn't in SGD, and surprisingly, the acetaldehyde -> acetate rxn 
%(acetaldehyde dehydrogenase) doesn't seem to be in the model (which would 
%explain part of the trouble with growth on ethanol! 
%YMR170C is model.genes(694) 
model=addReaction(model,'NRXN3',{'s_0359', 's_0803', 's_1198', ... 
    's_0362', 's_1203', 's_0794'}, [-1 -1 -1 1 1 1], false, 0, 1000, 0,... 
    '','YMR170C'); 
  
%rxn 232 is annotated with genes that don't have that function in SGD, and 
%are not in the cytosol compartment (a mix of ER and mitochondria). *not 
%changed now b/c concerened that ER compartmentalisation isn't right, and 




%rxn 235 should be in ER *note: this has a flux in WT, and blocking the 




%rxn 316 appears miscompartmentalized, annotation doesn't agree with SGD. 
%*note: this has a flux in WT, but blocking the reaction doesn't stop 




%Basically, something seems odd with ergosterol metabolism in Y5. 
  





%rxn 445 can be catalyzed by FDH2 in CEN.PK 113-7D strain (see pmid: 
%11921099) 
model=changeGeneAssociation(model,model.rxns(445),... 
    '(YOR388C or (YPL275W AND YPL276W))'); 
  
%rxn 470 is annotated as mitochondrial and is reversible in SGD. I made it 
%reversible, but didn't move it to the mitochondria b/c I'm not sure how to 
%reconsile that rxn with rxn 472 (below) 
model=changeRxnBounds(model,model.rxns(470),-1000,'l'); 
model=changeRxnBounds(model,model.rxns(470),1000,'u'); 
%model.S([180 419 794 803 991 1198 1203],470)=0; 
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%model.S([182 421 799 1205],470)=1; %2-oxoglutarate, ammonium, H+, NADH 
%model.S([807 993 1200],470)=-1; %H20, L-glutamate, NAD 
  
%rxn 472 is annotated as mitochondrial in SGD - but y5 doesn't have 
%mitochodrial L-glutamine, so I have to add that. Per SGD, it's synthesized 
%by LGN1/YPR035W from glutamate. There is a glutamate transporter 
%(AGC1/YPR021C, rxn 1193) in yeast (but SGD has LGN1 is in cytosol...) 
%model.S([180 794 991 999 1198 1203],472)=0; 








%rxn 677 - SGD uses NADP as a cofactor, not NAD (which is rxn 678). 









%rxn 696 - no gene annotation; looks like maybe GRE2/YOL151W, which SGD has 
%as NADP-dependent, and uses D- (R-)lactaldehyde as a substrate, not 
%(S)-lactaldehyde. (R-) lactaldehyde isn't in the model. (S)-lactaldehyde 
%is only in 2 rxns... I think there's something wrong here, but am not 
%sure how to correct it... 
  
%rxn 714 should be reversible  
%*NOTE: this change increases max growth rate from .09 to .1, but now don't 
%have fluxes through all rxns of TCA cycle - hopefully this fixes itself 
%with further corrections* 
%SGD says its regulated by glucose repression, and notes "unfavorable 
%equilibrium for formation of oxaloacetate from malate" - but I'd interpret 
%that to mean the reaction prefers to go in the to malate direction 
%(negative flux) 
%see also: http://dx.doi.org/10.1074/jbc.M213231200 
%model.lb(714)=-1000; model.ub(714)=1000; 
model=changeRxnBounds(model,model.rxns(714),0,'l');%a modeling constraint. 
model=changeRxnBounds(model,model.rxns(714),1000,'u'); 
  









%rxn 1952 - no gene, no ref; KEGG rxn R05050, which KEGG annotates as 
%YER073W. SGD says YER073W is mitochondrial, uses NADP. searching for 











%rxn 1955 - no gene, no ref; a modeling rxn (when unconstrained, has 





%rxn 1957 - no gene, no ref; I can't find evidence that yeast has a NADP 




%rxn 2019 - no gene, no ref; KEGG rxn R01728, which KEGG doesn't have in 
%yeast (though it does have a NADP prephenate dehydrogenase annotated as 





%cytoplasmic reactions involving NADP 
  
%rxn 15 - SGD doesn't have NADP involved. KEGG rxn R09376 does. Lit appears 
%to support the use of NADP (and maybe NAD), but I don't see lots of 
%yeast-specific refs. 
  
%rxn 80 - SGD has MET 13 in mitochondria (MET 12 seems less well 
%characterized), but downstream MET6 is in cytoplasm, so don't relocate for 
%now. 
  
%rxn 164 - I'm not sure that the YHR104W annotation is correct. 
  
%rxn 233 - annotation incorrect; per SGD, YHR042W is associated with Erg11, 




%rxn 234 - SGD localizes to ER. I didn't change it. Also - what kind of met 
%are " zymosterol intermediate 1c" or "zymosterol intermediate 2"? 
  
%rxn 324 - SGD doesn't include glucose as a substrate, and there's no ref 




%I didn't look at fatty acid synthase rxns closely (rxns 385:395 397 398 
%432:435) 
  
%I didn't check annotation of rxn 481 too closely, but rxn agrees with SGD. 
  




%rxn 678 - SGD doesn't involve ATP/ADP in this rxn, and the lit ref isn't 
%great for the stoichiometry. SGD lists water as a product, not 
%diphosphate. 
model.S(434,678)=0; model.S(423,678)=0; model.S(633,678)=0;   
model.S(803,678)=1; 
  
%rxn 687 - SGD has product of proline, not trans-4-hydroxy-L-proline. So, 
%change this, and then don't need mito transport or met 1501. note: it 
%doesn't appear that Y5 can synthesize proline prior to this change? 
%my note is wrong - see rxn 956. Still not sure what rxn 687 is. 
model.S(1501,687)=0; model.S(1035,687)=1; 
  
%rxn 688 - not high confidence, but unchanged 
  
%rxn 690 "The high Km for NADP+ may suggest that the equilibrium position 
%of the YdfG and YMR226c reactions markedly favors the reduction of the 




%rxn 763 - misannotated, perhaps should be DIT1/DIT2 instead of DIT2/NCP1? 
%(I have low confidince in this, and suggest it due to SGD phrasing DIT2 
%"involved in the production of N,N-bisformyl dityrosine" and DIT1 
%"involved in the production of a soluble LL-dityrosine-containing 
%precursor of the spore wall" 
%this means adding DIT1 to the model. 
%DIT1 is YDR403W ; DIT2 is YDR402C, model.genes(221); and NCP1 is YHR042W, 
%model.genes(409) 
model=changeGeneAssociation(model,model.rxns(763),'(YDR403W and YDR402C)'); 
model=changeGeneAssociation(model,model.rxns(919),'YDR402C'); 
  
%rxn 836 - should be in ER? SGD does not have NADP as a cofactor. NOTE: 
%"OLE1 encodes the sole S. cerevisiae Delta-9 fatty acid desaturase, an ER 
%membrane protein required for the production of monounsaturated fatty 
%acids. Because these fatty acids are critical components of cell 
%membranes, the OLE1 gene is essential unless the media are supplemented 
%with unsaturated fatty acids." - so this (and rxn 1012) are critically 
%important rxns. (I'm not sure if media has unsaturated FAs at the moment) 
% At the moment, the only specifically named palmitoleoyl-CoA in model is 
% in ER - met 1299, palmitoleoyl-CoA [endoplasmic reticulum] 
%something is odd with rxn 836's products. For now, I'm just removing the 
%NADP/H from the rxn. 
model.S(794,836)=-2; %(2 H+, not 1) 
model.S([1207 1212],836)=0; 
  
%rxn 956 - how different from 687, above? 
  
%rxn 988 - not reversible that I've seen. This prompts the idea: rather 
%than assume rxns are reversible, what if we assume they're irreversible, 




%rxn 997 - SGD has NAD as the cofactor. 




%rxn 1012 - SGD doesn't have NADP as a cofactor. (like rxn 836, above) 
model.S([1207 1212],1212)=0; 
  





    '(YFR030W and YJR137C)'); 
  
%rxn 1037 - strange rxn, seems pretty general in SGD. unchanged for now. 
  









%rxn 1961 - I think NADP can't cross into the ER, either... This might 
%be needed for some compartmentalization (it has a flux in WT sln), 




%rxn 1984 - the mechanism of the second unsaturation is unknown, but 





%other changes - random things I come across while validating this: 
  
%rxn 1109 should be reversible - per SGD, "However, under certain 
%conditions, such as during exponential growth on glucose under aerobic 





%rxn 444 citation is for a paper describing FDH1/FDH2, which doesn't use 
%ubiquinol-6, but uses NAD - rxn 445. rxn 445 annotation changed above. 




%rxn 1227 annotation should include MPH2 and MPH3 
model=changeGeneAssociation(model,model.rxns(1227),... 
    '(YBR298C or YDL247W or YGR289C or YDL247W or YJR160C)'); 
  
%rxn 194 - per SGD, YBR001C "does not appear to encode significant 
%trehalase activity, or be involved in trehalose catabolism" 
model=changeGeneAssociation(model,model.rxns(194),... 




%rxn 80 - name needs a space 
model.rxnNames(80)={'5,10-methylenetetrahydrofolate reductase (NADPH)'}; 
  
%rxn 906 - per SGD, this should be "a phosphopantothenoylcysteine 
%decarboxylase (PPCDC; Cab3p, Sis2p, Vhs3p) complex" (cab3 is essential, 
%sis2 is not essential, vhs3 is not essential). I suspect that sis2 and 
%vhs3 were left out b/c they're inessential - I think they both encode 
%negative regulatory subunits, so if they're missing, the enzyme function 
%couldn't be regulated. 
model=changeGeneAssociation(model,model.rxns(906),... 
    '(YKL088W or (YKL088W and YKR072C) or (YKL088W and YOR054C) or (YKL088W 
and YKR072C and YOR054C))'); 
  
%I'm not confident about rxn 1031 - esp the RMA1 annotation 
  
%% Pathway coverage changes 
% modifications based on comparison to yeastCyc pathway classification of 
% genes 
  
%rxn 762 currently misannotated as BNA3. per SGD, the activity described is 
%catalyzed by BNA7: http://pathway.yeastgenome.org/YEAST/new-
image?type=PATHWAY&object=NADSYN-PWY&detail-level=2 
%(per SGD, BNA3 catalyzes formation of kynurenic acid from kynurenine) 
model=changeGeneAssociation(model,model.rxns(762),... 
    'YDR428C'); 
  
%per SGD, rxn 2027 catalyzed by BUD16. currently not annotated. Lit ref is 
%not a smoking gun, so perhaps lower confidence annotation. 
model=changeGeneAssociation(model,model.rxns(2027),... 
    'YEL029C'); 
  
%per SGD, rxn 905 is catalyzed by the phosphopantothenoylcysteine 
%decarboxylase (PPCDC; Cab3p, Sis2p, Vhs3p) complex. Currently annotated 
%with only CAB3 (note: check which might be essential - sis2 is not) 
model=changeGeneAssociation(model,model.rxns(905),... 
    '(YKL088W  or (YKR072C and YKL088W) or (YOR054C and YKL088W) or (YOR054C 
and YKR072C and YKL088W))'); 
  
%sis2 and vhs3 also form a complex with ppz1 (which isn't in Y5). 
  
%% 
%check rxns of glycolosys, gluconeogenesis, TCA cycle, gloxylate cycle, and 
%Pentose Phosphate pathway. At this point, there are changes between the 
%pre-modified model and the post-modified model fluxes. 
  
%An essential question is: what SHOULD the fluxes be? 
  
%% 
%glycolysis - the following rxns all have positive fluxes 
%post-modifications (not all do prior to changes) 
  
%pathway 
%rxn 1165 -'glucose transport' - exc to cyto -> 
%rxn 534 - 'hexokinase (D-glucose:ATP)' - cyto -> 
%rxn 467 'glucose-6-phosphate isomerase' - cyto <-> 
%rxn 885 'phosphofructokinase' - cyto ->  
%rxn 450 'fructose-bisphosphate aldolase' - cyto <-> 
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%rxn 1053 'triose-phosphate isomerase' - cyto <-> 
%rxn 486 'glyceraldehyde-3-phosphate dehydrogenase' - cyto <-> 
%rxn 891 'phosphoglycerate kinase' - cyto <-> 
%rxn 892 'phosphoglycerate mutase' - cyto <-> 
%rxn 366 'enolase' - cyto <-> 
%rxn 961 'pyruvate kinase' - cyto -> 
%rxn 958 'pyruvate decarboxylase' - cyto -> 
  
%notes:  
%g-6-p (from r534) participates in 7 rxns. 5 of them have fluxes 
%f-6-p (from r467) participates in 11 rxns. 5 of them have fluxes 
%f-1,6-bp (from r885) participates in 4 rxns. 2 have fluxes (glycolysis) 
%DHAP (from r450) participates in 8. 3 have fluxes (glycolysis + r491) 
%GADP (from r1053 and 450) in 7. all have fluxes. 
%1,3BPG (from r486) in 3. 2 have fluxes (glycolysis) 
%3PG (from r891) in 3. all have fluxes (glycolysis + TCA) 
%2PG (from r892) in 2. both have fluxes 
  
%PEP (from r366) in 6. 4 have fluxes. rxn 65 is an inferred gene function, 
%but no FBA sln if I block it. but, YDR127W is not an essential gene. 
%merits some more investiagation. (ah - not essential in complex media!) 
  
%pyruvate (from r961) in 18. 5 have fluxes (203 957 958 961 2032). I think 
%if r958 has a flux, ethanol should be produced...(maybe regulated, though, 
%and I'm not very sure of this). As it is, acetaldehyde is transported to 
%the mitochondria via rxn 1631, where it is converted to acetate via rxn 
%175. The acetate goes to the cyto (rxn 1635), where there are 3 other rxns 
%using acetate. FBA works if I block it. This also helps with TCA fluxes (8 
%of 11 have fluxes instead of 6 of 11). Or, rxn 958 may be part of TCA or 
%glyoxylate cycles? 
  
%model.ub(958)=0; %possible regulatory constraint - I'm not sure. 
  




%gluconeogenesis - post-modifications, rxns 883 and 449 have 0 flux (883 
%has a flux prior to changes) 
  
%pathway 
%rxn 957 'pyruvate carboxylase' 
%rxn 883 'phosphoenolpyruvate carboxykinase' 
%rxn 366 'enolase' - cyto <-> 
%rxn 892 'phosphoglycerate mutase' - cyto <-> 
%rxn 891 'phosphoglycerate kinase' - cyto <-> 
%rxn 486 'glyceraldehyde-3-phosphate dehydrogenase' - cyto <-> 
%rxn 450 'fructose-bisphosphate aldolase' - cyto <-> 
%rxn 449 'fructose-bisphosphatase' - cyto -> 
%rxn 467 'glucose-6-phosphate isomerase' - cyto <-> 
  
%notes 
%so, gluconeogenesis fluxes seem good at the moment. 
  
%% 
%Pentose Phosphate pathway - post modifications, these the first 3 rxns on 





%rxn 466 'glucose 6-phosphate dehydrogenase' 
%rxn 91 '6-phosphogluconolactonase' 
%rxn 888 'phosphogluconate dehydrogenase' 
%rxn 981 'ribose-5-phosphate isomerase' 
%rxn 983 'ribulose 5-phosphate 3-epimerase' 
%rxn 1048 'transketolase 1' 
%rxn 1047 'transaldolase' 
%rxn 1049 'transketolase 2' 
  
%notes 
%D-6-P-G-D-L (met 335 from rxn 466) is in 3 rxns. none have fluxes. 
%6-P-D-G (met 340 from rxn 91) is in 2 rxns. niether has a flux. 
%rxn 888 produced NADPH - should have a flux! (question: where is NADPH 
%currently produced?) 
%R-5-P (met 577 from rxn 888) is in 4 rxns. produced in rxn 983, consumed 
%in 981 and 38. So where is the xylulose 5-p coming from? 
%X-5-P (met 581 in rxn 983) in 5 rxns. 3 have - fluxes (all in PPP) 
  
%I think that PPP can have these fluxes, in the absence of NADPH demand. 
%This might be fixed with changed biomass def? 
%What if add NADP sink/demand (I don't see the differenceat the moment) 
%reaction? 
%model=addSinkReactions(model,{'s_1212'},1,1000); %breaks FBA. 
  
%rxn 1048 has negative flux. What if restrict direction? 
model=changeRxnBounds(model,model.rxns(1048),0,'l'); %MODELING CONSTRAINT 
%same for rxn 1049 
model=changeRxnBounds(model,model.rxns(1049),0,'l'); %MODELING CONSTRAINT 
  
%now first 6 rxns have fluxes; glycolysis looks good. TCA still needs 
%attention. 
  
% per Yeasts 2ed v3 p 223 "it should be emphasized that, contrary to an 
% extended belief, this pathway cannot function in yeast as a cycle 
% oxidizing glucose to 6 CO2 and 12 NADPH during hexose metabolism. This 
% function would imply the operation of fructose-1,6-bipshosphatase, an 
% enzyme repressed by hexoses in Sacch. cerevisiae. 
  
%F-1,6-BP is YLR377C, catalyzing rxn 449, which is currently constrained to 
%the forward direction. 
  
%see http://dx.doi.org/10.1006/mben.1998.0110 - expect 20-50% of glucose is 
%oxidized via PPP in aerobic conditions. So I think there should be fluxes 
%through each rxn of the PPP. 
  
%see also http://dx.doi.org/10.1099/00221287-129-4-953 - a very interesting 
%ref! 
  
%so, at this point, I've got some directional constraints on transketolase 
%rxns (lit support?). With those, I get glycolysis and PPP fluxes I like, 
%but not TCA yet. 
  
%% 
%TCA cycle (in mito) - post modifications, these the first 5 and final rxns 
%on the following list have fluxes, and the others do not. If rxn 714 is 
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%irreversible, all TCA rxns have positive fluxes. I'll examine with 
%irreversible rxn 714 first. 
  
%pathway 
% rxn 2032 'pyruvate transport' 
% rxn 960 'pyruvate dehydrogenase' 
% rxn 300 'citrate synthase' 
% rxn 302 'citrate to cis-aconitate(3-)' 
% rxn 280 'cis-aconitate(3-) to isocitrate' 
% rxn 658 'isocitrate dehydrogenase (NAD+)' 
% rxn 831 'oxoglutarate dehydrogenase (lipoamide)' 
% rxn 830 'oxoglutarate dehydrogenase (dihydrolipoamide S-
succinyltransferase)' 
% rxn 1021 'succinate-CoA ligase (ADP-forming)' 
% rxn 1020 'succinate dehydrogenase (ubiquinone-6)' 
% rxn 451 'fumarase' 
% rxn 713 'malate dehydrogenase' 
  
%notes 
% pyruvate (met 1401) from r2032 in 11 rxns. 5 have fluxes consuming. 
% acc-CoA (met 376) from r960 in 13 rxns. 3 have fluxes 
% citrate (met 524) from r300 in 6 rxns. 4 have fluxes(vs 2 w/rev 714)  
  
% citrate is going cyto in r1125 (importing malate), and returning in 
% r1127(exporting isocitrate) 
  
% cis-aconitate (met 517) from r302 in 3 rxns. 2 have fluxes 
% isocitrate (met 941) from r280 in 4 rxns. 3 have fluxes, seem ok 
  
% 2-oxoglutarate (met 182) from r658 and 660 in 14 rxns. 8 have fluxes. In 
% reversible r714 case, r660 has flux, r831 does not. 
% produced in r 118 (k), 217 (k), 674 (k), 1087 (k), 1098 (k, maybe glu 
% repressed), consumed in rxn 1836 
  
%rxn 1836 isn't annotated with a gene - looks like LYS20. 
model=changeGeneAssociation(model,model.rxns(183),'YDL182W'); 
  
% succinyl-CoA (met 1464) from r830 in 3 rxns. 2 have fluxes 
% succinate (met 1460) from r1021 in 7 rxns. 3 have fluxes. 
% fumarate (met 727) from r1020 in 5 rxns. 2 have fluxes. 
  
%rxn 1020 should use FAD? see http://dx.doi.org/10.1074/jbc.271.8.4055  
%only required in 1 direction. see 10.1111/j.1432-1033.1994.tb18949.x 
  
%"The covalent attachment of FAD is therefore necessary for succinate 
%oxidation but is dispensable for both fumarate reduction and for the 
%import and assembly of the flavoprotein subunit." 
  
%so, maybe split into 3 rxns? (I haven't done this at the moment) 
%succinate + ubiquinone-6 + FAD -> fumarate + ubiquinol-6 + FADH 
%succinate + ubiquinone-6 + FAD <- fumarate + ubiquinol-6 + FADH 
%succinate + ubiquinone-6 <- fumarate + ubiquinol-6 
  
% malate (met 68) from r451 in 6 rxns. 4 have fluxes (including 2 exchange 
% rxns that seem ok) 





%glyoxylate cycle (mostly in cyto). Post-changes (irreversible rxn 714), x 
%of the following N rxns have fluxes. 
  
%"In the presence of 1% glucose, the synthesis of all enzymes, except 
%fumarase, was repressed. However, no indication for a specific regulation 
%mechanism for the entire cycle could be found. Studies on the localization 
%of the glyoxylate cycle enzymes in the yeast cell revealed that the key 
%enzymes, isocitrate lyase and malate synthase, are located in the 
%cytoplasm, whereas succinate dehydrogense was found only in the 
%mitochondrial fraction. Activites of all other enzymes are found in the 
%cytoplasm as well as in the mitochondira. In anaerobically grown cells, no 
%mitochondria could be detected. Succinate dehydrogenase, isocritrate 
%lyase, and malate synthase were absent. However, appreciable activities of 
%citrate synthase, aconitase, fumarase, and malate dehydrogenase were found 
%in the Cytoplasm." - http://dx.doi.org/10.1111/j.1432-1033.1969.tb00658.x 
  
% pathway (starting with Malate) 
  
% rxn 713 'malate dehydrogenase' - malate to oxaloacetate(mito) 
% rxn 714 'malate dehydrogenase, cytoplasmic ' - 0 flux 
% rxn 300 'citrate synthase' - mitochondrial generation of citrate 
% MISSING RXN - 'citrate synthase' - cyto? - YCR005C? 
% rxn 302 'citrate to cis-aconitate(3-)' - mitochondrial 
% rxn 303 'citrate to cis-aconitate(3-), cytoplasmic' 
% rxn 280 'cis-aconitate(3-) to isocitrate' - mitochondrial - YJL200C? 
% MISSING RXN? 'cis-aconitate(3-) to isocitrate' - cyto? - YLR304C? 
% rxn 662 'isocitrate lyase' - isocitrate to glyoxylate and succinate 
% rxn 716 'malate synthase' - glyoxylate to malate (in cyto) 
% rxn 1020 'succinate dehydrogenase (ubiquinone-6)' - succ to fum (mito) 
% rxn 452 'fumarase' - fumarate to malate (cyto) 
% rxn 451 'fumarase' - fumarate to malate (mito) 
  
%tansport rxns 
% rxn 1225 'malate transport' - to mitochondria 
% rxn 1238 'oxaloacetate transport' - to mitochondria 
% rxn 1127 'citrate transport' - to cyto 
% rxn 1264 'succinate-fumarate transport' - succinate to mito 
  
%notes 
%again, 1020 should perhaps have FAD cofactor? 
  
%rxn 280 may be misannotated as YLR304C, which may catalyze cytosol rxn. 
%280 could be annotated YJL200C. cytosol cis-Aconitate to Isocitrate may be 
%missing. 
  
%missing a cytosol citrate synthase? 
  
%so it seems that enough have fluxes for the cycle to function. 
  
%% output 
rxnNames = { 
    % glycolysis 
    'GLYCOLYSIS' 
    'glucose transport' 
    'hexokinase (D-glucose:ATP)' 
    'glucose-6-phosphate isomerase' 
333 
 
    'phosphofructokinase' 
    'fructose-bisphosphate aldolase' 
    'triose-phosphate isomerase' 
    'glyceraldehyde-3-phosphate dehydrogenase' 
    'phosphoglycerate kinase' 
    'phosphoglycerate mutase' 
    'enolase' 
    'pyruvate kinase' 
    'pyruvate decarboxylase' 
    '' 
    %ethanol production 
    %'alcohol dehydrogenase, reverse rxn (acetaldehyde -> ethanol)' 
    %should be 'alcohol dehydrogenase (ethanol)' 
    'ETHANOL PRODUCTION' 
    'alcohol dehydrogenase (ethanol)' 
    'ethanol transport' 
    '' 
    % gluconeogenesis 
    'GLUCONEOGENESIS' 
    'pyruvate carboxylase' 
    'phosphoenolpyruvate carboxykinase' 
    'enolase' 
    'phosphoglycerate mutase' 
    'phosphoglycerate kinase' 
    'glyceraldehyde-3-phosphate dehydrogenase' 
    'fructose-bisphosphate aldolase' 
    'fructose-bisphosphatase' 
    'glucose-6-phosphate isomerase' 
    '' 
    % PPP 
    'PENTOSE PHOSPHATE PATHWAY' 
    'glucose 6-phosphate dehydrogenase' 
    '6-phosphogluconolactonase' 
    'phosphogluconate dehydrogenase' 
    'ribose-5-phosphate isomerase' 
    'ribulose 5-phosphate 3-epimerase' 
    'transketolase 1' 
    'transaldolase' 
    'transketolase 2' 
    '' 
    % TCA 
    'TCA CYCLE' 
    %'pyruvate transport' %commented out b/c multiple rxns have this name 
    'pyruvate dehydrogenase' 
    'citrate synthase' 
    'citrate to cis-aconitate(3-)' 
    'cis-aconitate(3-) to isocitrate' 
    'isocitrate dehydrogenase (NAD+)' 
    'oxoglutarate dehydrogenase (lipoamide)' 
    'oxoglutarate dehydrogenase (dihydrolipoamide S-succinyltransferase)' 
    'succinate-CoA ligase (ADP-forming)' 
    'succinate dehydrogenase (ubiquinone-6)' 
    'fumarase' 
    'malate dehydrogenase' 
    '' 
    %glyoxylate cycle 
    'GLYOXYLATE CYCLE' 
334 
 
    'malate dehydrogenase' 
    'malate dehydrogenase, cytoplasmic' 
    'citrate synthase' 
    'citrate synthase' 
    'citrate to cis-aconitate(3-)' 
    'citrate to cis-aconitate(3-), cytoplasmic' 
    'cis-aconitate(3-) to isocitrate' 
    'isocitrate lyase' 
%    'malate synthase' %commented out b/c multiple rxns have this name 
    'succinate dehydrogenase (ubiquinone-6)' 
    'fumarase' 
    'malate transport' 
%    'oxaloacetate transport' %commented out b/c multiple rxns have this name 
%    'citrate transport' %commented out b/c multiple rxns have this name 
    'succinate-fumarate transport' 
    '' 
    % other 
    }; 
  
fprintf('\nAerobic growth prior to 
changes\nrate:\t%.2f\n\n',unchangedsolution.f); 
  
for k = 1:length(rxnNames) 
   ind = strcmp(rxnNames{k},model.rxnNames); 
   if sum(ind)>1, disp(rxnNames{k}); end 
   fprintf('%.2f\t%s\n',unchangedsolution.x(ind),rxnNames{k}); 
end 
  
FBAsolution = optimizeCbModel(model,[],'one'); 
fprintf('Aerobic growth after changes\nrate:\t%.2f\n\n',FBAsolution.f); 
  
for k = 1:length(rxnNames) 
   ind = strcmp(rxnNames{k},model.rxnNames); 
   if sum(ind)>1, disp(rxnNames{k}); end 





% ind = strcmp('oxygen exchange',ana.rxnNames); ana.lb(ind) = 0; 
%  
% ind = ismember(ana.rxnNames,{... 
%     'lipid pseudoreaction [no 14-demethyllanosterol, no ergosta-
5,7,22,24(28)-tetraen-3beta-ol]' 
%     'ergosterol exchange' 
%     'lanosterol exchange' 
%     'zymosterol exchange' 
%     'phosphatidate exchange' 
%     }); 
% ana.lb(ind) = -Inf; 
% ana.ub(ind) = Inf; 
%  
% ind = strcmp('lipid pseudoreaction',ana.rxnNames); ana.ub(ind) = 0; 
%  
% ana_FBAsolution = optimizeCbModel(ana,[],'one'); 




% for k = 1:length(rxnNames) 
%    ind = find(strcmp(rxnNames{k},ana.rxnNames)); 






Supplementary File 5.4.1: Y5_3_three_knockout1.m script 
% FILE NAME: Y5_three_knockout1 
% 
% DATE CREATED: 9 Feb 2012 
% 
% PROGRAMMER: B. Heavner 
% Department of Biological 
% and Environmental Engineering 
% Cornell University 
% Ithaca, NY 14853 
% 
% LAST REVISED: 11 July 2012 
% 




% 11 July 2012 - BH - cleaned up for publication 
% 22 May 2012 - BH - change to use Y5.30 
% 13 May 2012 - BH - change media to have 18:1 and 16:1 
% 11 May 2012 - BH - fix strain background misunderstanding 
% 5 April 2012 - BH - get it working with modified Y5. 
% 
% PURPOSE:  
% To attempt to reproduce the model results reported by Kennedy et al. with 
% the Yeast 5.30 model instead of the iND750 model. 
% 
% In this script, I apply constraints to Y5 to duplicate the Kennedy et al. 
% media and mutants to see if I still get a predicted formic acid secretion 
% with the mutants reported in Kennedy et al. Table 1. 
% 
% REFERENCE:  
% Kennedy CJ, Boyle PM, Waks Z, Silver PA. "Systems-Level Engineering of 




% none - it's a script. But you need Y5_3.mat in the working directory (or 
% load the Y5 GEM using readcbmodel, and comment out the "load" line of the 
% script. 
% 
% EXPECTED OUTPUT: 
% growth rates and fluxes for the mutants listed in Table 1 of Kennedy et 
% al. 
% 
% REQUIRED SOFTWARE: 













fprintf('Yeast model v 5.30 loaded.\n'); 
fprintf(' \r'); 
  
%one more change found later - sent to Kieran to add to the model, too. 
model.lb([490 491])=0;model.ub([490 491])=0; 
  
%make sure we're using the gurobi solver (glpk gives different answers!) 
changeCobraSolver('gurobi'); 
  




%next modify the changed model by relaxing modeling constraints I imposed 
%to get PPP pathway working as expected, and to add some strain-specific 
%changes. 
  




%add the alt2 gene, which is not in Y5.01 b/c it's a putative ORF in SGD. 
model=addReaction(model,'NRXN11',{'s_0180', 's_0955', 's_0991', ... 
    's_1399'}, [-1 -1 1 1], true, -1000, 1000, 0, '', 'YDR111C'); 
  
%add the YPL276W ORF, which is not in Y5.30 b/c it's not in s288c per SGD. 
%rxn 429 (formate dehydrogenase) can be catalyzed by FDH2 in CEN.PK 113-7D 
%strain (see pmid: 11921099) 
model=changeGeneAssociation(model,model.rxns(429),... 
    '(YOR388C or (YPL275W AND YPL276W))'); 
  
%paper wt background is fdh1 fdh2 deletion 
[model,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YOR388C','YPL275W','YPL276W'}); 
  
%paper strain background is wt for ura3 his3 leu2 trp1, and a mal2 mutant 
%MAL2 isn't in s288c background, so no locus in SGD. 
%background strain codes for SUC2 invertase, others are not in s288c 
%background, so no locus in SGD  
  
%% 
%next, make the media the same as that in Kennedy et al. (based on their 
%supplemental table 1).  
% 
%NOTE: the COBRA exchange reaction convention means that I need to use the 
%opposite sign than Kennedy et al. 
% 
%NOTE 2: Table S1 lists "pydxn", "4abz", "nac", and "dhf" as having an 
%upper bound of 0.5. I think these are: Pyridoxine (met 875), 
%4-Aminobenzoate (met 98), Nicotinate (met 714), and 7,8-Dihydrofolate (met 
%383). They don't have exchange reactions in iND750. Kennedy et al. may 
%have added them, but they don't have fluxes in Table S2, so they're not 
%essential. 
% 




%start with a clean slate: set all exchange reactions to upper bound = 1000 
%and lower bound = 0 (ie, unconstrained excretion, no uptake) 
  




%the following exchange rxns have an upper bound and lower bound of 20 in 






    index=find(strcmp(ub_lb_20(i),model.rxnNames)); 
    model.lb(index)=-20; 
    model.ub(index)=-20; 
end 
  
%the following have upper and lower bounds of inf in Table S1.  
% 
%NOTE: oxygen not in table S1, but added to do aerobic, based on 
%text of paper 
  
ub_inf={'water exchange', 'ammonium exchange', 'phosphate exchange', ... 
    'sulphate exchange', 'sodium exchange', 'potassium exchange', ...  
    'carbon dioxide exchange', 'oxygen exchange'}; 
  
for i=1:length(ub_inf) 
    index=find(strcmp(ub_inf(i),model.rxnNames)); 
    model.lb(index)=-1000; 
end 
  
%the following have an upper bound of 0.5 in Table S1 (but I'm switching 
%signs, so do a lower bound of -0.5). 
  
ub_05 = {'L-asparagine exchange', 'L-aspartate exchange', ...  
    'L-valine exchange', 'L-tyrosine exchange', ... 
    'L-tryptophan exchange', 'L-threonine exchange', ...  
    'L-serine exchange', 'L-proline exchange', ...  
    'L-phenylalanine exchange', 'L-methionine exchange', ... 
    'L-lysine exchange', 'L-leucine exchange', ... 
    'L-isoleucine exchange', 'L-histidine exchange', ... 
    'glycine exchange', 'L-glutamate exchange', ... 
    'L-glutamine exchange', 'L-cysteine exchange', ... 
    'L-arginine exchange', 'L-alanine exchange' ... 
    'riboflavin exchange', 'thiamine(1+) exchange', ... 
    'zymosterol exchange', 'uracil exchange', ... 
    '(R)-pantothenate exchange', 'linoleic acid exchange', ... 
    'myo-inositol exchange', 'palmitoleate exchange', ... 
    'ergosterol exchange', 'biotin exchange', 'adenine exchange'}; 
  
%note: Y5 doesn't have octadecynoate (n-C18:2) or octadecenoate (n-C18:1) 
%exchange reactions. I used linoleic (18:1). It also doesn't have 
%hexadecenoate (n-C16:1). I used palmitoleate (16:1) for that. I don't 





    index=find(strcmp(ub_05(i),model.rxnNames)); 
    model.lb(index)=-0.5; %constrained uptake 
end 
  
%the following have a lower bound of -inf in Table S1 (but I'm switching 
%signs, so do an upper bound of 1000) 
% 
% Note: 'Deoxycytidine exchange' not included in Table S1, but has a flux 
% in Table S2, so I added it here. 
  
lb_inf = {'(1->3)-beta-D-glucan exchange', ... 
    'gamma-aminobutyrate exchange', '(S)-3-methyl-2-oxopentanoate exchange', 
... 
    ' 8-amino-7-oxononanoate exchange', 'L-arabinitol exchange', ... 
    'acetaldehyde exchange', 'acetate exchange', 'adenosine exchange', ... 
    ' 2-oxoglutarate exchange', 'allantoin exchange', ... 
    'S-adenosyl-L-methionine exchange', 'D-arabinose exchange', ... 
    'L-arabinose exchange', 'choline exchange', 'citrate(3-) exchange', ... 
    '(R)-carnitine exchange', 'cytosine exchange', 'cytidine exchange', ... 
    '2''-deoxyadenosine exchange', ' 7,8-diaminononanoate exchange', ... 
    '2''-deoxyguanosine exchange', '2''-deoxyinosine exchange', ... 
    'dTTP exchange', '2''-deoxyuridine exchange', 'ethanol exchange', ... 
    'FMN exchange', 'palmitate exchange', 'H+ exchange', ... 
    'hypoxanthine exchange', 'inosine exchange', '(S)-lactate exchange', ... 
    '(S)-malate exchange', 'maltose exchange', 'D-mannose exchange', ... 
    'melibiose exchange', 'S-methyl-L-methionine exchange', ... 
    'NMN exchange', 'stearate exchange', ... 
    'ornithine exchange', 'adenosine 3'',5''-bismonophosphate exchange', ... 
    'peptide exchange', 'putrescine exchange', 'pyruvate exchange', ... 
    'D-ribose exchange', 'D-glucitol exchange', 'L-glucitol exchange', ... 
    'spermidine exchange', 'spermine exchange', 'L-sorbose exchange', ... 
    'succinate exchange', 'sucrose exchange', ... 
    'thiamine(1+) monophosphate exchange', 'thiamine(1+) diphosphate(1-) 
exchange', ... 
    'thymidine exchange', 'thymine exchange', 'alpha,alpha-trehalose 
exchange', ... 
    'myristate exchange', 'urea exchange', ... 
    'uridine exchange', '9H-xanthine exchange', 'xanthosine exchange', ... 
    'D-xylose exchange', 'xylitol exchange', 'deoxycytidine exchange'}; 
  
%note: Y5 doesn't have 4-Aminobutanoate exchangeI used gamma-aminobutyrate. 




    index=find(strcmp(lb_inf(i),model.rxnNames)); 
    model.lb(index)=0; 
    model.ub(index)=1000; 
end 
  




%next step: demonstrate the results of Table 1 (strains 1-5, b/c yat2 isn't 





%Kennedy reported in silico knockouts: 
%1 fdh1=YOR388C fdh2=YPL275W/YPL276W alt2=YDR111C fum1=YPL262W zwf1=YNL241C 
%2 fdh1 fdh2 aat2=YLR027C fum1=YPL262W zwf1=YNL241C 
%3 fdh1 fdh2 cat2=YML042W fum1=YPL262W zwf1=YNL241C 
%4 fdh1 fdh2 cat2=YML042W fum1=YPL262W rpe1=YJL121C 
%5 fdh1 fdh2 cat2=YML042W fbp1=YLR377C fum1=YPL262W 
%6 fdh1 fdh2 cat2=YML042W yat2=YER024W slc1=YDL052C 
%7 fdh1 fdh2 cat2=YML042W yat2=YER024W cho1=YER026C 
%8 fdh1 fdh2 cat2=YML042W yat2=YER024W alt2=YDR111C 
  
%% 





fprintf('The WT growth flux is: %6.4f.\n', wt_sln.f); %2.5889 
fprintf('Formate exchange is reaction %d.\n', formate_ex); %0 
fprintf('The formate exchange flux is: %6.4f.\n', wt_sln.x(formate_ex)); 
fprintf(' \r'); 
  
%make the knockouts and test them 
%fdh1/2 mutant applied earlier 
%[model,hasEffect,constrRxnNames,deletedGenes] = ... 
%        deleteModelGenes(model,{'YOR388C','YPL275W','YPL276W'}); 
     
[KO1,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YDR111C','YPL262W','YNL241C'}); 
KO1_sln=optimizeCbModel(KO1,[],'one'); 
  
fprintf('The KO1 growth flux is: %6.4f.\n', KO1_sln.f); %1.6065 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 




[KO2,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YLR027C', 'YPL262W', 'YNL241C'}); 
KO2_sln=optimizeCbModel(KO2,[],'one'); 
  
fprintf('The KO2 growth flux is: %6.4f.\n', KO2_sln.f); %1.6065 
fprintf('Formate exchange is reaction %d.\n', formate_ex); % 




[KO3,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YPL262W', 'YNL241C'}); 
KO3_sln=optimizeCbModel(KO3,[],'one'); 
  
fprintf('The KO3 growth flux is: %6.4f.\n', KO3_sln.f); %1.6065 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 






[KO4,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YPL262W', 'YJL121C'}); 
KO4_sln=optimizeCbModel(KO4,[],'one'); 
  
fprintf('The KO4 growth flux is: %6.4f.\n', KO4_sln.f); %1.6065 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 





[KO5,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YLR377C', 'YPL262W'}); 
KO5_sln=optimizeCbModel(KO5,[],'one'); 
  
fprintf('The KO5 growth flux is: %6.4f.\n', KO5_sln.f); 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 




[KO6,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YER024W', 'YDL052C'}); 
KO6_sln=optimizeCbModel(KO6,[],'one'); 
  
fprintf('The KO6 growth flux is: %6.4f.\n', KO6_sln.f); 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 




[KO7,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YER024W', 'YER026C'}); 
KO7_sln=optimizeCbModel(KO7,[],'one'); 
  
fprintf('The KO7 growth flux is: %6.4f.\n', KO7_sln.f); 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 




[KO8,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YER024W', 'YDR111C'}); 
KO8_sln=optimizeCbModel(KO8,[],'one'); 
  
fprintf('The KO8 growth flux is: %6.4f.\n', KO8_sln.f); 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 






Supplementary File 5.4.3: apply_y5_3_changes.m script 
% FILE NAME: apply_y5_3_changes 
% 
% DATE CREATED: 23 May 2012 
% 
% PROGRAMMER: B. Heavner 
% Department of Biological 
% and Environmental Engineering 
% Cornell University 
% Ithaca, NY 14853 
% 
% LAST REVISED: 11 July 2012 
% 
% REVISIONS:  
% 
% 7/11/12 - BDH - cleaned up for publication 
% 7/4/12 - BDH - added lines 396-421 (NAD/P constraints, and some rxn 
% changes) 
% 5/23/12 - BDH - started with Y5.30 
% 
% PURPOSE:  
% To document and apply all changes I find to correct the Y5.30 model. 
% 
% REFERENCES:  
% Various, included as comments to changes 
% 
% VARIABLES: 
% none - it's a script. But you need Y5_3.mat in the working directory (or 
% load the Y5 GEM using readcbmodel, and comment out the "load" line of the 
% script. 
% 
% EXPECTED OUTPUT: 
% updated model based on Y5.30 
% 
% REQUIRED SOFTWARE: 





%first, load the Y5.30 model. This matlab variable was made by running 







fprintf('Yeast model v 5.30 loaded.\n'); 
fprintf(' \r'); 
  
%make sure we're using the gurobi solver (glpk gives different answers!) 
changeCobraSolver('gurobi'); 
  





%check the media: 






fprintf('rxnName \t lb\n') 
for i=1:length(media_indexes) 






%Check the solution prior to any changes 
unchangedsolution = optimizeCbModel(model,[],'one'); 
  
%% 
%model updates and fixes - note: add new to the end - numbers may change! 
%I'm working off a list of reactions generated by examining genes that only 




%Start with a tricky one - succinate and fumarate stuff 
% 
%rxns 439 and 945 (r_0455 and r_1000) are annotated with YEL047C (FRD1), 
%citing http://identifiers.org/kegg.reaction/R00408. However, that KEGG rxn 
%isn't present in saccharomyces cerevsiae. Looking at SGD to determine 
%YEL047C's function, it states "Soluble fumarate reductase, required with 
%isoenzyme Osm1p for anaerobic growth". osm1 is YJR051W. of OSM1, SGD says 
%"Fumarate reductase, catalyzes the reduction of fumarate to succinate, 
%required for the reoxidation of intracellular NADH under anaerobic 
%conditions" 
  
%PMID: 8946166 says that FRD1 binds FAD. So, it may be that SGD is 
%confusing or perhaps FRD1 uses FAD, and OSM1 uses NAD. for now, I'll stick 
%with them both using FAD. 
  
%per SGD, OSM1 localizes to the mitochondria, and FRD1 localizes to the 
%cytosol (or mitochondria or ribosome)... 
  
%OSM1 currently catalyzes mitochondrial rxns 438 and 440, involving FAD and 
%FMN, not NAD/H.. 
% 438 cites http://identifiers.org/kegg.reaction/R00408 (which uses FAD, 
% but is not in Yeast, per KEGG) 
% 440 doesn't cite a source. 
% 
%looking at rxn 438, it's catalyzed by "(YJR051W or (YDR178W and YJL045W 
%and YKL141W and YLL041C) or (YDR178W and YKL141W and YKL148C and 
%YLL041C))"  
% 
%from SGD's description of these other ORFs, including YJR051W with them 
%appears to be wrong. (the others form succinate dehydrogenase, which 





%additionally, rxn 438 is constrained to work only fumarate -> succinate, 
%which is opposite from what SGD describes and what YeastCyc shows for 
%succinate dehydrogenase. And, Y5_3 has it using FAD, not ubiquinone, which 
%differs from Yeastcyc's description of succinate dehydrogenase. 
  
%proposed fixes: 1) reannoatate rxn 438 to use YEL047C or YEL047C (cite: 
%PMID: 9587404 and PMID: 8946166). The rxn catalyzed by succinate 
%dehydrogenase is more correctly covered by rxn 966; 2) remove rxn 440; 3) 
%change rxn 439 to use FAD cofactor; 
  




model.S([709 712],439)=0; model.S(685,439)=-1; model.S(683,439)=1; 
  
%TCA cycle still ok 
  
%% 
%MetaCyc shows rxn 966 constrained to go in forward direction only  
model=changeRxnBounds(model,model.rxns(966),0,'l'); 
  
%TCA cycle still ok 
  
%% 
%While looking at succinate dehydrogenase, notice rxn 965 - no ref, rxn 
%shown is kinda like that annotated by YML120C in yeastCyc.. But YML120C 
%annotates rxn 748 in Y5_3. 
  








%model.S([787 782],748)=0;  
% breaks the TCA and glyoxylate cycle fluxes - perhaps the Yeast electron 
% transport chain isn't correctly reconstructed? 
  
%% 
%pubmed: 16226833, cited for rxn 939, says YFL030W is highly specific for 
%substrate - that described in rxn 153. It says there's very low activity 
%for something like rxn 939. So, get rid of rxn 939 (note: this is related 






%rxns catalyzed by YGL202W or YHR137W seem not quite right... the two genes 
%catalyze different rxns, per SGD... 
  
%Both YGL202W (ARO8) and YHR137W (ARO9) currently catalyze rxns 803 1001 
345 
 
%1008 (with OR)  
  
% SGD gives the following refs for both ARO8 and ARO9: PMID: 9491082 PMID: 
% 9491083 
  
% rxn 803:  2-oxoglutarate + L-phenylalanine  <-> keto-phenylpyruvate + 
% L-glutamate. SGD has this catalyzed by ARO8, reversible. 
  
% rxn 1001:2-oxoglutarate + L-tryptophan <-> indole-3-pyruvate+ 
% L-glutamate. SGD has this catalyzed by ARO8, in -> direction. 
  
% rxn 1008:3-(4-hydroxyphenyl)pyruvate + L-glutamate <-> 2-oxoglutarate+ 
% L-tyrosine. SGD has this catalyzed by ARO8, reversible. 
  
%proposed fix: remove ARO9 from these rxns, add 3 more for it's work. 









% new ARO9 rxn 1:  pyruvate s_1399 + L-phenylalanine s_1032  <-> 
% keto-phenylpyruvate s_0951 + L-alanine s_0955. reversible. 
model=addReaction(model,'NRXN1',{'s_1399', 's_1032', 's_0951', ... 
     's_0955'}, [-1 -1 1 1], true, -1000, 1000,'', 'YHR137W'); 
  
% new ARO9 rxn 2: keto-phenylpyruvate s_0951 + L-tryptophan s_1048 -> 
% indole-3-pyruvate s_0855 + L-phenylalanine s_1032. irreversible. 
model=addReaction(model,'NRXN2',{'s_0951', 's_1048', 's_0855', ... 
    's_1032'}, [-1 -1 1 1], false, 0, 1000,'', 'YHR137W'); 
  
% new ARO9 rxn 3: 3-(4-hydroxyphenyl)pyruvate s_0204 + L-alanine s_0955 <-> 
% pyruvate s_1399 + L-tyrosine s_1051. reversible. 
model=addReaction(model,'NRXN3',{'s_0204', 's_0955', 's_1399', ... 
    's_1051'}, [-1 -1 1 1], true, -1000, 1000,'', 'YHR137W'); 
  
% 
%TCA fluxes are increased, at this point simulating Kennedy KOs gives same 
%growth rates and formate fluxes for KO1,2,3,and 5. 
  
%% 
%rxns 754 and 755 are very similar, but use different species. 
%Additionally, SGD localizes YGR010W to the nucleus, so it shouldn't 




%For now, it appears that both of these reactions are parts of NAD 




%should rxn 956 be annotated the same as rxn 955? 
% from SGD, YHR042W seems incorrect for 956. 
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% but YNL111C seems wrong for 955, too. (and YIL043C and all others, which 
% are all related to cytochrome B5, and locate in mitochondria) 
% 
% these reactions seems to incorporate ERG9's use of NAD(P), while SGD 






%is rxn 1095 right? (1094 same as iND 549, FWIW) 
%SGD says "it is still under debate as to whether Flx1p imports FAD into 
%the mitochondria or exports it to the cytoplasm" but PMID: 14555654 says 
%"Flx1p is proposed to be the mitochondrial FAD export carrier". 
%rxn 1094 doesn't have a reference in Y5.30 
  





%rxns 271:273 are constrained; 274:285, catalyzed by same genes, are 
%unconstrained. And 286:289, catalyzed by one of the genes, are also 
%unconstrained. This portion of metabolism is related to protein 
%glycosylation, which I know very little about. I suspect the reaction are 
%catalyzed by both to support the observation that rer2 srt1 double 
%deletion is lethal. 
% 
%the compartmentalization of these reactions differs from the 
%compartmentalization of the genes in SGD. 
  
%proposed mod: change annotation so all are catalyzed by both, all 
%constrained 
model=changeGeneAssociation(model,model.rxns(286), '(YBR002C or YMR101C'); 
model=changeGeneAssociation(model,model.rxns(287), '(YBR002C or YMR101C'); 
model=changeGeneAssociation(model,model.rxns(288), '(YBR002C or YMR101C'); 
model=changeGeneAssociation(model,model.rxns(289), '(YBR002C or YMR101C'); 
model.lb(274:289)=0; 
  
%TCA fluxes are increased, at this point simulating Kennedy KOs gives same 
%growth rates and formate fluxes for KO1,2,3,and 5. 
  
%% 
%rxns 266 and 267 seem similar, but one has more general species. Probably 
%not quite right to have them both, but I don't know how they're connected 
%to other portions of PC metabolism. 266 is unconstrained, 267 is 
%constrained. 





%YOR128C catalyzes rxns 481 and 863. Though 863 is in iND too, neither 






%rxn 481 is annotated with http://identifiers.org/pubmed/21190580 - the 
%iMM904 paper; and http://identifiers.org/kegg.reaction/R06974 - which 
%doesn't link to a enzyme or pathway 
  
%rxn 863 is annotated with http://identifiers.org/kegg.reaction/R04209, 
%which is closer to what's in SGD/Yeastcyc 
  
%Proposed fix: remove rxn 481, modify rxn 863 to match SGD/Yeastcyc 
model.lb(481)=0;model.ub(481)=0; 
model.S([433 791],863)=-1;model.S([393 1304],863)=1; 
  
%% 
% PPP checks in light of PMID: 21663798 
  
% I don't know about rxn 839, but its reverse should exist. (there's a fair 
% amount of lit supporting rxn 839 in other organisms, particularly 
% rabbit). 
  
% The reverse rxn is catalyzed by SHB17, YKR043C. And it doesn't take ATP, 
% and it liberates a Phosphate.  (PMID: 21663798) 
  
model=addReaction(model,'NRXN4',{'s_1426', 's_1427', 's_1322'}, [-1 1 1], ... 




%changes from DOI: 10.1111/j.1742-4658.2012.08649.x 
model.lb(108)=-1000; model.ub(108)=0; 
model.lb([438 439 440])=-1000; 
model.ub(440)=1000; 
model.ub(470)=0; %not sure about ref on this one 
model.lb(486)=0; %not definitive, but paper noted why 
model.ub([639 640])=0; %a regulatory constraint 
model.ub([997 998])=0; %to force TAG synthesis flux 





%NADP phosphatases have already been removed. 
  
model=addReaction(model,'NRXN5',{'s_0061', 's_1198', 's_1269', 's_1203'}, ... 
    [-1 -1 1 1], false, 0, 1000,'', 'YKL216W'); 
model=addReaction(model,'NRXN6',{'s_0973', 's_0441', 's_0734'}, [-1 1 1], ... 
    false, 0, 1000,'', 'YMR250W '); 
model=addReaction(model,'NRXN7',{'s_1262', 's_1263'}, [-1 1], ... 
    false, 0, 1000,'', ''); 
model=addReaction(model,'NRXN8',{'s_1262', 's_1264'}, [-1 1], ... 
    false, 0, 1000,'', ''); 
model=addReaction(model,'NRXN9',{'s_0529', 's_0531'}, [-1 1], ... 
    true, -1000, 1000,'', ''); 
model=addReaction(model,'NRXN10',{'s_0799', 's_0794',}, [-1 1], ... 
    false, 0, 0,'', ''); %to be tuned for P/O ratio.. 
  
%% 




%change constraints as documented in 6/8/12 notes. 
% or, see 6/13 notes: 
  
%relax lit-supported NAD rxns 
model.lb([163 166 176 179 183 428 454 469 690 933 1888])=-1000; 
model.ub([163 166 176 179 183 428 454 469 690 933 1888])=1000; 
  
%refs: 
%163 - YDL168W catalyzes the following in Y5: [163 166 176 179 183 428]. 
%428 should be reversible, others also catalyzed by other genes:  
%   YBR145W or YDL168W or YOL086C. For now, make these all reversible, but 
%   a better fix could be to split rxns 163 166 176 179 183 to two, with 
%   only the version catalyzed by YDL168W reversible - o ther ADH rxns may 
%   not be reversible 
%428  - sfa1 reversible per SGD 
%454 - "overexpression of GDH2 can promote catalysis of the reverse reaction" 
%469 - glyceraldehyde-3-phosphate dehydrogenase - glycolysis and 
gluconeogenesis 
%690 - malate dehydrogenase - catalyze interconversion of malate and 
oxaloacetate (per SGD) 
%933 - PMID: 418069 - but lysene biosynthsis in Yeast merits more attention 
%1888 - NAD transport (nucleus/cyto) 
  
%and a ref that BDH1 (rxn 3) isn't reversible: "Therefore, the enzyme would 
%preferentially function as a reductase rather than as a dehydrogenase." - 
%PMID 10938079  
model.lb(3)=-1000; model.ub(3)=0; 
  
%relax lit-supported NADP 
model.lb([310])=-1000; %removed 455, 934 
model.lb([656])=0; %PMID: 12535615 
  
%refs: 
%310 - http://dx.doi.org/10.1016/j.jmb.2007.05.097, but for different 
%organism 
%455 - ?  
%934 - PMID 3098733 says reversible at pH 9.3 
  
%other refs:  
% 174 - aldehyde dehydrogenase, YPL061W 
%   YPL061W is ALD6. DOI: 10.1111/j.1432-1033.1971.tb01574.x says  
%   irreversible in pig brain. Make it irreversible. 
%  
% 464 - glutathione oxidoreductase, ((YCL035C and YPL091W) or (YDR098C and  
%   YPL091W) or (YDR513W and YPL091W) or (YER174C and YPL091W))  
%   - seems irreversible, but haven't found much lit to support yet. 
  
% look at SGD lit links for YPL091W 
% PMID: 22093810 - http://www.ncbi.nlm.nih.gov/pubmed/22093810 
% PMID: 21549177 - http://www.ncbi.nlm.nih.gov/pubmed/21549177 
% 
% note: if I make 174 and 464 irreversible, big - fluxes through 310 and 
375... 
%  
% 310 is D-arabinose 1-dehydrogenase (NADP), YBR149W  
%   PMID: 17151466 suggests limited fluxes 




% 375 is  fatty acid synthase (n-C16:1), YJL196C 
%   I think unlikely to be reversible. 
% 
%538    hydroxymethylglutaryl CoA reductase (YLR450W or YML075C) 
%   YLR450W is HMG2, irreversible http://genomebiology.com/2004/5/11/248 
%   YML075C is HMG1, irreversible http://genomebiology.com/2004/5/11/248 
%  
%   656 L-allo-threonine dehydrogenase YMR226C 
%   YMR226C was TMA29, but doesn't have a name now..  
%   should be irreversible, towards NADPH. (PMID: 12535615) 
  
%% 
% rxn 783 is annotated with http://identifiers.org/pubmed/8511969. Per that 







%rxn 1010 (r_1065) is annotated with YLR027C, but should be YGL202W, and 






%check rxns of glycolosys, gluconeogenesis, TCA cycle, gloxylate cycle, and 
%Pentose Phosphate pathway. At this point, there are changes between the 
%pre-modified model and the post-modified model fluxes. 
  
%note that rxn numbers in comments below are wrong (they're based on 5.01) 
  






%rxn 1165 -'glucose transport' - exc to cyto -> 
%rxn 534 - 'hexokinase (D-glucose:ATP)' - cyto -> 
%rxn 467 'glucose-6-phosphate isomerase' - cyto <-> 
%rxn 885 'phosphofructokinase' - cyto ->  
%rxn 450 'fructose-bisphosphate aldolase' - cyto <-> 
%rxn 1053 'triose-phosphate isomerase' - cyto <-> 
%rxn 486 'glyceraldehyde-3-phosphate dehydrogenase' - cyto <-> 
%rxn 891 'phosphoglycerate kinase' - cyto <-> 
%rxn 892 'phosphoglycerate mutase' - cyto <-> 
%rxn 366 'enolase' - cyto <-> 
%rxn 961 'pyruvate kinase' - cyto -> 
%rxn 958 'pyruvate decarboxylase' - cyto -> 
  
%% 





%rxn 957 'pyruvate carboxylase' 
%rxn 883 'phosphoenolpyruvate carboxykinase' 
%rxn 366 'enolase' - cyto <-> 
%rxn 892 'phosphoglycerate mutase' - cyto <-> 
%rxn 891 'phosphoglycerate kinase' - cyto <-> 
%rxn 486 'glyceraldehyde-3-phosphate dehydrogenase' - cyto <-> 
%rxn 450 'fructose-bisphosphate aldolase' - cyto <-> 
%rxn 449 'fructose-bisphosphatase' - cyto -> 
%rxn 467 'glucose-6-phosphate isomerase' - cyto <-> 
  
%% 
%Pentose Phosphate pathway - post modifications, these the first 3 rxns on 
%the following list don't have fluxes, and the last 4 are negative 
  
%pathway 
%rxn 466 'glucose 6-phosphate dehydrogenase' 
%rxn 91 '6-phosphogluconolactonase' 
%rxn 888 'phosphogluconate dehydrogenase' 
%rxn 981 'ribose-5-phosphate isomerase' 
%rxn 983 'ribulose 5-phosphate 3-epimerase' 
%rxn 1048 'transketolase 1' 
%rxn 1047 'transaldolase' 
%rxn 1049 'transketolase 2' 
  
%% 
%TCA cycle (in mito) - post modifications, these the first 5 and final rxns 
%on the following list have fluxes, and the others do not. If rxn 714 is 
%irreversible, all TCA rxns have positive fluxes. I'll examine with 
%irreversible rxn 714 first. 
  
%pathway 
% rxn 2032 'pyruvate transport' 
% rxn 960 'pyruvate dehydrogenase' 
% rxn 300 'citrate synthase' 
% rxn 302 'citrate to cis-aconitate(3-)' 
% rxn 280 'cis-aconitate(3-) to isocitrate' 
% rxn 658 'isocitrate dehydrogenase (NAD+)' 
% rxn 831 'oxoglutarate dehydrogenase (lipoamide)' 
% rxn 830 'oxoglutarate dehydrogenase (dihydrolipoamide S-
succinyltransferase)' 
% rxn 1021 'succinate-CoA ligase (ADP-forming)' 
% rxn 1020 'succinate dehydrogenase (ubiquinone-6)' 
% rxn 451 'fumarase' 




%glyoxylate cycle (mostly in cyto). Post-changes (irreversible rxn 714), x 
%of the following N rxns have fluxes. 
  
%"In the presence of 1% glucose, the synthesis of all enzymes, except 
%fumarase, was repressed. However, no indication for a specific regulation 
%mechanism for the entire cycle could be found. Studies on the localization 
%of the glyoxylate cycle enzymes in the yeast cell revealed that the key 
%enzymes, isocitrate lyase and malate synthase, are located in the 
%cytoplasm, whereas succinate dehydrogense was found only in the 
%mitochondrial fraction. Activites of all other enzymes are found in the 
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%cytoplasm as well as in the mitochondira. In anaerobically grown cells, no 
%mitochondria could be detected. Succinate dehydrogenase, isocritrate 
%lyase, and malate synthase were absent. However, appreciable activities of 
%citrate synthase, aconitase, fumarase, and malate dehydrogenase were found 
%in the Cytoplasm." - http://dx.doi.org/10.1111/j.1432-1033.1969.tb00658.x 
  
% pathway (starting with Malate) 
  
% rxn 713 'malate dehydrogenase' - malate to oxaloacetate(mito) 
% rxn 714 'malate dehydrogenase, cytoplasmic ' - 0 flux 
% rxn 300 'citrate synthase' - mitochondrial generation of citrate 
% MISSING RXN - 'citrate synthase' - cyto? - YCR005C? 
% rxn 302 'citrate to cis-aconitate(3-)' - mitochondrial 
% rxn 303 'citrate to cis-aconitate(3-), cytoplasmic' 
% rxn 280 'cis-aconitate(3-) to isocitrate' - mitochondrial - YJL200C? 
% MISSING RXN? 'cis-aconitate(3-) to isocitrate' - cyto? - YLR304C? 
% rxn 662 'isocitrate lyase' - isocitrate to glyoxylate and succinate 
% rxn 716 'malate synthase' - glyoxylate to malate (in cyto) 
% rxn 1020 'succinate dehydrogenase (ubiquinone-6)' - succ to fum (mito) 
% rxn 452 'fumarase' - fumarate to malate (cyto) 
% rxn 451 'fumarase' - fumarate to malate (mito) 
  
%tansport rxns 
% rxn 1225 'malate transport' - to mitochondria 
% rxn 1238 'oxaloacetate transport' - to mitochondria 
% rxn 1127 'citrate transport' - to cyto 
% rxn 1264 'succinate-fumarate transport' - succinate to mito 
  
%% output 
rxnNames = { 
    % glycolysis 
    'GLYCOLYSIS' 
    'glucose transport' 
    'hexokinase (D-glucose:ATP)' 
    'glucose-6-phosphate isomerase' 
    'phosphofructokinase' 
    'fructose-bisphosphate aldolase' 
    'triose-phosphate isomerase' 
    'glyceraldehyde-3-phosphate dehydrogenase' 
    'phosphoglycerate kinase' 
    'phosphoglycerate mutase' 
    'enolase' 
    'pyruvate kinase' 
    'pyruvate decarboxylase' 
    '' 
    %ethanol production 
    %'alcohol dehydrogenase, reverse rxn (acetaldehyde -> ethanol)' 
    %should be 'alcohol dehydrogenase (ethanol)' 
    'ETHANOL PRODUCTION' 
    'alcohol dehydrogenase (ethanol)' 
    'ethanol transport' 
    '' 
    % gluconeogenesis 
    'GLUCONEOGENESIS' 
    'pyruvate carboxylase' 
    'phosphoenolpyruvate carboxykinase' 
    'enolase' 
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    'phosphoglycerate mutase' 
    'phosphoglycerate kinase' 
    'glyceraldehyde-3-phosphate dehydrogenase' 
    'fructose-bisphosphate aldolase' 
    'fructose-bisphosphatase' 
    'glucose-6-phosphate isomerase' 
    '' 
    % PPP 
    'PENTOSE PHOSPHATE PATHWAY' 
    'glucose 6-phosphate dehydrogenase' 
    '6-phosphogluconolactonase' 
    'phosphogluconate dehydrogenase' 
    'ribose-5-phosphate isomerase' 
    'ribulose 5-phosphate 3-epimerase' 
    'transketolase 1' 
    'transaldolase' 
    'transketolase 2' 
    '' 
    % TCA 
    'TCA CYCLE' 
    %'pyruvate transport' %commented out b/c multiple rxns have this name 
    'pyruvate dehydrogenase' 
    'citrate synthase' 
    'citrate to cis-aconitate(3-)' 
    'cis-aconitate(3-) to isocitrate' 
    'isocitrate dehydrogenase (NAD+)' 
    'oxoglutarate dehydrogenase (lipoamide)' 
    'oxoglutarate dehydrogenase (dihydrolipoamide S-succinyltransferase)' 
    'succinate-CoA ligase (ADP-forming)' 
    'succinate dehydrogenase (ubiquinone-6)' 
    'fumarase' 
    'malate dehydrogenase' 
    '' 
    %glyoxylate cycle 
    'GLYOXYLATE CYCLE' 
    'malate dehydrogenase' 
    'malate dehydrogenase, cytoplasmic' 
    'citrate synthase' 
    'citrate synthase' 
    'citrate to cis-aconitate(3-)' 
    'citrate to cis-aconitate(3-), cytoplasmic' 
    'cis-aconitate(3-) to isocitrate' 
    'isocitrate lyase' 
%    'malate synthase' %commented out b/c multiple rxns have this name 
    'succinate dehydrogenase (ubiquinone-6)' 
    'fumarase' 
    'malate transport' 
%    'oxaloacetate transport' %commented out b/c multiple rxns have this name 
%    'citrate transport' %commented out b/c multiple rxns have this name 
    'succinate-fumarate transport' 
    '' 
    % other 
    }; 
  





for k = 1:length(rxnNames) 
   ind = strcmp(rxnNames{k},model.rxnNames); 
   if sum(ind)>1, disp(rxnNames{k}); end 
   fprintf('%.2f\t%s\n',unchangedsolution.x(ind),rxnNames{k}); 
end 
  
FBAsolution = optimizeCbModel(model,[],'one'); 
fprintf('Aerobic growth after changes\nrate:\t%.2f\n\n',FBAsolution.f); 
  
for k = 1:length(rxnNames) 
   ind = strcmp(rxnNames{k},model.rxnNames); 
   if sum(ind)>1, disp(rxnNames{k}); end 






Supplementary File 5.4.3: Y5_3_three_knockout1_v2.m script 
% FILE NAME: Y5_three_knockout1_v2 
% 
% DATE CREATED: 11 June 2012 
% 
% PROGRAMMER: B. Heavner 
% Department of Biological 
% and Environmental Engineering 
% Cornell University 
% Ithaca, NY 14853 
% 
% LAST REVISED: 7/11/12 
% 
% REVISED BY: BDH 
% 
% REVISIONS: 
% 7/11/12 - cleaned up for publication 
% 
% PURPOSE:  
% To attempt to reproduce the model results reported by Kennedy et al. with 
% the updated Yeast 5.30 model instead of the iND750 model. 
% 
% This updated version incorporates various model updates that I've applied 
% prior to the file creation date. 
% 
% REFERENCE:  
% Kennedy CJ, Boyle PM, Waks Z, Silver PA. "Systems-Level Engineering of 




% none - it's a script. But you need updated_Y5_3.mat in the working 
% directory. 
% 
% EXPECTED OUTPUT: 
% growth rates and fluxes for the mutants listed in Table 1 of 
% Kennedy et al. 
% 
% REQUIRED SOFTWARE: 












fprintf('Updated Yeast model v 5.30 loaded.\n'); 
fprintf(' \r'); 
  









% now begin modifying model. 
  
%a change not yet incorporated. 
model.lb([490 491])=0;model.ub([490 491])=0; 
  
%next modify the changed model by relaxing modeling constraints I imposed 
%to get PPP pathway working as expected, and to add some strain-specific 
%changes. 
  




%add the alt2 gene, which is not in Y5.30 b/c it's a putative ORF in SGD. 
model=addReaction(model,'NRXN11',{'s_0180', 's_0955', 's_0991', ... 
    's_1399'}, [-1 -1 1 1], true, -1000, 1000, 0, '', 'YDR111C'); 
  
%add the YPL276W ORF, which is not in Y5.30 b/c it's not in s288c per SGD. 
%rxn 429 (formate dehydrogenase) can be catalyzed by FDH2 in CEN.PK 113-7D 
%strain (see pmid: 11921099) 
model=changeGeneAssociation(model,model.rxns(429),... 
    '(YOR388C or (YPL275W AND YPL276W))'); 
  
%paper wt background is fdh1 fdh2 deletion 
[model,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YOR388C','YPL275W','YPL276W'}); 
  
%paper strain background is wt for ura3 his3 leu2 trp1, and a mal2 mutant 
%MAL2 isn't in s288c background, so no locus in SGD. 
%background strain codes for SUC2 invertase, others are not in s288c 
%background, so no locus in SGD  
  
%the next step is optional, and I did it for testing. 
%add the YML082W ORF, which is not in Y5.01 b/c it's a putative ORF in SGD, 
%but is in iND750 and has a flux in the fum1/zwf1 mutant strain 
%model=addReaction(model,'NRXN12',{'s_0803', 's_1241', 's_0178', ... 
%    's_0794', 's_0419' ,'s_1458'}, [-1 -1 1 1 1 1], true, -1000, 1000, ... 
%    0, '', 'YML082W'); 
  
%% 
%next, make the media the same as that in Kennedy et al. (based on their 
%supplemental table 1).  
% 
%NOTE: the COBRA exchange reaction convention means that I need to use the 
%opposite sign than Kennedy et al. 
% 
%NOTE 2: Table S1 lists "pydxn", "4abz", 
%"nac", and "dhf" as having an upper bound of 0.5. I think these are: 
%Pyridoxine (met 875), 4-Aminobenzoate (met 98), Nicotinate (met 714), and 
%7,8-Dihydrofolate (met 383). They don't have exchange reactions in iND750. 
%Kennedy et al. may have added them, but they don't have fluxes in Table 




%NOTE 3: I'm guessing rxn names from their met names. 
  
%start with a clean slate: set all exchange reactions to upper bound = 1000 
%and lower bound = 0 (ie, unconstrained excretion, no uptake) 
  




%the following exchange rxns have an upper bound and lower bound of 20 in 






    index=find(strcmp(ub_lb_20(i),model.rxnNames)); 
    model.lb(index)=-20; 
    model.ub(index)=-20; 
end 
  
%the following have upper and lower bounds of inf in Table S1.  
% 
%NOTE: oxygen not in table S1, but added to do aerobic, based on 
%text of paper 
  
ub_inf={'water exchange', 'ammonium exchange', 'phosphate exchange', ... 
    'sulphate exchange', 'sodium exchange', 'potassium exchange', ...  
    'carbon dioxide exchange', 'oxygen exchange'}; 
  
for i=1:length(ub_inf) 
    index=find(strcmp(ub_inf(i),model.rxnNames)); 
    model.lb(index)=-1000; 
end 
  
%the following have an upper bound of 0.5 in Table S1 (but I'm switching 
%signs, so do a lower bound of -0.5). 
  
ub_05 = {'L-asparagine exchange', 'L-aspartate exchange', ...  
    'L-valine exchange', 'L-tyrosine exchange', ... 
    'L-tryptophan exchange', 'L-threonine exchange', ...  
    'L-serine exchange', 'L-proline exchange', ...  
    'L-phenylalanine exchange', 'L-methionine exchange', ... 
    'L-lysine exchange', 'L-leucine exchange', ... 
    'L-isoleucine exchange', 'L-histidine exchange', ... 
    'glycine exchange', 'L-glutamate exchange', ... 
    'L-glutamine exchange', 'L-cysteine exchange', ... 
    'L-arginine exchange', 'L-alanine exchange' ... 
    'riboflavin exchange', 'thiamine(1+) exchange', ... 
    'zymosterol exchange', 'uracil exchange', ... 
    '(R)-pantothenate exchange', 'linoleic acid exchange', ... 
    'myo-inositol exchange', 'palmitoleate exchange', ... 
    'ergosterol exchange', 'biotin exchange', 'adenine exchange'}; 
  
%note: Y5 doesn't have octadecynoate (n-C18:2) or octadecenoate (n-C18:1) 
%exchange reactions. I used linoleic (18:1). It also doesn't have 
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%hexadecenoate (n-C16:1). I used palmitoleate (16:1) for that. I don't 
%think they should really matter for aerobic simulations, though. 
  
for i=1:length(ub_05) 
    index=find(strcmp(ub_05(i),model.rxnNames)); 
    model.lb(index)=-0.5; %constrained uptake 
end 
  
%the following have a lower bound of -inf in Table S1 (but I'm switching 
%signs, so do an upper bound of 1000) 
% 
% Note: 'Deoxycytidine exchange' not included in Table S1, but has a flux 
% in Table S2, so I added it here. 
  
lb_inf = {'(1->3)-beta-D-glucan exchange', ... 
    'gamma-aminobutyrate exchange', '(S)-3-methyl-2-oxopentanoate exchange', 
... 
    ' 8-amino-7-oxononanoate exchange', 'L-arabinitol exchange', ... 
    'acetaldehyde exchange', 'acetate exchange', 'adenosine exchange', ... 
    ' 2-oxoglutarate exchange', 'allantoin exchange', ... 
    'S-adenosyl-L-methionine exchange', 'D-arabinose exchange', ... 
    'L-arabinose exchange', 'choline exchange', 'citrate(3-) exchange', ... 
    '(R)-carnitine exchange', 'cytosine exchange', 'cytidine exchange', ... 
    '2''-deoxyadenosine exchange', ' 7,8-diaminononanoate exchange', ... 
    '2''-deoxyguanosine exchange', '2''-deoxyinosine exchange', ... 
    'dTTP exchange', '2''-deoxyuridine exchange', 'ethanol exchange', ... 
    'FMN exchange', 'palmitate exchange', 'H+ exchange', ... 
    'hypoxanthine exchange', 'inosine exchange', '(S)-lactate exchange', ... 
    '(S)-malate exchange', 'maltose exchange', 'D-mannose exchange', ... 
    'melibiose exchange', 'S-methyl-L-methionine exchange', ... 
    'NMN exchange', 'stearate exchange', ... 
    'ornithine exchange', 'adenosine 3'',5''-bismonophosphate exchange', ... 
    'peptide exchange', 'putrescine exchange', 'pyruvate exchange', ... 
    'D-ribose exchange', 'D-glucitol exchange', 'L-glucitol exchange', ... 
    'spermidine exchange', 'spermine exchange', 'L-sorbose exchange', ... 
    'succinate exchange', 'sucrose exchange', ... 
    'thiamine(1+) monophosphate exchange', 'thiamine(1+) diphosphate(1-) 
exchange', ... 
    'thymidine exchange', 'thymine exchange', 'alpha,alpha-trehalose 
exchange', ... 
    'myristate exchange', 'urea exchange', ... 
    'uridine exchange', '9H-xanthine exchange', 'xanthosine exchange', ... 
    'D-xylose exchange', 'xylitol exchange', 'deoxycytidine exchange'}; 
  
%note: Y5 doesn't have 4-Aminobutanoate exchangeI used gamma-aminobutyrate. 




    index=find(strcmp(lb_inf(i),model.rxnNames)); 
    model.lb(index)=0; 
    model.ub(index)=1000; 
end 
  






%next step: demonstrate the results of Table 1 (strains 1-5, b/c yat2 isn't 
%in iND750 - I'm not sure how strains 6-8 were generated) 
% 
  
%Kennedy reported in silico knockouts: 
%1 fdh1=YOR388C fdh2=YPL275W/YPL276W alt2=YDR111C fum1=YPL262W zwf1=YNL241C 
%2 fdh1 fdh2 aat2=YLR027C fum1=YPL262W zwf1=YNL241C 
%3 fdh1 fdh2 cat2=YML042W fum1=YPL262W zwf1=YNL241C 
%4 fdh1 fdh2 cat2=YML042W fum1=YPL262W rpe1=YJL121C 
%5 fdh1 fdh2 cat2=YML042W fbp1=YLR377C fum1=YPL262W 
%6 fdh1 fdh2 cat2=YML042W yat2=YER024W slc1=YDL052C 
%7 fdh1 fdh2 cat2=YML042W yat2=YER024W cho1=YER026C 
%8 fdh1 fdh2 cat2=YML042W yat2=YER024W alt2=YDR111C 
  
%looking at Yeast 5.01: 
%fdh1 = gene 848, rxns: 445 
%fdh2 = gene added by my chages, rxns: 445 
%alt2 - added to model, above 
%fum1 = gene 883 rxns: 451 452 
%zwf1 = gene 743 rxns: 466 
%aat2 = gene 588 rxns: 216 218 681 683 1065 
%cat2 = gene 659 rxns: 253 254 
%rpe1 = gene 476 rxns: 984 
%fbp1 = gene 645 rxns: 449 
%yat2 = gene 263 rxns: 252 
%slc1 = gene 130 rxns: 9 
%cho1 = gene 264 rxns: 880 881 - essential for model. 
  
%% 





fprintf('The WT flux is: %6.4f.\n', wt_sln.f); %2.5889 
fprintf('Formate exchange is reaction %d.\n', formate_ex); %0 
fprintf('The formate exchange flux is: %6.4f.\n', wt_sln.x(formate_ex)); 
fprintf(' \r'); 
  
%make the knockouts and test them 
%fdh1/2 mutant applied earlier 
%[model,hasEffect,constrRxnNames,deletedGenes] = ... 
%        deleteModelGenes(model,{'YOR388C','YPL275W','YPL276W'}); 
    
[KO1,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YDR111C','YPL262W','YNL241C'}); 
KO1_sln=optimizeCbModel(KO1,[],'one'); 
  
fprintf('The KO1 flux is: %6.4f.\n', KO1_sln.f); %1.6065 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 




[KO2,hasEffect,constrRxnNames,deletedGenes] = ... 





fprintf('The KO2 flux is: %6.4f.\n', KO2_sln.f); %1.6065 
fprintf('Formate exchange is reaction %d.\n', formate_ex); % 




[KO3,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YPL262W', 'YNL241C'}); 
KO3_sln=optimizeCbModel(KO3,[],'one'); 
  
fprintf('The KO3 flux is: %6.4f.\n', KO3_sln.f); %1.6065 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 




[KO4,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YPL262W', 'YJL121C'}); 
KO4_sln=optimizeCbModel(KO4,[],'one'); 
  
fprintf('The KO4 flux is: %6.4f.\n', KO4_sln.f); %1.6065 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 





[KO5,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YLR377C', 'YPL262W'}); 
KO5_sln=optimizeCbModel(KO5,[],'one'); 
  
fprintf('The KO5 flux is: %6.4f.\n', KO5_sln.f); 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 




[KO6,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YER024W', 'YDL052C'}); 
KO6_sln=optimizeCbModel(KO6,[],'one'); 
  
fprintf('The KO6 flux is: %6.4f.\n', KO6_sln.f); 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 




[KO7,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YER024W', 'YER026C'}); 
KO7_sln=optimizeCbModel(KO7,[],'one'); 
  
fprintf('The KO7 flux is: %6.4f.\n', KO7_sln.f); 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 






[KO8,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,{'YML042W', 'YER024W', 'YDR111C'}); 
KO8_sln=optimizeCbModel(KO8,[],'one'); 
  
fprintf('The KO8 flux is: %6.4f.\n', KO8_sln.f); 
fprintf('Formate exchange is reaction %d.\n', formate_ex); 






Supplementary File 5.4.4: Y5_3_two_knockout2.m script 
% FILE NAME: Y5_3_two_knockout2 
% 
% DATE CREATED: 2 February 2012 
% 
% PROGRAMMER: B. Heavner 
% Department of Biological 
% and Environmental Engineering 
% Cornell University 
% Ithaca, NY 14853 
% 
% LAST REVISED: 11 July 2012 
% 
% REVISED BY: B. Heavner 
% 
% REVISIONS: 
% 11 July 2012 - BDH cleaned up for publishing 
% 13 June 2012 - BDH edit to work with updated constraints of new Y5.30 
% 22 May 2012 - BDH edit to work with Y5.30 instead of modified 5.01 
% 
% PURPOSE:  
% A variation on the model results reported by Kennedy et al. which 
% compares all viable 2-knockout mutants in iND750 to find those that will 
% cause formic acid secretion. 
% 
% In this script, I apply a "global" search for double deletions that 
% excrete formic acid to the the constrained Y5.30 I made in the 
% Y5_3_three_knockout1_v2 script (the variable "model", which has the same 
% media as Kennedy et al.) 
% 
% 
% REFERENCE:  
% Kennedy CJ, Boyle PM, Waks Z, Silver PA. "Systems-Level Engineering of 
% Nonfermentative Metabolism in Yeast" Genetics (2009) 183:385-397. DOI: 
% 10.1534/genetics.109.105254 
% 
% VARIABLES:  
% this script requires the updated_Y_5_3_KO_model.mat variable built by 
% Y5_3_three_kncokout1_v2.m in the working directory. 
% 
% EXPECTED OUTPUT: 










%double check that the model is a fdh1/2 background 
[model,hasEffect,constrRxnNames,deletedGenes] = ... 










%We need to restrict the list of genes which can be deleted to about 300. 
% 
%First, find reactions that are annotated with just 1 gene. Any of these 
%reactions can be blocked with a single gene deletion, so combinations of 
%two or three are feasible. Then, I'll remove duplicates and essential 
%genes, to have a first list to screen for triple deletions. 
% 
%Anther thing to think about: "and" vs "or" genes for double and triples 
% 
  




%number_of_genes is a row vector whose entries correspond to the number of 
%genes annotating each reaction (Ex: in iND750, there are 1266 reactions. 
%number_of_genes(1265) is 1 b/c rxn 1265 is catalyzed by YOR011W.) 
  
single_gene_reaction_genes=model.grRules(number_of_genes == 1); 
%single_gene_reaction_genes is a list of genes which catalyze reactions, 
%when the reaction is annotated as requiring only a single gene. There are 
%834 such genes. 
  
unique_single_gene_reaction_genes=unique(single_gene_reaction_genes); 
%There are 478 unique genes which catalyze reactions annotated as only 
%requiring a single gene (this is a nice reduction from the 926 genes in 
%the model already!). How many of them are essential? 
  
%next, let's remove known essential genes and dubious ORFs from our list. 
  
% 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































included_dubiousORFs = setdiff(... 
    unique_single_gene_reaction_genes, verified_genes);  
%there is 1 dubious ORF on the list of rxns catalyzed by 1 gene 
  
included_essential=intersect(... 
    unique_single_gene_reaction_genes,sgd_essential_genes);  




candidate_singles = setxor(included_essential,candidate_singles); 
  
%So, now there are 373 genes on the list of possible candidates. Let's also 





%the list of essential genes is as followes: 
%ko_tol = 1e-6; 
%grRatio = singleGeneDeletion(model); 










%As I work, I've found other genes which shouldn't be included 
others_to_remove = {'YNL280C',... %SGD annotates as inviable in aerobic 
    'YER005W',... %ynd1 excluded b/c it shows up unexpectedly w/high flux 
    'YML120C',... %ndi1 excluded b/c 353/355 top predicted involve it, and 
I'm not confident about NAD metabolism     
    model_essential{:}}; 
  
included_model_essential = intersect(others_to_remove,candidate_singles); 
  
candidate_singles = setxor(included_model_essential,candidate_singles); 
%Now there are 360 genes on the list of possible candidates. 
  





%So now I have a list of genes that annotate reactions that are only 
%annotated with a single genes. I (think) I can knock out any three of 
%these genes and look for increased formic acid secretion. 
  















h = waitbar(0,'Checking double knockouts ...'); 
  
for i=1:length(doubles) 
    if mod(i,100) == 0 
        waitbar(i/length(doubles),h); 
    end 
379 
 
    clear mex; 
    [newmodel,hasEffect,constrRxnNames,deletedGenes] = ... 
        deleteModelGenes(model,candidate_singles(doubles(i,:))); 
    if hasEffect 
        flux=optimizeCbModel(newmodel,[],'one'); 
        if numel(flux.x)==0 
            i 
        elseif (flux.x(formate_ex)>0 && (flux.f>0.5518)) %formate flux + >20% 
WT growth rate 
            double_formate_fluxes = [double_formate_fluxes; i 
flux.x(formate_ex) flux.f]; 
            sprintf('%12i %12.4f %12.4f\n',i, flux.x(formate_ex), flux.f) 
        end 




%the double_formate_fluxes variable should now be 3 columns, with each 
%row consisting of the KO number in column 1 (the index of "doubles"), and 




% To find which deletion gives a particular formate flux, do something like 
% this: 
max_formate_flux=max(double_formate_fluxes(:,2)); 
index=find(double_formate_fluxes(:,2)==max_formate_flux); 
max_double=double_formate_fluxes(index,1); 
singles_index=doubles(max_double,:); 
max_formate_genes=candidate_singles(singles_index) 
 
 
